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Campylobacter 
Campylobacter spp. are small motile, microaerophilic, S-shaped or spiral rods (0.2-0.5 µm 
wide by 0.5-5 µm long), gram-negative bacteria (Fig. 1). Campylobacter was first described in 1886 by 
Theodore Escherich (1) in the colon of children who had died of ‘cholera infantum’. The name 
Campylobacter is derived from the Greek word ‘καµpiυλοσ’ which means curved. In 1962, 
Campylobacter, then still known as ‘related Vibrio’ was described as a rare and opportunistic human 
pathogen that was isolated from blood culture of humans (2). In 1972, Campylobacter jejuni was first 
isolated from human diarrheal stools by applying a filtration technique (3). The subsequent 
development of selective Campylobacter stool culture techniques (4) led to the recognition that C. 
jejuni was a more common cause of human diarrheal illness.    
 
 
 
Figure 1: Scanning electron microscope micrograph of C. jejuni. Adopted from Jean-Paul 
Butzler.  
 
Though C. jejuni is identified as the most frequent cause of bacterial gastroenteritis in 
developed countries (5-8), it is a common cause of diarrheal illness in the developing world, 
particularly in the first few years of life (9). In Bangladesh, C. jejuni has been reported as the second 
(17%) commonest enteropathogen in diarrhoeal patients of young children after rotavirus (20%) (10). 
Substantial variation in incidence rates has been observed among Campylobacter related-
gastroenteritis in many developed countries (11). The incidence of symptomatic infections is highest 
among young children followed by young adults. In addition, there is a strong seasonality with a 
summer peak from June to September (12). The vast majorities of Campylobacter infections are not 
linked to outbreaks and occur as sporadic infections. Contact with farm animals, especially poultry, 
cattle and pigs are considered the main source of Campylobacter infection (13, 14). Consumption of 
untreated water, raw milk, or milk products are important additional sources of infection (12).     
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Campylobacter spp. are difficult to identify phenotypically because of relative biochemical 
inactivity, special growth requirements and complex taxonomy. Campylobacter can be isolated from 
fecal specimens using selective media that inhibit growth of normal gut flora. Most Campylobacter 
species require a microaerobic atmosphere and an incubation temperature of 370 to 420 for optimal 
growth. In most routine laboratories, the identification of Campylobacter spp. is based on growth on 
selective media, colony morphology, gram stain and a combination of biochemical test. Many studies 
report that the use of a combination of media, including either charcoal cefoperazone deoxycholate 
agar (CCDA) or charcoal-based selective medium, achieves a higher yield of Campylobacter from 
stool samples than the use of only a single medium (15, 16). As a single medium, CCDA medium was 
found to be the most sensitive for detecting C. jejuni and C. coli compared with Skirrow’s medium, 
CAT agar, and filtration technique (17). After the acute stage of disease when the concentration of 
organisms decreases, enrichment cultures may be necessary to recover Campylobacter (18). Stool 
antigen tests for Campylobacter have been developed, and are commercially available. The ProSpecT 
Campylobacter immunoassay varies in sensitivity from 80% to 96% and has a specificity of >97% (19, 
21). A large number of samples has been evaluated by Ridascreen Campylobacter (R-Biopharm. 
Darmstadt, Germany) immunoassay comparison with culture technique, and demonstrate that this 
technique has a sensitivity of 69% and a specificity of 87% (22). In addition, PCR-based detection, 
identification to the species level, and typing of Campylobacter directly from stool samples have been 
evaluated but are currently not frequently used in routine diagnostic procedures (23-25). During the 
first few weeks of infection, fecal and serum immunoglobulin (IgA)  antibodies are apparent and then 
decrease precipitously, and expected serum IgG, IgM, and IgA level increase in response to infection 
(26, 27). The presence of serum IgM, IgA, and/or high titres of IgG antibodies against C. jejuni is 
strongly supportive for an acute infection (28-30). However, serologic testing is not recommended for 
routine diagnosis of Campylobacter infection but appears to be useful for epidemiologic investigations 
(31). 
The clinical aspects of infection with C. jejuni are acute gastroenteritis, and extra-intestinal 
infections and post-infectious complications (Fig. 2). No specific treatment is required for most patients 
with Campylobacter enteritis, other than the oral replacement of fluid and electrolytes lost through 
diarrhea and vomiting (32). Due to increasing resistant against fluoroquinolones, a macrolide antibiotic 
such as clarithromycin is first choice when antibiotic treatment is indicated (32). Reactive arthritis, 
Reiter’s syndrome, and Guillain-Barré syndrome (GBS) are post-infectious complications of 
Campylobacter infection. The association of Campylobacter infection with GBS, which emerged during 
the mid-1980s, greatly improved the understanding of the morbidity of the disease. In view of the 
importance of GBS, and the high incidence of acute flaccid paralysis (33), in this thesis we described 
C. jejuni infection and GBS in Bangladesh. 
General introduction 
 
 
 
 
 
 
 
 
 
 
 
 
Guillain-Barré syndrome 
Guillain-Barré syndrome (GBS) is an immune-meditated polyradiculoneuropathy, a disease of 
the peripheral nervous system with a broad clinical spectrum and specific pathophysiological and 
electrophysiological features (34, 35). At present, it is the world most frequent cause of acute paralysis 
after the extinction of poliomyelitis (36). Since 2000, no virally and clinically confirmed polio cases 
were found in Bangladesh; however, non-polio acute flaccid paralysis (AFP) is frequently diagnosed 
(33). Most of the non-polio AFP is thought to be GBS in Bangladesh (37). In the past two decades, 
much progress has been made in understanding the pathophysiology and epidemiology of GBS in the 
developed world. There is a scarcity of report on GBS from developing world including Bangladesh.  
In the following part of this chapter, we will provide a comprehensive framework for reading 
the remaining chapters of this thesis. First, it will discuss the history and clinical aspects of GBS. Next, 
C. jejuni-related GBS and pathogenesis of this disease will be addressed in details. The role of GBS-
related C. jejuni strains and molecular epidemiology of C. jejuni will be discussed separately. Prime 
research objective in this thesis is that C. jejuni might play a key role to the development of GBS in 
Bangladesh. At the end of this chapter the scope and major objectives of the studies described in this 
thesis will be presented in brief.  
 
Acute gastroenteritis Cured 
Intestinal Complications  
Extra-Intestinal Infections 
• Bacteraemia 
• Metastatic seeding 
infections 
Post-infectious complications  
• Reactive arthiritis  
• Guillain-Barré syndrome 
• Postinfectious irritable bowel 
syndrome  
Immunodeficient 
Healthy  
Figure 2. Diagram illustrating an overview of illnesses due to C. jejuni  
Chapter 1 
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History 
The first accurate description of GBS was made in 1859 by Jean Baptiste Octave Landry de 
Thezillat (38). By 1876, the phrase 'Landry's ascending paralysis' became the standard name for the 
disease. The syndrome was named after G. Guillain and J. A. Barré, two French army neurologists, 
who in 1916 described, together with A. Strohl, the typical findings in the cerebrospinal fluid (39). They 
reported the combination of increased protein concentration with a normal cell count in the 
cerebrospinal fluid (CSF), or albuminocytological dissociation, which differentiated the condition from 
poliomyelitis (39). In 1927, H. Draganesco and J. Claudian coined the term 'Guillain-Barré Syndrome' 
(GBS), and regretfully failed to acknowledge Strohl's contribution to the research. Until now, GBS is a 
descriptive disease entity defined by a set of clinical, laboratory, and electrodiagnostic criteria for 
which there are no specific diagnostic tests (36). To date, GBS is no longer considered as one single 
disease entity, but as a continuous spectrum of distinct or overlapping variantss, ranging from a pure 
motor form to a combination of motor and sensory nervous system disturbance with or without cranial 
nerve involvement. 
 
Epidemiology 
The annual incidence of GBS is reported to be 0.6 to 4.0 cases per 100,000 per year 
throughout the world (40, 41), but well-controlled population-based studies in Europe report an 
incidence of 1.2 to 2.3 per 100,000 per year (34, 41-46). Atypical presentations, such as the Miller 
Fisher syndrome (MFS), are much less frequent, with an incidence of 0.1 per 100,000 (44). In some 
areas of the world, the incidence of GBS may be higher, as has been suggested for endemic forms in 
rural areas in northern China (47). A study carried out by the Dutch GBS group, observed a temporary 
rise in incidence of GBS from 1.6 to 3.1 per 100,000 per year over the period from 1987 to 1999 on 
the Caribbean island of Curaçao (48). However, a recent review reports that the temporarily increased 
incidence in Curaçao had nearly returned to normal by 2006 (36). Considering the above-mentioned 
incidence rates, 40,000 to 120,000 new cases are being diagnosed per year worldwide (49). The 
incidence increases with age from 1 per 100,000 per year in persons aged below 30 years, to about 4 
cases per 100,000 per year in persons older than 75 years (44). Men are 1.5 times more frequently 
affected than women (41, 42, 44). Multiple cases of GBS within one family have been described, 
although this appears to be an infrequent event and may represent a chance finding (50).  
 
Clinical features of GBS  
Diagnosis 
The reason for developing diagnostic criteria for GBS was related to its increasing incidence 
during the swine flu vaccination period in 1976 and 1977. The criteria were first published in 1978 at 
the request of the National Institute of Neurological and Communicative Disorders and Stroke 
(NINCDS) (51). The criteria were reaffirmed in 1990, and the electrodiagnostic criteria were expanded. 
These diagnostic criteria are widely accepted and seem appropriate to clinically define GBS (52).    
General introduction   
 
 
Diagnostic criteria for typical GBS are shown in Table 1. The patient may notice numbness or 
tingling in the arms or legs with symmetrical loss of strength in hands or feet. The weakness spreads 
during the next few hours to weeks and may finally lead to a paralysis of limb, trunk, extraocular, 
facial, pharyngeal, and tongue musculature. Up to one-third of patients need to be ventilated due to 
the involvement of respiratory muscle (53, 54). Patients may suffer from severe pain and show 
reduced sensibility or autonomic dysfunction (53-55). Clinical examination of the patients shows poor 
or absent tendon reflexes. In general, CSF examination shows an increased protein level with normal 
white cell count. A common misunderstanding is that CSF protein concentration is always increased in 
GBS; many patients with GBS have a normal protein level in the first week of disease, but this 
proportion increase in more than 90% at the end of the second week (56). Electrophysiological 
investigation further supports the diagnosis of GBS with the features of demyelination and axonal 
degeneration.   
  
Disease course and prognosis 
The clinical severity, course and outcome of GBS is highly variable (36). The maximum level 
of weakness is reached within 4 weeks after onset of symptoms followed by spontaneous recovery 
(Fig.3). It seems to be a general believe that most patients suffering from a mild clinical course of 
disease may show a neurological good recovery. However, patients with a mild course of disease may 
suffer from residual morbidity (57).  Many case series report that advanced age is indicative of a worse 
prognosis (34, 58, 59). 
In children, recovery is more rapid and more likely to be complete and death is exceptional 
(41). Respiratory failure occurs in 25% of patients and may need mechanical ventilation for a 
prolonged period (60-63). Prognosis ranges from complete neurological recovery with or without 
fatigue (64), to wheelchair dependency or death. Approximately 20% of patients have a severe 
functional deficit, and remain unable to walk or bedridden, and they even may need continuous 
artificial ventilation (65, 66). The mortality usually ranges from 2 to 13% (53, 67-69) and is mostly the 
result of respiratory failure, cardiovascular and autonomic disturbances (34, 58, 59). 
A prognostic model was developed that accurately predicts which patients will have a poor 
outcome (66). The worse prognostic factors include older age, severe and rapid onset of weakness, a 
preceding gastrointestinal illness or recent CMV infection, severely reduced compound muscle action 
potential amplitude, and a low Medical Research Council (MRC) sum core at randomization (53, 64, 
66, 70-72). 
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Table 1. Diagnos  criteria for Guillain-Barré syndromea  
Features required for diagnosis 
• Progressive motor  weakness of more than one limb 
• Low or absent reflexes 
• No other identifiable cause 
 
Features that strongly support the diagnosis 
Clinical 
• Progression of symptoms over days to 4 weeks 
• Relative symmetry of symptoms 
• Mild sensory symptoms or signs  
• Cranial nerve involvement, especially bilateral weakness of facial muscles  
• Onset of recovery 2-4 weeks after progression stops  
• Autonomic dysfunction  
• Pain (often present)  
Cerebrospinal fluid (CSF)   
• High concentration of CSF protein after the first week  
• Less than 50 mononuclear leukocytes per µl CSF 
Electrodiagnosis 
• Conduction slowing or block 
 
Features casting doubt on the diagnosis 
• Bladder or bowel dysfunction at onset  
• Sharp sensory level  
• Marked persistent asymmetry of weakness  
• Persistent bladder or bowel dysfunction  
• More than 50 mononuclear leukocytes per µl CSF  
• Presence of polymorphonuclear leukocytes in CSF 
 
 
aAdapted from the criteria supported by the National Institute of Neurological and Communication 
Disorders and Stroke (52). 
 
 
 
General introduction 
tic
  
 
 
 
 
Figure 3: Sequence of events in a typical case of C. jejuni-related GBS. Adopted from Jacobs et al. 
(49). 
 
General treatment  
The most important reduction of mortality in GBS has been due to advances in supportive 
care of critically ill patients (41). Patients with GBS need to be admitted to a hospital for close 
observation (58, 59). General medical support is extremely important, especially to prevent secondary 
complications such as infections and decubitus (49, 73). Respiratory failure occurs in 25% of patients 
and is more likely in cases with rapid progression, bulbar palsy, upper limb involvement, and 
autonomic dysfunction. Regular monitoring is essential for vital capacity, and early transfer to an 
intensive therapy unit for prophylactic intubation. All severe patients should be monitored for possible 
cardiac arrhythmia. In non-ambulant adult patients, subcutaneous heparin and graduated compression 
stockings should be used to prevent deep vein thrombosis. Wide fluctuations of pulse rate and blood 
pressure occur in severe cases and sustained autonomic failure. Patients need to be checked 
regularly for urinary tract infections, gastrointestinal dysfunction, and hyponatremia. Many patients 
suffer from serious pain, varying from severe back pain, radicular pain or dys- and parethesias (74). 
Throughout the illness, psychological aberrations and communication problems must be addressed 
(60, 75). 
Increased understanding of the immunologic basis of this disease over the past 15 years has 
allowed changing the natural course of this disease. Plasma exchange became accepted as the gold 
standard treatment for GBS almost 20 years ago (41). Since a randomized controlled trial showed that 
Chapter 1
17 
Table 1. Diagnos  criteria for Guillain-Barré syndromea  
Features required for diagnosis 
• Progressive motor  weakness of more than one limb 
• Low or absent reflexes 
• No other identifiable cause 
 
Features that strongly support the diagnosis 
Clinical 
• Progression of symptoms over days to 4 weeks 
• Relative symmetry of symptoms 
• Mild sensory symptoms or signs  
• Cranial nerve involvement, especially bilateral weakness of facial muscles  
• Onset of recovery 2-4 weeks after progression stops  
• Autonomic dysfunction  
• Pain (often present)  
Cerebrospinal fluid (CSF)   
• High concentration of CSF protein after the first week  
• Less than 50 mononuclear leukocytes per µl CSF 
Electrodiagnosis 
• Conduction slowing or block 
 
Features casting doubt on the diagnosis 
• Bladder or bowel dysfunction at onset  
• Sharp sensory level  
• Marked persistent asymmetry of weakness  
• Persistent bladder or bowel dysfunction  
• More than 50 mononuclear leukocytes per µl CSF  
• Presence of polymorphonuclear leukocytes in CSF 
 
 
aAdapted from the criteria supported by the National Institute of Neurological and Communication 
Disorders and Stroke (52). 
 
 
 
General introduction 
tic
  
 
 
 
 
Figure 3: Sequence of events in a typical case of C. jejuni-related GBS. Adopted from Jacobs et al. 
(49). 
 
General treatment  
The most important reduction of mortality in GBS has been due to advances in supportive 
care of critically ill patients (41). Patients with GBS need to be admitted to a hospital for close 
observation (58, 59). General medical support is extremely important, especially to prevent secondary 
complications such as infections and decubitus (49, 73). Respiratory failure occurs in 25% of patients 
and is more likely in cases with rapid progression, bulbar palsy, upper limb involvement, and 
autonomic dysfunction. Regular monitoring is essential for vital capacity, and early transfer to an 
intensive therapy unit for prophylactic intubation. All severe patients should be monitored for possible 
cardiac arrhythmia. In non-ambulant adult patients, subcutaneous heparin and graduated compression 
stockings should be used to prevent deep vein thrombosis. Wide fluctuations of pulse rate and blood 
pressure occur in severe cases and sustained autonomic failure. Patients need to be checked 
regularly for urinary tract infections, gastrointestinal dysfunction, and hyponatremia. Many patients 
suffer from serious pain, varying from severe back pain, radicular pain or dys- and parethesias (74). 
Throughout the illness, psychological aberrations and communication problems must be addressed 
(60, 75). 
Increased understanding of the immunologic basis of this disease over the past 15 years has 
allowed changing the natural course of this disease. Plasma exchange became accepted as the gold 
standard treatment for GBS almost 20 years ago (41). Since a randomized controlled trial showed that 
Chapter 1
18  
intravenous immunoglobulins (IVIg) has a similar efficacy as plasma exchange (62), IVIg (0.4 g/kg 
body weight for 5 days) has replaced plasma exchange as the preferred treatment for severe GBS in 
most hospital because of its greater convenience (76). The mechanism of action of IVIg is probably 
multifactorial, possibly involving blockade of Fc receptors, provision of anti-idiotypic antibodies, 
interference with complement activation, and T-cell regulation (77). Corticosteroids do not have a 
beneficial effect but in combination with IVIg there may be a synergistic effect (78-80).  
 Although the past 13 years have seen the emergence of treatments that at least shorten the 
duration of GBS, 20% of patients are left disabled, and a considerable proportion of these patients has 
a persistent severe disability (41). Some patients with severe disease may benefit from repeating IVIg 
treatment, although such an additional therapeutic effects still needs to be demonstrated. Further 
research is needed to identify the key mechanisms at work in the different subtypes of the disease. 
Complement-mediated mechanisms have been implicated in all subtypes and drugs that inhibit the 
complement cascade should be considered. In those patients with detectable antibodies against 
gangliosides, a novel approach is to absorb the antibodies on a column that has a specific affinity for 
the individual ganglioside (81). 
 
Variants of GBS 
GBS comprises cases in which the type of nerve fiber injury is predominantly caused by 
demyelination as well as cases in which the primary pathological process is primary axonal 
degeneration (82). The most common subtype of the syndrome is acute inflammatory demyelinating 
polyradiculoneuropathy (AIDP) (82), and another subtype described in China, in which the 
neurological deficit is purely motor, has come to be known as acute motor axonal neuropathy (AMAN) 
(83-85). Patients in which the axonal degeneration is present in both motor and sensory nerve fibres, 
have a so called acute motor and sensory axonal neuropathy (AMSAN) (86). In Europe and North 
America the most frequent pattern is AIDP, present in 90% of GBS cases. In Asia, South and Central 
America, however, AIDP is relatively rare, and the predominant type is the axonal form of GBS which 
constitutes 30% to 47% of cases (41). The axonal subtype is rare in North America and Europe (5%-
10%). Individual patients with demyelinating or axonal forms of GBS cannot be distinguished based on 
clinical features, but only by electrophysiology. Both axonal degeneration and very distal 
demyelination may lead to inexcitable nerves (87, 88). In addition to the variation in clinical symptoms 
between GBS patients, several cranial nerve variant of GBS can be distinguished of which the MFS 
occurs most frequently (89). In 1956, C Miller Fisher described the combination of acute 
ophthalmoplegia, limb ataxia, and areflexia in the absence of limb weakness known as MFS and 
postulated that this set of features was a form of GBS (90). Patients with MFS may have facial and 
lower cranial-nerve involvement. Some patients have severe swallowing problems for which they 
require temporary intubation. In general, however, patients with MFS show a good recovery. Overlap 
cases between MFS and GBS with a combination of oculomotor and limb weakness also occur.  
 
 
General introduction   
 
 
Pathogenesis 
Antecedent illness and preceding infections associated with GBS 
Two-thirds of GBS patients have symptoms suggestive of an infection in the 3 weeks before 
the onset of weakness (36, 41, 91). In a prospective study conducted in England a respiratory 
infection occurred in 38% of the GBS patients and 12% of the controls, and gastrointestinal infections 
in 17% of the patients and 3% of the controls (71). Respiratory infections generally started within 1 to 
2 weeks before neuropathy onset, gastrointestinal infections usually only 1 week or less before the 
start of neurological symptoms (54). The most frequent antecedent symptoms in GBS and related 
disorders were fever (52%), cough (48%), sore throat (39%), nasal discharge (30%), and diarrhoea 
(27%) (92). In most GBS studies, symptoms of a preceding infection in the upper respiratory tract or 
gastrointestinal tract predominate, but various infections and other preceding events such as 
vaccination, operation or stressful events have been reported (41, 71, 93). 
Several reports have documented the occurrence of GBS shortly after vaccinations, 
operations, or stressful events, but the specific relation with GBS is still debated (34, 41, 94-96). There 
was an increase in incidence of GBS after the swine influenza vaccination program in the USA in 1976 
(97). Other influenza vaccines have not been associated with the same risk (94). A retrospective study 
of the 1992 to1994 vaccine campaigns in the USA identified that vaccines were associated with a very 
small but significant increased risk of developing GBS of about one GBS case per million vaccines 
above the background incidence (96). A case–control from the UK did not show any significant 
association between GBS and previous immunization (95). However, in a recent US report on 
vaccinations and their side-effects, not only influenza vaccinations but also hepatitis vaccinations were 
suggested to be associated with the occurrence of GBS (98). 
GBS is a heterogeneous syndrome with a wide spectrum of clinical, immunological, 
electrophysiological and pathological findings (49, 117). A wide variety of infectious agents have been 
proposed as a possible triggering factor in patients with GBS. In the United Kingdom and The 
Netherlands, C. jejuni infection was identified as the predominant antecedent infection and 
cytomegalovirus (CMV) as the second most prevalent (53, 93) (Table 2). Other infections associated 
with GBS were Epstein-Barr virus (EBV) and Mycoplasma pneumonia (53, 93, 109). A very recent 
prospective multicentre study in children with GBS demonstrated that coxsackie viruses were 
associated as antecedent infection (116). The relative frequency of antecedent infection however may 
differ between countries. In Northern China, C. jejuni infections occur in up to 66% of the GBS. 
 
C. jejuni and GBS 
C. jejuni can be cultured from stool specimens of GBS patients, although this appears to 
necessitate laborious isolation protocol including enrichment media. C. jejuni was first isolated from 
stool specimen of GBS patient in 1982 (118). Subsequently, C. jejuni infections were frequently 
identified in GBS patients by culture or serology in case-reports and small series (Table 3). Still, stool 
cultures are often negative at the onset of the neurological symptoms, considering the mean period of 
bacterial excretion after onset of diarrhea is only 16 days (119). GBS typically starts 1 to 3 weeks after 
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a Campylobacter infection. Therefore, studies based on stool culture alone will underestimate the 
frequency of previous C. jejuni infections in GBS. However, recent studies report that Campylobacter 
serology is highly sensitive and specific in GBS patients (30). In Northern China, C. jejuni infections 
occur in up to 66% of the GBS patients, depending on the serological assays and criteria for  
  
Table 2. Antecedent infections in patients with the Guillain-Barré syndrome 
 Infectious agents  Frequency References 
C. jejuni 14-66% 47, 53, 71, 93, 99-107 
Cytomegalovirus 5-15% 53, 108-112  
Epstein-Barr virus 0-10% 53, 93, 108,109,113  
M. pneumonia 1-11% 53, 93,108, 113,114  
H. influenza 1-13% 93, 115 
Coxsackie viruses 15% 116 
 
seropositivity  it is very difficult to compare the results from different studies (28, 29, 47). Population-
based comparative geographical studies conducted by a central laboratory are therefore needed to 
address this issue.         
 
Numerous investigators have looked for serological evidence of a Campylobacter infection in GBS 
patients. These studies show a high prevalence of antibodies to C. jejuni in the patients with GBS 
(Table 3). In the first serological study on a larger series of patients, Kaldor and Speed found evidence 
for a recent infection in 21 (38%) of 56 patients with GBS, but in none of the controls (100). Winer and 
colleagues found that 14 (14%) of 99 patients with GBS had recent C. jejuni infection, compared to 
only 2% of controls (53). Gruenewald and colleagues found that 3 (18%) of 17 patients with GBS in an 
uncontrolled population had elevated titers in two or more immunoglobulin classes (99). Kuroki et al. 
found that 36% of the patients were seropositive for Campylobacter in Japan (101).  
In a large, blinded, case-control study demonstrate that 36% of the GBS patients were seropositive for 
Campylobacter (104). Rees et al. subsequently made a prospective case-control study, and found the 
evidence of recent C. jejuni infection in 26% of the patients with GBS, compared with 2% of the 
household controls, and 1% of the age-matched hospital controls (71). In a large comparative and 
prospective study in the Netherlands, C. jejuni infection was found to be predominant (32%) 
antecedent event in GBS patient. In Northern China, C. jejuni infections are more frequent (66%) in 
patients with AMAN than AIDP (47). C. jejuni are strongly associated with the axonal variants of GBS, 
and some studies concluded that this type of infection is exclusively found in patients with axonal 
forms of GBS (120). Geographical differences in the incidence of C. jejuni infections may therefore 
also influence the predominant clinical and electrophysiological phenotype. Whether this exclusive 
association between C. jejuni and axonal variants is also present in other geographical areas remains 
to be determined. Preceding infections with C. jejuni are also the predominant type of preceding 
infections in patients with MFS (121). 
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Table 3: Campylobacter jejuni infections in patients with Guillain-Barré syndromea  
Reference Frequencyb Axonald Clinical association Poor outcomee 
 
Case reports 
    
Rhodes,  (1982) (118) 1c,f + pure motor + 
Molnar,  (1982) (122) 1c + NT + 
Constant, (1983) (123) 1c NT MFS - 
Pryor,  (1984) (124) 1c - pure motor - 
Wroe, (1985) (125) 1c - MFS - 
De Bont,  (1986) (126) 1c,f + severe weakness - 
Kohler, (1987) (127) 1c NT NT + 
Sovilla, (1988) (128) 3c,f NT - + 
Ropper, (1988) (102) 1c + severe pure motor + 
Yuki, (1990) (129) 2c + severe pure motor + 
Kuroki,  (1991) (101) 7c - - - 
Yuki,  (1991) (130) 6c + pure motor NT 
Duret,  (1991) (131) 1c + pure motor - 
Yuki,  (1992) (132) 13c,f NT NT NT 
Fujimoto,  (1992) (133) 4c NT NT NT 
Frequency studies     
Kaldor,  (1984) (100) 21/56 (38%)f NT severe weakness - 
Speed,  (1987) (103) 22/45 (49%)f NT NT NT 
Winer,  (1988a) (53) 14/99 (14%)f NT NT - 
Walsh, (1991) (134) 14/94 (15%)f + NT NT 
Gruenewald,  (1991) (99) 3/17 (18%)f,c NT NT NT 
Boucquey, (1991) (135) 6/42 (14%)f NT - - 
Nobile-Orazio,  (1992) (136) 3/16 (19%)f NT NT NT 
Gregson,  (1993) (137) 15/42 (36%)f NT   
Kuroki,  (1993) (138) 14/46 (30%)f NT NT NT 
Enders,  (1993) (139) 15/38 (39%)f No NT NT 
Vriesendorp,  (1993) (140) 10/58 (17%)f + Severe weakness NT 
Mishu, (1993) (104) 43/118 (36%)f NT NT NT 
Von Wulffen, (1994) (141) 11/42 (26%)f NT NT NT 
Rees,  (1995) (71) 25/96 (26%)c,s + pure motor + 
Ho, et al. (1995) (47) 25/38 (66%)f    
Jacobs,  (1996) (142) 46/154 (32%)f NT severe, pure motor + after PE 
Hadden, (2001) (143) 
Takahashi,  (2005) (144) 
53/229 (23%)f 
113/1049 (11%)c 
+ + + 
Sivandon, (2005) (145) 58/264 (22%)f - severe weakness - 
Sinha,  (2006) (105) 19/80 (5%)f + + - 
Nachamkin,  (2007) (106)) 32/78 (41%)f - NT NT 
Barzegar,  (2008) (146) 23/48 (48%)f + pure motor + 
 
aNT, not tested; +, present; -, absent; MFS, Miller Fisher syndrome; PE, plasma exchange; IVIg, intravenous immunoglobulins. 
bNumber of patients in case-reports, or number of C. jejuni infected patients per number of tested patients in frequency studies. 
cDetermined by stool culture 
dAssociation with severe axonal degeneration 
eDetermined at least three months after diagnosis of GBS 
 
fDetermined by serology 
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a Campylobacter infection. Therefore, studies based on stool culture alone will underestimate the 
frequency of previous C. jejuni infections in GBS. However, recent studies report that Campylobacter 
serology is highly sensitive and specific in GBS patients (30). In Northern China, C. jejuni infections 
occur in up to 66% of the GBS patients, depending on the serological assays and criteria for  
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Anti-ganglioside antibodies  
The recent literature about GBS and related disorders has been dominated by the discovery of 
antibodies to a wide variety of gangliosides. Gangliosides were first identified as peripheral nerve 
targets for antibodies in patients with paraproteinaemic neuropathy (147, 148). Research has been 
driven by the hypothesis that the different syndromes underlying GBS could be explained by the 
different patterns of nerve damage caused by antibodies directed against different glycoconjugates 
shared by infective organisms and the nervous system. Gangliosides are complex glycosphingolipids 
containing sialic acid (149). Different gangliosides are distinguished by both number and position of 
sialyl residues attached to a common tetraose backbone (Fig. 4). They are widely distributed in the 
membranes of many cells and are concentrated in neuronal membranes but occur in low 
concentrations in glia and myelin. They have multiple functions controlling cell interactions, receptor 
function and growth (150). Within the nervous system there is marked regional variation in relative 
abundance of the different molecular species. Behind the search for antibodies that define different 
clinical syndromes lies the hypothesis that these syndromes are caused by the occurrence of 
antibodies to different gangliosides which match those regions of the nervous system showing clinical 
involvement (151).  
In 1988, IIyas et al. first reported the presence of antibodies against gangliosdies in the serum 
from GBS patients (152). Since then, in about half of patients with GBS, serum antibodies to various 
gangliosides can be demonstrated in the acute stage of disease (153-155). Antibodies to more than 
20 different gangliosides have been identified in various frequencies in serum from GBS patients. The 
most frequent antibodies in GBS are directed to the gangliosides LM1, GM1, GM1b, GM2, GD1a, 
GalNAc-GD1a, GD1b, GD2, GD3, GT1a, and GQ1b  (154, 155). These antibodies specifically 
recognize parts of the oligosaccharide moieties and may bind to various gangliosides with the similar 
carbohydrate structures. Other antibodies might bind to mixtures or complexes of different 
gangliosides instead of individual gangliosides (156-159). 
The first anti-ganglioside antibodies in GBS described the presence of anti-GM1 antibodies 
(152). Antibodies against the GM1 have been demonstrated in various frequencies ranging from 9 to 
78%. The presence of serum anti-GM1 antibodies was found to be associated with a more severe, 
pure motor variant of GBS, with more extensive axonal degeneration, and poor recovery (129, 160-
163). In most studies, C. jeuni infections have been linked to anti-GM1 reactivity (41, 142), although 
this is not absolute. Anti-ganglioside antibodies in C. jejuni infected GBS patients are not exclusively 
directed against GM1. Several groups have documented the presence of antibody reactivity against 
GM1-like structures such as GalNAc-GD1a and GM1b (164, 165). Furthermore, C. jejuni-infected GBS 
patients have antibodies against a variety of glycolipids and this could explain the lack of an absolute 
correlation between anti-GM1 antibodies and C. jejuni infection (166). In Chinese and Japanese GBS 
patients there is a correlation between anti-GD1a antibodies and C. jejuni infection but this was not 
found in studies from Europe and Northern America (93, 132, 167). The presence of anti-GQ1b 
antibodies is highly associated with MFS variant of GBS (168-171). Antibodies to this ganglioside are 
present in more than 90% of patients and are absent in other forms of inflammatory neuropathy except 
for an overlap syndrome in which GBS is associated with ophthalmoplegia (41). Most anti-GQ1b 
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positive patients with GBS and MFS have additional antibody activity against GT1a, while half of the 
patients have additional antibody activity against GD1b and GD3 (131, 159, 172).  
 
Molecular mimicry between C. jejuni LOS and gangliosides 
The original concept of molecular mimicry was based on the structural resemblancees 
between component of a micro-organism and a host (173). Later this term was also used for the idea 
that infections because of structural resemblance might result in a cross-reactive antibody or T cells 
response leading to damage of tissue of the host and causing an autoimmune disease (174). 
 
Figure 4. List and schematic representation of ganglioside molecular structures. ⃞ galactose, ▼ sialic acid, ⃝ 
glucose,        N-acetyl- galactosamine, CER ceramide. 
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The role of molecular mimicry between microbial and autologous antigens in producing a 
cross-reactive immune response can be established on different level: 1) homology in biochemical 
structure or linear amino acid sequence, 2) cross-reactivity of antibodies with both structures, 3) 
induction of cross-reactive antibodies by immunization with the microbial antigen, and 4) induction of 
cross-reactive antibodies which induce dysfunction or tissue damage. Molecular mimicry between 
microbial antigens and host tissue is a popular and attractive hypothetical mechanism for the 
triggering of autoimmune disease by preceding infections (175). According to the mimicry hypothesis, 
autoantibodies and/or autoreactive T cells that are induced by the infection are initially directed against 
microbial antigens. Because of the structural resemblance between microbial and particular  
host antigens, the antibodies and T cells not only destroy the invading pathogen but also attack host 
tissue. In addition, infections can also lead to activation of auto-reactive immune cells by antigenic 
non-specific mechanisms, called bystander activation (176). GBS is an autoimmune peripheral 
neuropathy which has been largely overseen. The crucial contribution of molecular mimicry at the B-
cell level in the immunopathogenesis of GBS is overwhelming. GBS is an excellent paradigm for how 
post-infectious immune-mediated disease in humans can be triggered by molecular mimicry (175). 
 
Molecular mimicry between C. jejuni LOS and gangliosides 
 C. jejuni strains isolated from several GBS and MFS patients showed a similar carbohydrate 
moiety in LOS and peripheral nerve gangliosides confirmed by mass spectrometry (Fig. 5) (163, 177, 
178).   
 
 
Figure 5. Cross-reactive antibodies to the peripheral nerve gangliosides. Adopted from Jacobs et al. 
(49). 
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Certain C. jejuni serotypes possess sialylated LOS structures, confined to the outer core of the 
LOS molecules, which mimic a wide range of peripheral nerve gangliosides including GM1, GA1 
(asialo-GM1), GM1b, GalNAc-GM1b, GM2, GD1a, GalNAc-GD1a, GT1a, GQ1b and GD3 (163-165, 
177-184). The molecular mimicry in C. jejuni has been demonstrated by an immune response in 
susceptible hosts that results in demyelination or axonal damage of peripheral nerves, partly by the 
anti-ganglioside antibody response (91). A very recent study reports that GBS- and MFS-related C. 
jejuni strains expressed a ganglioside-like LOS, with up to five identical glycan structures (185). 
Most of the strains expressed a heterogeneous LOS, in which the combination of GM1- and 
GD1a-like structures was most frequently found. The ganglioside mimicry in C. jejuni determines the 
specificity of the anti-ganglioside antibodies and the associated variant of GBS. C. jejuni isolates from 
patients with pure motor or axonal GBS frequently express a GM1-like and GD1a-like LOS, whereas 
those isolated from patients with ophthalmoplegia or MFS usually express a GD3-like, GT1a-like, or 
GD1c-like LOS (121, 159, 172). The LOS of some strains contained no sialic acids and showed no 
mimicry with gangliosides. Some authors report that the ganglioside-like structures in LOS are related 
to certain HS serotype, which would explain the predominance of certain HS serotypes in GBS (132, 
186). Interestingly, LOS from serostrain HS:3 is not sialylated, and HS serotype is not associated with 
GBS (187). Mass spectrometry analysis indicate that C. jejuni strains isolated from GBS and MFS 
patients more frequently have a ganglioside-like LOS than strains isolated from enteritis controls. 
However, the association is not absolute. GBS-related strains may not have ganglioside mimicry (188) 
whereas some strains from enteritis controls do (188). In addition, co-infection with multiple C. jejuni 
strains also occurs in GBS patients. The isolation of only one strain may easily lead to a wrong 
conclusion with respect to absence or presence of molecular mimicry involved in the pathogenesis of 
GBS (189).   
Though the biochemical analysis of C. jejuni LOS clearly identified ganglioside-like structures, 
it remains to be clarified whether these structures can induce anti-ganglioside antibodies with the 
specificity found in patients with GBS and MFS. The first study reporting that cross-reactivity of serum 
anti-GM1 antibodies from GBS patients with the LOS from the autologous C. jejuni isolates was 
published by Yuki et al. (132). Subsequently, serological studies have clearly demonstrated that anti-
ganglioside antibodies in serum from patients with GBS and MFS cross-react with the LOS from 
autologous C. jejuni isolate (190-192). Serum antibodies to GM1 and GD1a are specifically adsorbed 
by C. jejuni strains expressing LOS with GM1 and GD1a mimics. Conversely, antibodies to GQ1b are 
adsorbed by strains expressing a GD3 or GT1a mimics, and antibodies to ganglioside complexes 
cross-react with C. jejuni LOS (159).  
 
Molecular epidemiology of Campylobacter 
In order to better understand the epidemiology of Campylobacter infections in both humans 
and poultry, reproducible typing methods which can distinguish individual strains are necessary. 
Several phenotypic methods for typing C. jejuni and C. coli have been described; these methods 
include serotyping, phage typing, and biotyping (193-195). A major drawback of this combination of 
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methods is that it is time-consuming and costly. Some other disadvantages of phenotypic methods are 
that they have restricted differentiation powers and a high proportion of strains are non-typeable. 
Since 1980, molecular typing methods have emerged to determine the genetic polymorphisms and 
possible clonal relationship of Campylobacter spp. At present, comparative genotyping methods such 
as Pulsed-field gel electrophoresis (PFGE), Multilocus sequence typing (MLST), and amplified 
fragment length polymorphism (AFLP), are currently available to study the population structure of 
Campylobacter (196).  
 
PFGE 
PFGE is widely regarded as among the most discriminatory typing methods generally 
available for bacteria. It involves the digestion of intact genomic DNA with rare-cutting restriction 
enzymes that cut the DNA into relatively few fragments, in contrast with its predecessor, restriction 
enzyme analysis (197). Widespread, worldwide adoption of the PulseNet protocol developed at the 
CDC (198) has significantly improved the compatibility of PFGE. In the case of C. jejuni, most 
researchers have used the enzyme SmaI, which typically generates 4 to 10 fragments (199, 200). 
Comparisons between large numbers of isolates have been facilitated by the widespread availability of 
software such as BioNumerics (Applied Maths, Ghent, Belgium), which are able to electronically 
compare electrophoresis patterns generated. Though, this technique has high discriminatory power for 
subtyping Campylobacter (201); however, the stability of PFGE may be insufficient for reliable 
application in long-term epidemiological studies (202).  
 
AFLP 
AFLP analysis is based on selective amplification of restriction fragments of chromosomal 
DNA and has been widely used in a variety of bacterial genera, including Campylobacter  both for 
identification and typing purpose (203). This is a reproducible and high discriminatory a whole genome 
typing method, particularly well suited for computer-assisted data analysis. AFLP schemes were 
initially developed for typing purpose, incorporating only C. jejuni and C. coli (203, 204). Subsequently, 
these observations were extended to other Campylobacter species (205, 206) and demonstrated that 
numerical analysis of AFLP profiles is well suited for identification at the species, subspecies, and 
strain levels. Numerous subsequent studies have applied AFLP to explore intraspecies diversity (207) 
and epidemiological relationships (208, 209-212) of Campylobacter strains. 
 
MLST 
Since the first description of MLST in 1998 (213), major progress has been made in 
understanding the population biology of C. jejuni. Now, this technique has emerged as the state-of-
the-art method for the resolution of bacterial population genetics (214) and is recognized as the gold 
standard typing method for the phylogenetic study of Campylobacter genus (215, 216). MLST involves 
the sequencing of genes, typically those with housekeeping functions, whereby each sequence variant 
represent a distinct allelic type. Combining the analysis of seven genes alongside appropriate 
computational analysis is a powerful tool for the study of population biology, epidemiology, and 
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evolution of microbes that has expanded tremendously (217). The level of genetic divergence among 
Campylobacter housekeeping genes is as high 80.9% (216). C. jejuni is highly diverse with a total of 
2,243 distinct STs from 3,704 isolates deposited in the pubMLST database (http:// 
pubmlst.org/campylobactecr) (218).  
Sequence typing data provide the resolution and reproducibility necessary to investigate the 
diversity of Campylobacter isolates obtained from farms and environment (219-221). These studies 
reported that genotypes from human disease are recovered from farm animals (219, 221), while the 
genotypes from environmental sources seem to be distinct (220). Certain clonal complexes are 
associated with particular food animal sources, with the ST-61 complex especially associated with 
cattle (215, 220) and the ST-403 with pigs, and dogs (221-223). Large-scales studies of isolates from 
a wide variety of sources provide the prospect that in the near future, it will be possible to trace the 
movement of Campylobacter genotypes through the food chain (224) and attribute cases of human 
infection to particular host sources with reasonable precision (225). MLST has also been used to 
examine antibiotic-resistant isolates obtained from poultry (226, 227).   
 
C. jejuni HS-serotype associated with GBS 
Earlier studies demonstrated that certain Penner HS-serotypes are over-represented among 
neuropathogenic GBS- and MFS-associated strains in some parts of the world. Studies form different 
geographical locations such as Japan, South Africa, China, and Mexico revealed that most of the 
clinical isolates belonged to a restricted set of serotypes including HS:19 and HS:41 (132, 138, 228-
231).  C. jejuni HS:19 and HS:41 are clonal which suggests that these serotypes may have unique 
and specific virulence properties that trigger GBS (232). Unfortunately, these data were in a sense 
ambiguous. Subsequent research revealed that the neuropathogenic properties are not  restricted to 
specific HS serotypes as other serotypes (HS:1, HS:2, HS:4, HS:4 complex, HS:5, HS:10, HS:16, 
HS:23, HS:37, HS:44, and HS:64) commonly isolated from enteritis patients are also found in patients 
with GBS (71, 138, 177, 190, 233-237). This observation suggested that the ability of strains to cause 
neuropathological syndrome was more widely disseminated than previously anticipated on the basis of 
the clonality hypothesis. As GBS- and MFS- associated strains were derived from a variety of different 
genetic backgrounds, focused experimental searches for non-serotype dependent factors important in 
the induction of GBS/MFS were facilitated (49). 
 
Comparative genomics of GBS-associated C. jejuni  
Many researchers have studied collections of GBS- and enteritis- associated strains in search 
of GBS-specific microbial features. MLST typing and flagellin gene sequencing confirmed the 
polyclonality among GBS- and MFS-related Campylobacter strains (214). AFLP did not contribute 
substantially for getting the GBS-specific markers. Although AFLP has been used for identifying clonal 
expansion among clinical, veterinary, and environmental isolates, no specific markers could be 
identified on the basis of the DNA fingerprints developed for the GBS/MFS isolates (236, 238). 
Furthermore, no molecular markers specific to GBS were detected after analyzing a highly clonal 
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methods is that it is time-consuming and costly. Some other disadvantages of phenotypic methods are 
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standard typing method for the phylogenetic study of Campylobacter genus (215, 216). MLST involves 
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HS:41 strains by using a high-throughput AFLP (188). The use of whole genome DNA arrays did not 
reveal any GBS-specific markers when comparing gene content for strains derived from non-
complicated enteritis cases versus GBS (239). Very recently, Taboda et al. determined the gene 
conservation profile of 1,712 virulence and other genes in GBS-associated and controls strains (240). 
However, it has been demonstrated that genes involved in the sialylation of LOS are significantly 
associated with GBS-associated strains (240).  
 
C. jejuni LOS and gene specific variation   
Molecular mimicry between Campylobacter LOS and gangliosides in human nerves is the 
causative mechanism for the development of GBS (178, 241). The presence of LOS-associated genes 
that were identified through genome sequencing revealed that several genes were selectively present 
or absent, depending on the composition of LOS gene clusters (242). Comparisons of the various C. 
jejuni LOS biosynthesis loci indicate that a variety of genetic mechanisms is responsible for the 
synthesis of different structures (243). Particularly, the most obvious genetic differences are 
differences in gene content and organization (Fig. 6). The sequence of LOS biosynthesis genes 
between Cj1133 (waaC) and Cj1148 (waaF) are available for C. jejuni strains (185, 242, 243, 244).  A 
total of 19 LOS classes (A to S) were identified on the basis of the gene content and organization 
showing extensive variability in length (244). Some genes are unique to one class, whereas some 
other genes are present in more than one class but not in all. The significant interest in the LOS 
biosynthesis gene cluster stems from the potential involvement of the ganglioside-like structure of C. 
jejuni LOSs inducing GBS and MFS (245, 246). Comparison of various C. jejuni strains demonstrated 
that a group of five LOS biosynthesis locus classes (A, B, C, M, and R) (Fig. 6) contain the genes that 
are necessary for the biosynthesis of ganglioside mimics, in particular genes encoding a 
sialyltransferase (cst-II), a sialic acid synthase (neuB), an N-acetylglucosamine-6-phosphatase 2-
epimerase (neuC), and a CMP-Neu5Ac synthetase (neuA) (242, 243).  
The presence of certain genes could be associated with a specific clinical symptom and GBS 
variants. The presence of cst-II gene and the presence of GQ1b epitopes on the Campylobacter outer 
LOS surface were intimately linked to the development of MFS (248). Interestingly, specific point 
mutation with specific genes could also be associated with LOS variation and hence different clinical 
presentation of the diseases induced (172). The LOS locus classification and some highly specific 
amino acid changes in, such as the cstII gene ultimately determine the LOS biosynthesis capacity. 
The sialyltransferase gene cstII has an Asn/Thr polymorphism at codon 51, which determines 
substrate specificity; cstII (Thr51) has only α-2,3-sialyltransferase activity and is termed 
monofunctional, whereas cstII (Asn51) has both α-2,3-and a-2,8-sialyltransferase activities is termed 
bifunctional  (249). cstII (Thr51) is closely associated with GBS and anti-GM1 and anti-GD1a 
autoantibodies, and cstII (Asn51) is closely associated with MFS and anti-GQ1b autoantibodies (121, 
232, 250).  
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Figure 6. C. jejuni LOS classes that posses a sialyltransferase gene. Classes A, B, C, M and R. 
Adopted from Gilbert et al. (247). 
 
Scope and outline of thesis 
 
The aim of the thesis was to define the clinical epidemiology, preceding infections and 
antibody response in GBS in Bangladesh. Most knowledge of GBS is currently based on studies in 
patients from developed countries and very little is known about patients form developing countries. 
We speculate these disease characteristics may show geographical differences because the type of 
preceding infections in developing countries may differ from those in developed countries. In 
developing countries such as Bangladesh, compared to developed countries, there is a much more 
frequent and repeated exposure to Campylobacter occurring already from early childhood. Because of 
this high exposure in developing countries, Campylobacter may more frequently trigger the onset of 
GBS and in fact may increase the incidence of GBS. These Campylobacter from Bangladesh may 
also differ genetically or biochemically from isolates from other areas. Considering the crucial role of 
antecedent infections play in inducing cross-reactive anti-ganglioside antibodies, the pathogenesis 
and neurological deficits and outcome of GBS may differ depending on the geographical region. More 
specifically, the studies described in this thesis have focused on GBS in Bangladesh, were we have 
defined the: 
- epidemiology in children 
- clinical presentation, course and outcome 
- spectrum of antecedent infections and anti-ganglioside antibodies  
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- molecular mimicry of C. jejuni and gangliosides 
- fine specificity of cross-reactive anti-ganglioside antibodies 
- comparative genomics of C. jejuni strains from GBS and enteritis patients, and poultry 
 
In Chapter 2 we will describe the crude incidence rates of GBS in Bangladesh among children <15 
years of age. A detailed clinical, epidemiological, and neurophysiological data will be described in 
GBS patients.  We will determine the frequency of C. jejuni infection in GBS patients compared to 
family controls and age- and sex-matched controls with other neurological diseases. Also, serum anti-
ganglioside antibodies will be determined in patients compared to two controls groups. 
 
 In Chapter 3 we will determine frequency of antecedent infections in GBS patients including those 
caused by Campylobacter, cytomegalovirus, Epstein-Barr virus, Mycoplasma pneumoniae, and 
enterovirus.  
 
Chapter 4 will describe the cross-reactivity of anti-ganglioside antibodies with C. jejuni isolates from 
patients with GBS. The cross-reactivity of anti-ganglioside antibodies from GBS and GBS/MFS 
patients will be determined by inhibition ELISA. In addition, monoclonal mouse antibodies against 
different gangliosides will be used to determine if ganglioside-mimics were present in the LOS. We will 
also determine the LOS outer core structures of C. jejuni strains associated with GBS/MFS by 
capillary electrophoresis coupled with electrospray ionization mass spectrometry. 
 
Chapter 5 will describes new C. jejuni serotypes and new sequence types overrepresented among 
isolates from GBS patients in Bangladesh. We will investigate the genetic heterogeneity of C. jejuni 
strains isolated from GBS and enteritis patients. In this comparative genomic analysis, multi-locus 
sequence typing (MLST), amplified fragment length polymorphism (AFLP), LOS class PCR typing, and 
pulsed-field gel electrophoresis (PFGE) will be used. In addition, we will study the diversity and clonal 
relationships among C. jejuni from humans and poultry in Bangladesh. 
 
Chapter 6 will discuss the importance of the results described in chapters 2-5. The observations from 
the studies in chapters 2-5 will be summarized and discussed in relation to current literature, and 
directions for future research will be given.   
 
General introduction   
 
 
REFERENCES 
 
1. Escherich Th. Beiträge zur kenntniss der darmbacterien II. Vibrio felinum. Munch. Med. Wochschr  
1886;33:756-763. 
2. King EO. The laboratory recognition of Vibrio fetus and closely related Vibrio species isolated from 
cases of human vibriosis. Ann N Y Acad Sci 1962;98:700-711. 
3. Dekeyser P, Gossuin-Detrain M, Butzler JP, Sternon J. Acute enteritis due to related vibrio: first 
positive stool cultures. J Infect Dis 1972;125:390-392. 
4. Skirrow MB. Campylobacter enteritis: a "new" disease. Br Med J 1977;2:9-11. 
5. Allos BM. Campylobacter jejuni infections: update on emerging issues and trends. Clin Infect Dis 
2001;32:1201–1206. 
6. Butzler JP. Campylobacter from obscurity to celebrity. Clin Microbiol Infect 2004;10:868–876. 
7. Anonymous. The community summary report on trends and sources of zoonoses, zoonotic agents, 
antimicrobial resistance and foodborne outbreaks in the European Union in 2006. EFSA J 
2007;130:118–145. 
8. Humphrey T, O'Brien S, Madsen M. Campylobacters as zoonotic pathogens: a food production 
perspective. Int J Food Microbiol 2007;15:237-257. 
9. Coker AO, Isokpehi RD, Thomas BN, Amisu KO, Obi CL. Human Campylobacteriosis in developing 
countries. Emerg Infect Dis 2002;8:237-244. 
10. Albert MJ, Faruque AS, Faruque SM, Sack RB, Mahalanabis D. Case-control study of 
enteropathogens associated with childhood diarrhea in Dhaka, Bangladesh. J Clin Microbiol 
1999;37:3458-3464. 
11. Gauci A and A. Ammon. The first European Communicable disease Epidemiological Report. 
European Centre of Disease Prevention and Control, Stockholm 2007 
12. Olson CK, Ethelberg S, van Pelt W, Tauxe RV. Epidemiology of Campylobacter jejuni infections in 
industrialized nations. In Campylobacter, I. Nachamkin, C. M. Szymanski, and M. J. Blaser, editors. 
Washington, D.C.: ASM Press 2008:163-189. 
13. Friedman CR, Hoekstra RM, Samuel M, Marcus R, Bender J, Shiferaw B, Reddy S, Ahuja SD, 
Helfrick DL, Hardnett F, Carter M, Anderson B, Tauxe RV; Emerging Infections Program FoodNet 
Working Group. Risk factors for sporadic Campylobacter infection in the United States: A case-
control study in FoodNet sites. Clin Infect Dis 2004;38:S285-296. 
14. Stafford RJ, Schluter P, Kirk M, Wilson A, Unicomb L, Ashbolt R, Gregory J; OzFoodNet Working 
Group. A multi-centre prospective case-control study of Campylobacter infection in persons aged 5 
years and older in Australia. Epidemiol Infect 2007;135:978-988. 
15. Endtz HP, Ruijs GJ, Zwinderman AH, van der Reijden T, Biever M, Mouton RP. Comparison of six 
media, including a semisolid agar, for the isolation of various Campylobacter species from stool 
specimens. J Clin Microbiol 1991;29:1007-1010. 
16. Gun-Munro J, Rennie RP, Thornley JH, Richardson HL, Hodge D, Lynch J. Laboratory and clinical 
evaluation of isolation media for Campylobacter jejuni. J Clin Microbiol 1987;25:2274-2277. 
17. Engberg J, On SL, Harrington CS, Gerner-Smidt P. Prevalence of Campylobacter, Arcobacter, 
Helicobacter, and Sutterella spp. in human fecal samples as estimated by a reevaluation of isolation 
methods for Campylobacters. J Clin Microbiol 2000;38:286-291. 
18. Nachamkin I. Microbiologic approaches for studying Campylobacter species in patients with 
Guillain-Barré syndrome. J Infect Dis 1997;176:S106-114. 
19. Dediste A, Vandenberg O, Vlaes L, Ebraert A, Douat N, Bahwere P, Butzler JP. Evaluation of the 
ProSpecT Microplate Assay for detection of Campylobacter: a routine laboratory perspective. Clin 
Microbiol Infect 2003;9:1085-1090. 
20. Tolcin R, LaSalvia MM, Kirkley BA, Vetter EA, Cockerill FR 3rd, Procop GW. Evaluation of the 
Alexon-trend ProSpecT Campylobacter microplate assay. J Clin Microbiol 2000;38:3853-3855. 
21. Endtz HP, Ang CW, van den Braak N, Luijendijk A, Jacobs BC, de Man P, van Duin JM, van Belkum 
A, Verbrugh HA. Evaluation of a new commercial immunoassay for rapid detection of 
Campylobacter jejuni in stool samples. Eur J Clin Microbiol Infect Dis 2000;19:794-797. 
Chapter 1
31 
- molecular mimicry of C. jejuni and gangliosides 
- fine specificity of cross-reactive anti-ganglioside antibodies 
- comparative genomics of C. jejuni strains from GBS and enteritis patients, and poultry 
 
In Chapter 2 we will describe the crude incidence rates of GBS in Bangladesh among children <15 
years of age. A detailed clinical, epidemiological, and neurophysiological data will be described in 
GBS patients.  We will determine the frequency of C. jejuni infection in GBS patients compared to 
family controls and age- and sex-matched controls with other neurological diseases. Also, serum anti-
ganglioside antibodies will be determined in patients compared to two controls groups. 
 
 In Chapter 3 we will determine frequency of antecedent infections in GBS patients including those 
caused by Campylobacter, cytomegalovirus, Epstein-Barr virus, Mycoplasma pneumoniae, and 
enterovirus.  
 
Chapter 4 will describe the cross-reactivity of anti-ganglioside antibodies with C. jejuni isolates from 
patients with GBS. The cross-reactivity of anti-ganglioside antibodies from GBS and GBS/MFS 
patients will be determined by inhibition ELISA. In addition, monoclonal mouse antibodies against 
different gangliosides will be used to determine if ganglioside-mimics were present in the LOS. We will 
also determine the LOS outer core structures of C. jejuni strains associated with GBS/MFS by 
capillary electrophoresis coupled with electrospray ionization mass spectrometry. 
 
Chapter 5 will describes new C. jejuni serotypes and new sequence types overrepresented among 
isolates from GBS patients in Bangladesh. We will investigate the genetic heterogeneity of C. jejuni 
strains isolated from GBS and enteritis patients. In this comparative genomic analysis, multi-locus 
sequence typing (MLST), amplified fragment length polymorphism (AFLP), LOS class PCR typing, and 
pulsed-field gel electrophoresis (PFGE) will be used. In addition, we will study the diversity and clonal 
relationships among C. jejuni from humans and poultry in Bangladesh. 
 
Chapter 6 will discuss the importance of the results described in chapters 2-5. The observations from 
the studies in chapters 2-5 will be summarized and discussed in relation to current literature, and 
directions for future research will be given.   
 
General introduction   
 
 
REFERENCES 
 
1. Escherich Th. Beiträge zur kenntniss der darmbacterien II. Vibrio felinum. Munch. Med. Wochschr  
1886;33:756-763. 
2. King EO. The laboratory recognition of Vibrio fetus and closely related Vibrio species isolated from 
cases of human vibriosis. Ann N Y Acad Sci 1962;98:700-711. 
3. Dekeyser P, Gossuin-Detrain M, Butzler JP, Sternon J. Acute enteritis due to related vibrio: first 
positive stool cultures. J Infect Dis 1972;125:390-392. 
4. Skirrow MB. Campylobacter enteritis: a "new" disease. Br Med J 1977;2:9-11. 
5. Allos BM. Campylobacter jejuni infections: update on emerging issues and trends. Clin Infect Dis 
2001;32:1201–1206. 
6. Butzler JP. Campylobacter from obscurity to celebrity. Clin Microbiol Infect 2004;10:868–876. 
7. Anonymous. The community summary report on trends and sources of zoonoses, zoonotic agents, 
antimicrobial resistance and foodborne outbreaks in the European Union in 2006. EFSA J 
2007;130:118–145. 
8. Humphrey T, O'Brien S, Madsen M. Campylobacters as zoonotic pathogens: a food production 
perspective. Int J Food Microbiol 2007;15:237-257. 
9. Coker AO, Isokpehi RD, Thomas BN, Amisu KO, Obi CL. Human Campylobacteriosis in developing 
countries. Emerg Infect Dis 2002;8:237-244. 
10. Albert MJ, Faruque AS, Faruque SM, Sack RB, Mahalanabis D. Case-control study of 
enteropathogens associated with childhood diarrhea in Dhaka, Bangladesh. J Clin Microbiol 
1999;37:3458-3464. 
11. Gauci A and A. Ammon. The first European Communicable disease Epidemiological Report. 
European Centre of Disease Prevention and Control, Stockholm 2007 
12. Olson CK, Ethelberg S, van Pelt W, Tauxe RV. Epidemiology of Campylobacter jejuni infections in 
industrialized nations. In Campylobacter, I. Nachamkin, C. M. Szymanski, and M. J. Blaser, editors. 
Washington, D.C.: ASM Press 2008:163-189. 
13. Friedman CR, Hoekstra RM, Samuel M, Marcus R, Bender J, Shiferaw B, Reddy S, Ahuja SD, 
Helfrick DL, Hardnett F, Carter M, Anderson B, Tauxe RV; Emerging Infections Program FoodNet 
Working Group. Risk factors for sporadic Campylobacter infection in the United States: A case-
control study in FoodNet sites. Clin Infect Dis 2004;38:S285-296. 
14. Stafford RJ, Schluter P, Kirk M, Wilson A, Unicomb L, Ashbolt R, Gregory J; OzFoodNet Working 
Group. A multi-centre prospective case-control study of Campylobacter infection in persons aged 5 
years and older in Australia. Epidemiol Infect 2007;135:978-988. 
15. Endtz HP, Ruijs GJ, Zwinderman AH, van der Reijden T, Biever M, Mouton RP. Comparison of six 
media, including a semisolid agar, for the isolation of various Campylobacter species from stool 
specimens. J Clin Microbiol 1991;29:1007-1010. 
16. Gun-Munro J, Rennie RP, Thornley JH, Richardson HL, Hodge D, Lynch J. Laboratory and clinical 
evaluation of isolation media for Campylobacter jejuni. J Clin Microbiol 1987;25:2274-2277. 
17. Engberg J, On SL, Harrington CS, Gerner-Smidt P. Prevalence of Campylobacter, Arcobacter, 
Helicobacter, and Sutterella spp. in human fecal samples as estimated by a reevaluation of isolation 
methods for Campylobacters. J Clin Microbiol 2000;38:286-291. 
18. Nachamkin I. Microbiologic approaches for studying Campylobacter species in patients with 
Guillain-Barré syndrome. J Infect Dis 1997;176:S106-114. 
19. Dediste A, Vandenberg O, Vlaes L, Ebraert A, Douat N, Bahwere P, Butzler JP. Evaluation of the 
ProSpecT Microplate Assay for detection of Campylobacter: a routine laboratory perspective. Clin 
Microbiol Infect 2003;9:1085-1090. 
20. Tolcin R, LaSalvia MM, Kirkley BA, Vetter EA, Cockerill FR 3rd, Procop GW. Evaluation of the 
Alexon-trend ProSpecT Campylobacter microplate assay. J Clin Microbiol 2000;38:3853-3855. 
21. Endtz HP, Ang CW, van den Braak N, Luijendijk A, Jacobs BC, de Man P, van Duin JM, van Belkum 
A, Verbrugh HA. Evaluation of a new commercial immunoassay for rapid detection of 
Campylobacter jejuni in stool samples. Eur J Clin Microbiol Infect Dis 2000;19:794-797. 
Chapter 1
32  
22. Tissari P, Rautelin H. Evaluation of an enzyme immunoassay-based stool antigen test to detect 
Campylobacter jejuni and Campylobacter coli. Diagn Microbiol Infect Dis 2007;58:171-175.  
23. Amar CF, East CL, Gray J, Iturriza-Gomara M, Maclure EA, McLauchlin J. Detection by PCR of 
eight groups of enteric pathogens in 4,627 faecal samples: re-examination of the English case-
control Infectious Intestinal Disease Study (1993-1996). Eur J Clin Microbiol Infect Dis 2007;26:311-
323. 
24. Best EL, Fox AJ, Owen RJ, Cheesbrough J, Bolton FJ. Specific detection of Campylobacter jejuni 
from faeces using single nucleotide polymorphisms. Epidemiol Infect 2007;135:839-846.  
25. Linton D, Lawson AJ, Owen RJ, Stanley J. PCR detection, identification to species level, and 
fingerprinting of Campylobacter jejuni and Campylobacter coli direct from diarrheic samples. J Clin 
Microbiol 1997;35:2568-2572. 
26. Black RE, Perlman D, Clements ML, Levine MM, Blaser MJ. Human volunteer studies with 
Campylobacter jejuni,. In I. Nachamkin, M. J. Blaser, and L. S. Tomkins (ed.). Campylobacter jejuni: 
Current status and Future Trends. American Society for Microbiology, Washington, DC 1992:207-
215. 
27. Taylor DN, Perlman DM, Echeverria PD, Lexomboon U, Blaser MJ. Campylobacter immunity and 
quantitative excretion rates in Thai children. J Infect Dis 1993;168:754-758. 
28. Blaser MJ, Duncan DJ. Human serum antibody response to Campylobacter jejuni infection as 
measured in an enzyme-linked immunosorbent assay. Infect Immun 1984;44:292-298. 
29. Herbrink P, van den Munckhof HA, Bumkens M, Lindeman J, van Dijk WC. Human serum antibody 
response in Campylobacter jejuni enteritis as measured by enzyme-linked immunosorbent assay. 
Eur J Clin Microbiol Infect Dis 1988;7:388-393. 
30. Ang CW, Krogfelt K, Herbrink P, Keijser J, van Pelt W, Dalby T, Kuijf M, Jacobs BC, Bergman MP, 
Schiellerup P, Visser CE. Validation of an ELISA for the diagnosis of recent Campylobacter 
infections in Guillain-Barré and reactive arthritis patients. Clin Microbiol Infect 2007;13:915-922.  
31. Taylor BV, Williamson J, Luck J, Coleman D, Jones D, McGregor A. Sensitivity and specificity of 
serology in determining recent acute Campylobacter infection. Intern Med J 2004;34:250-258. 
32. Blaser MJ and Engberg J. Clinical aspects of Campylobacter jejuni and Campylobacter coli 
infections. In Campylobacter, I. Nachamkin, C. M. Szymanski, and M. J. Blaser, editors. 
Washington, D.C.: ASM Press 2008:99-121. 
33. WHO. EPI Surveillance Bulletin. 2008. Vol. 11. no.6. Available at: 
(http://www.searo.who.int/vaccine).  
34. Hahn AF. Guillain-Barré syndrome. Lancet 1998;352:635–641. 
35. Hughes RA. The concept and classification of Guillain-Barré syndrome and related disorders. Rev 
Neurol (Paris) 1995;151:291-294. 
36. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré 
syndrome. Lancet Neurol 2008;7:939-950. 
37. Rasul CH, Das PL, Alam S, Ahmed S, Ahmed M. Clinical profile of acute flaccid paralysis. Med J 
Malaysia 2002;57:61-65.  
38. Landry JBO. Note sur la paralysis aigue. Gaz Hebd Med Chir 1959;6:472-488. 
39. Guillain G, Barré JA, Strohl A. Sur un syndrome de radiculo-névrite avec hyperalbuminose du 
liquide céphalo-rachidien sans réaction cellulaire: remarques sur les caractères cliniques et 
graphiques des réflexes tendineux. Bull Soc Méd Hôp Paris 1916;40:1462-1470. 
40. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barre syndrome. J Infect Dis 
1997;176:S92-98. 
41. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 2005;366:1653-1666. 
42. van Koningsveld R, van Doorn PA, Schmitz PI, Ang CW, van der Meche FG. Mild forms of Guillain-
Barré syndrome in an epidemiologic survey in The Netherlands. Neurology 2000;54:620–625. 
43. Alshekhlee A, Hussain Z, Sultan B, Katirji B. Immunotherapy for Guillain-Barré syndrome in the US 
hospitals. J Clin Neuromuscul Dis 2008;10:4-10. 
44. Bogliun G, Beghi E, Italian GBS Registry Study Group. Incidence and clinical features of acute 
inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. Acta Neurol Scand 2004;110:100-
106. 
General introduction   
 
 
45. Hauck LJ, Carpenter MG, Frank JS. Task-specific measures of balance efficacy, anxiety, and 
stability and their relationship to clinical balance performance. Gait Posture 2008;27:676-682.  
46. Lehmann HC, Köhne A, Meyer zu Hörste G, Kieseier BC. Incidence of Guillain-Barré syndrome in 
Germany. J Peripher Nerv Syst 2007;12:285. 
47. Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, Asbury AK, Blaser MJ, McKhann GM. 
Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-
glycolipid antibodies. Brain 1995;118:597-605. 
48. van Koningsveld R, Rico R, Gerstenbluth I, Schmitz PI, Ang CW, Merkies IS, Jacobs BC, Halabi Y, 
Endtz HP, van der Meché FG, van Doorn PA. Gastroenteritisassociated Guillain-Barré syndrome on 
the Caribbean island Curacao. Neurology 2001;56:1467–1472. 
49. Jacobs BC, van Belkum A, Endtz HP. Guillain-Barré syndrome and Campylobacter infection. In 
Campylobacter, I. Nachamkin, C.M. Szymanski, and M.J. Blaser, editors. Washington, D.C.: ASM 
Press 2008:245-261. 
50. Geleijns K, Brouwer BA, Jacobs BC, Houwing-Duistermaat JJ, van Duijn CM, van Doorn PA. The 
occurrence of Guillain-Barré syndrome within families. Neurology 2004;63:1747-1750. 
51. Ann Neurol. National Institute of Neurological and Communicative Disorders and Stroke ad hoc 
Committee (NINCDS). Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol 1978;3:565-
566. 
52. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. 
Ann Neurol 1990;27:S21-24. 
53. Winer JB, Hughes RA, Osmond C. A prospective study of acute idiopathic neuropathy. I. Clinical 
features and their prognostic value. J Neurol Neurosurg Psychiatry 1988a;51:605–612. 
54. Winer JB, Hughes RA. Identification of patients at risk of arrhythmia in the Guillain-Barré syndrome. 
Q J Med 1988b;68:735–739. 
55. Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: a review. Muscle Nerve 
1994;17:1145-1155. 
56. van der Meché FG, van Doorn PA. Guillain-Barré syndrome and chronic inflammatory demyelinating 
polyneuropathy: immune mechanisms and update on current therapies. Ann Neurol 1995;37:S14-
31. 
57. van Koningsveld R, Schmitz PI, Ang CW, Groen J, Osterhaus AD, van der Meché FG, van Doorn 
PA. Infections and course of disease in mild forms of Guillain-Barré syndrome. Neurology 
2002;58:610-614. 
58. Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, 
Sladky JT, Stevens JC. Quality Standards Subcommittee of the American Academy of Neurology. 
Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards 
Subcommittee of the American Academy of Neurology.  Neurology 2003;61:736-740. 
59. Hadden RD, Hughes RA. Treatment of immune-mediated inflammatory neuropathies. Curr Opin 
Neurol 1999;12:573-579. 
60. Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992;326:1130-1136. 
61. McKhann GM, Griffin JW, Cornblath DR, Quaskey SA, Mellits ED. Role of therapeutic 
plasmapheresis in the acute Guillain-Barré syndrome. J Neuroimmunol 1988;20:297-300. 
62. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and 
plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 
1992;326:1123-1129. 
63. Forsberg A, Press R, Einarsson U, de Pedro-Cuesta J, Widen HL. Impairment in Guillain-Barré 
syndrome during the first 2 years after onset: a prospective study. J Neurol Sci 2004;227:131–138. 
64. Merkies IS, Schmitz PI, Samijn JP, van der Meché FG, van Doorn PA. Fatigue in immune-mediated 
polyneuropathies.European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. 
Neurology 1999;53:1648–1654. 
65. Ropper AH. Ischemic compression paresthesias in Guillain-Barré syndrome. Arch Neurol 
1991;48:1261-1262. 
66. van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical 
prognostic scoring system for Guillain-Barre syndrome. Lancet Neurol 2007;6:589-594. 
Chapter 1
33 
22. Tissari P, Rautelin H. Evaluation of an enzyme immunoassay-based stool antigen test to detect 
Campylobacter jejuni and Campylobacter coli. Diagn Microbiol Infect Dis 2007;58:171-175.  
23. Amar CF, East CL, Gray J, Iturriza-Gomara M, Maclure EA, McLauchlin J. Detection by PCR of 
eight groups of enteric pathogens in 4,627 faecal samples: re-examination of the English case-
control Infectious Intestinal Disease Study (1993-1996). Eur J Clin Microbiol Infect Dis 2007;26:311-
323. 
24. Best EL, Fox AJ, Owen RJ, Cheesbrough J, Bolton FJ. Specific detection of Campylobacter jejuni 
from faeces using single nucleotide polymorphisms. Epidemiol Infect 2007;135:839-846.  
25. Linton D, Lawson AJ, Owen RJ, Stanley J. PCR detection, identification to species level, and 
fingerprinting of Campylobacter jejuni and Campylobacter coli direct from diarrheic samples. J Clin 
Microbiol 1997;35:2568-2572. 
26. Black RE, Perlman D, Clements ML, Levine MM, Blaser MJ. Human volunteer studies with 
Campylobacter jejuni,. In I. Nachamkin, M. J. Blaser, and L. S. Tomkins (ed.). Campylobacter jejuni: 
Current status and Future Trends. American Society for Microbiology, Washington, DC 1992:207-
215. 
27. Taylor DN, Perlman DM, Echeverria PD, Lexomboon U, Blaser MJ. Campylobacter immunity and 
quantitative excretion rates in Thai children. J Infect Dis 1993;168:754-758. 
28. Blaser MJ, Duncan DJ. Human serum antibody response to Campylobacter jejuni infection as 
measured in an enzyme-linked immunosorbent assay. Infect Immun 1984;44:292-298. 
29. Herbrink P, van den Munckhof HA, Bumkens M, Lindeman J, van Dijk WC. Human serum antibody 
response in Campylobacter jejuni enteritis as measured by enzyme-linked immunosorbent assay. 
Eur J Clin Microbiol Infect Dis 1988;7:388-393. 
30. Ang CW, Krogfelt K, Herbrink P, Keijser J, van Pelt W, Dalby T, Kuijf M, Jacobs BC, Bergman MP, 
Schiellerup P, Visser CE. Validation of an ELISA for the diagnosis of recent Campylobacter 
infections in Guillain-Barré and reactive arthritis patients. Clin Microbiol Infect 2007;13:915-922.  
31. Taylor BV, Williamson J, Luck J, Coleman D, Jones D, McGregor A. Sensitivity and specificity of 
serology in determining recent acute Campylobacter infection. Intern Med J 2004;34:250-258. 
32. Blaser MJ and Engberg J. Clinical aspects of Campylobacter jejuni and Campylobacter coli 
infections. In Campylobacter, I. Nachamkin, C. M. Szymanski, and M. J. Blaser, editors. 
Washington, D.C.: ASM Press 2008:99-121. 
33. WHO. EPI Surveillance Bulletin. 2008. Vol. 11. no.6. Available at: 
(http://www.searo.who.int/vaccine).  
34. Hahn AF. Guillain-Barré syndrome. Lancet 1998;352:635–641. 
35. Hughes RA. The concept and classification of Guillain-Barré syndrome and related disorders. Rev 
Neurol (Paris) 1995;151:291-294. 
36. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré 
syndrome. Lancet Neurol 2008;7:939-950. 
37. Rasul CH, Das PL, Alam S, Ahmed S, Ahmed M. Clinical profile of acute flaccid paralysis. Med J 
Malaysia 2002;57:61-65.  
38. Landry JBO. Note sur la paralysis aigue. Gaz Hebd Med Chir 1959;6:472-488. 
39. Guillain G, Barré JA, Strohl A. Sur un syndrome de radiculo-névrite avec hyperalbuminose du 
liquide céphalo-rachidien sans réaction cellulaire: remarques sur les caractères cliniques et 
graphiques des réflexes tendineux. Bull Soc Méd Hôp Paris 1916;40:1462-1470. 
40. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barre syndrome. J Infect Dis 
1997;176:S92-98. 
41. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 2005;366:1653-1666. 
42. van Koningsveld R, van Doorn PA, Schmitz PI, Ang CW, van der Meche FG. Mild forms of Guillain-
Barré syndrome in an epidemiologic survey in The Netherlands. Neurology 2000;54:620–625. 
43. Alshekhlee A, Hussain Z, Sultan B, Katirji B. Immunotherapy for Guillain-Barré syndrome in the US 
hospitals. J Clin Neuromuscul Dis 2008;10:4-10. 
44. Bogliun G, Beghi E, Italian GBS Registry Study Group. Incidence and clinical features of acute 
inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. Acta Neurol Scand 2004;110:100-
106. 
General introduction   
 
 
45. Hauck LJ, Carpenter MG, Frank JS. Task-specific measures of balance efficacy, anxiety, and 
stability and their relationship to clinical balance performance. Gait Posture 2008;27:676-682.  
46. Lehmann HC, Köhne A, Meyer zu Hörste G, Kieseier BC. Incidence of Guillain-Barré syndrome in 
Germany. J Peripher Nerv Syst 2007;12:285. 
47. Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, Asbury AK, Blaser MJ, McKhann GM. 
Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-
glycolipid antibodies. Brain 1995;118:597-605. 
48. van Koningsveld R, Rico R, Gerstenbluth I, Schmitz PI, Ang CW, Merkies IS, Jacobs BC, Halabi Y, 
Endtz HP, van der Meché FG, van Doorn PA. Gastroenteritisassociated Guillain-Barré syndrome on 
the Caribbean island Curacao. Neurology 2001;56:1467–1472. 
49. Jacobs BC, van Belkum A, Endtz HP. Guillain-Barré syndrome and Campylobacter infection. In 
Campylobacter, I. Nachamkin, C.M. Szymanski, and M.J. Blaser, editors. Washington, D.C.: ASM 
Press 2008:245-261. 
50. Geleijns K, Brouwer BA, Jacobs BC, Houwing-Duistermaat JJ, van Duijn CM, van Doorn PA. The 
occurrence of Guillain-Barré syndrome within families. Neurology 2004;63:1747-1750. 
51. Ann Neurol. National Institute of Neurological and Communicative Disorders and Stroke ad hoc 
Committee (NINCDS). Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol 1978;3:565-
566. 
52. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. 
Ann Neurol 1990;27:S21-24. 
53. Winer JB, Hughes RA, Osmond C. A prospective study of acute idiopathic neuropathy. I. Clinical 
features and their prognostic value. J Neurol Neurosurg Psychiatry 1988a;51:605–612. 
54. Winer JB, Hughes RA. Identification of patients at risk of arrhythmia in the Guillain-Barré syndrome. 
Q J Med 1988b;68:735–739. 
55. Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: a review. Muscle Nerve 
1994;17:1145-1155. 
56. van der Meché FG, van Doorn PA. Guillain-Barré syndrome and chronic inflammatory demyelinating 
polyneuropathy: immune mechanisms and update on current therapies. Ann Neurol 1995;37:S14-
31. 
57. van Koningsveld R, Schmitz PI, Ang CW, Groen J, Osterhaus AD, van der Meché FG, van Doorn 
PA. Infections and course of disease in mild forms of Guillain-Barré syndrome. Neurology 
2002;58:610-614. 
58. Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, 
Sladky JT, Stevens JC. Quality Standards Subcommittee of the American Academy of Neurology. 
Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards 
Subcommittee of the American Academy of Neurology.  Neurology 2003;61:736-740. 
59. Hadden RD, Hughes RA. Treatment of immune-mediated inflammatory neuropathies. Curr Opin 
Neurol 1999;12:573-579. 
60. Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992;326:1130-1136. 
61. McKhann GM, Griffin JW, Cornblath DR, Quaskey SA, Mellits ED. Role of therapeutic 
plasmapheresis in the acute Guillain-Barré syndrome. J Neuroimmunol 1988;20:297-300. 
62. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and 
plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 
1992;326:1123-1129. 
63. Forsberg A, Press R, Einarsson U, de Pedro-Cuesta J, Widen HL. Impairment in Guillain-Barré 
syndrome during the first 2 years after onset: a prospective study. J Neurol Sci 2004;227:131–138. 
64. Merkies IS, Schmitz PI, Samijn JP, van der Meché FG, van Doorn PA. Fatigue in immune-mediated 
polyneuropathies.European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. 
Neurology 1999;53:1648–1654. 
65. Ropper AH. Ischemic compression paresthesias in Guillain-Barré syndrome. Arch Neurol 
1991;48:1261-1262. 
66. van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical 
prognostic scoring system for Guillain-Barre syndrome. Lancet Neurol 2007;6:589-594. 
Chapter 1
34  
67. Rees JH, Thompson RD, Smeeton NC, Hughes RAC. An epidemiological study of Guillain-Barré 
syndrome in South East England. J Neurol Neurosurg Psychiatry 1998;64:74–77. 
68. Vucic S, Kiernan MC, Cornblath DR. Guillain-Barré syndrome: an update. J Clin Neurosci 
2009;16:733-741.  
69. Winer JB. When the Guillain-Barre patient fails to respond to treatment. Pract Neurol 2009;9:227-
230. 
70. Visser LH, Schmitz PI, Meulstee J, van Doorn PA, van der Meché FG. Prognostic factors of Guillain-
Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study 
Group. Neurology 1999;53:598-604. 
71. Rees JH, Soudain SE, Gregson NA, Hughes RAC. A prospective case control study to investigate 
the relationship between Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 
1995;333:1374–1379. 
72. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, Swan AV. 
Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. 
Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 1998;44:780-
788. 
73. Hadden RD, Hughes RA. Treatment of immune-mediated inflammatory neuropathies. Curr Opin 
Neurol 1999;12:573-579. 
74. Ruts L, Jacobs BC, van van Koningsveld R, van Doorn PA. Pain syndrome in Guillain-Barré 
syndrome: incidence and response to methylprednisolone. J Peripheral nervous Systm,  2003. 
75. Rooper A. Intensive care of acute Guillain-Barré syndrome. Can J Neurol Sci 1994;21:S23-27. 
76. Cornblath DR, Hughes RA. Treatment for Guillain-Barré syndrome. Ann Neurol 2009;66:569-570.  
77. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune 
neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 
2004;102:177-193. 
78. Hughes RA, Swan AV, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane 
Database Syst Rev 2010. 
79. Dutch Guillain-Barré study group, 1994. 
80. Guillain- Barré syndrom steroid trial group, 1993. 
81. Willison HJ, Townson K,  Veitch J, Boffey J, Isaacs N,  Andersen SM, Zhang P, Ling CC, Bundle 
DR. Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune 
nueropathy sera. Brain 2004;127:680-681. 
82. Hughes RA, Hadden RD, Gregson NA, Smith KJ. Pathogenesis of Guillain-Barré syndrome. J 
Neuroimmunol 1999;100:74-97. 
83. McKhann GM, Cornblath DR, Ho T, Li CY, Bai AY, Wu HS, Yei QF, Zhang WC, Zhaori Z, Jiang Z. 
Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in 
northern China. Lancet 1991;338:593-597. 
84. McKhann GM, Cornblath DR, Griffin JW, Ho TW, Li CY, Jiang Z, Wu HS, Zhaori G, Liu Y, Jou LP. 
Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 
1993;33:333–342. 
85. Griffin JW, Li CY, Ho TW, Xue P, Macko C, Gao CY, Yang C, Tian M, Mishu B, Cornblath DR. 
Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically 
defined cases. Brain 1995;118:577-595. 
86. Griffin JW, Li CY, Ho TW, Tian M, Gao CY, Xue P, Mishu B, Cornblath DR, Macko C, McKhann GM, 
Asbury AK. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 
1996;39:17–28. 
87. Berciano J, Coria F, Montón F, Calleja J, Figols J, LaFarga M. Axonal form of Guillain-Barré 
syndrome: evidence for macrophage-associated demyelination. Muscle Nerve. 1993;16:744-751. 
88. Feasby TE, Hahn AF, Brown WF, Bolton CF, Gilbert JJ, Koopman WJ. Severe axonal degeneration 
in acute Guillain-Barré syndrome: evidence of two different mechanisms. J Neurol Sci 
1993;116:185-192. 
89. Ropper AH. Ischemic compression paresthesias in Guillain-Barré syndrome. Arch Neurol 1991 
48:1261-2. 
General introduction   
 
 
90. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia 
and areflexia). N Engl J Med 1956;255:57-65. 
91. Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes. Lancet 
Infect Dis 2001;1:29-37. 
92. Koga M, Yuki N, Hirata K. Antecedent symptoms in Guillain-Barré syndrome: an important indicator 
for clinical and serological subgroups. Acta Neurol Scand 2001;103:278–287. 
93. Jacobs BC, Rothbarth PH, van der Meché FG, Herbrink P, Schmitz PI, de Klerk MA, van Doorn PA. 
The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 
1998;51:1110-1115. 
94. Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, Chen RT. Guillain-Barré 
syndrome following influenza vaccination. JAMA 2004;292:2478–2481. 
95. Hughes RA, Choudhary PP, Osborn M, Rees JH, Sanders EA. Immunization and risk of relapse of 
Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy. Muscle 
Nerve 1996;19:1230-1231. 
96. Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, Clark S, Haber P, Stolley PD, 
Schonberger LB, Chen RT. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 
influenza vaccines. N Engl J Med 1998;339:1797-1802. 
97. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, 
Eddins DL, Bryan JA. Guillain-Barré syndrome following vaccination in the National Influenza 
Immunization Program, United States, 1976–1977. Am J Epidemiol 1979;110:105–123. 
98. Souayah N, Nasar A, Suri MF, Qureshi AI. Guillain-Barré syndrome after vaccination in United 
States. A report from the CDC/FDA Vaccine Adverse Event Reporting System. Vaccine 
2007;25:5253–5255. 
99. Gruenewald R, Ropper AH, Lior H, Chan J, Lee R, Molinaro VS. Serologic evidence of 
Campylobacter jejuni/coli enteritis in patients with Guillain-Barré syndrome. Arch Neurol 
1991;48:1080-1082. 
100. Kaldor J, Speed BR. Guillain-Barré syndrome and Campylobacter jejuni: a serologic study. Br Med J 
1984;288:1867–1870. 
101. Kuroki S, Haruta T, Yoshioka M, Kobayashi Y, Nukina M, Nakanishi H. Guillain-Barré syndrome 
associated with Campylobacter infection. Pediatr Infect Dis J 1991;10:149-151. 
102. Ropper AH. Campylobacter diarrhea and Guillain-Barré syndrome. Arch Neurol 1988;45:655–656. 
103. Speed BR, Kaldor J, Watson J, Newton-John H, Tee W, Noonan D, Dwyer BW. Campylobacter 
jejuni/Campylobacter coli-associated Guillain-Barré syndrome. Immunoblot confirmation of the 
serological response. Med J Aust 1987;147:13-16. 
104. Mishu B, Blaser MJ. Role of infection due to Campylobacter jejuni in the initiation of Guillain-Barré 
syndrome. Clin Infect Dis 1993;17:104-108. 
105. Sinha S, Prasad KN, Jain D, Pandey CM, Jha S, Pradhan S. Preceding infections and anti-
ganglioside antibodies in patients with Guillain-Barré syndrome: a single centre prospective case-
control study. Clin Microbiol Infect 2007;13:334-337. 
106. Nachamkin I, Arzarte Barbosa P, Ung H, Lobato C, Gonzalez Rivera A, Rodriguez P, Garcia 
Briseno A, Cordero LM, Garcia Perea L, Perez JC, Ribera M, Aldama PC, Guitérrez GD, Sarnat LF, 
García MR, Veitch J, Fitzgerald C, Cornblath DR, Rodriguez Pinto M, Griffin JW, Willison HJ, 
Asbury AK, McKhann GM. Patterns of Guillain-Barré syndrome in children: results from a Mexican 
population. Neurology 2007;69:1665-1671. 
107. Wierzba TF, Abdel-Messih IA, Gharib B, Baqar S, Hendaui A, Khalil I, Omar TA, Khayat HE, 
Putnam SD, Sanders JW, Ng LK, Price LJ, Scott DA, Frenck RR. Campylobacter infection as a 
trigger for Guillain-Barré syndrome in Egypt. PLoS One 2008;3:e3674.  
108. Dowling PC, Cook SD. Role of infection in Guillain-Barré syndrome: laboratory confirmation of 
herpesviruses in 41 cases. Ann Neurol 1981;9:44-55. 
109. Hao Q, Saida T, Kuroki S, Nishimura M, Nukina M, Obayashi H, Saida K. Antibodies to gangliosides 
and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter 
jejuni and other identified infections.  J Neuroimmunol 1998;81:116–126. 
Chapter 1
35 
67. Rees JH, Thompson RD, Smeeton NC, Hughes RAC. An epidemiological study of Guillain-Barré 
syndrome in South East England. J Neurol Neurosurg Psychiatry 1998;64:74–77. 
68. Vucic S, Kiernan MC, Cornblath DR. Guillain-Barré syndrome: an update. J Clin Neurosci 
2009;16:733-741.  
69. Winer JB. When the Guillain-Barre patient fails to respond to treatment. Pract Neurol 2009;9:227-
230. 
70. Visser LH, Schmitz PI, Meulstee J, van Doorn PA, van der Meché FG. Prognostic factors of Guillain-
Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study 
Group. Neurology 1999;53:598-604. 
71. Rees JH, Soudain SE, Gregson NA, Hughes RAC. A prospective case control study to investigate 
the relationship between Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 
1995;333:1374–1379. 
72. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, Swan AV. 
Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. 
Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 1998;44:780-
788. 
73. Hadden RD, Hughes RA. Treatment of immune-mediated inflammatory neuropathies. Curr Opin 
Neurol 1999;12:573-579. 
74. Ruts L, Jacobs BC, van van Koningsveld R, van Doorn PA. Pain syndrome in Guillain-Barré 
syndrome: incidence and response to methylprednisolone. J Peripheral nervous Systm,  2003. 
75. Rooper A. Intensive care of acute Guillain-Barré syndrome. Can J Neurol Sci 1994;21:S23-27. 
76. Cornblath DR, Hughes RA. Treatment for Guillain-Barré syndrome. Ann Neurol 2009;66:569-570.  
77. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune 
neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 
2004;102:177-193. 
78. Hughes RA, Swan AV, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane 
Database Syst Rev 2010. 
79. Dutch Guillain-Barré study group, 1994. 
80. Guillain- Barré syndrom steroid trial group, 1993. 
81. Willison HJ, Townson K,  Veitch J, Boffey J, Isaacs N,  Andersen SM, Zhang P, Ling CC, Bundle 
DR. Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune 
nueropathy sera. Brain 2004;127:680-681. 
82. Hughes RA, Hadden RD, Gregson NA, Smith KJ. Pathogenesis of Guillain-Barré syndrome. J 
Neuroimmunol 1999;100:74-97. 
83. McKhann GM, Cornblath DR, Ho T, Li CY, Bai AY, Wu HS, Yei QF, Zhang WC, Zhaori Z, Jiang Z. 
Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in 
northern China. Lancet 1991;338:593-597. 
84. McKhann GM, Cornblath DR, Griffin JW, Ho TW, Li CY, Jiang Z, Wu HS, Zhaori G, Liu Y, Jou LP. 
Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 
1993;33:333–342. 
85. Griffin JW, Li CY, Ho TW, Xue P, Macko C, Gao CY, Yang C, Tian M, Mishu B, Cornblath DR. 
Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically 
defined cases. Brain 1995;118:577-595. 
86. Griffin JW, Li CY, Ho TW, Tian M, Gao CY, Xue P, Mishu B, Cornblath DR, Macko C, McKhann GM, 
Asbury AK. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 
1996;39:17–28. 
87. Berciano J, Coria F, Montón F, Calleja J, Figols J, LaFarga M. Axonal form of Guillain-Barré 
syndrome: evidence for macrophage-associated demyelination. Muscle Nerve. 1993;16:744-751. 
88. Feasby TE, Hahn AF, Brown WF, Bolton CF, Gilbert JJ, Koopman WJ. Severe axonal degeneration 
in acute Guillain-Barré syndrome: evidence of two different mechanisms. J Neurol Sci 
1993;116:185-192. 
89. Ropper AH. Ischemic compression paresthesias in Guillain-Barré syndrome. Arch Neurol 1991 
48:1261-2. 
General introduction   
 
 
90. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia 
and areflexia). N Engl J Med 1956;255:57-65. 
91. Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes. Lancet 
Infect Dis 2001;1:29-37. 
92. Koga M, Yuki N, Hirata K. Antecedent symptoms in Guillain-Barré syndrome: an important indicator 
for clinical and serological subgroups. Acta Neurol Scand 2001;103:278–287. 
93. Jacobs BC, Rothbarth PH, van der Meché FG, Herbrink P, Schmitz PI, de Klerk MA, van Doorn PA. 
The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 
1998;51:1110-1115. 
94. Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, Chen RT. Guillain-Barré 
syndrome following influenza vaccination. JAMA 2004;292:2478–2481. 
95. Hughes RA, Choudhary PP, Osborn M, Rees JH, Sanders EA. Immunization and risk of relapse of 
Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy. Muscle 
Nerve 1996;19:1230-1231. 
96. Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, Clark S, Haber P, Stolley PD, 
Schonberger LB, Chen RT. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 
influenza vaccines. N Engl J Med 1998;339:1797-1802. 
97. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, 
Eddins DL, Bryan JA. Guillain-Barré syndrome following vaccination in the National Influenza 
Immunization Program, United States, 1976–1977. Am J Epidemiol 1979;110:105–123. 
98. Souayah N, Nasar A, Suri MF, Qureshi AI. Guillain-Barré syndrome after vaccination in United 
States. A report from the CDC/FDA Vaccine Adverse Event Reporting System. Vaccine 
2007;25:5253–5255. 
99. Gruenewald R, Ropper AH, Lior H, Chan J, Lee R, Molinaro VS. Serologic evidence of 
Campylobacter jejuni/coli enteritis in patients with Guillain-Barré syndrome. Arch Neurol 
1991;48:1080-1082. 
100. Kaldor J, Speed BR. Guillain-Barré syndrome and Campylobacter jejuni: a serologic study. Br Med J 
1984;288:1867–1870. 
101. Kuroki S, Haruta T, Yoshioka M, Kobayashi Y, Nukina M, Nakanishi H. Guillain-Barré syndrome 
associated with Campylobacter infection. Pediatr Infect Dis J 1991;10:149-151. 
102. Ropper AH. Campylobacter diarrhea and Guillain-Barré syndrome. Arch Neurol 1988;45:655–656. 
103. Speed BR, Kaldor J, Watson J, Newton-John H, Tee W, Noonan D, Dwyer BW. Campylobacter 
jejuni/Campylobacter coli-associated Guillain-Barré syndrome. Immunoblot confirmation of the 
serological response. Med J Aust 1987;147:13-16. 
104. Mishu B, Blaser MJ. Role of infection due to Campylobacter jejuni in the initiation of Guillain-Barré 
syndrome. Clin Infect Dis 1993;17:104-108. 
105. Sinha S, Prasad KN, Jain D, Pandey CM, Jha S, Pradhan S. Preceding infections and anti-
ganglioside antibodies in patients with Guillain-Barré syndrome: a single centre prospective case-
control study. Clin Microbiol Infect 2007;13:334-337. 
106. Nachamkin I, Arzarte Barbosa P, Ung H, Lobato C, Gonzalez Rivera A, Rodriguez P, Garcia 
Briseno A, Cordero LM, Garcia Perea L, Perez JC, Ribera M, Aldama PC, Guitérrez GD, Sarnat LF, 
García MR, Veitch J, Fitzgerald C, Cornblath DR, Rodriguez Pinto M, Griffin JW, Willison HJ, 
Asbury AK, McKhann GM. Patterns of Guillain-Barré syndrome in children: results from a Mexican 
population. Neurology 2007;69:1665-1671. 
107. Wierzba TF, Abdel-Messih IA, Gharib B, Baqar S, Hendaui A, Khalil I, Omar TA, Khayat HE, 
Putnam SD, Sanders JW, Ng LK, Price LJ, Scott DA, Frenck RR. Campylobacter infection as a 
trigger for Guillain-Barré syndrome in Egypt. PLoS One 2008;3:e3674.  
108. Dowling PC, Cook SD. Role of infection in Guillain-Barré syndrome: laboratory confirmation of 
herpesviruses in 41 cases. Ann Neurol 1981;9:44-55. 
109. Hao Q, Saida T, Kuroki S, Nishimura M, Nukina M, Obayashi H, Saida K. Antibodies to gangliosides 
and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter 
jejuni and other identified infections.  J Neuroimmunol 1998;81:116–126. 
Chapter 1
36  
110. Irie S, Saito T, Nakamura K, Kanazawa N, Ogino M, Nukazawa T, Ito H, Tamai Y, Kowa H. 
Association of anti-GM2 antibodies in Guillain-Barré syndrome with acute cytomegalovirus infection. 
J Neuroimmunol 1996;68:19-26. 
111. Jacobs BC, van Doorn PA, Groeneveld JH, Tio-Gillen AP, van der Meché FG. Cytomegalovirus 
infections and anti-GM2 antibodies in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 
1997;62:641-643. 
112. Yuki N, Yamamoto T, Hirata K. Correlation between cytomegalovirus infection and IgM anti-
MAG/SGPG antibody-associated neuropathy. Ann Neurol 1998;44:408-410. 
113. Terryberry J, Sutjita M, Shoenfeld Y, Gilburd B, Tanne D, Lorber M, Alosachie I, Barka N, Lin HC, 
Youinou P, et al. Myelin- and microbe-specific antibodies in Guillain-Barré syndrome. J Clin Lab 
Anal 1995;9:308-319. 
114. Kusunoki S, Chiba A, Hitoshi S, Takizawa H, Kanazawa I. Anti-Gal-C antibody in autoimmune 
neuropathies subsequent to mycoplasma infection. Muscle Nerve. 1995;18:409-413. 
115. Mori M, Kuwabara S, Miyake M, Noda M, Kuroki H, Kanno H, Ogawara K, Hattori T.Haemophilus 
influenzae infection and Guillain-Barré syndrome. Brain 2000;123:2171-2178. 
116. Schessl J, Luther B, Kirschner J, Mauff G, Korinthenberg R. Infections and vaccinations preceding 
childhood Guillain-Barré syndrome: a prospective study. Eur J Pediatr 2006;165:605-612. 
117. Asbury AK, McKhann GM. Changing views of Guillain-Barré syndrome. Ann Neurol 1997;41:287-
288. 
118. Rhodes KM, Tattersfield AE. Guillain-Barré syndrome associated with Campylobacter infection.Br 
Med J  1982;285:173-174. 
119. Svedhem A and Kaijser B. Campylobacter fetus subspecies jejuni: a common cause of diarrhea in 
Sweden. J Infect Dis 1980;142:353–359. 
120. Kuwabara S, Bostock H, Ogawara K, Sung JY, Kanai K, Mori M, Hattori T, Burke D. The refractory 
period of transmission is impaired in axonal Guillain-Barré syndrome. Muscle Nerve 2003;28:683-
689. 
121. Koga M, Koike S, Hirata K, Yuki N. Ambiguous value of Haemophilus influenzae isolation in Guillain-
Barré and Fisher syndromes. J Neurol Neurosurg Psychiatry 2005;76:1736-1738. 
122. Molnar GK, Mertsola J, Erkko M. Guillain-Barré syndrome associated with Campylobacter infection. 
Br Med J 1982;285:652. 
123. Constant OC, Bentley CC, Denman AM, Lehane JR, Larson HE. The Guillain-Barré syndrome 
following Campylobacter enteritis with recovery after plasmapheresis. J Infect 1983;6:89-91. 
124. Pryor WM, Freiman JS, Gillies MA, Tuck RR. Guillain-Barré syndrome associated with 
Campylobacter infection. Aust N Z J Med 1984;14:687-688. 
125. Wroe SJ, Blumhardt LD. Acute polyneuritis with cranial nerve involvement following Campylobacter 
jejuni infection. J Neurol Neurosurg Psychiatry 1985;48:593. 
126. De Bont B, Matthews N, Abbott K, Davidson GP. Guillain-Barré syndrome associated with 
Campylobacter enteritis in a child. J Pediatr 1986;109:660-662. 
127. Kohler PC, Goldblatt D. Guillain-Barré syndrome following Campylobacter jejuni enteritis. Arch 
Neurol 1987;44:1219.  
128. Sovilla JY, Regli F, Francioli PB. Guillain-Barré syndrome following Campylobacter jejuni enteritis. 
Report of three cases and review of the literature. Arch Intern Med 1988;148:739-741. 
129. Yuki N, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 
antibodies following Campylobacter enteritis. Neurology 1990;40:1900-1902. 
130. Yuki N, Sato S, Itoh T, Miyatake T. HLA-B35 and acute axonal polyneuropathy following 
Campylobacter infection. Neurology 1991;41:1561-1563. 
131. Duret M, Herbaut AG, Flamme F, Gerard JM. Another case of atypical acute axonal polyneuropathy 
following Campylobacter enteritis. Neurology 1991;41:2008-2009.  
132. Yuki N, Sato S, Fujimoto S, Yamada S, Tsujino Y, Kinoshita A, Itoh T. Serotype of Campylobacter 
jejuni, HLA, and the Guillain-Barré syndrome. Muscle Nerve 1992;15:968-969. 
133. Fujimoto S, Yuki N, Itoh T, Amako K. Specific serotype of Campylobacter jejuni associated with 
Guillain-Barré syndrome. J Infect Dis 1992;165:183. 
General introduction   
 
 
134. Walsh FS, Cronin M, Koblar S, Doherty P, Winer J, Leon A, Hughes RA. Association between 
glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barré syndrome. J 
Neuroimmunol 1991;34:43-51. 
135. Boucquey D, Sindic CJ, Lamy M, Delmée M, Tomasi JP, Laterre EC. Clinical and serological studies 
in a series of 45 patients with Guillain-Barré syndrome. J Neurol Sci 1991;104:56-63. 
136. Nobile-Orazio E, Carpo M, Meucci N, Grassi MP, Capitani E, Sciacco M, Mangoni A, Scarlato G. 
Guillain-Barré syndrome associated with high titers of anti-GM1 antibodies. J Neurol Sci 
1992;109:200-206. 
137. Gregson NA, Koblar S, Hughes RA. Antibodies to gangliosides in Guillain-Barré syndrome: 
specificity and relationship to clinical features. Q J Med 1993;86:111-117. 
138. Kuroki S, Saida T, Nukina M, Haruta T, Yoshioka M, Kobayashi Y, Nakanishi H. Campylobacter 
jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and 
contain beta-N-acetylglucosamine residues. Ann Neurol 1993;33:243-247. 
139. Enders U, Karch H, Toyka KV, Michels M, Zielasek J, Pette M, Heesemann J, Hartung HP. The 
spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré 
syndrome and in other neuroimmunological disorders. Ann Neurol 1993;34:136-144. 
140. Vriesendorp FJ, Mishu B, Blaser MJ, Koski CL. Serum antibodies to GM1, GD1b, peripheral nerve 
myelin and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: correlation 
and prognosis. Ann Neurol 1993;34:130-135. 
141. von Wulffen H, Hartard C, Scharein E. Seroreactivity to Campylobacter jejuni and gangliosides in 
patients with Guillain-Barré syndrome. J Infect Dis 1994;170:828-833. 
142. Jacobs BC, van Doorn PA, Schmitz PI, Tio-Gillen AP, Herbrink P, Visser LH, Hooijkass H, van der 
Meché FG. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. 
Ann Neurol 1996;40:181-187. 
143. Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, Weishaupt A, Cornblath 
DR, Swan AV, Hughes RA, Toyka KV; Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome 
Trial Group.  Neurology 2001;56:758-765. 
144. Takahashi M, Koga M, Yokoyama K, Yuki N. Epidemiology of Campylobacter jejuni isolated from 
patients with Guillain-Barré and Fisher syndromes in Japan. J Clin Microbiol 2005;43:335-339. 
145. Sivadon V, Orlikowski D, Rozenberg F, Quincampoix JC, Caudie C, Durand MC, Fauchère JL, 
Sharshar T, Raphaël JC, Gaillard JL. Prevalence and characteristics of Guillain-Barré syndromes 
associated with Campylobacter jejuni and cytomegalovirus in greater Paris. Pathol Biol (Paris) 
2005;53:536-538. 
146. Barzegar M, Alizadeh A, Toopchizadeh V, Dastgiri S, Majidi J. Association of Campylobacter jejuni 
infection and GuillainBarré syndrome: a cohort study in the northwest of Iran.Turk J Pediatr 
2008;50:443-448. 
147. Ilyas AA, Quarles RH, Dalakas MC, Brady RO. Polyneuropathy with monoclonal gammopathy: 
glycolipids are frequently antigens for IgM paraproteins. Proc Natl Acad Sci U S A. 1985;82:6697-
6700. 
148. Latov N, Hays AP, Donofrio PD, Liao J, Ito H, McGinnis S, Konstadoulakis M, Freddo L, Shy ME, 
Sherman WH, Chang HW, Greenberg HS, Albers JW, Alessi AG, Keren D, Yu RK, Rowland LP, 
Kabat EA. Monoclonal IgM with unique specificity to gangliosides GM1 and GD1b and to lacto-N-
tetraose associated with human motor neuron disease. Neurology. 1988;38:763-768. 
149. Ledeen RW, Yu RK. Gangliosides: structure, isolation, and analysis. Methods Enzymol 
1982;83:139-191. 
150. Ledeen RW. Biology of gangliosides: neuritogenic and neuronotrophic properties. J Neurosci Res 
1984;12:147-159. 
151. Hughes RA, Gregson NA, Hadden RDM, Smith KJ. Pathogenesis of Guillain-Barré syndrome. J 
Neuroimmunol 1999;100:74–97.  
152. Ilyas AA, Willison HJ, Quarles RH, Jungalwala FB, Cornblath DR, Trapp BD, Griffin DE, Griffin JW, 
McKhann GM. Serum antibodies to gangliosides in Guillain-Barré syndromes. Ann Neurol 
1988;23:440-447. 
153. Willison HJ. Ganglioside complexes: new autoantibody targets in Guillain-Barré syndromes. Nat Clin 
Pract Neurol 2005;1:2-3. 
Chapter 1
37 
110. Irie S, Saito T, Nakamura K, Kanazawa N, Ogino M, Nukazawa T, Ito H, Tamai Y, Kowa H. 
Association of anti-GM2 antibodies in Guillain-Barré syndrome with acute cytomegalovirus infection. 
J Neuroimmunol 1996;68:19-26. 
111. Jacobs BC, van Doorn PA, Groeneveld JH, Tio-Gillen AP, van der Meché FG. Cytomegalovirus 
infections and anti-GM2 antibodies in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 
1997;62:641-643. 
112. Yuki N, Yamamoto T, Hirata K. Correlation between cytomegalovirus infection and IgM anti-
MAG/SGPG antibody-associated neuropathy. Ann Neurol 1998;44:408-410. 
113. Terryberry J, Sutjita M, Shoenfeld Y, Gilburd B, Tanne D, Lorber M, Alosachie I, Barka N, Lin HC, 
Youinou P, et al. Myelin- and microbe-specific antibodies in Guillain-Barré syndrome. J Clin Lab 
Anal 1995;9:308-319. 
114. Kusunoki S, Chiba A, Hitoshi S, Takizawa H, Kanazawa I. Anti-Gal-C antibody in autoimmune 
neuropathies subsequent to mycoplasma infection. Muscle Nerve. 1995;18:409-413. 
115. Mori M, Kuwabara S, Miyake M, Noda M, Kuroki H, Kanno H, Ogawara K, Hattori T.Haemophilus 
influenzae infection and Guillain-Barré syndrome. Brain 2000;123:2171-2178. 
116. Schessl J, Luther B, Kirschner J, Mauff G, Korinthenberg R. Infections and vaccinations preceding 
childhood Guillain-Barré syndrome: a prospective study. Eur J Pediatr 2006;165:605-612. 
117. Asbury AK, McKhann GM. Changing views of Guillain-Barré syndrome. Ann Neurol 1997;41:287-
288. 
118. Rhodes KM, Tattersfield AE. Guillain-Barré syndrome associated with Campylobacter infection.Br 
Med J  1982;285:173-174. 
119. Svedhem A and Kaijser B. Campylobacter fetus subspecies jejuni: a common cause of diarrhea in 
Sweden. J Infect Dis 1980;142:353–359. 
120. Kuwabara S, Bostock H, Ogawara K, Sung JY, Kanai K, Mori M, Hattori T, Burke D. The refractory 
period of transmission is impaired in axonal Guillain-Barré syndrome. Muscle Nerve 2003;28:683-
689. 
121. Koga M, Koike S, Hirata K, Yuki N. Ambiguous value of Haemophilus influenzae isolation in Guillain-
Barré and Fisher syndromes. J Neurol Neurosurg Psychiatry 2005;76:1736-1738. 
122. Molnar GK, Mertsola J, Erkko M. Guillain-Barré syndrome associated with Campylobacter infection. 
Br Med J 1982;285:652. 
123. Constant OC, Bentley CC, Denman AM, Lehane JR, Larson HE. The Guillain-Barré syndrome 
following Campylobacter enteritis with recovery after plasmapheresis. J Infect 1983;6:89-91. 
124. Pryor WM, Freiman JS, Gillies MA, Tuck RR. Guillain-Barré syndrome associated with 
Campylobacter infection. Aust N Z J Med 1984;14:687-688. 
125. Wroe SJ, Blumhardt LD. Acute polyneuritis with cranial nerve involvement following Campylobacter 
jejuni infection. J Neurol Neurosurg Psychiatry 1985;48:593. 
126. De Bont B, Matthews N, Abbott K, Davidson GP. Guillain-Barré syndrome associated with 
Campylobacter enteritis in a child. J Pediatr 1986;109:660-662. 
127. Kohler PC, Goldblatt D. Guillain-Barré syndrome following Campylobacter jejuni enteritis. Arch 
Neurol 1987;44:1219.  
128. Sovilla JY, Regli F, Francioli PB. Guillain-Barré syndrome following Campylobacter jejuni enteritis. 
Report of three cases and review of the literature. Arch Intern Med 1988;148:739-741. 
129. Yuki N, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 
antibodies following Campylobacter enteritis. Neurology 1990;40:1900-1902. 
130. Yuki N, Sato S, Itoh T, Miyatake T. HLA-B35 and acute axonal polyneuropathy following 
Campylobacter infection. Neurology 1991;41:1561-1563. 
131. Duret M, Herbaut AG, Flamme F, Gerard JM. Another case of atypical acute axonal polyneuropathy 
following Campylobacter enteritis. Neurology 1991;41:2008-2009.  
132. Yuki N, Sato S, Fujimoto S, Yamada S, Tsujino Y, Kinoshita A, Itoh T. Serotype of Campylobacter 
jejuni, HLA, and the Guillain-Barré syndrome. Muscle Nerve 1992;15:968-969. 
133. Fujimoto S, Yuki N, Itoh T, Amako K. Specific serotype of Campylobacter jejuni associated with 
Guillain-Barré syndrome. J Infect Dis 1992;165:183. 
General introduction   
 
 
134. Walsh FS, Cronin M, Koblar S, Doherty P, Winer J, Leon A, Hughes RA. Association between 
glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barré syndrome. J 
Neuroimmunol 1991;34:43-51. 
135. Boucquey D, Sindic CJ, Lamy M, Delmée M, Tomasi JP, Laterre EC. Clinical and serological studies 
in a series of 45 patients with Guillain-Barré syndrome. J Neurol Sci 1991;104:56-63. 
136. Nobile-Orazio E, Carpo M, Meucci N, Grassi MP, Capitani E, Sciacco M, Mangoni A, Scarlato G. 
Guillain-Barré syndrome associated with high titers of anti-GM1 antibodies. J Neurol Sci 
1992;109:200-206. 
137. Gregson NA, Koblar S, Hughes RA. Antibodies to gangliosides in Guillain-Barré syndrome: 
specificity and relationship to clinical features. Q J Med 1993;86:111-117. 
138. Kuroki S, Saida T, Nukina M, Haruta T, Yoshioka M, Kobayashi Y, Nakanishi H. Campylobacter 
jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and 
contain beta-N-acetylglucosamine residues. Ann Neurol 1993;33:243-247. 
139. Enders U, Karch H, Toyka KV, Michels M, Zielasek J, Pette M, Heesemann J, Hartung HP. The 
spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré 
syndrome and in other neuroimmunological disorders. Ann Neurol 1993;34:136-144. 
140. Vriesendorp FJ, Mishu B, Blaser MJ, Koski CL. Serum antibodies to GM1, GD1b, peripheral nerve 
myelin and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: correlation 
and prognosis. Ann Neurol 1993;34:130-135. 
141. von Wulffen H, Hartard C, Scharein E. Seroreactivity to Campylobacter jejuni and gangliosides in 
patients with Guillain-Barré syndrome. J Infect Dis 1994;170:828-833. 
142. Jacobs BC, van Doorn PA, Schmitz PI, Tio-Gillen AP, Herbrink P, Visser LH, Hooijkass H, van der 
Meché FG. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. 
Ann Neurol 1996;40:181-187. 
143. Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, Weishaupt A, Cornblath 
DR, Swan AV, Hughes RA, Toyka KV; Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome 
Trial Group.  Neurology 2001;56:758-765. 
144. Takahashi M, Koga M, Yokoyama K, Yuki N. Epidemiology of Campylobacter jejuni isolated from 
patients with Guillain-Barré and Fisher syndromes in Japan. J Clin Microbiol 2005;43:335-339. 
145. Sivadon V, Orlikowski D, Rozenberg F, Quincampoix JC, Caudie C, Durand MC, Fauchère JL, 
Sharshar T, Raphaël JC, Gaillard JL. Prevalence and characteristics of Guillain-Barré syndromes 
associated with Campylobacter jejuni and cytomegalovirus in greater Paris. Pathol Biol (Paris) 
2005;53:536-538. 
146. Barzegar M, Alizadeh A, Toopchizadeh V, Dastgiri S, Majidi J. Association of Campylobacter jejuni 
infection and GuillainBarré syndrome: a cohort study in the northwest of Iran.Turk J Pediatr 
2008;50:443-448. 
147. Ilyas AA, Quarles RH, Dalakas MC, Brady RO. Polyneuropathy with monoclonal gammopathy: 
glycolipids are frequently antigens for IgM paraproteins. Proc Natl Acad Sci U S A. 1985;82:6697-
6700. 
148. Latov N, Hays AP, Donofrio PD, Liao J, Ito H, McGinnis S, Konstadoulakis M, Freddo L, Shy ME, 
Sherman WH, Chang HW, Greenberg HS, Albers JW, Alessi AG, Keren D, Yu RK, Rowland LP, 
Kabat EA. Monoclonal IgM with unique specificity to gangliosides GM1 and GD1b and to lacto-N-
tetraose associated with human motor neuron disease. Neurology. 1988;38:763-768. 
149. Ledeen RW, Yu RK. Gangliosides: structure, isolation, and analysis. Methods Enzymol 
1982;83:139-191. 
150. Ledeen RW. Biology of gangliosides: neuritogenic and neuronotrophic properties. J Neurosci Res 
1984;12:147-159. 
151. Hughes RA, Gregson NA, Hadden RDM, Smith KJ. Pathogenesis of Guillain-Barré syndrome. J 
Neuroimmunol 1999;100:74–97.  
152. Ilyas AA, Willison HJ, Quarles RH, Jungalwala FB, Cornblath DR, Trapp BD, Griffin DE, Griffin JW, 
McKhann GM. Serum antibodies to gangliosides in Guillain-Barré syndromes. Ann Neurol 
1988;23:440-447. 
153. Willison HJ. Ganglioside complexes: new autoantibody targets in Guillain-Barré syndromes. Nat Clin 
Pract Neurol 2005;1:2-3. 
Chapter 1
38  
154. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002;125:2591-
625.  
155. Yuki N. Ganglioside mimicry and peripheral nerve disease. Muscle Nerve 2007;35:691–711. 
156. Kaida K, Kanzaki M, Morita D, Kamakura K, Motoyoshi K, Hirakawa M, Kusunoki S. Anti-ganglioside 
complex antibodies in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 2006;77:1043-1046. 
157. Kaida K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, Hirakawa M, Kusunoki S. Anti-ganglioside 
complex antibodies associated with severe disability in GBS. J Neuroimmunol 2007;182:212-218. 
158. Kaida K, Kusunoki S. Antibodies to gangliosides and ganglioside complexes in Guillain-Barré 
syndrome and Fisher syndrome.  J Neuroimmunol 2010. 
159. Kuijf ML, Godschalk PC, Gilbert M, Endtz HP, Tio-Gillen AP, Ang CW, van Doorn PA, Jacobs BC. 
Origin of ganglioside complex antibodies in Guillain-Barré syndrome. J Neuroimmunol 2007;188:69-
73. 
160. Ledeen RW, Yu RK. Gangliosides: structure, isolation and analysis. Methods Enzymol 
1982;83:139–191 
161. Simone IL, Annunziata P, Maimone D, Liguori M, Leante R, Livrea P. Serum and CSF anti-GM1 
antibodies in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating 
polyneuropathy. J Neurol Sci 1993;114:49-55. 
162. Gregson NA, Jones D, Thomas PK, Willison HJ. Acute motor neuropathy with antibodies to GM1 
ganglioside. J Neurol 1991;238:447-451. 
163. Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, Handa S, Miyatake T. A bacterium 
lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp 
Med 1993;178:1771-1775. 
164. KusunokiS, Iwamori M, Chiba A, Hitoshi S, Arita M, Kanazawa I. GM1b is a new member of antigen 
for serum antibody in Guillain-Barré syndrome. Neurology 1996;47:237-242. 
165. Yuki N, Taki T, Handa S. Antibody to GalNAc-GD1a and GalNAc-GM1b in Guillain-Barré syndrome 
subsequent to Campylobacter jejuni enteritis. J Neuroimmunol 1996;71:155-161. 
166. Yuki N. Treatment of anti-glycolipid antibody-associated neuropathy. Rinsho Shinkeigaku 
1999;39:1232-1234. 
167. Ho TW, Willison HJ, Nachamkin I, Li CY, Veitch J, Ung H, Wang GR, Liu RC, Cornblath DR, Asbury 
AK, Griffin JW, McKhann GM. Anti-GD1a antibody is associated with axonal but not demyelinating 
forms of Guillain-Barre syndrome. Ann Neurol 1999;45:168–173. 
168. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b antibody is associated 
with ophthalmoplegia in MillerFisher syndrome and Guillain-Barre  syndrome: clinical and 
immunohistochemical studies. Neurology 1993;43:1911–1917. 
169. Willison HJ, Kennedy PG. Gangliosides and bacterial toxins in Guillain-Barré syndrome. J 
Neuroimmunol 1993;46:105-112. 
170. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a 
possible marker of Miller Fisher syndrome. Ann Neurol 1992;31:677–679. 
171. O'Leary CP, Veitch J, Durward WF, Thomas AM, Rees JH, Willison HJ. Acute oropharyngeal palsy 
is associated with antibodies to GQ1b and GT1a gangliosides. Psychiatry 1996;61:649-651. 
172. Kimoto K, Koga M, Odaka M, Hirata K, Takahashi M, Li J, Gilbert M, Yuki N. Relationship of 
bacterial strains to clinical syndromes of Campylobacter-associated neuropathies. Neurology 
2006;67:1837-1843. 
173. Damian RT. Molecular mimicry: antigen sharing by parasite and host and its consequences. Amer 
Nat 1964;98:129-149. 
174. Rowley D, Jenkin CR. Antigenic cross-reaction between host and parasite as a possible cause of 
pathogenicity. Nature 1962;193:151-154.  
175. Ang CW, Jacobs BC, Laman JD. The Guillain-Barré syndrome: a true case of molecular mimicry. 
Trends Immunol 2004;25:61-66. 
176. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999;341:2068-2074. 
177. Aspinall GO, McDonald AG, Pang H, Kurjanczyk LA, Penner JL. Lipopolysaccharides of 
Campylobacter jejuni serotype O:19: structures of core oligosaccharide regions from the serostrain 
and two bacterial isolates from patients with the Guillain-Barré syndrome. Biochemistry 
1994a;33:241-249. 
General introduction   
 
 
178. Aspinall GO, Fujimoto S, McDonald AG, Pang H, Kurjanczyk LA, Penner JL. Lipopolysaccharides 
from Campylobacter jejuni associated with Guillain-Barré syndrome patients mimic human 
gangliosides in structure. Infect Immun 1994c;62:2122-2125. 
179. Aspinall GO, McDonald AG, Raju TS, Pang H, Kurjanczyk LA, Penner JL, Moran AP. Chemical 
structure of the core region of Campylobacter jejuni serotype O:2 lipopolysaccharide. Eur J Biochem 
1993a;213:1029-1037. 
180. Aspinall GO, McDonald AG, Raju TS, Pang H, Moran AP, Penner JL. Chemical structures of the 
core regions of Campylobacter jejuni serotypes O:1, O:4, O:23, and O:36 lipopolysaccharides. Eur J 
Biochem 1993b;216:880. 
181. Aspinall GO, McDonald AG, Pang H. Lipopolysaccharides of Campylobacter jejuni serotype O:19: 
structures of O-antigen chains from the serostrain and two bacterial isolates from patients with the 
Guillain-Barré syndrome. Biochemistry 1994b;33:250-255. 
182. Moran AP.Biological and serological characterization of Campylobacter jejuni lipopolysaccharides 
with deviating core and lipid A structures. FEMS Immunol Med Microbiol 1995;11:121-130. 
183. Bersudsky M, Rosenberg P, Rudensky B, Wirguin I. Lipopolysaccharides of a Campylobacter coli 
isolate from a patient with Guillain-Barré syndrome display ganglioside mimicry. Neuromuscul 
Disord 2000;10:182-186. 
184. Nachamkin I. Rabbit model of Guillain-Barré syndrome. Ann Neurol 2002;52:127-128. 
185. Godschalk PC, Kuijf ML, Li J, St Michael F, Ang CW, Jacobs BC, Karwaski MF, Brochu D, 
Moterassed A, Endtz HP, van Belkum A, Gilbert M. Structural characterization of Campylobacter 
jejuni lipooligosaccharide outer cores associated with Guillain-Barré and Miller Fisher syndromes. 
Infect Immun 2007;75:1245–1254. 
186. Aspinall GO, McDonald AG, Pang H. Structures of the O chains from lipopolysaccharides of 
Campylobacter jejuni serotypes O:23 and O:36. Carbohydr Res 1992;231:13-30. 
187. Aspinall GO, Lynch CM, Pang H, Shaver RT, Moran AP. Chemical structures of the core region of 
Campylobacter jejuni O:3 lipopolysaccharide and an associated polysaccharide. Eur J Biochem 
1995;231:570-578. 
188. Godschalk PC, Bergman MP, Gorkink RF, Simons G, van den Braak N, Lastovica AJ, Endtz HP, 
Verbrugh HA, van Belkum A. Identification of DNA sequence variation in Campylobacter jejuni 
strains associated with the Guillain-Barré syndrome by high-throughput AFLP analysis. BMC 
Microbiol 2006a;4;6:32. 
189. Godschalk PC, Gilbert M, Jacobs BC, Kramers T, Tio-Gillen AP, Ang CW, van den Braak N, Li J, 
Verbrugh HA, Van Belkum A, Endtz HP. Co-infection with two different Campylobacter jejuni strains 
in a patient with the Guillain-Barré syndrome. Microbes Infect 2006b;8:248-253. 
190. Jacobs BC, Endtz H, van der Meché FG, Hazenberg MP, Achtereekte HA, van Doorn PA. Serum 
anti-GQ1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with 
Miller Fisher syndrome. Ann Neurol 1995;37:260-264. 
191. Jacobs BC, Endtz HP, van der Meché FG, Hazenberg MP, de Klerk MA, van Doorn PA. Humoral 
immune response against Campylobacter jejuni lipopolysaccharides in Guillain-Barré and Miller 
Fisher syndrome. J Neuroimmunol 1997;79:62-68. 
192. Yuki N, Taki T, Takahashi M, Saito K, Yoshino H, Tai T, Handa S, Miyatake T. Molecular mimicry 
between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients 
with Fisher's syndrome. Ann Neurol 1994;36:791-793. 
193. Penner JL, Hennessy JN, Congi RV. Serotyping of Campylobacter jejuni and Campylobacter coli on 
the basis of thermostable antigens. Eur J Clin Microbiol 1983;2:378-383. 
194. Grajewski BA, Kusek JW, Gelfand HM. Development of a bacteriophage typing system for 
Campylobacter jejuni and Campylobacter coli. J Clin Microbiol 1985;22:13-18. 
195. Bolton FJ, Holt AV, Hutchinson DN. Campylobacter biotyping scheme of epidemiological value. J 
Clin Pathol 1984;37:677-681. 
196. Wassenaar TM, Fry BN, Lastovica AJ, Wagenaar JA, Coloe PJ, Duim B. Genetic characterization of 
Campylobacter jejuni O:41 isolates in relation with Guillain-Barré syndrome. J Clin Microbiol 
2000;38:874-876. 
197. Lind L, Sjögren E, Melby K, Kaijser B. DNA fingerprinting and serotyping of Campylobacter jejuni 
isolates from epidemic outbreaks. Clin Microbiol 1996;34:892-896. 
Chapter 1
39 
154. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002;125:2591-
625.  
155. Yuki N. Ganglioside mimicry and peripheral nerve disease. Muscle Nerve 2007;35:691–711. 
156. Kaida K, Kanzaki M, Morita D, Kamakura K, Motoyoshi K, Hirakawa M, Kusunoki S. Anti-ganglioside 
complex antibodies in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 2006;77:1043-1046. 
157. Kaida K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, Hirakawa M, Kusunoki S. Anti-ganglioside 
complex antibodies associated with severe disability in GBS. J Neuroimmunol 2007;182:212-218. 
158. Kaida K, Kusunoki S. Antibodies to gangliosides and ganglioside complexes in Guillain-Barré 
syndrome and Fisher syndrome.  J Neuroimmunol 2010. 
159. Kuijf ML, Godschalk PC, Gilbert M, Endtz HP, Tio-Gillen AP, Ang CW, van Doorn PA, Jacobs BC. 
Origin of ganglioside complex antibodies in Guillain-Barré syndrome. J Neuroimmunol 2007;188:69-
73. 
160. Ledeen RW, Yu RK. Gangliosides: structure, isolation and analysis. Methods Enzymol 
1982;83:139–191 
161. Simone IL, Annunziata P, Maimone D, Liguori M, Leante R, Livrea P. Serum and CSF anti-GM1 
antibodies in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating 
polyneuropathy. J Neurol Sci 1993;114:49-55. 
162. Gregson NA, Jones D, Thomas PK, Willison HJ. Acute motor neuropathy with antibodies to GM1 
ganglioside. J Neurol 1991;238:447-451. 
163. Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, Handa S, Miyatake T. A bacterium 
lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp 
Med 1993;178:1771-1775. 
164. KusunokiS, Iwamori M, Chiba A, Hitoshi S, Arita M, Kanazawa I. GM1b is a new member of antigen 
for serum antibody in Guillain-Barré syndrome. Neurology 1996;47:237-242. 
165. Yuki N, Taki T, Handa S. Antibody to GalNAc-GD1a and GalNAc-GM1b in Guillain-Barré syndrome 
subsequent to Campylobacter jejuni enteritis. J Neuroimmunol 1996;71:155-161. 
166. Yuki N. Treatment of anti-glycolipid antibody-associated neuropathy. Rinsho Shinkeigaku 
1999;39:1232-1234. 
167. Ho TW, Willison HJ, Nachamkin I, Li CY, Veitch J, Ung H, Wang GR, Liu RC, Cornblath DR, Asbury 
AK, Griffin JW, McKhann GM. Anti-GD1a antibody is associated with axonal but not demyelinating 
forms of Guillain-Barre syndrome. Ann Neurol 1999;45:168–173. 
168. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b antibody is associated 
with ophthalmoplegia in MillerFisher syndrome and Guillain-Barre  syndrome: clinical and 
immunohistochemical studies. Neurology 1993;43:1911–1917. 
169. Willison HJ, Kennedy PG. Gangliosides and bacterial toxins in Guillain-Barré syndrome. J 
Neuroimmunol 1993;46:105-112. 
170. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a 
possible marker of Miller Fisher syndrome. Ann Neurol 1992;31:677–679. 
171. O'Leary CP, Veitch J, Durward WF, Thomas AM, Rees JH, Willison HJ. Acute oropharyngeal palsy 
is associated with antibodies to GQ1b and GT1a gangliosides. Psychiatry 1996;61:649-651. 
172. Kimoto K, Koga M, Odaka M, Hirata K, Takahashi M, Li J, Gilbert M, Yuki N. Relationship of 
bacterial strains to clinical syndromes of Campylobacter-associated neuropathies. Neurology 
2006;67:1837-1843. 
173. Damian RT. Molecular mimicry: antigen sharing by parasite and host and its consequences. Amer 
Nat 1964;98:129-149. 
174. Rowley D, Jenkin CR. Antigenic cross-reaction between host and parasite as a possible cause of 
pathogenicity. Nature 1962;193:151-154.  
175. Ang CW, Jacobs BC, Laman JD. The Guillain-Barré syndrome: a true case of molecular mimicry. 
Trends Immunol 2004;25:61-66. 
176. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999;341:2068-2074. 
177. Aspinall GO, McDonald AG, Pang H, Kurjanczyk LA, Penner JL. Lipopolysaccharides of 
Campylobacter jejuni serotype O:19: structures of core oligosaccharide regions from the serostrain 
and two bacterial isolates from patients with the Guillain-Barré syndrome. Biochemistry 
1994a;33:241-249. 
General introduction   
 
 
178. Aspinall GO, Fujimoto S, McDonald AG, Pang H, Kurjanczyk LA, Penner JL. Lipopolysaccharides 
from Campylobacter jejuni associated with Guillain-Barré syndrome patients mimic human 
gangliosides in structure. Infect Immun 1994c;62:2122-2125. 
179. Aspinall GO, McDonald AG, Raju TS, Pang H, Kurjanczyk LA, Penner JL, Moran AP. Chemical 
structure of the core region of Campylobacter jejuni serotype O:2 lipopolysaccharide. Eur J Biochem 
1993a;213:1029-1037. 
180. Aspinall GO, McDonald AG, Raju TS, Pang H, Moran AP, Penner JL. Chemical structures of the 
core regions of Campylobacter jejuni serotypes O:1, O:4, O:23, and O:36 lipopolysaccharides. Eur J 
Biochem 1993b;216:880. 
181. Aspinall GO, McDonald AG, Pang H. Lipopolysaccharides of Campylobacter jejuni serotype O:19: 
structures of O-antigen chains from the serostrain and two bacterial isolates from patients with the 
Guillain-Barré syndrome. Biochemistry 1994b;33:250-255. 
182. Moran AP.Biological and serological characterization of Campylobacter jejuni lipopolysaccharides 
with deviating core and lipid A structures. FEMS Immunol Med Microbiol 1995;11:121-130. 
183. Bersudsky M, Rosenberg P, Rudensky B, Wirguin I. Lipopolysaccharides of a Campylobacter coli 
isolate from a patient with Guillain-Barré syndrome display ganglioside mimicry. Neuromuscul 
Disord 2000;10:182-186. 
184. Nachamkin I. Rabbit model of Guillain-Barré syndrome. Ann Neurol 2002;52:127-128. 
185. Godschalk PC, Kuijf ML, Li J, St Michael F, Ang CW, Jacobs BC, Karwaski MF, Brochu D, 
Moterassed A, Endtz HP, van Belkum A, Gilbert M. Structural characterization of Campylobacter 
jejuni lipooligosaccharide outer cores associated with Guillain-Barré and Miller Fisher syndromes. 
Infect Immun 2007;75:1245–1254. 
186. Aspinall GO, McDonald AG, Pang H. Structures of the O chains from lipopolysaccharides of 
Campylobacter jejuni serotypes O:23 and O:36. Carbohydr Res 1992;231:13-30. 
187. Aspinall GO, Lynch CM, Pang H, Shaver RT, Moran AP. Chemical structures of the core region of 
Campylobacter jejuni O:3 lipopolysaccharide and an associated polysaccharide. Eur J Biochem 
1995;231:570-578. 
188. Godschalk PC, Bergman MP, Gorkink RF, Simons G, van den Braak N, Lastovica AJ, Endtz HP, 
Verbrugh HA, van Belkum A. Identification of DNA sequence variation in Campylobacter jejuni 
strains associated with the Guillain-Barré syndrome by high-throughput AFLP analysis. BMC 
Microbiol 2006a;4;6:32. 
189. Godschalk PC, Gilbert M, Jacobs BC, Kramers T, Tio-Gillen AP, Ang CW, van den Braak N, Li J, 
Verbrugh HA, Van Belkum A, Endtz HP. Co-infection with two different Campylobacter jejuni strains 
in a patient with the Guillain-Barré syndrome. Microbes Infect 2006b;8:248-253. 
190. Jacobs BC, Endtz H, van der Meché FG, Hazenberg MP, Achtereekte HA, van Doorn PA. Serum 
anti-GQ1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with 
Miller Fisher syndrome. Ann Neurol 1995;37:260-264. 
191. Jacobs BC, Endtz HP, van der Meché FG, Hazenberg MP, de Klerk MA, van Doorn PA. Humoral 
immune response against Campylobacter jejuni lipopolysaccharides in Guillain-Barré and Miller 
Fisher syndrome. J Neuroimmunol 1997;79:62-68. 
192. Yuki N, Taki T, Takahashi M, Saito K, Yoshino H, Tai T, Handa S, Miyatake T. Molecular mimicry 
between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients 
with Fisher's syndrome. Ann Neurol 1994;36:791-793. 
193. Penner JL, Hennessy JN, Congi RV. Serotyping of Campylobacter jejuni and Campylobacter coli on 
the basis of thermostable antigens. Eur J Clin Microbiol 1983;2:378-383. 
194. Grajewski BA, Kusek JW, Gelfand HM. Development of a bacteriophage typing system for 
Campylobacter jejuni and Campylobacter coli. J Clin Microbiol 1985;22:13-18. 
195. Bolton FJ, Holt AV, Hutchinson DN. Campylobacter biotyping scheme of epidemiological value. J 
Clin Pathol 1984;37:677-681. 
196. Wassenaar TM, Fry BN, Lastovica AJ, Wagenaar JA, Coloe PJ, Duim B. Genetic characterization of 
Campylobacter jejuni O:41 isolates in relation with Guillain-Barré syndrome. J Clin Microbiol 
2000;38:874-876. 
197. Lind L, Sjögren E, Melby K, Kaijser B. DNA fingerprinting and serotyping of Campylobacter jejuni 
isolates from epidemic outbreaks. Clin Microbiol 1996;34:892-896. 
Chapter 1
40  
198. Ribot EM, Fitzgerald C, Kubota K, Swaminathan B, Barrett TJ. Rapid pulsed-field gel 
electrophoresis protocol for subtyping of Campylobacter jejuni. J Clin Microbiol 2001;39:1889-1894. 
199. Cornelius AJ, Nicol C, Hudson JA. Campylobacter spp. in New Zealand raw sheep liver and human 
Campylobacteriosis cases. Int J Food Microbiol 2005;99:99-105. 
200. Devane ML, Nicol C, Ball A, Klena JD, Scholes P, Hudson JA, Baker MG, Gilpin BJ, Garrett N, 
Savill MG. The occurrence of Campylobacter subtypes in environmental reservoirs and potential 
transmission routes. J Appl Microbiol 2005;98:980-990. 
201. Fitzgerald C, Helsel LO, Nicholson MA, Olsen SJ, Swerdlow DL, Flahart R, Sexton J, Fields PI. 
Evaluation of methods for subtyping Campylobacter jejuni during an outbreak involving a food 
handler. J Clin Microbiol 2001;39:2386-2390. 
202. Hallin S, Throbäck IN, Dicksved J, Pell M. Metabolic profiles and genetic diversity of denitrifying 
communities in activated sludge after addition of methanol or ethanol. Appl Environ Microbiol 
2006;72:5445-5452. 
203. Duim B, Wassenaar TM, Rigter A, Wagenaar J. High-resolution genotyping of Campylobacter 
strains isolated from poultry and humans with amplified fragment length polymorphism 
fingerprinting. Appl Environ Microbiol 1999;65:2369-2375. 
204. On SL. High-resolution genomic fingerprinting of Campylobacter jejuni and Campylobacter coli by 
analysis of amplified fragment length polymorphisms. FEMS Microbiol Lett 1999;173:77-84. 
205. Duim B, Vandamme PA, Rigter A, Laevens S, Dijkstra JR, Wagenaar JA. Differentiation of 
Campylobacter species by AFLP fingerprinting. Microbiology 2001;147:2729-2737. 
206. On SL, Harrington CS. Identification of taxonomic and epidemiological relationships among 
Campylobacter species by numerical analysis of AFLP profiles. FEMS Microbiol Lett 2000;193:161-
169. 
207. Duim B, Wagenaar JA, Dijkstra JR, Goris J, Endtz HP, Vandamme PA. Identification of distinct 
Campylobacter lari genogroups by amplified fragment length polymorphism and protein 
electrophoretic profiles. Appl Environ Microbiol 2004;70:18-24. 
208. Johnsen G, Kruse H, Hofshagen M. Genotyping of thermotolerant Campylobacter from poultry 
slaughterhouse by amplified fragment length polymorphism. J Appl Microbiol 2007;103:271-279. 
209. Duim B, Wagenaar J. Amplified fragment-length polymorphism and protein profiling for identification 
of Campylobacter lari subgroups. Methods Mol Biol 2006;345:119-130. 
210. Wittwer M, Keller J, Wassenaar TM, Stephan R, Howald D, Regula G, Bissig-Choisat B. Genetic 
diversity and antibiotic resistance patterns in a Campylobacter population isolated from poultry 
farms in Switzerland. Appl Environ Microbiol 2005;71:2840-2847. 
211. Siemer BL, Nielsen EM, On SL. Identification and molecular epidemiology of Campylobacter coli 
isolates from human gastroenteritis, food, and animal sources by amplified fragment length 
polymorphism analysis and Penner serotyping. Appl Environ Microbiol 2005;71:1953-1958. 
212. Schouls LM, Reulen S, Duim B, Wagenaar JA, Willems RJ, Dingle KE, Colles FM, van Embden JD. 
Comparative genotyping of Campylobacter jejuni by amplified fragment length polymorphism, 
multilocus sequence typing, and short repeat sequencing: strain diversity, host range, and 
recombination. J Clin Microbiol 2003;41:15-26. 
213. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, Zhang Q, Zhou J, Zurth K, 
Caugant DA, Feavers IM, Achtman M, Spratt BG. Multilocus sequence typing: a portable approach 
to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U 
S A 1998;95:3140-3145. 
214. Dingle KE, van Den Braak N, Colles FM, Price LJ, Woodward DL, Rodgers FG, Endtz HP, van 
Belkum A, Maiden MC. Sequence typing confirms that Campylobacter jejuni strains associated with 
Guillain-Barré and Miller-Fisher syndromes are of diverse genetic lineage, serotype, and flagella 
type. J Clin Microbiol 2001;39:3346-3349. 
215. Dingle KE, Colles FM, Ure R, Wagenaar JA, Duim B, Bolton FJ, Fox AJ, Wareing DR, Maiden MC. 
Molecular characterization of Campylobacter jejuni clones: a basis for epidemiologic investigation. 
Emerg Infect Dis 2002;8:949-955. 
216. Miller WG, Pearson BM, Wells JM, Parker CT, Kapitonov VV, Mandrell RE. Diversity within the 
Campylobacter jejuni type I restriction-modification loci. Microbiology 2005;151:337-351. 
217. Maiden MC. Multilocus sequence typing of bacteria. Annu Rev Microbiol 2006;60:561-588. 
General introduction   
 
 
218. Maiden MC and Dingle KE. Population biology of Campylobacter jejuni and related organism. In 
Campylobacter,I. Nachamkin, C. M. Szymanski, and M. J. Blaser, editors. Washington, D.C.: ASM 
Press 2008;245-261. 
219. Colles FM, Jones K, Harding RM, Maiden MC. Genetic diversity of Campylobacter jejuni isolates 
from farm animals and the farm environment. Appl Environ Microbiol 2003;69:7409-7413. 
220. French N, Barrigas M, Brown P, Ribiero P, Williams N, Leatherbarrow H, Birtles R, Bolton E, 
Fearnhead P, Fox A. Spatial epidemiology and natural population structure of Campylobacter jejuni 
colonizing a farmland ecosystem. Environ Microbiol 2005;7:1116-1126. 
221. Manning G, Dowson CG, Bagnall MC, Ahmed IH, West M, Newell DG. Multilocus sequence typing 
for comparison of veterinary and human isolates of Campylobacter jejuni. Appl Environ Microbiol 
2003;69:6370-6379. 
222. Parsons BN, Cody AJ, Porter CJ, Stavisky JH, Smith JL, Williams NJ, Leatherbarrow AJ, Hart CA, 
Gaskell RM, Dingle KE, Dawson S. Typing of Campylobacter jejuni isolates from dogs by use of 
multilocus sequence typing and pulsed-field gel electrophoresis.  J Clin Microbiol 2009;47:3466-
3471. 
223. McTavish SM, Pope CE, Nicol C, Campbell D, French N, Carter PE. Multilocus sequence typing of 
Campylobacter jejuni, and the correlation between clonal complex and pulsed-field gel 
electrophoresis macrorestriction profile. FEMS Microbiol Lett 2009;298:149-156. 
224. Allen VM, Bull SA, Corry JE, Domingue G, Jørgensen F, Frost JA, Whyte R, Gonzalez A, Elviss N, 
Humphrey TJ. Campylobacter spp. contamination of chicken carcasses during processing in relation 
to flock colonisation. Int J Food Microbiol 2007;113:54-61. 
225. McCarthy ND, Colles FM, Dingle KE, Bagnall MC, Manning G, Maiden MC, Falush D. Host-
associated genetic import in Campylobacter jejuni. Emerg Infect Dis 2007;13:267-272. 
226. Kinana AD, Cardinale E, Bahsoun I, Tall F, Sire JM, Garin B, Boye CS, Dromigny JA, Perrier-Gros-
Claude JD. Analysis of topoisomerase mutations in fluoroquinolone-resistant and susceptible 
Campylobacter jejuni strains isolated in Senegal. Int J Antimicrob Agents 2007;29:397-401.  
227. Kinana AD, Cardinale E, Tall F, Bahsoun I, Sire JM, Garin B, Breurec S, Boye CS, Perrier-Gros-
Claude JD. Genetic diversity and quinolone resistance in Campylobacter jejuni isolates from poultry 
in Senegal. Appl Environ Microbiol 2006;72:3309-3313. 
228. Allos BM, Lippy FT, Carlsen A, Washburn RG, Blaser MJ. Campylobacter jejuni strains from 
patients with Guillain-Barré syndrome. Emerg Infect Dis 1998;4:263-268. 
229. Lastovica AJ, Goddard EA, Argent AC. Guillain-Barré syndrome in South Africa associated with 
Campylobacter jejuni O:41 strains. J Infect Dis 1997;1762:S139-143. 
230. Nishimura M, Nukina M, Kuroki S, Obayashi H, Ohta M, Ma JJ, Saida T, Uchiyama T. 
Characterization of Campylobacter jejuni isolates from patients with Guillain-Barré syndrome. J 
Neurol Sci 1997;153:91-99. 
231. Saida T, Kuroki S, Hao Q, Nishimura M, Nukina M, Obayashi H. Campylobacter jejuni isolates from 
Japanese patients with Guillain-Barré syndrome. J Infect Dis 1997;176:S129-134. 
232. Koga M, Gilbert M, Takahashi M, Li J, Koike S, Hirata K, Yuki N. Comprehensive analysis of 
bacterial risk factors for the development of Guillain-Barré syndrome after Campylobacter jejuni 
enteritis. J Infect Dis 2006;193:547-555. 
233. Salloway S, Mermel LA, Seamans M, Aspinall GO, Shin JEN, Kurjanczyk A, Penner JL. Miller-
Fisher syndrome associated with Campylobacter jejuni bearing lipopolysaccharide molecules that 
mimic human ganglioside GD3. Infect Immun 1996;64:2945–2949. 
234. Sheikh KA, Ho TW, Nachamkin I, Li CY, Cornblath DR, Asbury AK, Griffin JW, McKhann GM. 
Molecular mimicry in Guillain-Barré syndrome. Ann N Y Acad Sci 1998;845:307-321. 
235. Yuki N. Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni 
isolated from patients with Guillain-Barré syndrome and Miller Fisher syndrome. J Infect Dis 
1997;176:S150-153. 
236. Endtz HP, Ang CW, van Den Braak N, Duim B, Rigter A, Price LJ, Woodward DL, Rodgers FG, 
Johnson WM, Wagenaar JA, Jacobs BC, Verbrugh HA, van Belkum A. Molecular characterization of 
Campylobacter jejuni from patients with Guillain-Barré and Miller Fisher syndromes. J Clin Microbiol 
2000;38:2297-2301. 
Chapter 1
41 
198. Ribot EM, Fitzgerald C, Kubota K, Swaminathan B, Barrett TJ. Rapid pulsed-field gel 
electrophoresis protocol for subtyping of Campylobacter jejuni. J Clin Microbiol 2001;39:1889-1894. 
199. Cornelius AJ, Nicol C, Hudson JA. Campylobacter spp. in New Zealand raw sheep liver and human 
Campylobacteriosis cases. Int J Food Microbiol 2005;99:99-105. 
200. Devane ML, Nicol C, Ball A, Klena JD, Scholes P, Hudson JA, Baker MG, Gilpin BJ, Garrett N, 
Savill MG. The occurrence of Campylobacter subtypes in environmental reservoirs and potential 
transmission routes. J Appl Microbiol 2005;98:980-990. 
201. Fitzgerald C, Helsel LO, Nicholson MA, Olsen SJ, Swerdlow DL, Flahart R, Sexton J, Fields PI. 
Evaluation of methods for subtyping Campylobacter jejuni during an outbreak involving a food 
handler. J Clin Microbiol 2001;39:2386-2390. 
202. Hallin S, Throbäck IN, Dicksved J, Pell M. Metabolic profiles and genetic diversity of denitrifying 
communities in activated sludge after addition of methanol or ethanol. Appl Environ Microbiol 
2006;72:5445-5452. 
203. Duim B, Wassenaar TM, Rigter A, Wagenaar J. High-resolution genotyping of Campylobacter 
strains isolated from poultry and humans with amplified fragment length polymorphism 
fingerprinting. Appl Environ Microbiol 1999;65:2369-2375. 
204. On SL. High-resolution genomic fingerprinting of Campylobacter jejuni and Campylobacter coli by 
analysis of amplified fragment length polymorphisms. FEMS Microbiol Lett 1999;173:77-84. 
205. Duim B, Vandamme PA, Rigter A, Laevens S, Dijkstra JR, Wagenaar JA. Differentiation of 
Campylobacter species by AFLP fingerprinting. Microbiology 2001;147:2729-2737. 
206. On SL, Harrington CS. Identification of taxonomic and epidemiological relationships among 
Campylobacter species by numerical analysis of AFLP profiles. FEMS Microbiol Lett 2000;193:161-
169. 
207. Duim B, Wagenaar JA, Dijkstra JR, Goris J, Endtz HP, Vandamme PA. Identification of distinct 
Campylobacter lari genogroups by amplified fragment length polymorphism and protein 
electrophoretic profiles. Appl Environ Microbiol 2004;70:18-24. 
208. Johnsen G, Kruse H, Hofshagen M. Genotyping of thermotolerant Campylobacter from poultry 
slaughterhouse by amplified fragment length polymorphism. J Appl Microbiol 2007;103:271-279. 
209. Duim B, Wagenaar J. Amplified fragment-length polymorphism and protein profiling for identification 
of Campylobacter lari subgroups. Methods Mol Biol 2006;345:119-130. 
210. Wittwer M, Keller J, Wassenaar TM, Stephan R, Howald D, Regula G, Bissig-Choisat B. Genetic 
diversity and antibiotic resistance patterns in a Campylobacter population isolated from poultry 
farms in Switzerland. Appl Environ Microbiol 2005;71:2840-2847. 
211. Siemer BL, Nielsen EM, On SL. Identification and molecular epidemiology of Campylobacter coli 
isolates from human gastroenteritis, food, and animal sources by amplified fragment length 
polymorphism analysis and Penner serotyping. Appl Environ Microbiol 2005;71:1953-1958. 
212. Schouls LM, Reulen S, Duim B, Wagenaar JA, Willems RJ, Dingle KE, Colles FM, van Embden JD. 
Comparative genotyping of Campylobacter jejuni by amplified fragment length polymorphism, 
multilocus sequence typing, and short repeat sequencing: strain diversity, host range, and 
recombination. J Clin Microbiol 2003;41:15-26. 
213. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, Zhang Q, Zhou J, Zurth K, 
Caugant DA, Feavers IM, Achtman M, Spratt BG. Multilocus sequence typing: a portable approach 
to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U 
S A 1998;95:3140-3145. 
214. Dingle KE, van Den Braak N, Colles FM, Price LJ, Woodward DL, Rodgers FG, Endtz HP, van 
Belkum A, Maiden MC. Sequence typing confirms that Campylobacter jejuni strains associated with 
Guillain-Barré and Miller-Fisher syndromes are of diverse genetic lineage, serotype, and flagella 
type. J Clin Microbiol 2001;39:3346-3349. 
215. Dingle KE, Colles FM, Ure R, Wagenaar JA, Duim B, Bolton FJ, Fox AJ, Wareing DR, Maiden MC. 
Molecular characterization of Campylobacter jejuni clones: a basis for epidemiologic investigation. 
Emerg Infect Dis 2002;8:949-955. 
216. Miller WG, Pearson BM, Wells JM, Parker CT, Kapitonov VV, Mandrell RE. Diversity within the 
Campylobacter jejuni type I restriction-modification loci. Microbiology 2005;151:337-351. 
217. Maiden MC. Multilocus sequence typing of bacteria. Annu Rev Microbiol 2006;60:561-588. 
General introduction   
 
 
218. Maiden MC and Dingle KE. Population biology of Campylobacter jejuni and related organism. In 
Campylobacter,I. Nachamkin, C. M. Szymanski, and M. J. Blaser, editors. Washington, D.C.: ASM 
Press 2008;245-261. 
219. Colles FM, Jones K, Harding RM, Maiden MC. Genetic diversity of Campylobacter jejuni isolates 
from farm animals and the farm environment. Appl Environ Microbiol 2003;69:7409-7413. 
220. French N, Barrigas M, Brown P, Ribiero P, Williams N, Leatherbarrow H, Birtles R, Bolton E, 
Fearnhead P, Fox A. Spatial epidemiology and natural population structure of Campylobacter jejuni 
colonizing a farmland ecosystem. Environ Microbiol 2005;7:1116-1126. 
221. Manning G, Dowson CG, Bagnall MC, Ahmed IH, West M, Newell DG. Multilocus sequence typing 
for comparison of veterinary and human isolates of Campylobacter jejuni. Appl Environ Microbiol 
2003;69:6370-6379. 
222. Parsons BN, Cody AJ, Porter CJ, Stavisky JH, Smith JL, Williams NJ, Leatherbarrow AJ, Hart CA, 
Gaskell RM, Dingle KE, Dawson S. Typing of Campylobacter jejuni isolates from dogs by use of 
multilocus sequence typing and pulsed-field gel electrophoresis.  J Clin Microbiol 2009;47:3466-
3471. 
223. McTavish SM, Pope CE, Nicol C, Campbell D, French N, Carter PE. Multilocus sequence typing of 
Campylobacter jejuni, and the correlation between clonal complex and pulsed-field gel 
electrophoresis macrorestriction profile. FEMS Microbiol Lett 2009;298:149-156. 
224. Allen VM, Bull SA, Corry JE, Domingue G, Jørgensen F, Frost JA, Whyte R, Gonzalez A, Elviss N, 
Humphrey TJ. Campylobacter spp. contamination of chicken carcasses during processing in relation 
to flock colonisation. Int J Food Microbiol 2007;113:54-61. 
225. McCarthy ND, Colles FM, Dingle KE, Bagnall MC, Manning G, Maiden MC, Falush D. Host-
associated genetic import in Campylobacter jejuni. Emerg Infect Dis 2007;13:267-272. 
226. Kinana AD, Cardinale E, Bahsoun I, Tall F, Sire JM, Garin B, Boye CS, Dromigny JA, Perrier-Gros-
Claude JD. Analysis of topoisomerase mutations in fluoroquinolone-resistant and susceptible 
Campylobacter jejuni strains isolated in Senegal. Int J Antimicrob Agents 2007;29:397-401.  
227. Kinana AD, Cardinale E, Tall F, Bahsoun I, Sire JM, Garin B, Breurec S, Boye CS, Perrier-Gros-
Claude JD. Genetic diversity and quinolone resistance in Campylobacter jejuni isolates from poultry 
in Senegal. Appl Environ Microbiol 2006;72:3309-3313. 
228. Allos BM, Lippy FT, Carlsen A, Washburn RG, Blaser MJ. Campylobacter jejuni strains from 
patients with Guillain-Barré syndrome. Emerg Infect Dis 1998;4:263-268. 
229. Lastovica AJ, Goddard EA, Argent AC. Guillain-Barré syndrome in South Africa associated with 
Campylobacter jejuni O:41 strains. J Infect Dis 1997;1762:S139-143. 
230. Nishimura M, Nukina M, Kuroki S, Obayashi H, Ohta M, Ma JJ, Saida T, Uchiyama T. 
Characterization of Campylobacter jejuni isolates from patients with Guillain-Barré syndrome. J 
Neurol Sci 1997;153:91-99. 
231. Saida T, Kuroki S, Hao Q, Nishimura M, Nukina M, Obayashi H. Campylobacter jejuni isolates from 
Japanese patients with Guillain-Barré syndrome. J Infect Dis 1997;176:S129-134. 
232. Koga M, Gilbert M, Takahashi M, Li J, Koike S, Hirata K, Yuki N. Comprehensive analysis of 
bacterial risk factors for the development of Guillain-Barré syndrome after Campylobacter jejuni 
enteritis. J Infect Dis 2006;193:547-555. 
233. Salloway S, Mermel LA, Seamans M, Aspinall GO, Shin JEN, Kurjanczyk A, Penner JL. Miller-
Fisher syndrome associated with Campylobacter jejuni bearing lipopolysaccharide molecules that 
mimic human ganglioside GD3. Infect Immun 1996;64:2945–2949. 
234. Sheikh KA, Ho TW, Nachamkin I, Li CY, Cornblath DR, Asbury AK, Griffin JW, McKhann GM. 
Molecular mimicry in Guillain-Barré syndrome. Ann N Y Acad Sci 1998;845:307-321. 
235. Yuki N. Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni 
isolated from patients with Guillain-Barré syndrome and Miller Fisher syndrome. J Infect Dis 
1997;176:S150-153. 
236. Endtz HP, Ang CW, van Den Braak N, Duim B, Rigter A, Price LJ, Woodward DL, Rodgers FG, 
Johnson WM, Wagenaar JA, Jacobs BC, Verbrugh HA, van Belkum A. Molecular characterization of 
Campylobacter jejuni from patients with Guillain-Barré and Miller Fisher syndromes. J Clin Microbiol 
2000;38:2297-2301. 
Chapter 1
42
General introduction 
 
237. Engberg J, Nachamkin I, Fussing V, McKhann GM, Griffin JW, Piffaretti JC, Nielsen EM, Gerner-
Smidt P. Absence of clonality of Campylobacter jejuni in serotypes other than HS:19 associated with 
Guillain-Barré syndrome and gastroenteritis. J Infect Dis 2001;184:215-220.  
238. Duim B, Ang CW, van Belkum A, Rigter A, van Leeuwen NW, Endtz HP, Wagenaar JA. Amplified 
fragment length polymorphism analysis of Campylobacter jejuni strains isolated from chickens and 
from patients with gastroenteritis or Guillain-Barré or Miller Fisher syndrome. Appl Environ Microbiol 
2000;66:3917-3923. 
239. Leonard EE 2nd, Tompkins LS, Falkow S, Nachamkin I. Comparison of Campylobacter jejuni 
isolates implicated in Guillain-Barré syndrome and strains that cause enteritis by a DNA microarray. 
Infect Immun 2004;72:1199-1203. 
240. Taboada EN, van Belkum A, Yuki N, Acedillo RR, Godschalk PC, Koga M, Endtz HP, Gilbert M, 
Nash JH. Comparative genomic analysis of Campylobacter jejuni associated with Guillain-Barré and 
Miller Fisher syndromes: neuropathogenic and enteritis-associated isolates can share high levels of 
genomic similarity. BMC Genomics 2007;8:359. 
241. Ang CW, Laman JD, Willison HJ, Wagner ER, Endtz HP, De Klerk MA, Tio-Gillen AP, van Den 
Braak N, Jacobs BC, Doorn PA. Structure of Campylobacter jejuni lipopolysaccharides determines 
antiganglioside specificity and clinical features of Guillain-Barré and Miller Fisher patients. Infect 
Immun 2002;70:1202-1208. 
242. Parker CT, Horn ST, Gilbert M, Miller WG, Woodward DL, Mandrell RE. Comparison of 
Campylobacter jejuni lipooligosaccharide biosynthesis loci from a variety of sources. J Clin Microbiol 
2005;43:2771-2781. 
243. Gilbert M, Godschalk PC, Parker CT, Endtz HP, Wakarchuk WW. Genetic basis for the variation in 
the lipooligouter core of Campulobacter jejuni and possible associstion of glycosyltransferase genes 
with post-infectioous neuropathies. In J. M. Ketely and M. E. Konkel (ed.), Campylobacter: 
Molecular and cellular Biology. Horizon Bioscience, Norfolk, United Kingdom 2005:219-248. 
244. Parker CT, Gilbert M, Yuki N, Endtz HP, Mandrell RE. Characterization of lipooligosaccharide-
biosynthetic loci of Campylobacter jejuni reveals new lipooligosaccharide classes: evidence of 
mosaic organizations. J Bacteriol 2008;190:5681-5689. 
245. Komagamine T and Yuki N. Ganglioside mimicry as a cause of Guillain-Barré syndrome. CNS 
Neurol. Disord. Drug Targets 2006;5:391-400. 
246. Prendergast MM, Moran AP. Lipopolysaccharides in the development of the Guillain-Barré 
syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies. J 
Endotoxin Res 2000;6:341-359. 
247. Gilbert M, Parker CT, Moran AP. Campylobacter jejuni Lipooligosaccharides: Structures and 
Biosynthesis. In Campylobacter, I. Nachamkin, C.M. Szymanski, and M.J. Blaser, editors. 
Washington, D.C.: ASM Press 2008:483-504. 
248. van Belkum A, van den Braak, Godschalk PC, Ang CW, Jacobs BC, Gilbert M, Wakarchuk W, 
Verbrugh H, Endtz HP. A Campylobacter jejuni gene associated with immunemediated neuropathy. 
Nat Med 2001;7:752-753. 
249. Gilbert M, Karwaski MF, Bernatchez S, Young NM, Taboada E, Michniewicz J, Cunningham AM, 
Wakarchuk WW. The genetic bases for the variation in the lipo-oligosaccharide of the mucosal 
pathogen, Campylobacter jejuni. Biosynthesis of sialylated ganglioside mimics in the core 
oligosaccharide. J Biol Chem 2002;277:327-337. 
250. Hye JB, Nachamkin I. Campylobacter jejuni cst-II polymorphisms and association with development 
of Guillain-Barré syndrome. Neurology 2007;68:1633-1634. 
 
 
 
 
 
 
 
Chapter 2.1 
 
 
 
 
 
 
 
General introduction 
 
237. Engberg J, Nachamkin I, Fussing V, McKhann GM, Griffin JW, Piffaretti JC, Nielsen EM, Gerner-
Smidt P. Absence of clonality of Campylobacter jejuni in serotypes other than HS:19 associated with 
Guillain-Barré syndrome and gastroenteritis. J Infect Dis 2001;184:215-220.  
238. Duim B, Ang CW, van Belkum A, Rigter A, van Leeuwen NW, Endtz HP, Wagenaar JA. Amplified 
fragment length polymorphism analysis of Campylobacter jejuni strains isolated from chickens and 
from patients with gastroenteritis or Guillain-Barré or Miller Fisher syndrome. Appl Environ Microbiol 
2000;66:3917-3923. 
239. Leonard EE 2nd, Tompkins LS, Falkow S, Nachamkin I. Comparison of Campylobacter jejuni 
isolates implicated in Guillain-Barré syndrome and strains that cause enteritis by a DNA microarray. 
Infect Immun 2004;72:1199-1203. 
240. Taboada EN, van Belkum A, Yuki N, Acedillo RR, Godschalk PC, Koga M, Endtz HP, Gilbert M, 
Nash JH. Comparative genomic analysis of Campylobacter jejuni associated with Guillain-Barré and 
Miller Fisher syndromes: neuropathogenic and enteritis-associated isolates can share high levels of 
genomic similarity. BMC Genomics 2007;8:359. 
241. Ang CW, Laman JD, Willison HJ, Wagner ER, Endtz HP, De Klerk MA, Tio-Gillen AP, van Den 
Braak N, Jacobs BC, Doorn PA. Structure of Campylobacter jejuni lipopolysaccharides determines 
antiganglioside specificity and clinical features of Guillain-Barré and Miller Fisher patients. Infect 
Immun 2002;70:1202-1208. 
242. Parker CT, Horn ST, Gilbert M, Miller WG, Woodward DL, Mandrell RE. Comparison of 
Campylobacter jejuni lipooligosaccharide biosynthesis loci from a variety of sources. J Clin Microbiol 
2005;43:2771-2781. 
243. Gilbert M, Godschalk PC, Parker CT, Endtz HP, Wakarchuk WW. Genetic basis for the variation in 
the lipooligouter core of Campulobacter jejuni and possible associstion of glycosyltransferase genes 
with post-infectioous neuropathies. In J. M. Ketely and M. E. Konkel (ed.), Campylobacter: 
Molecular and cellular Biology. Horizon Bioscience, Norfolk, United Kingdom 2005:219-248. 
244. Parker CT, Gilbert M, Yuki N, Endtz HP, Mandrell RE. Characterization of lipooligosaccharide-
biosynthetic loci of Campylobacter jejuni reveals new lipooligosaccharide classes: evidence of 
mosaic organizations. J Bacteriol 2008;190:5681-5689. 
245. Komagamine T and Yuki N. Ganglioside mimicry as a cause of Guillain-Barré syndrome. CNS 
Neurol. Disord. Drug Targets 2006;5:391-400. 
246. Prendergast MM, Moran AP. Lipopolysaccharides in the development of the Guillain-Barré 
syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies. J 
Endotoxin Res 2000;6:341-359. 
247. Gilbert M, Parker CT, Moran AP. Campylobacter jejuni Lipooligosaccharides: Structures and 
Biosynthesis. In Campylobacter, I. Nachamkin, C.M. Szymanski, and M.J. Blaser, editors. 
Washington, D.C.: ASM Press 2008:483-504. 
248. van Belkum A, van den Braak, Godschalk PC, Ang CW, Jacobs BC, Gilbert M, Wakarchuk W, 
Verbrugh H, Endtz HP. A Campylobacter jejuni gene associated with immunemediated neuropathy. 
Nat Med 2001;7:752-753. 
249. Gilbert M, Karwaski MF, Bernatchez S, Young NM, Taboada E, Michniewicz J, Cunningham AM, 
Wakarchuk WW. The genetic bases for the variation in the lipo-oligosaccharide of the mucosal 
pathogen, Campylobacter jejuni. Biosynthesis of sialylated ganglioside mimics in the core 
oligosaccharide. J Biol Chem 2002;277:327-337. 
250. Hye JB, Nachamkin I. Campylobacter jejuni cst-II polymorphisms and association with development 
of Guillain-Barré syndrome. Neurology 2007;68:1633-1634. 
 
 
 
 
 
 
 
Chapter 2.1 
 
 
 
 
 
 
 
44
 
 
ACUTE FLACCID PARALYSIS SURVEYS TO DETERMINE INCIDENCE RATES FOR GBS 
 
1,2Zhahirul Islam, 3Bart C. Jacobs, 4Quazi D. Mohammad, 5Sergei Diorditsa, 1,2Hubert P. Endtz   
 
1,2International Centre for Diarrheal Disease Research, Dhaka, Bangladesh; 2 Department of Medical 
Microbiology and Infectious Diseases,  3Departments of Neurology and Immunology , Erasmus 
University Medical Centre, Rotterdam, The Netherlands; 4Department of Neurology, Dhaka Medical 
College and Hospital, Dhaka, Bangladesh; 5Immunization and Vaccine Development, World Health 
Organization, Dhaka, Bangladesh  
 
 
 
Submitted for publication 
GBS incidence   
 
  
 
 
Bangladesh has achieved remarkable success in its drive to eradicate poliomyelitis as no case 
has been reported from the year 2000 and onwards. Still, the non-polio incidence rate of paralytic 
syndromes in Bangladesh is currently 3.25 per 100,000 children <15 year (1). Guillain–Barré 
syndrome (GBS) is an acute polyradiculoneuropathy and is the most frequent cause of acute flaccid 
paralysis (AFP) with a worldwide incidence ranging from 1.2 to 2.3 per 100,000 persons per year (2). 
Campylobacter jejuni has been identified as the predominant antecedent infection of GBS in 
Bangladesh (3). Frequent exposure to enteropathogens in developing countries may lead to an 
increased incidence of GBS. Our objective was to estimate the crude incidence rates of GBS among 
children <15 years of age in Bangladesh in 2006 and 2007 on the basis of the ongoing AFP 
surveillance program.  
 
Methods 
 
An active surveillance program for AFP is conducted by The Government of Bangladesh 
(GoB) in collaboration with World Health Organization (WHO). AFP is defined as acute onset of focal 
or general flaccid (hypotonic) weakness without other obvious cause (e.g., trauma) in children <15 
years, including GBS. Data on the number of reported AFP cases in Bangladesh in 2006 and 2007 
were obtained. Based on the clinical and other information routinely collected through the surveillance 
system, we defined a GBS case (4).  In addition, we considered the absence of injury or birth trauma 
in our diagnostic criteria. Bangladesh is divided in six divisions and 64 districts. Crude incidence data 
of GBS were calculated per division and per district, based upon <15 years population reported by 
WHO/GoB.  
 
Results 
  
 The total number of reported AFP cases in children <15 years in 2006 and 2007 was 1619 
and 1844, respectively. Among those, the number of cases that fulfilled the case definition of GBS was 
608 (37%) and 855 (46%), respectively. The crude incidence of GBS in children <15 years varied from 
1.5 to 1.7 per 100,000 populations in the three northern divisions Dhaka, Rajshahi, and Sylhet, and 
from 2.1 to 2.5 per 100,000 in the three southern divisions Khulna, Barisal and Chittagong of 
Bangladesh (Fig.). Overall, crude incidence rates of GBS in children <15 years varied from 1.5 to 2.5 
per 100,000 per year in the six divisions of Bangladesh. High incidence rates greater than 5.0 per 
100,000 were observed in the Meherpur and Barisal district, the southern part of Bangladesh. There 
was a seasonal fluctuation in the frequency of patients with GBS; the highest number of cases was 
found in May, with 159 cases, and lowest for February with 84 cases (Fig.). GBS was predominant 
among boys (59.1% of cases).    
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increased incidence of GBS. Our objective was to estimate the crude incidence rates of GBS among 
children <15 years of age in Bangladesh in 2006 and 2007 on the basis of the ongoing AFP 
surveillance program.  
 
Methods 
 
An active surveillance program for AFP is conducted by The Government of Bangladesh 
(GoB) in collaboration with World Health Organization (WHO). AFP is defined as acute onset of focal 
or general flaccid (hypotonic) weakness without other obvious cause (e.g., trauma) in children <15 
years, including GBS. Data on the number of reported AFP cases in Bangladesh in 2006 and 2007 
were obtained. Based on the clinical and other information routinely collected through the surveillance 
system, we defined a GBS case (4).  In addition, we considered the absence of injury or birth trauma 
in our diagnostic criteria. Bangladesh is divided in six divisions and 64 districts. Crude incidence data 
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WHO/GoB.  
 
Results 
  
 The total number of reported AFP cases in children <15 years in 2006 and 2007 was 1619 
and 1844, respectively. Among those, the number of cases that fulfilled the case definition of GBS was 
608 (37%) and 855 (46%), respectively. The crude incidence of GBS in children <15 years varied from 
1.5 to 1.7 per 100,000 populations in the three northern divisions Dhaka, Rajshahi, and Sylhet, and 
from 2.1 to 2.5 per 100,000 in the three southern divisions Khulna, Barisal and Chittagong of 
Bangladesh (Fig.). Overall, crude incidence rates of GBS in children <15 years varied from 1.5 to 2.5 
per 100,000 per year in the six divisions of Bangladesh. High incidence rates greater than 5.0 per 
100,000 were observed in the Meherpur and Barisal district, the southern part of Bangladesh. There 
was a seasonal fluctuation in the frequency of patients with GBS; the highest number of cases was 
found in May, with 159 cases, and lowest for February with 84 cases (Fig.). GBS was predominant 
among boys (59.1% of cases).    
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Comments 
  
 To our knowledge, this is the first report of a population based crude incidence rates of GBS in 
Bangladesh. A significant proportion of the AFP cases in Bangladesh appear to be caused by GBS. 
The incidence of GBS in the three northern divisions is much lower than in the three coastal divisions 
Khulna, Barisal and Chittagong, for which we currently have no explanation. However, differences in 
incidence rates between northern and southern part of Bangladesh may be explained difference in 
climate, or epidemiology, further research is required to determine why GBS would occur more 
frequently in southern part of Bangladesh. The population-based data correlate very well with a 
smaller scale hospital-based study done in Khulna, Bangladesh (5). The authors reported that 47% of 
the hospitalized AFP cases were diagnosed with GBS.  Based on our population-based and hospital-
based study (3), we estimate that the total number of newly diagnosed GBS patients in Bangladesh is 
approx. 3500 per year– an incidence 3 to 4 times higher than in the rest of the world. A recent review 
showed that the best estimate of the global incidence of GBS is between 1.1/100,000/year and 
1.8/100,000/year with lower rates reported in children (<15 years) of 0.6/100,000/year (6). This review 
relies mostly on studies from Europe and North America. Rates from other parts of the world were 
hardly presented. There is a scarcity of GBS incidence data from Asia and Africa.  
      The association with antecedent viral and upper respiratory infections in GBS has been known for 
over 100 years. The association of C. jejuni and GBS was first reported in 1982 (7). C. jejuni is 
associated in particular with axonal and motor neuron forms of GBS (8, 9). We reported recently a first 
systematic hospital surveillance of GBS in Bangladesh. In this study, we report a strong association of 
the acute motor axonal neuropathy variant of GBS in young adults with preceding C. jejuni infections 
(3). The population-based study reported here has some limitations. The study is retrospective and the 
case definition was based on existing and available clinical data in the AFP surveillance system. Our 
case definition therefore does not meet the strict NINDS criteria. Future studies should therefore 
include a validation of the case definition used here.  
The possibility of GBS being related to the H1N1 pandemic and its affiliated H1N1 vaccination 
campaign has resurfaced again (10). For the surveillance of excess cases of GBS after H1N1 
influenza and also for post-marketing surveillance of the safety new vaccines in general, background 
GBS incidence data are critical. This report suggests that the burden of GBS in Bangladesh is 
substantial, and data obtained through the ongoing AFP surveillance program can be used to obtain 
crude incidence data of GBS worldwide.   
GBS incidence   
 
 
 
 
Figure. Crude incidence rate (per 100,000 per year) of GBS in Bangladesh in 2006 and 2007 in 
children <15 years of age. 
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ABSTRACT 
 
Background: Campylobacter jejuni enteritis is the predominant bacterial infection preceding Guillain-
Barré syndrome (GBS), an acute post-infectious immune-mediated polyradiculoneuropathy. The 
purpose of this study was to define the clinical phenotype of GBS and the relation with preceding C. 
jejuni infections in Bangladesh.  
 Methods: We performed a prospective matched case-control hospital surveillance including 100 
patients fulfilling the National Institute of Neurological Disorders and Stroke (NINDS) criteria for GBS 
from 2006 to 2007 in the Dhaka area of Bangladesh. Detailed clinical, electrophysiological, serologic 
and microbiological data were obtained with a follow-up of six months. 
Results:  GBS affected predominantly young adult males, living in rural areas. Sixty-nine percent of 
the patients had clinical evidence of a preceding infection. The most frequent symptom was diarrhea 
(36%). The majority of patients had a pure motor variant of GBS (92%) with relatively infrequent 
cranial nerve involvement (30%). Twenty-five percent of patients required respiratory support. 
Electrophysiological studies showed that 67% of patients had an axonal variant of GBS. Eleven (14%) 
patients died and 23 (29%) remained severely disabled during the follow-up. Positive C. jejuni 
serology was found in an unprecedented high frequency of 57% as compared to 8% in family controls 
and 3% in control patients with other neurological diseases (P<0.001). C. jejuni infection was 
significantly associated with serum antibodies to the gangliosides GM1 and GD1a, axonal neuropathy, 
and greater disability. 
 Conclusions: We report an unusually high frequency of the axonal variant of GBS in Bangladesh, 
associated with preceding C. jejuni infection, severe residual disability, and high mortality.
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Introduction 
Guillain–Barré syndrome (GBS) is an acute polyradiculoneuropathy and worldwide the most 
frequent cause of acute flaccid paralysis (AFP) with an incidence of 1.2 to 2.3 per 100,000 persons 
per year (1). The pathological spectrum of GBS includes acute inflammatory demyelinating 
polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN) and acute motor sensory axonal 
neuropathy (AMSAN) (1). GBS is a post-infectious disease and approximately two-third of patients 
report symptoms suggestive for a preceding infectious illnesses. GBS consists of various phenotypes 
which are associated with specific types of preceding infection. Campylobacter jejuni has been 
identified as the predominant type of antecedent infections (2-9). C. jejuni infections are associated 
with a severe (10, 11), pure motor (12, 13), axonal variant of GBS (14) and with poor outcome (4, 15). 
Infection with C. jejuni induces the production of cross-reactive antibodies to nerve gangliosides which  
are related to nerve damage (16, 17).  
 Considering the crucial role of C. jejuni infections in triggering GBS, we hypothesized that this 
disease may be more frequent in countries with a high incidence of diarrhea and a poor hygienic 
infrastructure. There is a paucity of data on the incidence and clinical phenotype of GBS in developing 
countries, including Bangladesh. Data on AFP incidence in Bangladesh are available through the 
World Health Organization (WHO) global polio eradication initiative and the national polio surveillance. 
The non-polio AFP incidence rate is currently 3.25 per 100,000 children under 15 years (18, 19). GBS 
is thought to be responsible for the majority of cases of AFP (20). Our objective was to identify the 
frequency of preceding C. jejuni infections, the clinical phenotype and the prognosis of GBS in a 
hospital-based prospective study. 
 
 
Methods 
 
Prospective hospital-based study 
 
Patients and study design 
We conducted a prospective case-controlled study with a follow-up of six months including 
100 subsequent cases of GBS admitted at the Dhaka Medical College Hospital (DMCH), 
Bangabandhu Sheikh Mujib Medical University (BSMMU) and Dhaka Central Hospital (DCH) in Dhaka 
between July 2006 and June 2007. DMCH and BSMMU are the largest tertiary medical hospitals in 
Bangladesh. DCH is one of the largest non-government hospitals. Upon admission of a patient 
presumptively diagnosed with GBS, a neurologist (M.B.I) from DMCH examined the patient within two 
days and validated the clinical diagnosis using the National Institute of Neurological Disorders and 
Stroke (NINDS) criteria for GBS (21). The final diagnosis was confirmed by a senior neurologist 
(Q.D.M).  
Data were collected regarding age, sex, antecedent events, detailed neurological signs and 
symptoms, treatment, days to nadir, complications, duration of admission, GBS disability score and 
the Medical Research Council (MRC) sum score at standard points (entry, and 2 weeks, 4 weeks, and  
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6 months after entry). Both the GBS disability score and MRC sum score give an indication of the 
severity of disease. The GBS disability score used in this study was defined by Hughes et al. (22). The 
MRC sum score was defined as the sum of MRC score of six muscles in the upper and lower limbs on 
both sides, ranging from 60 (normal) to 0 (quadriplegic) (15). The rapidity of progression was indicated 
by the number of days from onset of weakness to nadir, defined as the lowest MRC sum score. Poor 
outcome was defined as not reaching a GBS disability score of 2 (independent walking) within six 
months (15). The study had a follow-up period of six months during which monitoring of disease 
progression and sampling of serum was performed at predefined standard time points. Two controls 
were selected for each patient: control 1 was a family member living in the same household (family 
control, FC); control 2 was an age, sex, and day matched patient hospitalized in the same ward with 
another neurological disease not related to recent infections (other neurological control, OND).  
 
Standard Protocol Approvals, and Patient Consents 
Informed consent was obtained from all patients and controls. The project protocol was 
reviewed and approved by the institutional review board and the ethical committees at the Dhaka 
Medical College and Hospital, Dhaka, Bangladesh. 
 
Electrophysiological classification 
Standard diagnostic electrophysiology was performed between one and four weeks after 
onset of weakness. Patients were classified according to predefined criteria as having acute motor 
axonal neuropathy (AMAN), acute motor sensory axonal neuropathy (AMSAN), and acute 
inflammatory demyelinating polyneuropathy (AIDP) (23). Patients who did not meet the criteria for one 
of these subgroups were categorized as unclassified. 
 
Campylobacter culture and identification 
Stool samples were cultured according to methods previously described (24). A presumptive 
identification of Campylobacter was done with Gram stain, oxidase and hippurate hydrolysis tests and 
confirmed with a C. jejuni species-specific PCR (25).  
 
Campylobacter and anti-ganglioside serology 
Serum obtained from GBS patients at hospital admission and serum from family controls and 
other neurological disease controls obtained at the same time point were compared for Campylobacter 
and anti-ganglioside serology. Serum antibodies against C. jejuni were determined by an indirect 
enzyme-linked immunosorbent assay (ELISA) for IgG and by antibody class capture ELISA for IgM 
and IgA antibodies. This method and the criteria for a positive score were previously described (26). 
Sera were tested for IgM and IgG antibodies against the ganglioside GM1, and GD1a by ELISA 
according to methods and criteria for a positive score previously described (27).    
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Statistical analysis  
Differences in frequency of various infections between GBS patients and OND controls were tested 
with the McNemar’s test, and between GBS patients and FC with the Chi2-test without continuity 
correction or with the Fisher exact test. With respect to the clinical features of the GBS patients, 
differences in proportion between subgroups were tested with the Chi2-test or with the Fisher exact 
test, and differences in medians with Wilcoxon-Mann-Whitney U test. Conditional logistic-regression 
was used to compare the odds ratios for poor outcome between categories of the risk factors. Two-
tailed tests were used throughout and P<0.05 was regarded as significant. Statistical analysis was 
performed using Epi Info Version 3.5.1 and SPSS for Windows v.11.5 (SPSS Inc., Chicago, II, USA). 
 
Results 
 
Prospective hospital-based study 
 
Demography 
Among the 100 included GBS patients, 57 came from DMCH, 25 from BSMMU, and 18 from DCH, 
Dhaka. Baseline characteristics are shown in Table 1. In this cohort, patients predominantly were 
young adult males, living in rural areas. There was a seasonal fluctuation in the frequency of GBS 
patients included in the study with a peak between January and March (Figure). Clinical symptoms 
suggestive of an infection in the four weeks preceding onset of weakness was reported in 69% of 
patients; diarrhea was the most frequent antecedent symptom (36%) (Table 1).   
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Table 1: Demography, clinical and electrophysiological characteristics of GBS patientsa 
 
 
Abbreviations:  
AIDP = acute inflammatory demyelinating polyneuropathy; AMAN = acute motor axonal neuropathy; AMSAN = 
acute motor sensory axonal neuropathy; GBS = Guillain-Barré syndrome; MRC = Medical Research Council; 
unclassified = not fulfilling criteria for AMAN, AMSAN, or AIDP. 
aData are expressed as no. (%) unless otherwise indicated. 
b
 Age was divided into 4 categories; the first age group was below 15 years based on acute flaccid paralysis    
surveillance, and others were grouped by 15-year interval. 
cSymptoms of an infection in the 4 weeks preceding the onset of weakness. 
d
 MRC sum score was defined as the sum of 6 muscles in the upper and lower limbs on both sides, ranging from 
60 (normal) to 0 (quadriplegic) (15). 
e
 Sixty-four patients were available for electrophysiology. 
Demography   
Sex  (M/F)  72/28  
Median age, years (range)  21 (2.0-65.0) 
Age categories (years)b            <15 26 (26%) 
 16-30 47 (47%) 
 31-45 19 (19%) 
 >45 8 (8%) 
Preceding symptoms and signsc  Diarrhea 36 (36%) 
 Respiratory symptoms  19 (19%) 
 Fever 14 (14%) 
   
Cerebrospinal fluid  Protein level >40 mg/dl 77 (99%) 
(N=78)           Cell count < 15 cell/µl 78 (100%) 
   
Neurological symptoms   
Cranial nerve impairment        Facial nerve palsy 25 (25%) 
 Oculomotor palsy 4 (4%) 
 Lower bulbar palsy 10 (10%) 
 None 70 (70%) 
Sensory deficits   8 (8%) 
Pain  10 (10%) 
MRC sum score  (at entry)d 60-51 8 (8%) 
 50-41 21 (21%) 
 40-31 12 (12%) 
 30-21 19 (19%) 
 20-0 40 (40%) 
GBS disability score (at entry) 1 or 2 11 (11%) 
 3  11 (11%) 
 4  53 (53%) 
 5  25 (25%) 
Electrophysiology    
Classification (N=64)e AMAN 36 (56%) 
 AMSAN 7 (11%) 
 AIDP 14 (22%) 
 Unclassified 7 (11%) 
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Campylobacter infection and GBS 
Statistical analysis  
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Campylobacter infection and GBS 
Clinical features 
 In most patients the disease started as a rapidly progressive symmetrical weakness of the lower 
extremities. The median interval between onset and maximum of weakness was 8 days with an 
interquartile range (IQR) of 6-11 days. A large majority of patients had a pure motor variant of GBS 
without sensory deficits (92%), frequently without cranial nerve involvement (70%). Fifty-three patients 
were already bed-bound at entry. Twenty-five percent of patients required mechanical ventilation. 
During follow up, muscle atrophy was observed in 38% of patients which appeared only late in the 
course of the disease. CSF examination was performed in 78 cases at 2 to 10 days after onset of 
weakness, showing a mean cell count of 2.6 cell/µl (range 0-15 cells/µl) and a mean protein level of 
171 mg/dl (range 45-602 mg/dl, 95% CI). All patients except one had an elevated CSF protein level 
(>40.0 mg/dl), and all patients had normal cell counts (<15 cell/µl) (Table 1). 
 
Preceding Campylobacter infection 
Fifty-five GBS patients (57%) fulfilled the predefined serological criteria for a recent C. jejuni 
infection (Table 2). This proportion was higher than the frequency of positive serology in the two 
control populations: 3% for the OND (P<0.001) and 8% in the FC (P<0.001). Diarrhea in the four 
weeks preceding GBS was reported in 28 (51%) of the 55 C. jejuni-positive patients, which was more 
frequent compared to the 8 (19%) of 42 C. jejuni-negative patients (P<0.01) (Table 3). The association 
between GBS in Bangladesh and recent C. jejuni infections is further supported by the culture of C. 
jejuni in ten GBS patients. Serum anti-ganglioside antibodies (to GM1, and GD1a) were more frequent 
in GBS patients compared to controls (56 % versus 6% of FC and 1 % of OND, P<0.001) (Table 2). In 
GBS patients antibodies to GM1 were more frequent (50%) than to GD1a (14%). Anti-ganglioside 
antibodies were IgG (49%) or IgM (31%) or of both subclasses (20%). Serological evidence for a 
recent C. jejuni infection was more often found in the GBS patients with anti-ganglioside antibodies 
(78%) as compared to patients without anti-gangliosides antibodies (26%) (P<0.001) (Table 3). There 
was no association between C. jejuni serology and sex, age, degree of overall disability of arms, 
facial, and bulbar weakness at the peak of the illness. 
 
Electrophysiological classification 
Standard electrophysiological examination and classification was performed in 64 of 100 
patients with GBS following previously established criteria (23). A majority of 67% of patients had an 
axonal variant of GBS (56% AMAN and 11% AMSAN), while 22% had AIDP and 11% could not be 
classified (Table 1). AMAN appeared to occur more frequently in January to March. Preceding 
diarrhea was more frequent in axonal GBS patients (50%) versus demyelinating cases (28%). AMAN 
and AMSAN occurred more frequently in the C. jejuni-positive group (81%) than in the C. jejuni-
negative group (43%) (P<0.001) (Table 3).  
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Campylobacter infection and GBS 
Clinical features 
 In most patients the disease started as a rapidly progressive symmetrical weakness of the lower 
extremities. The median interval between onset and maximum of weakness was 8 days with an 
interquartile range (IQR) of 6-11 days. A large majority of patients had a pure motor variant of GBS 
without sensory deficits (92%), frequently without cranial nerve involvement (70%). Fifty-three patients 
were already bed-bound at entry. Twenty-five percent of patients required mechanical ventilation. 
During follow up, muscle atrophy was observed in 38% of patients which appeared only late in the 
course of the disease. CSF examination was performed in 78 cases at 2 to 10 days after onset of 
weakness, showing a mean cell count of 2.6 cell/µl (range 0-15 cells/µl) and a mean protein level of 
171 mg/dl (range 45-602 mg/dl, 95% CI). All patients except one had an elevated CSF protein level 
(>40.0 mg/dl), and all patients had normal cell counts (<15 cell/µl) (Table 1). 
 
Preceding Campylobacter infection 
Fifty-five GBS patients (57%) fulfilled the predefined serological criteria for a recent C. jejuni 
infection (Table 2). This proportion was higher than the frequency of positive serology in the two 
control populations: 3% for the OND (P<0.001) and 8% in the FC (P<0.001). Diarrhea in the four 
weeks preceding GBS was reported in 28 (51%) of the 55 C. jejuni-positive patients, which was more 
frequent compared to the 8 (19%) of 42 C. jejuni-negative patients (P<0.01) (Table 3). The association 
between GBS in Bangladesh and recent C. jejuni infections is further supported by the culture of C. 
jejuni in ten GBS patients. Serum anti-ganglioside antibodies (to GM1, and GD1a) were more frequent 
in GBS patients compared to controls (56 % versus 6% of FC and 1 % of OND, P<0.001) (Table 2). In 
GBS patients antibodies to GM1 were more frequent (50%) than to GD1a (14%). Anti-ganglioside 
antibodies were IgG (49%) or IgM (31%) or of both subclasses (20%). Serological evidence for a 
recent C. jejuni infection was more often found in the GBS patients with anti-ganglioside antibodies 
(78%) as compared to patients without anti-gangliosides antibodies (26%) (P<0.001) (Table 3). There 
was no association between C. jejuni serology and sex, age, degree of overall disability of arms, 
facial, and bulbar weakness at the peak of the illness. 
 
Electrophysiological classification 
Standard electrophysiological examination and classification was performed in 64 of 100 
patients with GBS following previously established criteria (23). A majority of 67% of patients had an 
axonal variant of GBS (56% AMAN and 11% AMSAN), while 22% had AIDP and 11% could not be 
classified (Table 1). AMAN appeared to occur more frequently in January to March. Preceding 
diarrhea was more frequent in axonal GBS patients (50%) versus demyelinating cases (28%). AMAN 
and AMSAN occurred more frequently in the C. jejuni-positive group (81%) than in the C. jejuni-
negative group (43%) (P<0.001) (Table 3).  
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Table 3: Clinical characteristics of GBS patients related to preceding C. jejuni infectiona 
Characteristics 
                            C. jejuni 
positive   
(n=55) 
Negative 
(n=42) 
Odds ratio 
(95% CI) 
P Valueb 
Age (median) 18 (2-65) 23 (5-55) - 0.375c 
Sex (M/F) 40/15 30/12 1.07 (0.4-2.86) 0.88 
Preceding diarrhea 28 (51%) 8 (19%) 4.4 (1.6-12.6) <0.01 
Ventilation  15 (27%) 8 (19%) 1.6 (0.5-4.7) 0.34 
Sensory deficit at entry 2 (4%) 6 (14%) 0.2 (0.03-1.35) 0.06 
Cranial nerve impairment 14 (25%) 16 (38%) 0.55 (0.2-1.4) 0.18 
Anti-GM1/GD1a antibodies 43 (78%) 11 (26%) 10.1 (3.6-29.1) <0.001 
Electrophysiology (n=64)      
Axonald 34/42 (81%) 9/22 (43%) 6.1 (1.7-23.0) <0.001 
AIDP 7/42 (17%) 7/22 (33%) 0.4 (0.1-1.7) 0.20 
Unclassified 1/42 (2%) 6/22 (24%) 0.07(0.0-0.63) <0.01 
 
Abbreviations: AIDP = acute inflammatory demyelinating polyneuropathy; CI = confidence interval;—  = cannot be 
calculated. 
aData are expressed no. (%) of patients unless otherwise indicated. 
bDetermined by Chi-square  or Fisher exact test. 
 
cDetermined by Wilcoxon-Mann-Whitney U test. 
dAxonal variants included acute motor axonal neuropathy and acute motor sensory axonal neuropathy. 
 
Outcome and prognostic factors 
Only 23 (23%) of the 100 GBS patients received a specific treatment with intravenous 
immunoglobulin (IVIg). The outcome analysis was performed in 79 patients as 21 patients were lost to 
follow-up. Poor outcome, defined as not reaching a GBS disability score of 2 within six months after 
disease onset, was found in 34 (43%). The patients with poor outcome reached a GBS disability score 
at six months of 3 in 16 (20%), of 4 in 7 (9%) and 11 (14%) died. Eight of these 11 deceased patients 
were initially admitted to the intensive care unit due to respiratory failure. The outcome analysis 
showed that there was no difference in the IVIg versus the non-treated group (Table 2). Poor outcome 
was significantly associated with the GBS disability score at entry, presence of preceding diarrhea, 
positive serology for recent C. jejuni infection and anti-GM1/GD1a antibodies (Table 4).  
 
Discussion 
 
To obtain a detailed description of the clinical and electrophysiological phenotype of GBS in 
relation to preceding infections we performed a prospective case-control hospital surveillance in the 
Dhaka area of Bangladesh. The majority of the patients were men, less than 30 years old, and 
suffering from a severe, pure motor and axonal variant of GBS for which they did not receive any 
specific treatment. After six months of follow-up, 43% of the patients were either unable to walk or had 
died. We found a strong association with preceding C. jejuni infection, in particular in those cases 
diagnosed with AMAN. Our study indicates that C. jejuni frequently induces a severe form of axonal 
Campylobacter infection and GBS    
 
 
GBS in young adults in Bangladesh. The demography and phenotype of GBS varies considerably 
between different geographical areas.   
In Australia, Europe and the USA, GBS occurs slightly more frequent in men. In addition, the 
median age in these areas is approximately 50 years, and the incidence shows no seasonal 
fluctuation (28-30). The predominant phenotype in those countries is a sensory-motor form of AIDP 
present in at least 80% of patients (28). In contrast, patients from China usually are young men from 
rural areas (31). In China, the disease has a seasonal distribution with peaks in the summer months. 
According to these studies, the predominant variant is AMAN (32). Large studies in northern China, 
Japan, Pakistan, and Central and South America show that axonal forms of the syndrome constitute 
30-47% of cases (9, 14, 32-34). In our study, the majority of the GBS cases are pure motor variants 
(92%) with predominant axonal degeneration (67%). In Bangladesh, the incidence of GBS appears to 
peak between January and March, especially in the AMAN subgroup. The geographical differences in 
demography and phenotype may relate to differences in exposure to specific infectious agents and/or 
to host-related or environmental factors.  
There are various arguments in support of the hypothesis that C. jejuni plays a major role in 
the pathogenesis of GBS in Bangladesh. First, diarrhea was the most frequent symptom of preceding 
infection. Second, 57% of GBS patients had serological evidence for a recent C. jejuni infection using 
an assay that has been reported to be very sensitive and specific in GBS patients (26). Third, C. jejuni 
was isolated in stool specimens of 10% of GBS patients as compared to none in the control groups. 
Fourth, C. jejuni related patients usually had serum anti-gangliosides antibodies, reflecting the well 
known cross-reactive immune response by which C. jejuni infections may lead to peripheral nerve 
damage (35). Fifth, the high association with Campylobacter may also explain the high frequency of 
pure motor and axonal variants of GBS. These data clearly indicate that more than half of GBS 
patients in Bangladesh are triggered by a C. jejuni infection. Studies from the Netherlands, UK, Mexico 
and Japan report preceding C. jejuni infections in 26% to 41% of the GBS patients (3, 4, 6, 9). 
Infections with C. jejuni were reported to be frequent in Chinese GSB patients, although if stringent 
criteria for seropositivity, comparable to those described in our study, were used, only 24% of GBS 
cases were related to Campylobacter (5). A recent study from Egypt also reported higher levels of 
antibody production against Campylobacter and gangliosides in GBS patients (36) but these 
investigators did not use a validated cut off level of positivity. Difference in diagnostic assays used in 
these various studies hampers the comparison of the frequency of C. jejuni related patients in these 
countries. 
The observed mean age of 21 years preponderance of men in our study is of particular 
interest. In larger studies from the UK, and The Netherlands, the mean age is around 50 years of age 
and men are slightly more frequently involved then women (4, 28). Our data confirm the outcome of a 
retrospective analysis of 175 GBS patients from Pakistan. The mean age in that study was 23 year 
and 68% of the patients were men (34). This retrospective study from Pakistan and our prospective 
surveillance in Bangladesh are both hospital-based studies, and selection bias could possibly have 
been introduced as preferential selection of men in hospitalization is not an unknown phenomenon in 
developing countries. 
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Table 3: Clinical characteristics of GBS patients related to preceding C. jejuni infectiona 
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positive   
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Abbreviations: AIDP = acute inflammatory demyelinating polyneuropathy; CI = confidence interval;—  = cannot be 
calculated. 
aData are expressed no. (%) of patients unless otherwise indicated. 
bDetermined by Chi-square  or Fisher exact test. 
 
cDetermined by Wilcoxon-Mann-Whitney U test. 
dAxonal variants included acute motor axonal neuropathy and acute motor sensory axonal neuropathy. 
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Only 23 (23%) of the 100 GBS patients received a specific treatment with intravenous 
immunoglobulin (IVIg). The outcome analysis was performed in 79 patients as 21 patients were lost to 
follow-up. Poor outcome, defined as not reaching a GBS disability score of 2 within six months after 
disease onset, was found in 34 (43%). The patients with poor outcome reached a GBS disability score 
at six months of 3 in 16 (20%), of 4 in 7 (9%) and 11 (14%) died. Eight of these 11 deceased patients 
were initially admitted to the intensive care unit due to respiratory failure. The outcome analysis 
showed that there was no difference in the IVIg versus the non-treated group (Table 2). Poor outcome 
was significantly associated with the GBS disability score at entry, presence of preceding diarrhea, 
positive serology for recent C. jejuni infection and anti-GM1/GD1a antibodies (Table 4).  
 
Discussion 
 
To obtain a detailed description of the clinical and electrophysiological phenotype of GBS in 
relation to preceding infections we performed a prospective case-control hospital surveillance in the 
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specific treatment. After six months of follow-up, 43% of the patients were either unable to walk or had 
died. We found a strong association with preceding C. jejuni infection, in particular in those cases 
diagnosed with AMAN. Our study indicates that C. jejuni frequently induces a severe form of axonal 
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GBS in young adults in Bangladesh. The demography and phenotype of GBS varies considerably 
between different geographical areas.   
In Australia, Europe and the USA, GBS occurs slightly more frequent in men. In addition, the 
median age in these areas is approximately 50 years, and the incidence shows no seasonal 
fluctuation (28-30). The predominant phenotype in those countries is a sensory-motor form of AIDP 
present in at least 80% of patients (28). In contrast, patients from China usually are young men from 
rural areas (31). In China, the disease has a seasonal distribution with peaks in the summer months. 
According to these studies, the predominant variant is AMAN (32). Large studies in northern China, 
Japan, Pakistan, and Central and South America show that axonal forms of the syndrome constitute 
30-47% of cases (9, 14, 32-34). In our study, the majority of the GBS cases are pure motor variants 
(92%) with predominant axonal degeneration (67%). In Bangladesh, the incidence of GBS appears to 
peak between January and March, especially in the AMAN subgroup. The geographical differences in 
demography and phenotype may relate to differences in exposure to specific infectious agents and/or 
to host-related or environmental factors.  
There are various arguments in support of the hypothesis that C. jejuni plays a major role in 
the pathogenesis of GBS in Bangladesh. First, diarrhea was the most frequent symptom of preceding 
infection. Second, 57% of GBS patients had serological evidence for a recent C. jejuni infection using 
an assay that has been reported to be very sensitive and specific in GBS patients (26). Third, C. jejuni 
was isolated in stool specimens of 10% of GBS patients as compared to none in the control groups. 
Fourth, C. jejuni related patients usually had serum anti-gangliosides antibodies, reflecting the well 
known cross-reactive immune response by which C. jejuni infections may lead to peripheral nerve 
damage (35). Fifth, the high association with Campylobacter may also explain the high frequency of 
pure motor and axonal variants of GBS. These data clearly indicate that more than half of GBS 
patients in Bangladesh are triggered by a C. jejuni infection. Studies from the Netherlands, UK, Mexico 
and Japan report preceding C. jejuni infections in 26% to 41% of the GBS patients (3, 4, 6, 9). 
Infections with C. jejuni were reported to be frequent in Chinese GSB patients, although if stringent 
criteria for seropositivity, comparable to those described in our study, were used, only 24% of GBS 
cases were related to Campylobacter (5). A recent study from Egypt also reported higher levels of 
antibody production against Campylobacter and gangliosides in GBS patients (36) but these 
investigators did not use a validated cut off level of positivity. Difference in diagnostic assays used in 
these various studies hampers the comparison of the frequency of C. jejuni related patients in these 
countries. 
The observed mean age of 21 years preponderance of men in our study is of particular 
interest. In larger studies from the UK, and The Netherlands, the mean age is around 50 years of age 
and men are slightly more frequently involved then women (4, 28). Our data confirm the outcome of a 
retrospective analysis of 175 GBS patients from Pakistan. The mean age in that study was 23 year 
and 68% of the patients were men (34). This retrospective study from Pakistan and our prospective 
surveillance in Bangladesh are both hospital-based studies, and selection bias could possibly have 
been introduced as preferential selection of men in hospitalization is not an unknown phenomenon in 
developing countries. 
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After a follow-up of six months a very large proportion of the patients in our cohort had either 
died (14%) or remained severely disabled (29%). This suggests that GBS has a much poorer 
prognosis in Bangladesh as compared to developed countries, where this proportion is usually less 
than 20% and where young age is usually associated with a good prognosis (15). The poor prognosis 
may be explained in part by the high frequency of Campylobacter diarrhea and the disease severity at 
entry, two known independent predictors for a poor prognosis (4, 15) and by the high frequency of 
patients that did not receive specific treatment. However, 23 (23%) of 100 GBS patients received a 
specific treatment with intravenous immunoglobulin (IVIg). With respect to outcome at six months, 
there was no difference in the IVIg versus the non-treated group, and IVIg treatment was also not a 
prognostic factor (15). It is important to notice that, as this study was not designed to compare  
treatment outcome significant bias due to variable access to treatment may have occurred. Also, the 
analysis of treatment outcome lacked sufficient power. In our cohort of patients we confirmed that C. 
jejuni infections and disease severity both are associated with poor outcome. Nutrition status and poor 
health are other factors that might interfere with outcome.  
Table 4: Factors related to a poor outcome after 6 months (not reaching disability score of 2 at 
six months) 
 
Factors Number of 
patients 
Number (%) of patients 
with poor outcome 
Odds ratio (95% 
CI) 
P-Value 
Total  79 34 (43%)   
Age (years) 
≤ 15 
16-30 
> 30 
 
25 
32 
22 
 
8 (32%) 
14 (44%) 
12 (55%) 
 
1.0 
1.6 (0.5-5.7) 
2.5 (0.7-10.0) 
 
- 
0.52 
0.20 
Preceding symptoms 
            Non-diarrhea 
Diarrhea 
 
26 
30 
 
7 (27%) 
18 (60%) 
 
1.0 
4.0 (1.1-15.0) 
 
 
0.02 
GBS disability score at entry 
3-4 
5 
 
58 
21 
 
18 (31%) 
16 (76%) 
 
1.0 
7.1 (2.0-26.6) 
 
 
<0.001 
Serology 
 C. jejuni negative 
C. jejuni positive 
Anti-GM1/GD1a negative 
Anti-GM1/GD1a positive 
 
32 
47 
34 
45 
 
7 (21%) 
24 (51%) 
8 (23%) 
23 (51%) 
 
1.0 
3.7 (1.2-11.7) 
1.0 
3.4 (1.2-10.3) 
 
 
0.01 
 
0.02 
Treatment 
        IVIg 
        Non-treated 
 
23 
56 
 
8 (34%) 
26 (46%) 
 
1.0 
1.6 (0.5-5.0) 
 
 
0.48 
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Our data strongly indicate that infections with C. jejuni are the most important trigger for AMAN 
variants of GBS in Bangladesh and are associated with significant morbidity and mortality. Population-
based studies are needed to determine the incidence of GBS. C. jejuni related GBS appear to be a 
dominant cause of AFP after the eradication of poliomyelitis in Bangladesh. The identification of 
associated host and microbial risk factors that contribute to the high endemicity of GBS in Bangladesh 
is imperative. Further studies should also allow the impact of the disease and disease burden to be 
estimated.  
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Abstract 
Background: Guillain-Barré syndrome (GBS) is an acute polyneuropathy and immune-mediated 
flaccid paralysis usually preceded by an infection. Campylobacter jejuni has recently been identified as 
a major cause of antecedent infection in GBS patients in Bangladesh. We here present antecedent 
infections including C. jejuni, cytomegalovirus (CMV), Epstein-Barr virus (EBV), Mycoplasma 
pneumoniae, and enterovirus of GBS patients compared with controls. 
 
Methodology/Principle Findings: We performed a prospective matched case-control study including 
100 patients fulfilling the National Institute of Neurological Disorders and Stroke (NINDS) criteria for 
GBS. Enzyme-linked immunosorbent assay (ELISA) was used for detecting antibodies against above 
mentioned infectious agents. Recent infections with CMV, EBV, and M. pneumoniae were 
demonstrated in GBS patients, but comparison with controls did not revealed statistical significance. 
The seroprevalence of Coxsackie B virus (CvB) (36%) was significantly associated with GBS (p<0.01). 
C. jejuni (57%) was the most common causes of recent infection of GBS patients in Bangladesh. In 
this study, 64% of CvB-associated GBS patients have a positive serology for C. jejuni infection. 
 
Conclusion/Significance: No significant association with CMV, EBV, and M. pneumonia was 
observed among GBS patients. We conclude that antecedent Campylobacter infections play a 
prominent role for the pathogenesis of GBS patients in Bangladesh. Our findings on CvB-associated 
GBS must be confirmed in prospective large case-control studies using sensitive and specific 
serological assays and new molecular detection tools.  
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Introduction 
 
Guillain–Barre´ syndrome (GBS) is the most common form of acute neuromuscular paralysis 
in countries where poliomyelitis has been eradicated (1). GBS represents patients with a wide clinical 
spectrum (2, 3); including variations in the clinical pattern and differences in immunologic, 
electrophysiological and pathologic findings (4, 5). Two-thirds of patients with GBS report symptoms of 
a preceding gastrointestinal or respiratory infectious illness (6, 7, 8). A wide variety of infectious 
agents have been reported as possible triggering factors in patients with GBS. Campylobacter jejuni 
has been identified as the predominant type of antecedent infections (1, 9). C. jejuni infections are 
associated with a severe (10, 11), pure motor, axonal variant of GBS and with poor outcome (12, 13). 
Infection with C. jejuni induces the production of cross-reactive antibodies to nerve gangliosides which 
triggers nerve damage (14). Other infections associated with GBS were cytomegalovirus (CMV), 
Epstein-Barr virus (EBV), and Mycoplasma pneumonia (7, 12, 15-19). A recent prospective 
multicentre study in children with GBS demonstrated that coxsackie viruses were associated as 
antecedent infection (20).    
We performed a prospective matched case-control study on patients with GBS admitted at the 
tertiary medical college hospital in Dhaka area of Bangladesh between 2006 and 2007. Recently, we 
reported that C. jejuni was the predominant cause of GBS in Bangladesh compared with controls (21). 
However, we do not know the status of other infectious agents whether responsible for the 
development of GBS. The aim of the current study was to determine the spectrum of antecedent 
infections including C. jejuni, CMV, EBV, M. pneumoniae, and enterovirus in a large group of GBS 
patients and to investigate whether these infections are more common in GBS than in a matched 
control group.  
 
 
 Materials and Methods 
 
Patients and methods 
We prospectively included all GBS cases admitted in Dhaka Medical College Hospital 
(DMCH), Bangabandhu Sheikh Mujib Medical University (BSMMU) and Dhaka Central Hospital (DCH) 
in Dhaka between July 2006 and June 2007. All patients fulfilled NINCDS diagnosis criteria for GBS 
(2). Data were collected on age, sex, antecedent events, detailed neurological signs and symptoms, 
treatment, days to nadir, complications, duration of admission, GBS disability score and the Medical 
Research Council (MRC) sum score at standard points (entry, and 2 weeks, 4 weeks, and 6 months 
later). Both the GBS disability score and MRC sum score give an indication of the severity of disease. 
The MRC sum score was defined the sum of MRC score of six muscles in the upper and lower limbs 
on both sides, ranging from 60 (normal) to 0 (quadriplegic) (13). The rapidity of progression was 
indicated by the number of days from onset of weakness to nadir, defined as the lowest MRC sum 
score.  Pre-treatment serum samples obtained within 2 weeks of neurological onset were available 
from 97 GBS patients. 
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Controls: Two controls were selected for each patient: control one was a family member living in the 
same household (family control, FC); control two was an age and sex matched patient hospitalized in 
the same ward with an other neurological disease (other neurological control, OND). Blood and up to 
three stool samples were collected from 194 controls. All studies were approved by appropriate 
institutional review boards and all patients gave informed consent.   
 
Infection serology 
Serum samples from GBS patients were tested to determine recent infections with viruses or 
bacteria frequently reported in GBS. Serum antibodies against C. jejuni were determined by an 
indirect enzyme-linked immunosorbent assay (ELISA) for IgG and by antibody class capture ELISA for 
IgM and IgA antibodies and criteria for positivity previously described (22). EBV early antigen and 
heterophile antibodies were qualitatively detected with the Plexus™ Multi-Analyte Diagnostic serology 
test kits (Focus Diagnostics). CMV-IgG were qualitatively determined by Microparticle Enzyme 
Immunoassay, MEIA, Abbott Diagnostics, USA. IgG were quantitatively detected with SERION ELISA 
classic Enterovirus (EV) IgG and SERION ELISA classic M. pneumoniae IgG (Virion Serion), 
respectively. 
 
Anti-ganglioside antibodies 
 Serum samples from all GBS patients were tested for IgM and IgG antibodies against GM1, 
GD1a, and GQ1b by ELISA according to methods and criteria for positivity previously described (23).   
 
Result 
 
Infectious serology 
Fifty-five GBS patients (57%) had a recent C. jejuni infection. This proportion was significantly 
higher than the frequency of positive serology in the two control populations: 3% for the OND 
(p<0.001) and 8% in the FC (p<0.001). Seroprevalences of EBV VCA IgG and IgM, and EBV-EA IgG 
were not increased in GBS patients compared with controls. In contrast, the prevalence of EB-NA 
antibodies was significantly higher in GBS patients (P<0.05) (Fig. 1). However EB-NA IgG titers were 
similar for GBS and controls. No patients or controls had detectable heterophile antibodies. CMV-IgG 
seroprevalence was nearly 100% in GBS patients and 100% in controls. CMV-IgG titers were 
significantly higher in GBS patients compared to OND and family controls (CO ratio 4.74 vs 4.35 and 
4.13 respectively; P<0.005). Enterovirus IgG prevalence was not increased in GBS patients compared 
to controls. However, EV IgG titers were significantly increased in GBS patients compared to OND 
and family controls (161.7 vs 139.4 and 118.9 U/ml; P<0,05 and P<0,01). Furthermore, echovirus IgG 
levels were significantly increased in GBS patients compared to family controls (168.4 vs 126.6; 
P<0.05) but not compared to OND controls. Seroprevalence Coxsackie B virus (CvB) was significantly 
increased in GBS patients compared to family controls (36.1 vs 19.0%, OR 2,5, P<0,01). In addition, 
antibody levels of CvB were higher in GBS vs controls (c/o ratios 181.3 vs 110.4; P<0.01). However, 
Chapter 3 
69
Introduction 
 
Guillain–Barre´ syndrome (GBS) is the most common form of acute neuromuscular paralysis 
in countries where poliomyelitis has been eradicated (1). GBS represents patients with a wide clinical 
spectrum (2, 3); including variations in the clinical pattern and differences in immunologic, 
electrophysiological and pathologic findings (4, 5). Two-thirds of patients with GBS report symptoms of 
a preceding gastrointestinal or respiratory infectious illness (6, 7, 8). A wide variety of infectious 
agents have been reported as possible triggering factors in patients with GBS. Campylobacter jejuni 
has been identified as the predominant type of antecedent infections (1, 9). C. jejuni infections are 
associated with a severe (10, 11), pure motor, axonal variant of GBS and with poor outcome (12, 13). 
Infection with C. jejuni induces the production of cross-reactive antibodies to nerve gangliosides which 
triggers nerve damage (14). Other infections associated with GBS were cytomegalovirus (CMV), 
Epstein-Barr virus (EBV), and Mycoplasma pneumonia (7, 12, 15-19). A recent prospective 
multicentre study in children with GBS demonstrated that coxsackie viruses were associated as 
antecedent infection (20).    
We performed a prospective matched case-control study on patients with GBS admitted at the 
tertiary medical college hospital in Dhaka area of Bangladesh between 2006 and 2007. Recently, we 
reported that C. jejuni was the predominant cause of GBS in Bangladesh compared with controls (21). 
However, we do not know the status of other infectious agents whether responsible for the 
development of GBS. The aim of the current study was to determine the spectrum of antecedent 
infections including C. jejuni, CMV, EBV, M. pneumoniae, and enterovirus in a large group of GBS 
patients and to investigate whether these infections are more common in GBS than in a matched 
control group.  
 
 
 Materials and Methods 
 
Patients and methods 
We prospectively included all GBS cases admitted in Dhaka Medical College Hospital 
(DMCH), Bangabandhu Sheikh Mujib Medical University (BSMMU) and Dhaka Central Hospital (DCH) 
in Dhaka between July 2006 and June 2007. All patients fulfilled NINCDS diagnosis criteria for GBS 
(2). Data were collected on age, sex, antecedent events, detailed neurological signs and symptoms, 
treatment, days to nadir, complications, duration of admission, GBS disability score and the Medical 
Research Council (MRC) sum score at standard points (entry, and 2 weeks, 4 weeks, and 6 months 
later). Both the GBS disability score and MRC sum score give an indication of the severity of disease. 
The MRC sum score was defined the sum of MRC score of six muscles in the upper and lower limbs 
on both sides, ranging from 60 (normal) to 0 (quadriplegic) (13). The rapidity of progression was 
indicated by the number of days from onset of weakness to nadir, defined as the lowest MRC sum 
score.  Pre-treatment serum samples obtained within 2 weeks of neurological onset were available 
from 97 GBS patients. 
Antecedent infections in GBS 
 
 
Controls: Two controls were selected for each patient: control one was a family member living in the 
same household (family control, FC); control two was an age and sex matched patient hospitalized in 
the same ward with an other neurological disease (other neurological control, OND). Blood and up to 
three stool samples were collected from 194 controls. All studies were approved by appropriate 
institutional review boards and all patients gave informed consent.   
 
Infection serology 
Serum samples from GBS patients were tested to determine recent infections with viruses or 
bacteria frequently reported in GBS. Serum antibodies against C. jejuni were determined by an 
indirect enzyme-linked immunosorbent assay (ELISA) for IgG and by antibody class capture ELISA for 
IgM and IgA antibodies and criteria for positivity previously described (22). EBV early antigen and 
heterophile antibodies were qualitatively detected with the Plexus™ Multi-Analyte Diagnostic serology 
test kits (Focus Diagnostics). CMV-IgG were qualitatively determined by Microparticle Enzyme 
Immunoassay, MEIA, Abbott Diagnostics, USA. IgG were quantitatively detected with SERION ELISA 
classic Enterovirus (EV) IgG and SERION ELISA classic M. pneumoniae IgG (Virion Serion), 
respectively. 
 
Anti-ganglioside antibodies 
 Serum samples from all GBS patients were tested for IgM and IgG antibodies against GM1, 
GD1a, and GQ1b by ELISA according to methods and criteria for positivity previously described (23).   
 
Result 
 
Infectious serology 
Fifty-five GBS patients (57%) had a recent C. jejuni infection. This proportion was significantly 
higher than the frequency of positive serology in the two control populations: 3% for the OND 
(p<0.001) and 8% in the FC (p<0.001). Seroprevalences of EBV VCA IgG and IgM, and EBV-EA IgG 
were not increased in GBS patients compared with controls. In contrast, the prevalence of EB-NA 
antibodies was significantly higher in GBS patients (P<0.05) (Fig. 1). However EB-NA IgG titers were 
similar for GBS and controls. No patients or controls had detectable heterophile antibodies. CMV-IgG 
seroprevalence was nearly 100% in GBS patients and 100% in controls. CMV-IgG titers were 
significantly higher in GBS patients compared to OND and family controls (CO ratio 4.74 vs 4.35 and 
4.13 respectively; P<0.005). Enterovirus IgG prevalence was not increased in GBS patients compared 
to controls. However, EV IgG titers were significantly increased in GBS patients compared to OND 
and family controls (161.7 vs 139.4 and 118.9 U/ml; P<0,05 and P<0,01). Furthermore, echovirus IgG 
levels were significantly increased in GBS patients compared to family controls (168.4 vs 126.6; 
P<0.05) but not compared to OND controls. Seroprevalence Coxsackie B virus (CvB) was significantly 
increased in GBS patients compared to family controls (36.1 vs 19.0%, OR 2,5, P<0,01). In addition, 
antibody levels of CvB were higher in GBS vs controls (c/o ratios 181.3 vs 110.4; P<0.01). However, 
Chapter 3 
70
seroprevalence for M. pneumoniae was not increased in GBS patients. The IgG titers of M. 
pneumoniae were significantly higher in GBS patients compared to OND controls (54.5 U/ml vs 36.9 
U/ml (P<0.005), but not compared to family controls.  
 
 
 
 
Figure 1. Serum samples from patients with GBS and from family controls and other neurological 
disease controls was tested to define the frequency of recent infections.  
 
Anti-ganglioside antibodies 
Serum anti-ganglioside antibodies (to GM1, GD1a and GQ1b) were more frequent in GBS 
patients compared with controls (56 % versus 6% of FC and 1 % of OND, p< 0.001). Anti-ganglioside 
antibodies were IgG (49%) or IgM (31%) or of both subclasses (20%). Serological evidence for a 
recent C. jejuni infection was more often found in the GBS patients with anti-ganglioside antibodies 
(80%) as compared to patients without anti-gangliosides antibodies (26%) (p<0.001) (Fig 2).  
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Discussion 
 
To reveal the aetiology of the antecedent infections in patients with GBS in Bangladesh, we 
performed a prospective case control study, and tested predominant infectious agents using standard 
microbiological tests and diagnostic criteria. In the present study, C. jejuni and CvB were identified as 
the most common causes of antecedent infections in GBS in Bangladesh. These infections were more 
frequently found in GBS patients than family controls and the age- and sex- matched controls with 
OND. Infections with CMV, EBV, and M. pneumoniae were also identified, but their frequency was not 
significantly higher than in controls (Table).   
Our finding is in accordance with earlier case-control studies demonstrated that C. jejuni 
infections in 14% to 66% of GBS patients, and 1% to 24% of controls (7, 12, 17, 24-26). This present 
study strongly support the previous data that C. jejuni is the predominant cause of antecedent 
infection in GBS. However, C. jejuni is also one of the predominant causes of acute bacterial enteritis 
in Bangladesh (27). Early eighties, Blaser et al. demonstrated that C. jejuni is more common in healthy 
individual among Bangladeshi population (28). Therefore, one may raise question that GBS is a post-
infectious disease not related to specific infections, in which the predominance of C. jejuni simply 
reflects the high frequency of this infection in the community. However, C. jejuni infections in GBS 
patients are related to distinct severe and pure motor variants of GBS (12, 11, 29). The high incidence 
of C. jejuni preceding GBS has given rise to a number of studies on the pathophysiological link 
between the infection and neurological disease. These have demonstrated a close association 
between C. jejuni aetiology, the axonal variants of GBS and elevated antibody titres against different 
ganglioisdes (11, 12, 30, 31). Common epitopes have been demonstrated between C. jejuni antigens 
and a number of gangliosides, predominantly GM1, thereby supporting the hypothesis of molecular 
mimicry (11, 31). Recently, we reported that C. jejuni infection was significantly associated with serum 
antibodies to the gangliosides GM1 and GD1a, axonal neuropathy, and greater disability (24).  
 
Of interest, the results for CvB revealed that both seroprevalence and IgG titers against CvB 
were significantly increased in GBS patients compared to controls. Our results therefore provide 
evidence for an association between GBS and acute CvB infection. More detailed analysis showed an 
increased CvB sero-prevalence mainly in the Campylobacter-positive GBS subgroup. This would 
either indicate that co-infection with CvB and Campylobacter in GBS patients or, alternatively, 
immunologic cross reactivity or cross reactivation could play a role. Positive serology for more than 
one infectious agent was not uncommon, as was also found in other serological studies (17, 32). This 
may indicate that dual-antigen induced immune responses play a role in a subgroup of GBS patients, 
as was suggested for other immune mediated neuropathies (17, 33). Our findings on CvB-associated 
GBS must be confirmed in prospective large case-control studies using sensitive and specific 
serological assays and new molecular detection tools. Our data are in accordance with a recent 
prospective multicentre study in children with GBS demonstrated that CvB are associated as 
antecedent infection (23).  
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Figure 2. Anti-ganglioside antibodies response among C. jejuni related Guillain-Barré 
syndrome in Bangladesh.  
 
Many case control studies demonstrated that CMV, EBV and M. pneumonia specifically 
associated with GBS (7, 17, 32). In this study, no associations in prevalence or titers of EBV 
antibodies were found. Moreover EB-NA titers were not increased in GBS patients. Therefore, our 
results argue against a role for EBV in the pathogenesis of GBS. The finding of a slightly enhanced 
seroprevalence of EB-NA IgG antibodies in GBS patients in fact indicates latent EBV, therefore has no 
relevance in the context of GBS pathogenesis. The very high seroprevalence for CMV in GBS patients 
and in the population makes a role of primary CMV infection in the pathogenesis of GBS patients 
unlikely. However, IgG titers were significantly increased in GBS patients which could indicate 
reactivation of CMV or up-regulation of anti CMV IgG by some immunologic reaction. The results for 
M. pneumonia showed a slight but significant increase of IgG titers in OND but not in family controls. 
Furthermore, seroprevalence was not increased in GBS patients compared with controls. Our data 
therefore, could not confirm an association of M. pneumonia infection and GBS.  
 
Based on our prospective case control study, we conclude that antecedent Campylobacter 
infections play a prominent role in GBS in Bangladesh, but that in addition, several other agents may 
be involved may play an important role as well. Our data strongly indicate that infections with C. jejuni 
are the most important trigger for axonal variants of GBS in Bangladesh and are associated with 
significant morbidity and mortality. C. jejuni related GBS appears to be a dominant cause of acute 
flaccid paralysis after the eradication of poliomyelitis in Bangladesh.  
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Figure 2. Anti-ganglioside antibodies response among C. jejuni related Guillain-Barré 
syndrome in Bangladesh.  
 
Many case control studies demonstrated that CMV, EBV and M. pneumonia specifically 
associated with GBS (7, 17, 32). In this study, no associations in prevalence or titers of EBV 
antibodies were found. Moreover EB-NA titers were not increased in GBS patients. Therefore, our 
results argue against a role for EBV in the pathogenesis of GBS. The finding of a slightly enhanced 
seroprevalence of EB-NA IgG antibodies in GBS patients in fact indicates latent EBV, therefore has no 
relevance in the context of GBS pathogenesis. The very high seroprevalence for CMV in GBS patients 
and in the population makes a role of primary CMV infection in the pathogenesis of GBS patients 
unlikely. However, IgG titers were significantly increased in GBS patients which could indicate 
reactivation of CMV or up-regulation of anti CMV IgG by some immunologic reaction. The results for 
M. pneumonia showed a slight but significant increase of IgG titers in OND but not in family controls. 
Furthermore, seroprevalence was not increased in GBS patients compared with controls. Our data 
therefore, could not confirm an association of M. pneumonia infection and GBS.  
 
Based on our prospective case control study, we conclude that antecedent Campylobacter 
infections play a prominent role in GBS in Bangladesh, but that in addition, several other agents may 
be involved may play an important role as well. Our data strongly indicate that infections with C. jejuni 
are the most important trigger for axonal variants of GBS in Bangladesh and are associated with 
significant morbidity and mortality. C. jejuni related GBS appears to be a dominant cause of acute 
flaccid paralysis after the eradication of poliomyelitis in Bangladesh.  
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Abstract  
Background. Molecular mimicry between lipo-oligosaccharides (LOS) of Campylobacter jejuni and 
gangliosides in peripheral nerves plays a crucial role in the pathogenesis of C. jejuni-related Guillain-
Barré syndrome (GBS) and Miller Fisher syndrome (MFS).  
Methods: We determined the molecular mimicry and the role of C. jejuni infections in GBS in 
Bangladesh, with focus on the role of cross-reactive antibodies to C. jejuni LOS and gangliosides. We 
also determined the LOS outer core structures of C. jejuni strains associated with GBS/MFS by 
capillary electrophoresis coupled with electrospray ionization mass spectrometry.  
Results: Anti-LOS C. jejuni BD-07, BD-39, BD-10, and BD-67 IgG antibodies were found in serum 
from 56%, 58%, 14% and 15% of GBS patients respectively, as compared to a very low frequency 
(<3%) in controls (p<0.001). Monoclonal antibodies specific for GM1, GM1/GD1b/GA1 and GD1a 
reacted strongly with LOS BD-07 and LOS BD-39. Mass spectrometry analysis are in agreement with 
the fact that both BD-07 and BD-39 expressed GM1 and GD1a ganglioside mimic. Both BD-10 and 
BD-67 express the same LOS outer core, which appears to be a novel structure of GA2 and GD3. Up 
to 90-100% of serum reactivity to gangliosides in two patients (DK-07 and DK-39) was inhibited by 50 
µg/ml of LOS from the autologous C. jejuni isolates. However, patient DK-07 developed an anti-GD1a 
immune response while patient DK-39 developed an anti-GM1 immune response.  
Conclusion: This is the first report to demonstrate that cross-reactive antibody responses to C. jejuni 
LOS and gangliosides precipitate the majority of GBS cases in Bangladesh. Our results strongly 
support the hypothesis that anti-GM1 antibodies in GBS patients are induced during antecedent 
infections with GM1-mimicking C. jejuni strains. We conclude that molecular mimicry between 
gangliosides and C. jejuni LOS is the pathogenic mechanism involved in the majority of cases of C. 
jejuni-related GBS in Bangladesh.  
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Barré syndrome (GBS) and Miller Fisher syndrome (MFS).  
Methods: We determined the molecular mimicry and the role of C. jejuni infections in GBS in 
Bangladesh, with focus on the role of cross-reactive antibodies to C. jejuni LOS and gangliosides. We 
also determined the LOS outer core structures of C. jejuni strains associated with GBS/MFS by 
capillary electrophoresis coupled with electrospray ionization mass spectrometry.  
Results: Anti-LOS C. jejuni BD-07, BD-39, BD-10, and BD-67 IgG antibodies were found in serum 
from 56%, 58%, 14% and 15% of GBS patients respectively, as compared to a very low frequency 
(<3%) in controls (p<0.001). Monoclonal antibodies specific for GM1, GM1/GD1b/GA1 and GD1a 
reacted strongly with LOS BD-07 and LOS BD-39. Mass spectrometry analysis are in agreement with 
the fact that both BD-07 and BD-39 expressed GM1 and GD1a ganglioside mimic. Both BD-10 and 
BD-67 express the same LOS outer core, which appears to be a novel structure of GA2 and GD3. Up 
to 90-100% of serum reactivity to gangliosides in two patients (DK-07 and DK-39) was inhibited by 50 
µg/ml of LOS from the autologous C. jejuni isolates. However, patient DK-07 developed an anti-GD1a 
immune response while patient DK-39 developed an anti-GM1 immune response.  
Conclusion: This is the first report to demonstrate that cross-reactive antibody responses to C. jejuni 
LOS and gangliosides precipitate the majority of GBS cases in Bangladesh. Our results strongly 
support the hypothesis that anti-GM1 antibodies in GBS patients are induced during antecedent 
infections with GM1-mimicking C. jejuni strains. We conclude that molecular mimicry between 
gangliosides and C. jejuni LOS is the pathogenic mechanism involved in the majority of cases of C. 
jejuni-related GBS in Bangladesh.  
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Introduction 
 
Campylobacter jejuni is recognized as the most common pathogen associated with Guillain–
Barré syndrome (GBS) and Miller Fisher syndrome (MFS), an acute autoimmune-mediated disease 
affecting the peripheral nerve system (1-3). The pathogenesis of Campylobacter-induced GBS is 
complex and involves bacterial virulence factors as well as host susceptibility factors (4-7). Certain C. 
jejuni serotypes possess sialylated LOS structures, confined to the outer core of the LOS molecules, 
which mimic a wide range of peripheral nerve gangliosides including GM1, GA1 (asialo-GM1), GM1b, 
GalNAc-GM1b, GM2, GD1a, GalNAc-GD1a, GT1a, GQ1b and GD3 (4, 6, 8-16). This molecular 
mimicry in C. jejuni is hypothesized to elicit an immune response in susceptible hosts that results in 
demyelination or axonal damage of peripheral nerves, partly by the anti-ganglioside antibody response 
(17). 
The exact pathogenesis of post-Campylobacter neuropathy is not clearly understood, but 
molecular mimicry between bacterial glycoconjugates and peripheral nerve gangliosides has been 
implicated (13, 18). Cross-reactive antibodies between C. jejuni lipopolysaccharides (LPS) and 
gangliosides have been identified in GBS and MFS patients (19-21). The specificity of this cross-
reactive antiganglioside-LPS response is associated with different disease profiles. Antibody reactivity 
against GM1, GM1b, and GalNAc-GD1a is associated with pure motor GBS (22), and anti-GQ1b 
antibody reactivity has a strong association with oculomotor symptoms and ataxia (23). Mass 
spectrometry showed that the oligosaccharide core of the lipo-oligosaccharide (LOS) molecules 
expressed by C. jejuni can structurally resemble the oligosaccharide core of certain molecules present 
in neural tissue (24). Neuropathic-associated C. jejuni strains more frequently express ganglioside-
mimics compared to C. jejuni associated with uncomplicated enteritis (25). Many studies have been 
carried out in the developed world to establish the pathogenesis of Campylobacter-induced GBS but 
little information is available concerning the expression of ganglioside mimics in neuropathy-
associated strains from developing countries such as Bangladesh.  
Recently, we reported an unusually high frequency of acute motor axonal neuropathy (AMAN) 
variant of GBS in Bangladesh, associated with preceding Campylobacter infections and the presence 
of serum antibodies against GD1a and GM1 (26). The aim of the present study is to investigate the 
pathogenic mechanism of the endemic GBS in Bangladesh. We hypothesize that C. jejuni infection 
causes GBS in these patients by inducing cross-reactive antibodies to nerve gangliosides by 
expressing gangliosides-like LOS. In order to evaluate the role of molecular mimicry as the pathogenic 
mechanism of the GBS endemic in Bangladesh, we screened C. jejuni LOS for ganglioside-mimics 
and sera of GBS patients were screened for cross-reactive antibodies against gangliosides and C. 
jejuni LOS. Furthermore, we determined the LOS outer core structure of 4 new GBS- and MFS-
associated C. jejuni strains isolated in Bangladesh.  
 
 
 
 
   
 
 
Materials and Methods 
 
Patient and control population 
Pre-treatment blood samples were obtained from all consecutive GBS patients admitted to 
Dhaka Medical College Hospital (DMCH), Bangabandhu Sheikh Mujib Medical University (BSMMU) 
and Dhaka Central Hospital (DCH) between July 2006 and June 2007. All patients fulfilled the 
diagnostic criteria for GBS (27), as evaluated by a neurologist and a senior neurologist (28). Data 
were collected on age, sex, antecedent events, detailed neurological signs and symptoms, treatment, 
days to nadir, complications, duration of admission, GBS disability score and the Medical Research 
Council (MRC) sum score at standard points (entry, and 2 weeks, 4 weeks, and 6 months later). Two 
controls were selected for each patient: control one was a family member living in the same household 
(family control, FC); control two was an age and sex matched patient hospitalized in the same ward 
with an other neurological disease (other neurological control, OND). Blood and up to three stool 
samples were collected from all patients and controls. All studies were approved by appropriate 
institutional review boards and all patients gave informed consent.    
 
Anti-ganglioside antibodies 
The first blood sample obtained upon hospitalization was used in this analysis. Sera were 
tested for IgM and IgG antibodies against the gangliosides GM1, GD1a and GQ1b by enzyme-linked 
immunosorbent assay (ELISA) according to methods and criteria for positivity previously described 
(29).  
 
C. jejuni and lipo-oligosaccharides 
We isolated C. jejuni from the stools of 10 patients with GBS/or MFS (30). Then C. jejuni 
isolates from the stools of five patients of the above mentioned GBS cohort were selected for studies 
on molecular mimicry and cross-reactivity. The clinical features and laboratory findings of these 
patients are given in Table 1. The C. jejuni isolates, BD-07, BD-10, BD-39, BD-67 and BD-94 (30), 
were classified  according to the heat-stable (HS) seroytyping  system described by Penner (31). The 
LOS fraction from all C. jejuni strains were isolated by hot phenol-water extraction and processed as 
described before (21, 32). 
 
Antibody reactivity to C. jejuni LOS 
Sera from 97 GBS patients, including the 5 patients from whom C. jejuni was isolated, were 
tested for IgG activity against LOS from C. jejuni (BD-07, BD-10, BD-39, BD-67 and BD-94) in ELISA. 
LOS from the C. jejuni serostrain (HS:3), lacking gangliosides mimicry, was included for control 
studies. Serum samples from 60 family control (FC) and 60 other neurological disease controls (OND) 
were used as controls.   
A 96 wells plate (Nunc Maxisorb) was coated with 1 µg/well LOS diluted in 50 µl PBS 
(pH=7.8). After incubation overnight, PBS containing 1% BSA (Sigma) was added to all wells to block 
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demyelination or axonal damage of peripheral nerves, partly by the anti-ganglioside antibody response 
(17). 
The exact pathogenesis of post-Campylobacter neuropathy is not clearly understood, but 
molecular mimicry between bacterial glycoconjugates and peripheral nerve gangliosides has been 
implicated (13, 18). Cross-reactive antibodies between C. jejuni lipopolysaccharides (LPS) and 
gangliosides have been identified in GBS and MFS patients (19-21). The specificity of this cross-
reactive antiganglioside-LPS response is associated with different disease profiles. Antibody reactivity 
against GM1, GM1b, and GalNAc-GD1a is associated with pure motor GBS (22), and anti-GQ1b 
antibody reactivity has a strong association with oculomotor symptoms and ataxia (23). Mass 
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expressed by C. jejuni can structurally resemble the oligosaccharide core of certain molecules present 
in neural tissue (24). Neuropathic-associated C. jejuni strains more frequently express ganglioside-
mimics compared to C. jejuni associated with uncomplicated enteritis (25). Many studies have been 
carried out in the developed world to establish the pathogenesis of Campylobacter-induced GBS but 
little information is available concerning the expression of ganglioside mimics in neuropathy-
associated strains from developing countries such as Bangladesh.  
Recently, we reported an unusually high frequency of acute motor axonal neuropathy (AMAN) 
variant of GBS in Bangladesh, associated with preceding Campylobacter infections and the presence 
of serum antibodies against GD1a and GM1 (26). The aim of the present study is to investigate the 
pathogenic mechanism of the endemic GBS in Bangladesh. We hypothesize that C. jejuni infection 
causes GBS in these patients by inducing cross-reactive antibodies to nerve gangliosides by 
expressing gangliosides-like LOS. In order to evaluate the role of molecular mimicry as the pathogenic 
mechanism of the GBS endemic in Bangladesh, we screened C. jejuni LOS for ganglioside-mimics 
and sera of GBS patients were screened for cross-reactive antibodies against gangliosides and C. 
jejuni LOS. Furthermore, we determined the LOS outer core structure of 4 new GBS- and MFS-
associated C. jejuni strains isolated in Bangladesh.  
 
 
 
 
   
 
 
Materials and Methods 
 
Patient and control population 
Pre-treatment blood samples were obtained from all consecutive GBS patients admitted to 
Dhaka Medical College Hospital (DMCH), Bangabandhu Sheikh Mujib Medical University (BSMMU) 
and Dhaka Central Hospital (DCH) between July 2006 and June 2007. All patients fulfilled the 
diagnostic criteria for GBS (27), as evaluated by a neurologist and a senior neurologist (28). Data 
were collected on age, sex, antecedent events, detailed neurological signs and symptoms, treatment, 
days to nadir, complications, duration of admission, GBS disability score and the Medical Research 
Council (MRC) sum score at standard points (entry, and 2 weeks, 4 weeks, and 6 months later). Two 
controls were selected for each patient: control one was a family member living in the same household 
(family control, FC); control two was an age and sex matched patient hospitalized in the same ward 
with an other neurological disease (other neurological control, OND). Blood and up to three stool 
samples were collected from all patients and controls. All studies were approved by appropriate 
institutional review boards and all patients gave informed consent.    
 
Anti-ganglioside antibodies 
The first blood sample obtained upon hospitalization was used in this analysis. Sera were 
tested for IgM and IgG antibodies against the gangliosides GM1, GD1a and GQ1b by enzyme-linked 
immunosorbent assay (ELISA) according to methods and criteria for positivity previously described 
(29).  
 
C. jejuni and lipo-oligosaccharides 
We isolated C. jejuni from the stools of 10 patients with GBS/or MFS (30). Then C. jejuni 
isolates from the stools of five patients of the above mentioned GBS cohort were selected for studies 
on molecular mimicry and cross-reactivity. The clinical features and laboratory findings of these 
patients are given in Table 1. The C. jejuni isolates, BD-07, BD-10, BD-39, BD-67 and BD-94 (30), 
were classified  according to the heat-stable (HS) seroytyping  system described by Penner (31). The 
LOS fraction from all C. jejuni strains were isolated by hot phenol-water extraction and processed as 
described before (21, 32). 
 
Antibody reactivity to C. jejuni LOS 
Sera from 97 GBS patients, including the 5 patients from whom C. jejuni was isolated, were 
tested for IgG activity against LOS from C. jejuni (BD-07, BD-10, BD-39, BD-67 and BD-94) in ELISA. 
LOS from the C. jejuni serostrain (HS:3), lacking gangliosides mimicry, was included for control 
studies. Serum samples from 60 family control (FC) and 60 other neurological disease controls (OND) 
were used as controls.   
A 96 wells plate (Nunc Maxisorb) was coated with 1 µg/well LOS diluted in 50 µl PBS 
(pH=7.8). After incubation overnight, PBS containing 1% BSA (Sigma) was added to all wells to block 
Chapter 4
82
Molecular mimicry and cross-reactive antibodies 
non-specific binding sites. The wells with PBS-1% BSA were incubated for 2 hours at room 
temperature and for another 2 hours at 4ºC. The pre-treatment sera were diluted 1:1000 for IgG in 
PBS-1%BSA (pH=7.8) for antibody determination. Each serum was tested in duplicate in LOS-coated 
wells and non-coated wells. The plates were incubated at 4ºC overnight. After the wells were washed 
with PBS (pH=7.8), 100 µl peroxidase-conjugated rabbit anti-human IgG antibody (Sanbio) diluted 
1:2500 in PBS-1% BSA was added to the wells. After the plates were incubated for 90 minutes at 
room temperature and subsequently washed, 100 µl citrate buffer (pH=5.1) containing the substrate 
ortho-phenyl diamine (Sigma) was added to the wells for 10 minutes at room temperature. The 
extinctions of the wells were measured in an ELISA-reader at 492 nm.  
The corrected optical densities (OD) were calculated by subtracting the extinctions of non-coated wells 
from the extinctions of LOS-coated wells. A serum was considered positive for anti-LOS reactivity 
when the corrected OD was higher than the cut-off value. The cut-off value was determined by the 
mean corrected OD of all controls plus 3 times the standard deviation. A cut-off value for serum IgG 
activity to LOS was determined for each C. jejuni. Serology was performed without knowledge of the 
clinical data. We also determined the cut-off value for IgM and IgA to LOS BD-07 and BD-39. 
 
Determination of cross-reactivity  
Cross-reactivity of anti-ganglioside antibodies to C. jejuni LOS was determined by pre-
incubation of serum with LOS from the C. jejuni isolated from the autologous patients and with LOS 
from the C. jejuni HS:3 serostrain as a control, according to methods previously described (33, 34). To 
detect cross-reactive antibodies, serum DK-07 (diluted 1:100) and DK-39 (diluted 1:200) were pre-
incubated with LOS from their autologous C. jejuni isolate and, serostrain HS:03. C. jejuni LOS 
concentrations of 200, 50, 12.5, 3.1, 0.8 and 0.2 g/ml were incubated with serum for 3 hours at 4ºC. 
After the incubation with LOS, the sera were centrifuged at 3000 rpm for 5 minutes at 4ºC. The 
supernatants were tested for residual anti-ganglioside IgG reactivity in a ganglioside ELISA. The 
percentage of inhibition was defined as:  
OD (serum without LOS) – OD (serum with LOS) x 100% 
OD (serum without LOS) 
 
Mass spectrometry analysis  
Samples were prepared for LOS mass spectrometric analysis by overnight growth of C. jejuni 
strains (BD-07. BD-10, BD-39, BD-67 and BD-94) at 37°C on Butzler agar plates in a microaerobic 
atmosphere. Material from one confluent agar plate was harvested and treated with proteinase K at 60 
g/ml, RNase A at 200 g/ml, and DNase I at 100 g/ml (Promega, Leiden, The Netherlands). O-
deacylated LOS samples were prepared and analyzed by capillary electrophoresis coupled to 
electrospray ionization mass spectrometry (24). 
 
Statistical analysis 
Differences in median values were tested with the Mann-Whitney U test. Differences in 
proportions were tested with the chi square test or Fisher’s exact test. Differences were considered 
   
 
significant at P<0.05 after two-sided testing. Statistical analysis was performed using InStat version 
4.0 (Graphpad Software, San Diego, CA).  
 
 Results 
Antibodies to C. jejuni LOS 
The IgG reactivity in serum from the patients with GBS, and the FC and OND control groups 
to C. jejuni LOS is shown in Fig. 1. Anti-LOS BD-07, BD-39, BD-10, and BD-67 IgG antibodies were 
found in 56%, 58%, 14% and 15% of GBS patients respectively, compared with very low frequency 
(<3%) of controls (p <0.001). Except two, anti-LOS BD-94 IgG antibodies were not found in GBS 
patients as well as controls. The IgG activity to LOS from the serostrain HS:3 in serum from the GBS 
patients did not differ from that in the two control groups. Anti-LOS BD-07 and anti-LOS BD-39 IgA 
antibodies were found in 50% and 48% of GBS patients, respectively, compared with low frequency 
(0% in OND and 4% in FC) in controls (p<0.001) (data not shown). Antibodies of the IgM isotype 
against LOS BD-07 were found in 22% of GBS patients, compared to 4% of OND controls (P=0.052) 
and 0% of family controls (P=0.012). Anti-LOS IgM BD-39 antibodies were found in 20% of GBS 
patients, in 4% of OND controls (p=0.088) and in 0% of family controls (P=0.025). The IgG activity to 
C. jejuni LOS was significantly higher in patients with a positive C. jejuni serology than in patients with 
a negative C. jejuni serology (P<0.005). In addition, diarrhea in the four weeks preceding GBS was 
reported in 26 (48%) of the 54 patients with IgG to C. jejuni LOS compared to 10 (23%) of 43 of the 
without anti-LOS patients (P=0.02).  
 
Antibodies to C. jejuni LOS and gangliosides 
Serum anti-ganglioside antibodies (to GM1, GD1a and GQ1b) were more frequent in GBS 
patients compared with controls (56% versus 6% of FC and 1 % of OND, P<0.001) (26). The GBS 
patients were divided into two subgroups according to their anti-ganglioside immune response: one 
group which  was positive for anti-GM1 and/or anti-GD1a antibodies and another group which  was 
negative for both anti-GM1 and anti-GD1a antibodies. 
Anti-LOS reactivity was significantly associated with the presence of anti-ganglioside 
antibodies (p<0.001) (Fig. 2). Diarrhea in the four weeks preceding GBS was reported in 26 (48%) of 
the 54 ganglioside-positive patients, which was more frequent compared to the 10 (19%) of 43 of the 
ganglioside-negative patients (P<0.01) (Table 2).  There was no association between anti-GM1/GD1a 
serology and sex, age, degree of overall disability of arms, facial, and bulbar weakness at the peak of 
the illness.  
 
LOS characterization 
Monoclonal mouse antibodies against different gangliosides were used to determine if 
ganglioside-mimics were present in the LOS. Monoclonal antibodies DG-1 (binding to GM1), DG-2 
(binding to GM1/GD1b/GA1) and TBG-3 (binding to GD1a) reacted strongly with LOS BD-07 and LOS 
BD-39 as shown in Fig. 3. These serological data indicate that C. jejuni BD-07 and BD-39 both have a 
GM1 and/or GD1a mimicking LOS. Control studies with monoclonal antibodies EG-7 (binding to 
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ganglioside-mimics were present in the LOS. Monoclonal antibodies DG-1 (binding to GM1), DG-2 
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GD1b), EG-3 (binding to GQ1b/GT1a) and EG-1 (binding to GQ1b) did not bind to the LOS, 
demonstrating that BD-07 and BD-39 have no GD1b, GQ1b and GQ1b/GT1a mimicry. The 
monoclonal antibodies bound to positive control C. jejuni LOS with known ganglioside-mimics (data 
not shown). None of the antibodies were bound by BD-10, BD-67, BD-94 and negative control C. 
jejuni LOS P:03.  
 
Cross-reactive antibodies 
Serum DK-07 and serum DK-39 showed reduced anti-ganglioside IgG antibody reactivity after 
pre-incubation with LOS from their autologous C. jejuni isolates (Fig. 4). Serum DK-07 was tested for 
residual anti-GD1a IgG antibodies, whereas serum DK-39 was tested for anti-GM1 IgG antibodies. 
The percentage inhibition of anti-ganglioside reactivity was dose-dependent with the LOS 
concentration. About 50% of inhibition was seen after pre-incubation with 3.1 µg/ml of LOS BD-07 and 
with 12.5 µg/ml of LOS BD-39. In control studies, LOS from C. jejuni serostrain HS:3 did not inhibit the 
ganglioside antibodies of serum DK-07 and DK-39, indicating that the cross-reactive anti-ganglioside 
antibodies show no specific binding to C. jejuni LOS (Fig.4).    
 
Expression of ganglioside mimics in the LOS.  
We used CE-ESI-MS on O-deacylated LOS to propose LOS outer core structures for five  
strains (Fig. 5 and supplemental Table 1). The CE-ESI-MS did not provide linkage information but 
provided information about the sugar composition of the LOS outer core. The glycosyltransferase 
variants present in the LOS locus of each strain (Table 3) and the comparison with strains of known 
LOS outer core structures were used to propose LOS outer core structures for four  strains (BD-07, 
BD-10, BD-39 and BD-67). The CE-ESI-MS data were not sufficient to propose a structure in the case 
of BD-94. However, we can conclude that the LOS outer core of BD-94 does not show ganglioside 
mimicry because no major ion was observed in a precursor ion mass spectrum at m/z 290.2 (data not 
shown), confirming that there is no sialic acid present. The CE-ESI-MS data obtained with BD-07 and 
BD-39 showed mass species with either one or two sialic acids (supplemental Table 1) which are 
proposed to be derived from GM1 and GD1a mimicry (Fig. 5). Tandem mass spectrometry of the triple 
charged ion at m/z 1289.3 revealed a fragment ion at m/z 290.2 (NeuAc) and none at 581.3 (NeuAc-
NeuAc). Since the composition of the triply charged ion at m/z 1289.3 contains two NeuAc, we 
conclude that these two residues are present on different Gal residues, which is consistent with GD1a 
mimicry. The glycosyltransferase variants in the LOS biosynthesis locus of BD-07 and BD-39 are 
consistent with GM1/GD1a mimicry (Table 3). They both contain a single domain glucosyltransferase 
(Cj1135) and an active β-1,3-galactosyltransferase (Cj1136) which suggests that the inner core will be 
extended with a Galβ-β1,3-linked residue on HepII. The Gal residue will be modified with a single 
NeuAc since the Cst-II variant in BD-07 and BD-39 is mono-functional (Thr51). The outer core is 
further extended with GalNAc and Gal residues by variants of CgtA and CgtB, respectively, which are 
specific for sialylated acceptors. The terminal Gal residue is partially substituted by the mono-
functional Cst-II, which results in a mixture of GM1 and GD1a mimicry. 
   
 
CE-ESI-MS on O-deacylated LOS from strains BD-10 and BD-67 resulted in spectra with 
similar mass species (supplemental Table1). These two strains also have LOS biosynthesis loci that 
are 100% identical to each other (GenBank accession numbers GQ249164 and GQ249165). We thus 
propose that they both express the same LOS outer core, which appears to be a novel structure with 
two extension sites from the inner core and two branches mimicking gangliosides GA2 and GD3 (Fig. 
5). The presence of di-NeuAc on one of the branches is confirmed by the fragment ion at m/z 581.3 
when tandem mass spectrometry was carried out on the triply charged ion at m/z 1302.3 (data not 
shown). The Cst-II variant in these two strains is bi-functional (Asn51) which further supports the 
presence of di-NeuAc. The absence of a terminal Galβ-1,3-linked residue is consistent with a cgtB 
gene that has a frame-shift mutation. 
 
 
Table 1. Clinical and laboratory findings in five patients with Guillain-Barré syndrome from 
whom a Campylobacter jejuni was isolated used in our studya 
 
 
Patients BD-39 BD-07 BD-10 BD-67 BD-94 
Clinical characteristics      
Age, years 30 40 15 40 10 
Sex F M M M F 
Diarrhoea + + + + - 
Days to nadir 12 2 5 6 3 
Ophthalmoplegia - - + + - 
Sensory sign - - - - - 
Motor involvement + + + + + 
GBS disability score      
At nadir 5 4 5 4 5 
At 26 weeks 4 0 3 3 4 
Serum IgG antibody      
GM1 + - - + - 
GD1a - + + + - 
GQ1b - - + + - 
C. jejuni serology ELISA + + + + + 
C. jejuni Penner serotype HS:19  HS:19 HS:23 HS:23 HS:21 
 
a. Abbreviations: M, Male; F, Female; +, present; -, absent; N, normal, GBS disability score,  
Chapter 4
85
Molecular mimicry and cross-reactive antibodies 
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BD-10, BD-39 and BD-67). The CE-ESI-MS data were not sufficient to propose a structure in the case 
of BD-94. However, we can conclude that the LOS outer core of BD-94 does not show ganglioside 
mimicry because no major ion was observed in a precursor ion mass spectrum at m/z 290.2 (data not 
shown), confirming that there is no sialic acid present. The CE-ESI-MS data obtained with BD-07 and 
BD-39 showed mass species with either one or two sialic acids (supplemental Table 1) which are 
proposed to be derived from GM1 and GD1a mimicry (Fig. 5). Tandem mass spectrometry of the triple 
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mimicry. The glycosyltransferase variants in the LOS biosynthesis locus of BD-07 and BD-39 are 
consistent with GM1/GD1a mimicry (Table 3). They both contain a single domain glucosyltransferase 
(Cj1135) and an active β-1,3-galactosyltransferase (Cj1136) which suggests that the inner core will be 
extended with a Galβ-β1,3-linked residue on HepII. The Gal residue will be modified with a single 
NeuAc since the Cst-II variant in BD-07 and BD-39 is mono-functional (Thr51). The outer core is 
further extended with GalNAc and Gal residues by variants of CgtA and CgtB, respectively, which are 
specific for sialylated acceptors. The terminal Gal residue is partially substituted by the mono-
functional Cst-II, which results in a mixture of GM1 and GD1a mimicry. 
   
 
CE-ESI-MS on O-deacylated LOS from strains BD-10 and BD-67 resulted in spectra with 
similar mass species (supplemental Table1). These two strains also have LOS biosynthesis loci that 
are 100% identical to each other (GenBank accession numbers GQ249164 and GQ249165). We thus 
propose that they both express the same LOS outer core, which appears to be a novel structure with 
two extension sites from the inner core and two branches mimicking gangliosides GA2 and GD3 (Fig. 
5). The presence of di-NeuAc on one of the branches is confirmed by the fragment ion at m/z 581.3 
when tandem mass spectrometry was carried out on the triply charged ion at m/z 1302.3 (data not 
shown). The Cst-II variant in these two strains is bi-functional (Asn51) which further supports the 
presence of di-NeuAc. The absence of a terminal Galβ-1,3-linked residue is consistent with a cgtB 
gene that has a frame-shift mutation. 
 
 
Table 1. Clinical and laboratory findings in five patients with Guillain-Barré syndrome from 
whom a Campylobacter jejuni was isolated used in our studya 
 
 
Patients BD-39 BD-07 BD-10 BD-67 BD-94 
Clinical characteristics      
Age, years 30 40 15 40 10 
Sex F M M M F 
Diarrhoea + + + + - 
Days to nadir 12 2 5 6 3 
Ophthalmoplegia - - + + - 
Sensory sign - - - - - 
Motor involvement + + + + + 
GBS disability score      
At nadir 5 4 5 4 5 
At 26 weeks 4 0 3 3 4 
Serum IgG antibody      
GM1 + - - + - 
GD1a - + + + - 
GQ1b - - + + - 
C. jejuni serology ELISA + + + + + 
C. jejuni Penner serotype HS:19  HS:19 HS:23 HS:23 HS:21 
 
a. Abbreviations: M, Male; F, Female; +, present; -, absent; N, normal, GBS disability score,  
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 Table 3. Variants of the glycosyltransferases involved in the synthesis of the LOS outer core 
structures in C. jejuni strains BD-07, BD-10, BD-39 and BD-67. a 
 
Strain BD-07 BD-10 BD-39 BD-67 
Class A B A B 
GenBank 
Accession No. 
GU289927 GQ249164 GU289928 GQ249165 
Cj1135 One-domain Two-domain One-domain Two-domain 
Cj1136 on b On On On 
CgtAI Mono-sialyl. c Non-sialyl. d Mono-sialyl. Non-sialyl. 
CgtAII Absent off  e Absent Off 
CgtB Mono-sialyl. Off Mono-sialyl. Off 
Cst-II Mono- f Bi- Mono- Bi- 
GalT Absent Present Absent Present 
 
a Assignment of the glycosyltransferase variants is based on amino acid sequence comparisons with variants of 
known specificities. 
b
 on: indicates that a gene has no frame-shift mutation. 
c Mono-sialyl.: the glycosyltransferase is specific for mono-sialylated acceptors. 
d
 Non-sialyl.: the glycosyltransferase is specific for non-sialylated acceptors. 
e
 off: indicates that a gene is inactive because of a frame-shift mutation. 
f
 Cst-II variants: mono-: monofunctional, Cst-II has α-2,3-sialyltransferase activity 
 bi-: bifunctional, Cst-II has both α-2,3-sialyltransferase and α-2,8-sialyltransferase activity 
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 Table 3. Variants of the glycosyltransferases involved in the synthesis of the LOS outer core 
structures in C. jejuni strains BD-07, BD-10, BD-39 and BD-67. a 
 
Strain BD-07 BD-10 BD-39 BD-67 
Class A B A B 
GenBank 
Accession No. 
GU289927 GQ249164 GU289928 GQ249165 
Cj1135 One-domain Two-domain One-domain Two-domain 
Cj1136 on b On On On 
CgtAI Mono-sialyl. c Non-sialyl. d Mono-sialyl. Non-sialyl. 
CgtAII Absent off  e Absent Off 
CgtB Mono-sialyl. Off Mono-sialyl. Off 
Cst-II Mono- f Bi- Mono- Bi- 
GalT Absent Present Absent Present 
 
a Assignment of the glycosyltransferase variants is based on amino acid sequence comparisons with variants of 
known specificities. 
b
 on: indicates that a gene has no frame-shift mutation. 
c Mono-sialyl.: the glycosyltransferase is specific for mono-sialylated acceptors. 
d
 Non-sialyl.: the glycosyltransferase is specific for non-sialylated acceptors. 
e
 off: indicates that a gene is inactive because of a frame-shift mutation. 
f
 Cst-II variants: mono-: monofunctional, Cst-II has α-2,3-sialyltransferase activity 
 bi-: bifunctional, Cst-II has both α-2,3-sialyltransferase and α-2,8-sialyltransferase activity 
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Discussion 
In this study we provide biophysical and serological evidence for the involvement of molecular 
mimicry in the pathogenesis of C. jejuni-related GBS in Bangladesh. The IgG response against C. 
jejuni LOS and gangliosides are closely associated in patients with GBS. We determined that serum 
ganglioside antibodies cross-reacted specifically with LOS from autologous C. jejuni LOS. To our 
knowledge, this is the first report in which MS is combined with DNA sequence data to determine the 
LOS outer core structures of neuropathy-associated C. jejuni strains isolated in South Asia. We found 
that strains with class A LOS gene loci express both GM1 and GD1a epitopes on their LOSs. 
Expression of GM1 and GD1a was enhanced in C. jejuni HS:19, and this expression was dependent 
on the predominance of the cstII (Thr51) gene. Our data confirm that ganglioside mimicry is the most 
likely pathogenic mechanism underlying the majority of C. jejuni-associated GBS cases. Our data 
further support the hypothesis that antecedent C. jejuni infections in GBS trigger the production of 
antibodies that cross-react with gangliosides. 
Molecular mimicry between gangliosides and LOS has been demonstrated with C. jejuni 
isolates from GBS and MFS patients (13, 19, 20, 35-38). Several findings in the current study support 
the hypothesis that cross-reactive antibodies to ganglioside in these patients contributed to the 
development of GBS in Bangladesh. Anti-LOS antibody levels are significantly associated with GBS 
as compared with data from two control groups (p<0.001). In the present study, we provide strong 
evidence that in GBS patients in Bangladesh anti-LOS antibody levels are strongly associated with 
recent C. jejuni infection. C. jejuni is a frequent antecedent pathogen associated with GBS in 
Bangladesh (26). The association between anti-LOS and anti-ganglioside antibodies is significant but 
not absolute. In some patients with anti-ganglioside antibodies we did not find a high IgG activity 
against LOS. This may result from relatively low titres or different fine-specificities of the anti-
ganglioside antibodies in these patients. In previous studies, Bart et al. found no binding of anti-GM1 
antibodies with LPS of C. jejuni from MFS and GBS patients (21). There are some GBS patients 
without anti-ganglioside antibodies but with anti-LOS antibodies. Patients with a C. jejuni infection may 
have antibodies against complexes of gangliosides (32). It is interesting to note that our preliminary 
data showed that patients with anti-LOS reactivity but without reactivity against single gangliosides 
can have antibodies against complexes gangliosides (data not shown). Our results are in agreement 
with recent observations that ganglioside complexes are important target antigens in GBS as well as 
in MFS (39, 40).  
Monoclonal antibodies against gangliosides were bound by LOS BD-07 and LOS BD-39 in a 
similar pattern. Serum DK-07 and DK-39 showed a dramatic reduction in anti- ganglioside reactivity 
after incubation with the autologous LOSs. Incubation with LOS that lacked ganglioside-mimics did not 
inhibit ganglioside-reactivity, demonstrating that serum DK-07 and serum DK-39 were specifically 
deprived of their ganglioside antibodies by the incubation with the autologous LOSs. This finding 
indicates that in these two GBS patients the antibodies against GM1 and GD1a were induced by LOS 
during the preceding C. jejuni infection. Immune response against C. jejuni involved in the 
pathogenesis of GBS by cross-reactivity with neural tissue (19, 32).   
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Discussion 
In this study we provide biophysical and serological evidence for the involvement of molecular 
mimicry in the pathogenesis of C. jejuni-related GBS in Bangladesh. The IgG response against C. 
jejuni LOS and gangliosides are closely associated in patients with GBS. We determined that serum 
ganglioside antibodies cross-reacted specifically with LOS from autologous C. jejuni LOS. To our 
knowledge, this is the first report in which MS is combined with DNA sequence data to determine the 
LOS outer core structures of neuropathy-associated C. jejuni strains isolated in South Asia. We found 
that strains with class A LOS gene loci express both GM1 and GD1a epitopes on their LOSs. 
Expression of GM1 and GD1a was enhanced in C. jejuni HS:19, and this expression was dependent 
on the predominance of the cstII (Thr51) gene. Our data confirm that ganglioside mimicry is the most 
likely pathogenic mechanism underlying the majority of C. jejuni-associated GBS cases. Our data 
further support the hypothesis that antecedent C. jejuni infections in GBS trigger the production of 
antibodies that cross-react with gangliosides. 
Molecular mimicry between gangliosides and LOS has been demonstrated with C. jejuni 
isolates from GBS and MFS patients (13, 19, 20, 35-38). Several findings in the current study support 
the hypothesis that cross-reactive antibodies to ganglioside in these patients contributed to the 
development of GBS in Bangladesh. Anti-LOS antibody levels are significantly associated with GBS 
as compared with data from two control groups (p<0.001). In the present study, we provide strong 
evidence that in GBS patients in Bangladesh anti-LOS antibody levels are strongly associated with 
recent C. jejuni infection. C. jejuni is a frequent antecedent pathogen associated with GBS in 
Bangladesh (26). The association between anti-LOS and anti-ganglioside antibodies is significant but 
not absolute. In some patients with anti-ganglioside antibodies we did not find a high IgG activity 
against LOS. This may result from relatively low titres or different fine-specificities of the anti-
ganglioside antibodies in these patients. In previous studies, Bart et al. found no binding of anti-GM1 
antibodies with LPS of C. jejuni from MFS and GBS patients (21). There are some GBS patients 
without anti-ganglioside antibodies but with anti-LOS antibodies. Patients with a C. jejuni infection may 
have antibodies against complexes of gangliosides (32). It is interesting to note that our preliminary 
data showed that patients with anti-LOS reactivity but without reactivity against single gangliosides 
can have antibodies against complexes gangliosides (data not shown). Our results are in agreement 
with recent observations that ganglioside complexes are important target antigens in GBS as well as 
in MFS (39, 40).  
Monoclonal antibodies against gangliosides were bound by LOS BD-07 and LOS BD-39 in a 
similar pattern. Serum DK-07 and DK-39 showed a dramatic reduction in anti- ganglioside reactivity 
after incubation with the autologous LOSs. Incubation with LOS that lacked ganglioside-mimics did not 
inhibit ganglioside-reactivity, demonstrating that serum DK-07 and serum DK-39 were specifically 
deprived of their ganglioside antibodies by the incubation with the autologous LOSs. This finding 
indicates that in these two GBS patients the antibodies against GM1 and GD1a were induced by LOS 
during the preceding C. jejuni infection. Immune response against C. jejuni involved in the 
pathogenesis of GBS by cross-reactivity with neural tissue (19, 32).   
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Various ganglioside mimics were found in the LOS of neuropathy-associated strains in 
Bangladesh. GM1/GD1a was the most prevalent ganglioside mimic in GBS-associated strains, and it 
was predominantly found in LOS class A strains. This finding is consistent with the results previously 
described (24, 41), but in contrast with those of Nachamkin et al., who reported previously that the 
expression of GD1a and not GM1 is associated with GBS (16). MS analysis has not demonstrated 
true GQ1b-like structures in C. jejuni LOS. The detection of structures with a terminal di-NeuAc-Gal in 
both strains (BD-10 and BD-67) from Bangladesh associated with ophthalmoplegia suggests that in 
these patients, pathogenic antibodies are raised against GA2- and GD3-like LOS. Both express the 
same LOS outer core, which appears to be a novel structure with two extension sites from the inner 
core and two branches mimicking gangliosides. There are alternative explanations for the observation 
that one GBS-associated strain (BD-94) did not express ganglioside mimic in its LOS. It has been 
demonstrated previously that GBS patients can occasionally be infected with two different C. jejuni 
strains. In such cases only one of the strains could be linked to GBS (24).  
LOS structure variability is defined by genetic polymorphism of C. jejuni. Hence also the 
specificity of the anti-ganglioside antibody response and clinical features of GBS is affected by 
mutability of the bacteria (37, 42, 43). The presence of, and polymorphism within the cstII gene has 
been associated with the expression of ganglioside mimics and with clinical features of GBS (25, 44). 
The Thr51 variant was associated with monosialylated LOS and seemed to occur more frequently in 
class A strains and in GBS-related strains (BD-07 and BD-39). We found that the CstII Asn51 variant 
was associated with the expression of disialylated LOS and seemed to occur more frequently in class 
B strains, and strains related with clinical symptoms of MFS or GBS with ophthalmoplegia. Our 
findings are concordant with recent data reported earlier (24, 25, 41). 
 Patients DK-07 and DK-39 have developed interesting immune responses. Bacterial 
genotypying showed that these patients were infected with clonal C. jejuni strains (30). Mass 
spectrometry results and our LOS characterization data demonstrated that LOS BD-07 and BD-39 
share the same ganglioside-mimics. However, patient DK-07 developed an anti-GD1a immune 
response while patient DK-39 developed an anti-GM1 immune response. These results suggest that 
the immune response against gangliosides is not only determined by ganglioside mimicry present in 
the C. jejuni LOS but may also be determined by genetic host factors.  
In conclusion, our study further supports the hypothesis that infections with specific C. jeuni 
strains induce cross-reactive IgG antibodies against LOS and gangliosides in GBS patients. The 
conformation of the oligosaccharide moieties in C. jejuni LOS and the recognition of the anti-
ganglioside antibodies by the adaptive immune system cannot be predicted by the biochemical 
structure only. Further research is necessary to elucidate the mechanism by which C. jejuni determine 
the fine-specificity of the anti-ganglioside antibodies.   
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Various ganglioside mimics were found in the LOS of neuropathy-associated strains in 
Bangladesh. GM1/GD1a was the most prevalent ganglioside mimic in GBS-associated strains, and it 
was predominantly found in LOS class A strains. This finding is consistent with the results previously 
described (24, 41), but in contrast with those of Nachamkin et al., who reported previously that the 
expression of GD1a and not GM1 is associated with GBS (16). MS analysis has not demonstrated 
true GQ1b-like structures in C. jejuni LOS. The detection of structures with a terminal di-NeuAc-Gal in 
both strains (BD-10 and BD-67) from Bangladesh associated with ophthalmoplegia suggests that in 
these patients, pathogenic antibodies are raised against GA2- and GD3-like LOS. Both express the 
same LOS outer core, which appears to be a novel structure with two extension sites from the inner 
core and two branches mimicking gangliosides. There are alternative explanations for the observation 
that one GBS-associated strain (BD-94) did not express ganglioside mimic in its LOS. It has been 
demonstrated previously that GBS patients can occasionally be infected with two different C. jejuni 
strains. In such cases only one of the strains could be linked to GBS (24).  
LOS structure variability is defined by genetic polymorphism of C. jejuni. Hence also the 
specificity of the anti-ganglioside antibody response and clinical features of GBS is affected by 
mutability of the bacteria (37, 42, 43). The presence of, and polymorphism within the cstII gene has 
been associated with the expression of ganglioside mimics and with clinical features of GBS (25, 44). 
The Thr51 variant was associated with monosialylated LOS and seemed to occur more frequently in 
class A strains and in GBS-related strains (BD-07 and BD-39). We found that the CstII Asn51 variant 
was associated with the expression of disialylated LOS and seemed to occur more frequently in class 
B strains, and strains related with clinical symptoms of MFS or GBS with ophthalmoplegia. Our 
findings are concordant with recent data reported earlier (24, 25, 41). 
 Patients DK-07 and DK-39 have developed interesting immune responses. Bacterial 
genotypying showed that these patients were infected with clonal C. jejuni strains (30). Mass 
spectrometry results and our LOS characterization data demonstrated that LOS BD-07 and BD-39 
share the same ganglioside-mimics. However, patient DK-07 developed an anti-GD1a immune 
response while patient DK-39 developed an anti-GM1 immune response. These results suggest that 
the immune response against gangliosides is not only determined by ganglioside mimicry present in 
the C. jejuni LOS but may also be determined by genetic host factors.  
In conclusion, our study further supports the hypothesis that infections with specific C. jeuni 
strains induce cross-reactive IgG antibodies against LOS and gangliosides in GBS patients. The 
conformation of the oligosaccharide moieties in C. jejuni LOS and the recognition of the anti-
ganglioside antibodies by the adaptive immune system cannot be predicted by the biochemical 
structure only. Further research is necessary to elucidate the mechanism by which C. jejuni determine 
the fine-specificity of the anti-ganglioside antibodies.   
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Guillain-Barré syndrome (GBS) is an acute peripheral neuropathy triggered by a preceding 
infectious illness. Gastroenteritis caused by Campylobacter jejuni is the most frequently reported 
antecedent event (1). In Japan, South Africa, China, and Mexico, Campylobacter strains with certain 
Penner heat-stable (HS) serotypes, including HS:19 and HS:41, are overrepresented among isolates 
from GBS case-patients, compared with isolates from enteritis case-patients (2,3). Several studies 
indicate that C. jejuni HS:19 and HS:41 have a clonal population structure and suggest that these 
serotypes might have unique virulence properties that are intricately linked to development of GBS (4). 
However, data from the United Kingdom and the Netherlands suggest that such virulence properties 
may not be restricted to specific HS serotypes because many other serotypes can be cultured from 
patients with GBS (5). We report a non-HS:19 and non-HS:41 C. jejuni serotype and sequence type 
(ST)–3219 that are overrepresented among isolates from GBS patients in Bangladesh. 
We conducted a prospective case-control study of the serotype and genotype of C. jejuni 
associated with GBS in Bangladesh. Case-patients were 97 persons with GBS admitted to Dhaka 
Medical College Hospital, Bangabandhu Sheikh Mujib Medical University, and Dhaka Central Hospital 
during July 2006–June 2007. All fulfilled the diagnostic criteria for GBS of the National Institute of 
Neurological Disorders and Stroke of the US National Institutes of Health (Bethesda, MD, USA) (6). 
The control group comprised 97 patients with other neurologic diseases, matched with case-patients 
by sex, age, and date of admission to the hospital. A second control group comprised 97 healthy 
family members of case-patients. Up to 3 stool samples were cultured from each case-patient and 
control. Campylobacter strains were presumptively identified with Gram stain, oxidase, and hippurate 
hydrolysis tests and confirmed with a C. jejuni species-specific PCR. Serotyping was performed at the 
National Laboratory for Enteric Pathogens, Canadian Science Centre for Human and Animal Health, 
Winnipeg, Manitoba, Canada. All strains were serotyped according to the HS serotyping schemes of 
Penner et al. (7). To determine the class of lipooligosaccharides (LOS) locus in each of the C. jejuni 
strains, genomic DNA was isolated by using the DNeasy tissue kit (QIAGEN, Venlo, the Netherlands). 
PCR analysis was performed with primer sets specific for classes A, B, C, D, and E (8).  
We isolated C. jejuni from fecal samples of 10 case-patients. Campylobacter strains were not 
isolated from the control groups (p<0.001). Serotyping of the 10 GBS-related strains showed 4 
different HS serotypes. C. jejuni HS:23 was found in 5 (50%) strains; HS:19, in 2 (20%); HS:55 and 
HS:21, in 1 strain each. One strain was untypeable according to the HS typing scheme. In a collection 
of clinical C. jejuni isolated during the same period from patients with enteritis, HS:23 was 
encountered in 9 (28%) of 32 patients. Serotypes previously associated with GBS were HS:1, HS:2, 
HS:4, HS:4/50, HS:5, HS:10, HS:13/65, HS:16, HS:19, HS:23, HS:35, HS:37, HS:41, HS:44, and 
HS:64 (5,9).  
Nine (90%) of the C. jejuni isolates from the case-patients had the class A or class B LOS, 
which are highly associated with the presence of ganglioside-mimicking structures in LOS (10). 
Godschalk et al. found that 14 (82%) of 17 GBS-associated isolates possessed a class A/B/C locus 
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Guillain-Barré syndrome (GBS) is an acute peripheral neuropathy triggered by a preceding 
infectious illness. Gastroenteritis caused by Campylobacter jejuni is the most frequently reported 
antecedent event (1). In Japan, South Africa, China, and Mexico, Campylobacter strains with certain 
Penner heat-stable (HS) serotypes, including HS:19 and HS:41, are overrepresented among isolates 
from GBS case-patients, compared with isolates from enteritis case-patients (2,3). Several studies 
indicate that C. jejuni HS:19 and HS:41 have a clonal population structure and suggest that these 
serotypes might have unique virulence properties that are intricately linked to development of GBS (4). 
However, data from the United Kingdom and the Netherlands suggest that such virulence properties 
may not be restricted to specific HS serotypes because many other serotypes can be cultured from 
patients with GBS (5). We report a non-HS:19 and non-HS:41 C. jejuni serotype and sequence type 
(ST)–3219 that are overrepresented among isolates from GBS patients in Bangladesh. 
We conducted a prospective case-control study of the serotype and genotype of C. jejuni 
associated with GBS in Bangladesh. Case-patients were 97 persons with GBS admitted to Dhaka 
Medical College Hospital, Bangabandhu Sheikh Mujib Medical University, and Dhaka Central Hospital 
during July 2006–June 2007. All fulfilled the diagnostic criteria for GBS of the National Institute of 
Neurological Disorders and Stroke of the US National Institutes of Health (Bethesda, MD, USA) (6). 
The control group comprised 97 patients with other neurologic diseases, matched with case-patients 
by sex, age, and date of admission to the hospital. A second control group comprised 97 healthy 
family members of case-patients. Up to 3 stool samples were cultured from each case-patient and 
control. Campylobacter strains were presumptively identified with Gram stain, oxidase, and hippurate 
hydrolysis tests and confirmed with a C. jejuni species-specific PCR. Serotyping was performed at the 
National Laboratory for Enteric Pathogens, Canadian Science Centre for Human and Animal Health, 
Winnipeg, Manitoba, Canada. All strains were serotyped according to the HS serotyping schemes of 
Penner et al. (7). To determine the class of lipooligosaccharides (LOS) locus in each of the C. jejuni 
strains, genomic DNA was isolated by using the DNeasy tissue kit (QIAGEN, Venlo, the Netherlands). 
PCR analysis was performed with primer sets specific for classes A, B, C, D, and E (8).  
We isolated C. jejuni from fecal samples of 10 case-patients. Campylobacter strains were not 
isolated from the control groups (p<0.001). Serotyping of the 10 GBS-related strains showed 4 
different HS serotypes. C. jejuni HS:23 was found in 5 (50%) strains; HS:19, in 2 (20%); HS:55 and 
HS:21, in 1 strain each. One strain was untypeable according to the HS typing scheme. In a collection 
of clinical C. jejuni isolated during the same period from patients with enteritis, HS:23 was 
encountered in 9 (28%) of 32 patients. Serotypes previously associated with GBS were HS:1, HS:2, 
HS:4, HS:4/50, HS:5, HS:10, HS:13/65, HS:16, HS:19, HS:23, HS:35, HS:37, HS:41, HS:44, and 
HS:64 (5,9).  
Nine (90%) of the C. jejuni isolates from the case-patients had the class A or class B LOS, 
which are highly associated with the presence of ganglioside-mimicking structures in LOS (10). 
Godschalk et al. found that 14 (82%) of 17 GBS-associated isolates possessed a class A/B/C locus 
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(8). Parker et al. (10) found that all GBS related strains and 64% of the other clinical and 
environmental isolates belonged to LOS class A/B/C loci. The expression of ganglioside-mimicking 
structures in Campylobacter, LOS is considered essential for the induction of autoantibodies that lead 
to GBS. Godschalk et al. (8) demonstrated that specific genes involved in C. jejuni LOS biosynthesis 
are crucial for the induction of antiganglioside antibodies that lead to GBS.  
We performed multilocus sequence typing to examine the overall genomic variation among 10 
GBS-related C. jejuni strains. We identified 6 different STs among the GBS-related C. jejuni strains 
(Table). However, ST-3219 has a new combination of alleles and was identified in 4 strains. 
Concordantly, the analysis demonstrated that C. jejuni isolates with serotype HS:23 were all ST-3219. 
Of particular interest, ST-985 (BD-67) shared 5 alleles (aspA, uncA, glnA, glyA, pgm) with ST-3219 
(Table).  
Our findings of a C. jejuni HS:23 serotype and ST-3219 that is highly prevalent among GBS-
related C. jejuni strains from Bangladesh are consistent with previous observations that specific LOS 
types and serotypes are overrepresented among GBS-related C. jejuni strains. These observations 
support the hypothesis that, although a great variety of C. jejuni serotypes can be isolated from GBS 
patients in some geographic areas, specific clonal serotypes and multilocus types are prevalent in 
GBS patients in other places. The association of GBS with C. jejuni LOS class A/B/C is the only 
consistent finding when universal collections of GBS- associated strains are considered. 
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(8). Parker et al. (10) found that all GBS related strains and 64% of the other clinical and 
environmental isolates belonged to LOS class A/B/C loci. The expression of ganglioside-mimicking 
structures in Campylobacter, LOS is considered essential for the induction of autoantibodies that lead 
to GBS. Godschalk et al. (8) demonstrated that specific genes involved in C. jejuni LOS biosynthesis 
are crucial for the induction of antiganglioside antibodies that lead to GBS.  
We performed multilocus sequence typing to examine the overall genomic variation among 10 
GBS-related C. jejuni strains. We identified 6 different STs among the GBS-related C. jejuni strains 
(Table). However, ST-3219 has a new combination of alleles and was identified in 4 strains. 
Concordantly, the analysis demonstrated that C. jejuni isolates with serotype HS:23 were all ST-3219. 
Of particular interest, ST-985 (BD-67) shared 5 alleles (aspA, uncA, glnA, glyA, pgm) with ST-3219 
(Table).  
Our findings of a C. jejuni HS:23 serotype and ST-3219 that is highly prevalent among GBS-
related C. jejuni strains from Bangladesh are consistent with previous observations that specific LOS 
types and serotypes are overrepresented among GBS-related C. jejuni strains. These observations 
support the hypothesis that, although a great variety of C. jejuni serotypes can be isolated from GBS 
patients in some geographic areas, specific clonal serotypes and multilocus types are prevalent in 
GBS patients in other places. The association of GBS with C. jejuni LOS class A/B/C is the only 
consistent finding when universal collections of GBS- associated strains are considered. 
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Abstract 
Background: Campylobacter jejuni is a common cause of acute gastroenteritis and is associated with 
post-infectious neuropathies such as the Guillain-Barré syndrome (GBS) and the Miller Fisher 
syndrome (MFS). We here present comparative genotyping of 49 C. jejuni strains from Bangladesh 
that were recovered from patients with enteritis or GBS. All strains were serotyped and analyzed by 
lipo-oligosaccharide (LOS) genotyping, amplified fragment length polymorphism (AFLP) analysis, 
multilocus sequence typing (MLST), and pulsed-field gel electrophoresis (PFGE).  
Methodology/Principle Findings: C. jejuni HS:23 was a predominant serotype among GBS patients 
(50%), and no  specific serotype was significantly associated with GBS compared to enteritis. PCR 
screening showed that 38/49 (78%) of strains could be assigned to LOS classes A, B, C, or E. The 
class A locus (4/7 vs 3/39; p<0.01) was significantly associated in the GBS-related strains as 
compared to enteritis strains. All GBS/oculomotor related strains contained the class B locus; which 
was also detected in 46% of control strains. Overlapping clonal groups were defined by MLST, AFLP 
and PFGE for strains from patients with gastroenteritis and GBS. MLST defined 22 sequence types 
(STs) and 7 clonal complexes including 7 STs not previously identified (ST-3742, ST-3741, ST-3743, 
ST-3748, ST-3968, ST-3969 and ST-3970). C. jejuni HS:23 strains from patients with GBS or enteritis 
were clonal and all strains belonged to ST-403 complex. Concordance between LOS class B and ST-
403 complex was revealed. AFLP defined 25 different types at 90% similarity. The predominant AFLP 
type AF-20 coincided with the C. jejuni HS:23 and ST-403 complex.  
Conclusion/Significance: LOS genotyping, MLST, AFLP and PFGE helped to identify the HS:23 
strains from GBS or enteritis patients as clonal. Overall, genotypes exclusive for enteritis or for GBS-
related strains were not obtained although LOS class A was significantly associated with GBS strains. 
Particularly, the presence of a clonal and putative neuropathogenic C. jejuni HS:23 serotype may 
contribute to the high prevalence of C. jejuni related GBS in Bangladesh.  
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Introduction 
 
Campylobacter jejuni is the most significant bacterial cause of human gastroenteritis (1-4). 
Clinical syndromes vary from mild to severe and from gastroenteritis to extraintestinal diseases. This 
latter category includes acute autoimmune neuromuscular complications such as the Guillain-Barré 
syndrome (GBS) and Miller-Fisher syndrome (5). The pathogenesis of Campylobacter-induced GBS is 
complex and involves host susceptibility factors as well as bacterial virulence factors (6-8). The 
development of these autoimmune neuropathies after C. jejuni infection is thought to be primarily 
related to sialylated lipooligosaccharides (LOS) on the cell surface of C. jejuni. These exhibit 
significant molecular mimicry with gangliosides on human peripheral nerves (9-13). Most patients who 
develop GBS after C. jejuni enteritis have IgG autoantibodies that react with gangliosides (such as 
GM1, GD1a, and GQ1b) (14). Comparison of the LOS loci of various C. jejuni strains has 
demonstrated that only the class A, B and C LOS loci contain the genes that are necessary for the 
biosynthesis of ganglioside mimics (15). 
Extensive effort has been put into the identification of novel determinants of C. jejuni 
associated with the development of GBS (16, 17). In Japan, South Africa, China, and Mexico, 
Campylobacter strains with specific Penner heat-stabile (HS) serotypes, including HS:19 and HS:41, 
were overrepresented among strains isolated from GBS  patients (5, 18, 19). C. jejuni HS:19 and 
HS:41 are clonal which suggests that these serotypes may have unique and specific virulence 
properties that trigger GBS (20). However,  more recent data has shown that these neuropathogenic  
properties  are not  restricted to specific HS serotypes as other serotypes commonly isolated from 
enteritis patients (HS:1, HS:2, and HS:4 complex) are also found in patients with GBS (21). We 
recently reported non-HS:19 and non-HS-41 C. jejuni serotypes that are overrepresented among 
strains from GBS patients in Bangladesh (22). Recently, we reported a high frequency of 
Campylobacter-related GBS from Bangladesh (12th ASCODD). 
The aim of the present study was to investigate the genetic heterogeneity of C. jejuni strains 
isolated from GBS and enteritis patients between 2006 and 2007 in Bangladesh. In this comparative 
genomic analysis, multi-locus sequence typing (MLST), amplified fragment length polymorphism 
(AFLP), LOS class PCR typing, and pulsed-field gel electrophoresis (PFGE) were employed to define 
detailed strain specific genotypes. 
 
 
Materials and Methods 
 
Bacterial strains 
A systematic hospital-based study has been carried out among GBS patients in Dhaka, 
Bangladesh between 2006 and 2007. During this period, we isolated 10 C. jejuni strains from stool 
specimens of GBS patients and 39 C. jejuni from enteritis patients (22). All GBS patients fulfilled the 
diagnostic of GBS criteria (23). Bacteria were grown on blood agar plates with 5% sheep blood, at 
37°C for 48 h under micro-aerobic conditions, with 6% O2, 7% CO2, 80% N2, and 7% H2 using the 
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Anoxomat system (AnoxomatTM Mart II, Drachten, The Netherlands). Bacteria were stored at -80°C in 
15% glycerol in brain heart infusion broth. All strains were serotyped with the heat-stable (HS) 
serotyping schemes of Penner at the National Laboratory for Enteric Pathogens, Canadian Science 
Centre for Human and Animal Health, Winnipeg, Canada (24). The project protocol was reviewed and 
approved by the institutional review board and the ethical committees at the Dhaka Medical College 
and Hospital, Dhaka, Bangladesh.  Verbal informed consent was obtained from all patients and 
controls.  
 
Bacterial DNA isolation 
Genomic DNA was isolated with the Qiagen Genomic DNA purification kit according to the 
manufacturer’s instructions (Qiagen, Venlo, The Netherlands).  
 
Determination of the LOS locus class 
  To determine the LOS class in C. jejuni strains, we used specific primer sets for the classes 
A/B, C, D, and E, based on the DNA sequence of genes unique to the respective LOS locus class(es) 
described earlier (9). To discern between classes A and B, we used a primer set that was based on 
the DNA sequence of orf5-II (9). PCR assays were performed using a Thermocycler 60 (Biomed 
GmbH) with a program consisting of 40 cycles of 1 minute at 94°C, 1 minute at 52°C, and 2 minutes at 
74°C. Per reaction, approximately 50 ng of template DNA was used in a buffer system consisting of 10 
mM Tris-HCl (pH 9.0), 50 mM KCl, 1.5 mM MgCl2, 0.01% gelatin, 0.1% Triton X-100, 0.2 mM of each 
of the deoxyribonucleotide triphosphates (Promega Corp.), and 0.2 U Super Taq polymerase (HT 
Biotechnology Ltd.).  
 
Multilocus sequence typing of C. jejuni strains  
Nucleotide sequence analysis of internal fragments of seven housekeeping genes (aspartase 
A, aspA; glutamine synthetase, glnA; citrate synthase, gltA; serine hydroxymethyl transferase, glyA; 
phosphoglucomutase, pgm; transketolase, tkt and ATP synthase α subunit, uncA) was performed as 
described by Dingle et al. (25). Where no amplification product was observed on agarose gel 
electrophoresis, the reaction was repeated substituting primers described by Miller et al. (26). The 
same primers used to obtain each amplicon were used for nucleotide sequencing, which was carried 
out at least once on each DNA strand using BigDyeTM Ready Reaction Mix (Version 3, Applied 
Biosystems, Foster City, CA) at a concentration of 1/32 of that described in the manufacturer's 
instructions. Existing and new alleles, sequence types (ST) and clonal complexes were assigned 
using the MLST database located at http://pubmlst.org/Campylobacter/). Sequence types (STs) were 
assigned to clonal complexes as described by Dingle et al. (25) by identification of central genotypes 
and the assignment of variants that differed at one, two, or three loci (25, 27). The data were used to 
draw an unweighted pair group mean average (UPGMA) dendrogram by using the program START 
(http://outbreak.ceid.ox.ac.uk/software.htm) (28).  
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specimens of GBS patients and 39 C. jejuni from enteritis patients (22). All GBS patients fulfilled the 
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controls.  
 
Bacterial DNA isolation 
Genomic DNA was isolated with the Qiagen Genomic DNA purification kit according to the 
manufacturer’s instructions (Qiagen, Venlo, The Netherlands).  
 
Determination of the LOS locus class 
  To determine the LOS class in C. jejuni strains, we used specific primer sets for the classes 
A/B, C, D, and E, based on the DNA sequence of genes unique to the respective LOS locus class(es) 
described earlier (9). To discern between classes A and B, we used a primer set that was based on 
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A, aspA; glutamine synthetase, glnA; citrate synthase, gltA; serine hydroxymethyl transferase, glyA; 
phosphoglucomutase, pgm; transketolase, tkt and ATP synthase α subunit, uncA) was performed as 
described by Dingle et al. (25). Where no amplification product was observed on agarose gel 
electrophoresis, the reaction was repeated substituting primers described by Miller et al. (26). The 
same primers used to obtain each amplicon were used for nucleotide sequencing, which was carried 
out at least once on each DNA strand using BigDyeTM Ready Reaction Mix (Version 3, Applied 
Biosystems, Foster City, CA) at a concentration of 1/32 of that described in the manufacturer's 
instructions. Existing and new alleles, sequence types (ST) and clonal complexes were assigned 
using the MLST database located at http://pubmlst.org/Campylobacter/). Sequence types (STs) were 
assigned to clonal complexes as described by Dingle et al. (25) by identification of central genotypes 
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AFLP analysis and data processing 
Strains were typed by AFLP (29). In short, chromosomal DNA was digested with HindIII and 
HhaI and simultaneously ligated with restriction site-specific adapters for 2 h at 37°C. This was 
followed by a preselective PCR using adapter-specific primers with HindIII (5’-
GACTGCGTACCAGCTT) and HhaI (5’-GATGAGTCCTGATCGC-3’). Next, an aliquot was subjected 
to a selective PCR using a fluorescently labelled HindIII primer that contained an additional A 
nucleotide at the 3’ end (5’-GACTGCGTACCAGC TTA) and a HhaI primer with an A extension (59-
GATGAGTCCTGATCGCA). The final products were run on a 7.3% denaturing acrylamide gel for 5 h 
using a ABI 373A automated DNA sequencer. Fingerprints were collected by fluorography and 
interpreted with ABI Genescan software (PE Applied Biosystems). Gels were normalized using an 
internal ROX-labeled size standard included in each lane. Densitometric curves were processed with 
the GelCompar version 4.1 software (Applied Maths, Kortrijk, Belgium). After normalization and 
background subtraction, the levels of genetic similarity between AFLP patterns were calculated with 
the Pearson product-moment correlation coefficient (r).  
 
PFGE 
 PFGE was performed as previously described (30). In short, samples of genomic DNA 
extracted from overnight cultures of the strains were digested with SmaI (Boehringer GmbH, 
Mannheim, Germany). Electrophoresis was performed in 1% SeaKem agarose in 0.53 Tris-borate-
EDTA buffer by using a Bio-Rad CHEF Mapper programmed in the auto-algorithm mode (run time, 18 
h; switch time, 6.76 to 35.38 s). Gels were stained with ethidium bromide for 30 min, destained in 
distilled water for 1 h; images of ethidium bromide-stained gels were captured under UV illumination 
by a video system (Gel DOC 1000; Bio-Rad). 
 
Data analysis 
Electrophoretic patterns from PFGE were compared by means of BioNumerics, version 4.01 
(Applied Maths, Sint-Martens-Latem, Belgium). Analysis was based on band position and derived by 
the Dice coefficient with a maximum position tolerance of 1%. Strains were clustered by the 
unweighted pair group method using arithmetic averages. Statistical analysis was performed with 
EpiInfo (version 3.0) using 2 × 2 contingency tables. Fisher’s exact tests were executed and 2-sided P 
values determined. Associations were considered significant at P < 0.05. 
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Serotyping 
Serotyping of the 10 GBS-related strains revealed 4 different HS serotypes (22). C. jejuni 
HS:19 was encountered in 2/10 (20%) patients. C. jejuni HS:23 was found in 5/10 (50%), a 
predominant serotype in GBS patients. Serotyping of enteritis strains revealed 15 HS-serotypes (Table 
1). C. jejuni HS:23 was predominant serotype (28%) among enteritis strains. 
 
LOS locus class 
  The results presented in Table 2 indicate that 38/49 (78%) of the C. jejuni strains 
characterized in this study could be assigned to one of the five LOS locus classes (A-E) screened by 
the class-specific PCR. The class A LOS locus was significantly associated with GBS-associated 
strains compared to controls strains (57% versus 8%, p<0.01; Table 2). In contrast, the three strains 
isolated in GBS patients with oculomotor symptoms contained a class B locus. LOS class B was 
detected in 18/39 (46%) of control strains (Table 2). No LOS locus classes C or D were found in GBS 
strains. LOS classes C and D were absent in enteritis strains with one exception; strain CZ-32 which 
had class C. The class E locus was rare in GBS and enteritis (1/10 vs 6/39 respectively). 
 
Multilocus sequence typing of C. jejuni strains 
A total of 22 different STs were found belonging to 7 clonal complexes, and a further 18 STs 
remained unassigned (Table 1). Seven new STs not previously registered in the Campylobacter 
pubMLST database were identified (ST-3742, ST-3741, ST-3743, ST-3748, ST-3968, ST-3969 and 
ST-3970). The most prevalent lineage was the ST-403 complex (Fig. 1), which included 5 of the 10 
(50%) GBS-related strains studied and 10 of the 38 (26%) enteritis strains. The ST-362 complex 
included 2 of 10 (20%) GBS-related strains studied and 5 of 38 (13%) enteritis strains (Fig. 1).  All 
Penner serotypes HS:23 strains belong to the ST-403 complex. ST-22 and ST-660, which both belong 
to the ST-22 complex, were found only in GBS-related strains and both strains belong to Penner 
serotype HS:19 (Table 1). UPGMA clustering of MLST data for C. jejuni strains isolated from GBS and 
enteritis patients yielded 4 major clonal groups (A, B, C and D) consisting 13 STs, and 8 STs were 
singletons (Fig. 2).  
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EpiInfo (version 3.0) using 2 × 2 contingency tables. Fisher’s exact tests were executed and 2-sided P 
values determined. Associations were considered significant at P < 0.05. 
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the class-specific PCR. The class A LOS locus was significantly associated with GBS-associated 
strains compared to controls strains (57% versus 8%, p<0.01; Table 2). In contrast, the three strains 
isolated in GBS patients with oculomotor symptoms contained a class B locus. LOS class B was 
detected in 18/39 (46%) of control strains (Table 2). No LOS locus classes C or D were found in GBS 
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had class C. The class E locus was rare in GBS and enteritis (1/10 vs 6/39 respectively). 
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A total of 22 different STs were found belonging to 7 clonal complexes, and a further 18 STs 
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ST-3970). The most prevalent lineage was the ST-403 complex (Fig. 1), which included 5 of the 10 
(50%) GBS-related strains studied and 10 of the 38 (26%) enteritis strains. The ST-362 complex 
included 2 of 10 (20%) GBS-related strains studied and 5 of 38 (13%) enteritis strains (Fig. 1).  All 
Penner serotypes HS:23 strains belong to the ST-403 complex. ST-22 and ST-660, which both belong 
to the ST-22 complex, were found only in GBS-related strains and both strains belong to Penner 
serotype HS:19 (Table 1). UPGMA clustering of MLST data for C. jejuni strains isolated from GBS and 
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Figure 1. Frequency distribution of C. jejuni clonal complexes isolated from GBS and enteritis patients  
 
AFLP 
AFLP fingerprints were identified as distinct types when band patterns shared less than 90% 
similarity according to Duim et al. [29]. Among 49 C. jejuni strains, 25 different AFLP types were 
found. Twelve AFLP types were encountered in more than one strain (Fig. 3). The predominant AFLP 
type AF-20 was observed in 9 (18%) strains and type AF-3 in 3 (6%) and AF-4 in 4 (8%) strains each 
(Fig. 3). Seven distinct AFLP fingerprints were found in GBS-related C. jejuni strains. The predominant 
AFLP type AF-20 consisted of two GBS-related strains (BD-22 and BD-34) and 7 enteritis strains; this 
AFLP type correlated with Penner serotype HS:23 and clonal complex ST-403 (Fig. 3). Strains BD-07 
and BD-39 displayed identical fingerprints (AF-9) and belong to the same Penner serotype HS:19. 
AFLP subdivided PFGE type A11 strains (BD-10 and BD-67) into two sub-clusters (AF-22 and AF-23). 
Twelve AFLP fingerprints of gastroenteritis strains (CZ-31, CZ-32, CZ-33, CZ-36, CZ-51, CZ-54, CZ-
77, CZ-81, CZ-94, CZ-96, BD-67 and BD-74) were unique (Fig. 3).  
 
 PFGE 
The SmaI-PFGE fingerprints contained six to nine bands and resolved into 4 major lineages at 
60% similarity [31] (data not shown). These results correlate well with both the MLST clonal 
complexes and the different sub-clusters as defined by AFLP (Fig. 3). The 4 PFGE lineages could be 
subdivided in 33 subclusters at 90% similarity (Fig. 3). The majority of the strains belonging to a given 
clonal complex (ST-403) were also included in the same PFGE group (A). PFGE subdivided AFLP 
type AF-20 into several subtypes. PFGE analysis of 10 GBS related C. jejuni revealed the presence of 
7 distinct types. Alhough AFLP and serotyping suggested that BD-07 and BD-39 were clonal (AF-9) 
these two strains were distinguishable by PFGE (A12 and A13).  
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Figure 2. Dendrogram of Campylobacter jejuni sequence types, including GBS and enteritis related strains from 
Bangladesh. The dendrogram was constructed by using UPGMA. 
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Figure 3. UPGMA dendrogram of AFLP fingerprints from 40 gastroenteritis and 10 strains related to patients with 
GBS. The percentage of genetic homology between banding patterns is indicated. Serotypes, LOS type, MLST, 
PFGE and AFLP types are plotted next to dendrogram. UA, unassigned; NT not typed; UT untypeable. 
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Congruence between typing methods 
After cluster analysis of the data obtained by the respective methods and construction of a 
composite data set comprising the LOS typing, MLST, PFGE and AFLP, a similar clustering of the 
strains was observed. All ST-403 complex strains belonged to LOS locus class B. The correlation 
between LOS class B and ST-403 complex was evident in both GBS and enteritis collections (Table 
1). Upon analysis of clustering of the sequence types by MLST, 81% showed overlap with AFLP types 
(Fig. 3).  
 
 
Discussion 
 
We performed comparative genomics of a set of 49 C. jejuni strains isolated from GBS and 
enteritis patients in Bangladesh by MLST, AFLP, LOS typing and PFGE fingerprinting. This is the first 
report on molecular characterization of GBS and enteritis related C. jejuni strains from Bangladesh. 
Cluster analysis of LOS typing, AFLP, PFGE and MLST showed significant overlaps. The LOS class A 
was significantly over-represented in the GBS-associated strains compared to the enteritis strains. Our 
MLST analysis demonstrated that all of the Bangladeshi strains with HS:23 serotype are clonal and 
clearly distinct from the non-HS:23 strains. The clonal complex ST-403 was  overlapped by LOS 
typing, AFLP and PFGE. We recently reported that C. jejuni HS:23 serotype  is prevalent among GBS 
and enteritis-related C. jejuni strains from Bangladesh (22). Our comparative genotyping analysis 
supported that C. jejuni HS:23 strains are clonal. However, comparison of a worldwide non-HS:19 
associated with GBS and enteritis showed heterogeneity (32).  
In the present study, we targeted only five specific classes (A-E) of LOS loci, despite recent 
increases in the number of LOS locus classes identified (33). LOS class A, B and C have been 
associated previously with GBS (9). We identified LOS A or B in 90% of GBS associated strains and in 
46% of enteritis strains. Interestingly, we found that the class A locus is significantly associated with 
GBS without oculomotor symptoms whereas the class B locus associated with GBS with oculomotor 
symptoms. Previously Nachamkin et al. (34) reported a strong association between GBS-associated 
C. jejuni strains and the simultaneous presence of three LOS biosynthesis genes, cst-II, cgtA and 
cgtB. Our data confirm these findings, as the combination of cstII, cgtA and cgtB only exist in class 
LOS A and B. Other studies have demonstrated that the class A, B and C LOS loci contain the specific 
genes involved in the biosynthesis of ganglioside mimics (9, 15). Molecular mimicry between 
Campylobacter LOS and gangliosides in human peripheral nerves is thought to be the mechanism 
involved in the development of GBS (35).  
We have used a variety of molecular techniques to demonstrate the genomic differences or 
similarities among the C. jejuni strains. In this study, we identified 7 distinct clonal complexes with 22 
different STs. The most common Bangladeshi lineage was the ST-403 complex (Fig. 2). This 
predominant clonal complex is corroborated by LOS class B loci. In addition, distribution of STs 
showed a good concordance between GBS and enteritis related strains (Fig. 2). No representatives of 
ST-21 were present among GBS and enteritis related strains from Bangladesh, whereas ST-21 is the 
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Figure 3. UPGMA dendrogram of AFLP fingerprints from 40 gastroenteritis and 10 strains related to patients with 
GBS. The percentage of genetic homology between banding patterns is indicated. Serotypes, LOS type, MLST, 
PFGE and AFLP types are plotted next to dendrogram. UA, unassigned; NT not typed; UT untypeable. 
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Congruence between typing methods 
After cluster analysis of the data obtained by the respective methods and construction of a 
composite data set comprising the LOS typing, MLST, PFGE and AFLP, a similar clustering of the 
strains was observed. All ST-403 complex strains belonged to LOS locus class B. The correlation 
between LOS class B and ST-403 complex was evident in both GBS and enteritis collections (Table 
1). Upon analysis of clustering of the sequence types by MLST, 81% showed overlap with AFLP types 
(Fig. 3).  
 
 
Discussion 
 
We performed comparative genomics of a set of 49 C. jejuni strains isolated from GBS and 
enteritis patients in Bangladesh by MLST, AFLP, LOS typing and PFGE fingerprinting. This is the first 
report on molecular characterization of GBS and enteritis related C. jejuni strains from Bangladesh. 
Cluster analysis of LOS typing, AFLP, PFGE and MLST showed significant overlaps. The LOS class A 
was significantly over-represented in the GBS-associated strains compared to the enteritis strains. Our 
MLST analysis demonstrated that all of the Bangladeshi strains with HS:23 serotype are clonal and 
clearly distinct from the non-HS:23 strains. The clonal complex ST-403 was  overlapped by LOS 
typing, AFLP and PFGE. We recently reported that C. jejuni HS:23 serotype  is prevalent among GBS 
and enteritis-related C. jejuni strains from Bangladesh (22). Our comparative genotyping analysis 
supported that C. jejuni HS:23 strains are clonal. However, comparison of a worldwide non-HS:19 
associated with GBS and enteritis showed heterogeneity (32).  
In the present study, we targeted only five specific classes (A-E) of LOS loci, despite recent 
increases in the number of LOS locus classes identified (33). LOS class A, B and C have been 
associated previously with GBS (9). We identified LOS A or B in 90% of GBS associated strains and in 
46% of enteritis strains. Interestingly, we found that the class A locus is significantly associated with 
GBS without oculomotor symptoms whereas the class B locus associated with GBS with oculomotor 
symptoms. Previously Nachamkin et al. (34) reported a strong association between GBS-associated 
C. jejuni strains and the simultaneous presence of three LOS biosynthesis genes, cst-II, cgtA and 
cgtB. Our data confirm these findings, as the combination of cstII, cgtA and cgtB only exist in class 
LOS A and B. Other studies have demonstrated that the class A, B and C LOS loci contain the specific 
genes involved in the biosynthesis of ganglioside mimics (9, 15). Molecular mimicry between 
Campylobacter LOS and gangliosides in human peripheral nerves is thought to be the mechanism 
involved in the development of GBS (35).  
We have used a variety of molecular techniques to demonstrate the genomic differences or 
similarities among the C. jejuni strains. In this study, we identified 7 distinct clonal complexes with 22 
different STs. The most common Bangladeshi lineage was the ST-403 complex (Fig. 2). This 
predominant clonal complex is corroborated by LOS class B loci. In addition, distribution of STs 
showed a good concordance between GBS and enteritis related strains (Fig. 2). No representatives of 
ST-21 were present among GBS and enteritis related strains from Bangladesh, whereas ST-21 is the 
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prevalent complex in the general population structure of C. jejuni (25), it is widespread in multiple 
hosts and has previously been described to be associated with infections in humans, and with 
livestock and environmental sources; as in chicken, cattle, contaminated milk and water (25, 36). 
Molecular epidemiological evidence suggests that this clonal complex is frequently associated with 
environmental and food borne transmission (36, 37). Recently, Habib et al. (31) demonstrated that ST-
21 complex strongly correlated with class LOS C loci. Both ST-21 and LOS C appear to be rare in 
Bangladesh. The GBS-associated strains were assigned to different clonal complexes (22), which 
correlated with earlier data describing heterogeneity among neuropathogenic C. jejuni strains (21, 25). 
ST-22 and ST-660 (both ST-22 complex) belong to Penner serotype HS:19 and were only found in 
GBS-related strains; ST-362 complex was the second most prevalent complex found in both GBS and 
enteritis strains; corroborated with LOS class A or B loci. A number of new STs were identified for the 
first time in this study (ST-3442, ST-3741, ST-3743, ST-3748, ST-3968, ST-3969 and ST-3970), but 
were not assigned to any known complex. To date, these unassigned STs have only been found only 
in enteritis strains from Bangladesh.  
 Cluster analysis of AFLP data in this study supports previous reports that no distinct 
subpopulation of C. jejuni strains is associated with GBS or enteritis (29). AFLP analysis revealed that 
HS:23 strains are clonal but substantial heterogeneity was found among non-HS:23 strains. PFGE 
and AFLP analysis were shown to have a high level of discriminatory power, although in some cases 
AFLP was able to distinguish further patterns. In some cases AFLP patterns of the strains were highly 
similar, whereas PFGE patterns showed differences (Fig. 2). Our PFGE and AFLP data also support 
those reported in a previous study carried out on Finnish C. jejuni strains (38). The genetic diversity of 
C. jejuni is well recognised and is attributed to a number of distinct phenomena, including genomic 
rearrangements and horizontal gene transfer (39). A study carried out in England by Owen et al. (39) 
showed that C. jejuni strains from human strains were highly diverse by PFGE analysis. Previous 
studies also described that MLST, AFLP, PFGE and DNA microarrays could not identify GBS-specific 
genetic markers by comparing the genomes of C. jejuni strains (16, 21, 25, 29). Furthermore, no 
molecular markers specific to GBS were detected after analyzing a highly clonal HS:41 population 
from South African patients by using a high-throughput AFLP (40). However, the LOS class typing 
significantly differentiated GBS-related strains from enteritis in Bangladesh. 
In conclusion, our results support C. jejuni HS:23 are over represented among GBS related 
strains in Bangladesh and appear to be clonally related; LOS class A is significantly associated with 
GBS. The present study revealed a correlation between MLST clonal complex (ST-403) and certain 
LOS locus class B. Particularly, putative neuropathogenic C. jejuni HS:23 serotype may circulate at an 
elevated prevalence in  Bangladesh.  
Comparative genotyping of Campylobacter jejuni    
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prevalent complex in the general population structure of C. jejuni (25), it is widespread in multiple 
hosts and has previously been described to be associated with infections in humans, and with 
livestock and environmental sources; as in chicken, cattle, contaminated milk and water (25, 36). 
Molecular epidemiological evidence suggests that this clonal complex is frequently associated with 
environmental and food borne transmission (36, 37). Recently, Habib et al. (31) demonstrated that ST-
21 complex strongly correlated with class LOS C loci. Both ST-21 and LOS C appear to be rare in 
Bangladesh. The GBS-associated strains were assigned to different clonal complexes (22), which 
correlated with earlier data describing heterogeneity among neuropathogenic C. jejuni strains (21, 25). 
ST-22 and ST-660 (both ST-22 complex) belong to Penner serotype HS:19 and were only found in 
GBS-related strains; ST-362 complex was the second most prevalent complex found in both GBS and 
enteritis strains; corroborated with LOS class A or B loci. A number of new STs were identified for the 
first time in this study (ST-3442, ST-3741, ST-3743, ST-3748, ST-3968, ST-3969 and ST-3970), but 
were not assigned to any known complex. To date, these unassigned STs have only been found only 
in enteritis strains from Bangladesh.  
 Cluster analysis of AFLP data in this study supports previous reports that no distinct 
subpopulation of C. jejuni strains is associated with GBS or enteritis (29). AFLP analysis revealed that 
HS:23 strains are clonal but substantial heterogeneity was found among non-HS:23 strains. PFGE 
and AFLP analysis were shown to have a high level of discriminatory power, although in some cases 
AFLP was able to distinguish further patterns. In some cases AFLP patterns of the strains were highly 
similar, whereas PFGE patterns showed differences (Fig. 2). Our PFGE and AFLP data also support 
those reported in a previous study carried out on Finnish C. jejuni strains (38). The genetic diversity of 
C. jejuni is well recognised and is attributed to a number of distinct phenomena, including genomic 
rearrangements and horizontal gene transfer (39). A study carried out in England by Owen et al. (39) 
showed that C. jejuni strains from human strains were highly diverse by PFGE analysis. Previous 
studies also described that MLST, AFLP, PFGE and DNA microarrays could not identify GBS-specific 
genetic markers by comparing the genomes of C. jejuni strains (16, 21, 25, 29). Furthermore, no 
molecular markers specific to GBS were detected after analyzing a highly clonal HS:41 population 
from South African patients by using a high-throughput AFLP (40). However, the LOS class typing 
significantly differentiated GBS-related strains from enteritis in Bangladesh. 
In conclusion, our results support C. jejuni HS:23 are over represented among GBS related 
strains in Bangladesh and appear to be clonally related; LOS class A is significantly associated with 
GBS. The present study revealed a correlation between MLST clonal complex (ST-403) and certain 
LOS locus class B. Particularly, putative neuropathogenic C. jejuni HS:23 serotype may circulate at an 
elevated prevalence in  Bangladesh.  
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ABSTRACT 
Campylobacter jejuni is one of the most important causes of human diarrhea worldwide.  The 
main objective was to understand the possible role of poultry in the transmission of Campylobacter to 
humans in Bangladesh. We used a comparative genotyping approach to determine the population 
structure of 66 C. jejuni isolated from poultry, and to determine the similarities with C. jejuni isolated 
from enteritis (n=39) and Guillain-Barré syndrome (GBS) (n=10) patients. MLST defined 16 sequence 
types (STs) and 5 clonal complexes (CCs) among poultry isolates, including 6 STs not previously 
documented in the public database. The most commonly identified clonal complex in chicken was ST-
353 (n=13), followed by ST-354 (9%), and ST-574 (8%). MLST data suggested that there was 
significant genetic diversity between chicken and human isolates. The predominant clonal complex 
(ST-403) in humans was not found in chicken. The profiles obtained by AFLP and PFGE were largely 
in concordance with the MLST results, and showed a similar level of genetic diversity. AFLP defined 
15 different types in chicken isolates at 90% similarity. The predominant AFLP type AF-1 mostly 
coincided with the ST-353 complex. The AFLP types observed in GBS-related C. jejuni were not found 
among the chicken isolates. The diversity of C. jejuni found among humans suggests that 
transmission occurs from various sources. The dissimilarity of the sequence types/or genotypes of C. 
jejuni from humans and poultry suggests the presence of additional sources other than poultry in 
Bangladesh.  
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ABSTRACT 
Campylobacter jejuni is one of the most important causes of human diarrhea worldwide.  The 
main objective was to understand the possible role of poultry in the transmission of Campylobacter to 
humans in Bangladesh. We used a comparative genotyping approach to determine the population 
structure of 66 C. jejuni isolated from poultry, and to determine the similarities with C. jejuni isolated 
from enteritis (n=39) and Guillain-Barré syndrome (GBS) (n=10) patients. MLST defined 16 sequence 
types (STs) and 5 clonal complexes (CCs) among poultry isolates, including 6 STs not previously 
documented in the public database. The most commonly identified clonal complex in chicken was ST-
353 (n=13), followed by ST-354 (9%), and ST-574 (8%). MLST data suggested that there was 
significant genetic diversity between chicken and human isolates. The predominant clonal complex 
(ST-403) in humans was not found in chicken. The profiles obtained by AFLP and PFGE were largely 
in concordance with the MLST results, and showed a similar level of genetic diversity. AFLP defined 
15 different types in chicken isolates at 90% similarity. The predominant AFLP type AF-1 mostly 
coincided with the ST-353 complex. The AFLP types observed in GBS-related C. jejuni were not found 
among the chicken isolates. The diversity of C. jejuni found among humans suggests that 
transmission occurs from various sources. The dissimilarity of the sequence types/or genotypes of C. 
jejuni from humans and poultry suggests the presence of additional sources other than poultry in 
Bangladesh.  
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INTRODUCTION 
 
Campylobacter jejuni is the most bacterial cause of human gastroenteritis in developed 
countries (1-4). C. jejuni infection in humans is associated with the sudden onset of fever, abdominal 
cramps, and bloody diarrhea (2). In addition, C. jejuni has been identified as an important trigger for 
Guillain-Barré syndrome, the most common cause of acute flaccid paralysis in polio-free regions (5). 
Campylobacter spp. are widespread in the environment and constitute part of the natural intestinal 
flora of many mammalian species and birds (6). This includes not only domestic farm animals such as 
cattle, sheep, and pigs but also pet animals such as cats and dogs (7). Poultry meat is considered to 
be the main vector of C. jejuni infection, and transmission is thought to occur either as a result of 
cross-contamination due to improper handling of raw meat or consumption of undercooked food (8).  
Molecular typing is an important tool to describe the diversity of Campylobacter and 
understand the transmission through the food chain. Several international molecular epidemiological 
studies indicate that genotypes of C. jejuni isolated from humans are shared with strains from poultry 
origin, indicating that poultry is an important source of Campylobacter (9, 10). Various molecular 
typing methods are currently available to study the population structure of Campylobacter (11). 
Pulsed-field gel electrophoresis (PFGE) is a highly discriminatory technique that has been effectively 
applied for subtyping Campylobacter (12). However, the stability of PFGE may be insufficient for 
reliable application in long-term epidemiological studies (13). Despite the efforts to standardize PFGE 
protocols and interpretation criteria of the data, comparison of inter-laboratory results remains difficult 
(14, 15). Multilocus sequence typing (MLST) has emerged as the state-of-the-art method for the 
resolution of bacterial population genetics (16) and is now recognized as the gold standard typing 
method for the phylogenetic study of the Campylobacter genus (17). MLST is not as discriminatory as 
PFGE for distinguishing between isolates but it does provide a direct measure of bacterial relationship. 
This technique is highly reproducible, easy to interpret, and results can be shared through a publicly-
accessible online database (18, 19). Conversely, amplified fragment length polymorphism (AFLP), a 
whole genome typing method, also documents the contribution of accessory genetic elements next to 
the core genome polymorphisms as defined by MLST (7, 20). AFLP fingerprinting has been shown to 
have high potential for strain identification (7, 21-24).  
In many low-income developing countries, hygienic conditions are severely compromised, and 
living in close contact with poultry and domestic animals within the same premises is common in both 
rural and urban areas. Recently, we reported an unusually high frequency of the axonal variant of 
GBS in Bangladesh, associated with preceding C. jejuni infection (57%) (25). We also reported C. 
jejuni MLST type ST-403 as being over-represented among GBS and enteritis related isolates in 
Bangladesh (26, 27). No information is available regarding the population structure of Campylobacter 
isolated from poultry in this country. To determine the role of poultry in the epidemiology of 
Campylobacter infections and their sequelae, we studied the diversity and clonal relationships among 
C. jejuni from humans and chicken with MLST, AFLP and pulsed-field gel electrophoresis (PFGE).  
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MATERIALS AND METHODS 
 
Bacterial isolates 
Sixty six C. jejuni isolated between January and June 2007 from chicken cloacae in the Dhaka 
area of Bangladesh, were included in the present study.  The chickens originated from diverse 
geographic locales in the Dhaka region and were randomly selected. All isolates were cultured and 
identified to the genus and species levels as previously described (28). In addition, 10 C. jejuni strains 
isolated from stool specimens of GBS patients and 39 C. jejuni from enteritis patients were included 
(26). All GBS patients fulfilled the diagnostic criteria of the National Institute of Neurological Disorders 
and Stroke (NINDS) (29). Bacteria were grown on blood agar plates with 5% sheep blood at 37°C for 
48 h under micro-aerophilic conditions, with 6% O2, 7% CO2, 80% N2, and 7% H2 using the Anoxomat 
system (AnoxomatTM Mark II, Drachten, The Netherlands). Bacteria were stored at -80°C in 15% 
glycerol in brain heart infusion broth.  
 
Bacterial DNA isolation 
Genomic DNA was isolated with the Qiagen Genomic DNA purification kit according to the 
manufacturer’s instructions (Qiagen, Venlo, The Netherlands).  
 
Multilocus sequence typing of C. jejuni isolates 
Nucleotide sequence analysis of internal fragments of seven housekeeping genes (aspartase 
A, aspA; glutamine synthetase, glnA; citrate synthase, gltA; serine hydroxymethyl transferase, glyA; 
phosphoglucomutase, pgm; transketolase, tkt and ATP synthase α subunit, uncA) was performed as 
described by Dingle et al. (16). Where no amplification product was observed on agarose gel 
electrophoresis, the reaction was repeated while substituting the primers by those described by Miller 
et al. (18). The same primers were used for nucleotide sequencing, which was carried out at least 
once on each DNA strand using BigDyeTM Ready Reaction Mix (Version 3, Applied Biosystems, Foster 
City, CA) at a concentration of 1/32 of that described in the manufacturer's instructions. Nucleotide 
sequences were deposited in the Internet-accessible pubMLST Campylobacter database 
(http://Campylobacter.mlst.net), enabling the identification and assignment of sequence types (STs) 
and clonal complexes (CC). Related STs were assigned to clonal complexes as described by Dingle 
et al. (16) by identification of central genotypes and the sequential assignment of variants that differed 
at one, two, or three loci (16, 17). Alleles already present in the database were assigned those 
numbers; novel alleles and STs were submitted to the C. jejuni MLST database and assigned new 
numbers.  
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INTRODUCTION 
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Phylogeny analysis 
The 7-allele profiles were concatenated and used to construct genealogies using two methods 
for inferring evolutionary relationships among C. jejuni STs. First, relatedness of isolates was 
represented by a dendrogram constructed by cluster analysis using the unweighted pair group method 
with arithmetic means (UPGMA) in the programme Start2, available at http://www.pubmlst.org (30). 
The second phylogenetic analysis estimated the clonal genealogy of STs using the model-based 
approach to determine bacterial microevolution (31). This is a model that calculates clonal 
relationships with improved accuracy as it distinguishes point mutations from chromosomal 
recombination events. The latter comprise the source of the majority of allelic polymorphisms in C. 
jejuni. Analysis was carried out on concatenated sequences representing 35 STs, from 102 isolates 
from chicken, GBS patients and gastroenteritis patients. The programme was run with 50,000 burn-in 
followed by 50,000 subsequent iterations. The consensus trees represent combined data from three 
independent runs with 50% majority rule consensus required for inference of relatedness.  
 
AFLP analysis and data processing 
Isolates were typed by AFLP (20). In short, chromosomal DNA was digested with HindIII and 
HhaI and simultaneously ligated with restriction site-specific adapters for 2 h at 37°C. This was 
followed by a preselective PCR using adapter-specific primers with HindIII (5’-
GACTGCGTACCAGCTT) and HhaI (5’-GATGAGTCCTGATCGC). Next, an aliquot was subjected to a 
selective PCR using a fluorescently labelled HindIII-specific primer that contained an additional A 
nucleotide at the 3’ end (5’-GACTGCGTACCAGC TTA) and a HhaI-specific primer with an A 
extension (59-GATGAGTCCTGATCGCA). The final products were run on a 7.3% denaturing poly-
acrylamide gel for 5 h using an ABI 373A automated DNA sequencer. Fingerprints were collected by 
fluorography and interpreted with ABI Genescan software (PE Applied Biosystems). Gels were 
normalized using an internal ROX-labeled size standard included in each lane. Densitometric curves 
were processed with the GelCompar version 4.1 software (Applied Maths, Kortrijk, Belgium). After 
normalization and background subtraction, the levels of genetic similarity between AFLP patterns were 
calculated with the Pearson product-moment correlation coefficient (r).  
 
PFGE and Data analysis 
PFGE was performed as previously described (27, 32). In short, samples of genomic DNA 
extracted from overnight cultures of the isolates were digested with SmaI (Boehringer GmbH, 
Mannheim, Germany). Electrophoresis was performed in 1% SeaKem agarose in 0.53 Tris-borate-
EDTA buffer by using a Bio-Rad CHEF Mapper programmed in the auto-algorithm mode (run time, 18 
h; switch time, 6.76 to 35.38 s). Gels were stained with ethidium bromide for 30 min, destained in 
distilled water for 1 h; images of ethidium bromide-stained gels were captured under UV illumination 
by a video system (Gel DOC 1000; Bio-Rad). 
Comparative genomics of C. jejuni
 
Electrophoretic patterns from PFGE were compared by means of BioNumerics, version 4.01 
(Applied Maths, Sint-Martens-Latem, Belgium). Analysis was based on band positions and derived by 
the Dice coefficient with a maximum position tolerance of 1%. Isolates were clustered by the 
unweighted pair group method using arithmetic averages. Statistical analysis was performed with 
EpiInfo (version 3.0) using 2 × 2 contingency tables. Fisher’s exact tests were executed and 2-sided P 
values determined. Associations were considered significant at P < 0.05. 
 
 
RESULTS 
Diversity of MLST sequence types (ST) and clonal complexes (CC) 
  Sixteen STs were identified among C. jejuni isolated from chicken cloacae in Bangladesh. Six 
(37.5%) of the STs were single isolates, while 10 STs included between 2 and 13 isolates (Fig. 1). 
 
Figure 1. Distribution of sequence types (ST) among C. jejuni isolated GBS/enteritis patients and chicken in 
Bangladesh. Ten STs contained one isolate each, and are not included in the figure. 
 ST-5 was the most frequent MLST type among poultry isolates (n=13; 24.5%), followed by ST-3740 
and ST-354,  indicating 7 (13%) and 5 (9%) isolates respectively. ST-3738, ST-3739, ST-3744, ST-
1374 and ST-305, covered 3 isolates each (Fig. 1). Overall, 6 STs representing 19 (36%) isolates 
were not reported previously (Table 1). The 16 STs were grouped into 5 previously defined clonal 
complexes (CCs). However, 9 STs featured in 28 isolates could not yet be grouped into defined clonal 
complexes. ST-353 complex encompassed the largest number of isolates (24.5%), followed by ST-
354 (9%), ST-574 (8%) and the remaining STs (6%; ST-828, ST-257, and ST-1374). Thus, these CCs 
encompass almost half (48%) of the C. jejuni isolates characterized in the present study.  
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Clonal population structure and comparative analysis 
The distribution of the C. jejuni isolated from enteritis, GBS and poultry were investigated by 
clonal frame tree demonstrating the genetic relationship of sequence types (Fig.2).  
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Figure 2. Clonal frame tree demonstrating the genetic relationship of sequence types between Campylobacter 
jejuni isolated from chicken, patients with gastroenteritis (GI) and Guillain-Barré syndrome (GBS) in Bangladesh. 
Chickens are shown as yellow boxes, GI blue boxes and GBS red boxes. Sequence types found associated with 
both GI and GBS patients are indicated by a white box, those found associated with both chicken and GI as white 
circle and those associated with both chicken and GBS patients as white triangle. 
GBS isolates were found in ST-22, 403, and 362 complexes. The isolates from enteritis were 
most frequently represented with the ST-403 (28%), and ST-362 complexes (13%) (2009b). The most 
frequent ST-353 in poultry isolates was infrequently found among human isolates (4%). The ST-403 
complex, the predominant ST in humans (GBS and enteritis) was not found among the isolates from 
poultry (Fig. 2). However, ST-22, which was only found among the isolates from GBS patients. We 
also compared 5 predominant STs from human and poultry; among them 22% isolates from human 
overlapped with poultry isolates (data not shown). Fisher exact test demonstrates a significant 
association between CC and the sources (p<0.02). UPGMA clustering of MLST data for C. jejuni 
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isolated from chicken and humans yielded 9 major clonal groups (A, B, C, D, E, F, G,  H and I) 
consisting 25 of STs. Eight STs were singletons (Fig. 3).  
 
Figure 3. Dendrogram of Campylobacter jejuni sequence types, including GBS/enteritis and chicken related 
isolates from Bangladesh. The dendrogram was constructed by using UPGMA. 
 
AFLP 
AFLP fingerprints were identified as distinct types when band patterns shared less than 90% 
similarity (20). At a cutoff of 90%, clustering yielded 15 different AFLP types among the 66 C. jejuni 
isolated from poultry (Fig. 5). The largest cluster (AF-1) of AFLP patterns in chickens with similarities 
of 90% consisted of 16 (24%) isolates; other predominant clusters were AF-2 (21%) and AF-3 (14%). 
In addition, there were nine small clusters that each contained two to five isolates isolated from 
poultry. Three AFLP fingerprints of poultry isolates (ZCC-24, ZCC-324, & ZCC-382) were unique (Fig. 
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5). In a further effort to determine whether the AFLP patterns could be separated into host-specific 
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Figure 4. UPGMA dendrogram of PFGE fingerprints from 66 C. jejuni isolates related with chicken. 
The percentage of genetic homology between banding patterns is indicated. MLST and AFLP types 
are plotted next to dendrogram. UA, unassigned; ND not done.
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5). In a further effort to determine whether the AFLP patterns could be separated into host-specific 
Pearson correlation [0.0%-100.0%]
XbaI
10
0
95908580757065
XbaI
ZCC-313
ZCC-353
ZCC-08
ZCC-21
ZCC-308
ZCC-158
ZCC-188
ZCC-225
ZCC-358
ZCC-128
ZCC-136
ZCC-127
ZCC-122
ZCC-85
ZCC-30
ZCC-350
ZCC-231
ZCC-154
ZCC-115
ZCC-242
ZCC-251
ZCC-82
ZCC-384
ZCC-174
ZCC-214
ZCC-140
ZCC-24
ZCC-125
ZCC-276
ZCC-223
ZCC-218
ZCC-187
ZCC-209
ZCC-380
ZCC-374
ZCC-314
ZCC-91
ZCC-150
ZCC-312
ZCC-349
ZCC-216
ZCC-37
ZCC-43
ZCC-230
ZCC-258
ZCC-32
ZCC-22
ZCC-148
ZCC-157
ZCC-10
ZCC-13
ZCC-143
ZCC-94
ZCC-271
ZCC-224
ZCC-368
ZCC-259
ZCC-67
ZCC-29
ZCC-213
ZCC-243
ZCC-66
ZCC-138
ZCC-68
ZCC-19
ZCC-370
ZCC-383
ND
ND
ST-5
ST-5
ST-5
ST-3744
ST-3744
ST-5
ND
ST-3739
ST-3739
ST-5
ST-5
ST-5
ST-5
ND
ST-1042
ST-1042
ST-3741
ST-3741
ST-3741
ST-3741
ND
ST-1374
ST-1042
ST-3738
ST-824
ST-1042
ST-1374
ST-1374
ST-3741
ND
ST-3747
ND
ND
ND
ND
ST-5
ST-849
ND
ST-829
ST-305
ST-3745
ST-305
ST-305
ST-3744
ST-5
ST-2895
ST-3746
ST-5
ST-5
ST-3740
ST-3740
ST-5
ST-3740
ND
ST-3740
ST-3739
ST-3740
ST-3740
ST-3740
ST-3738
ST-3745
ST-1042
ST-3738
ND
ND
AF-5
AF-5
AF-1
AF-1
AF-1
AF-1
AF-1
AF-1
AF-6
AF-11
AF-11
AF-1
AF-1
AF-1
AF-1
AF-13
AF-2
AF-2
AF-2
AF-2
AF-2
AF-2
AF-2
AF-14
AF-2
AF-8
AF-15
AF-2
AF-14
AF-14
AF-2
AF-2
AF-10
AF-2
AF-2
AF-6
AF-3
AF-1
AF-13
AF-4
AF-12
AF-4
AF-8
AF-4
AF-4
AF-1
AF-1
AF-4
AF-7
AF-1
AF-1
AF-3
AF-3
AF-1
AF-3
AF-2
AF-3
AF-11
AF-3
AF-3
AF-3
AF-8
AF-9
AF-2
AF-8
AF-7
AF-7
ND
ND
ST-353
ST-353
ST-353
UA
UA
ST-353
ND
UA
UA
ST-353
ST-353
ST-353
ST-353
ND
ST-354
ST-354
UA
UA
UA
UA
ND
UA
ST-354
UA
ST-257
ST-354
UA
UA
UA
ND
UA
ND
ND
ND
ND
ST-353
UA
ND
ST-828
ST-574
UA
ST-574
ST-574
UA
ST-353
ST-574
UA
ST-353
ST-353
UA
UA
ST-353
UA
ND
UA
UA
UA
UA
UA
UA
UA
ST-354
UA
ND
ND
 
Figure 4. UPGMA dendrogram of PFGE fingerprints from 66 C. jejuni isolates related with chicken. 
The percentage of genetic homology between banding patterns is indicated. MLST and AFLP types 
are plotted next to dendrogram. UA, unassigned; ND not done.
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Correlation between PFGE and MLST 
The SmaI-PFGE fingerprints contained six to twelve bands and resolved 3 major lineages at 
65% similarity. A significant degree of agreement between different typing methods was evident (Fig. 
4). However, a one-to-one correlation between PFGE types and STs did not always exist. Some 
isolates with the same PFGE type had different STs, and on the contrary, isolates with the same ST 
had distinct PFGE types.  
 
Congruence between typing methods 
After cluster analysis by the respective methods and construction of a composite data set 
comprising the MLST, PFGE, and AFLP, a similar clustering of the isolates was observed. Categorical 
clustering of the MLST and AFLP profiles according to the Pearson product-moment correlation 
coefficient resulted in 91% congruence (Fig. 4).  
 
 
DISCUSSION 
 
We performed comparative genotyping of C. jejuni isolated from poultry and patients with 
enteritis and GBS, respectively in Bangladesh by MLST, AFLP, and PFGE fingerprinting. Although the 
number of poultry isolates was relatively small, remarkable diversity was observed by identification of 
various genotypes and clonal complexes. PFGE analysis identified 3 major lineages, which were 
essentially similar to the major lineages as defined by MLST and AFLP. We observed discrepancies 
between the results of the three typing methods, although limited in number. In comparison with 
MLST, 5 of the 13 ST-5 isolates are clustered separately by PFGE, but not by AFLP. A study carried 
out in England by Owen et al. (33) showed that C. jejuni isolates were highly diverse by PFGE 
analysis. A recent study characterizing Australian isolates by MLST and PFGE (34) reported that 
PFGE profiles are not good predictors of CC. Overall, C. jejuni genotypes found in GBS patients 
partially overlap with those found in enteritis patients. There seems to be a similar partial overlap 
between genotypes isolated from chicken and enteritis patients. Interestingly, no overlap was 
documented between C. jejuni genotypes encountered in GBS patients and in poultry. However, the 
number of GBS-related C. jejuni is notably too small to allow for definite conclusion in this respect. 
In the present study, we identified five distinct clonal complexes with 16 STs in C. jejuni 
isolated from poultry. Consistent with our results, Dingle et al. 16 identified six clonal complexes in 34 
isolates obtained from poultry. Kinana et al. (35) found seven clonal complexes in 46 isolates from 
poultry in Senegal. In contrast to previous studies in which the ST-21 complex was the largest 
complex (16, 17, 36), this complex appears to be uncommon among Camylobacter poultry isolates 
from Bangladesh. However, the ST-21 complex is widespread in multiple hosts and has previously 
been described to be associated with infections in humans, and with livestock and environmental 
sources (poultry, cattle, contaminated milk, and water) (16, 37). The ST-353 complex, the most  
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Figure 5. UPGMA dendrogram of AFLP fingerprints from 66 C. jejuni isolates related with chicken. 
The percentage of genetic homology between banding patterns is indicated. AFLP types and PFGE 
clonal groups plotted next to dendrogram.  
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Correlation between PFGE and MLST 
The SmaI-PFGE fingerprints contained six to twelve bands and resolved 3 major lineages at 
65% similarity. A significant degree of agreement between different typing methods was evident (Fig. 
4). However, a one-to-one correlation between PFGE types and STs did not always exist. Some 
isolates with the same PFGE type had different STs, and on the contrary, isolates with the same ST 
had distinct PFGE types.  
 
Congruence between typing methods 
After cluster analysis by the respective methods and construction of a composite data set 
comprising the MLST, PFGE, and AFLP, a similar clustering of the isolates was observed. Categorical 
clustering of the MLST and AFLP profiles according to the Pearson product-moment correlation 
coefficient resulted in 91% congruence (Fig. 4).  
 
 
DISCUSSION 
 
We performed comparative genotyping of C. jejuni isolated from poultry and patients with 
enteritis and GBS, respectively in Bangladesh by MLST, AFLP, and PFGE fingerprinting. Although the 
number of poultry isolates was relatively small, remarkable diversity was observed by identification of 
various genotypes and clonal complexes. PFGE analysis identified 3 major lineages, which were 
essentially similar to the major lineages as defined by MLST and AFLP. We observed discrepancies 
between the results of the three typing methods, although limited in number. In comparison with 
MLST, 5 of the 13 ST-5 isolates are clustered separately by PFGE, but not by AFLP. A study carried 
out in England by Owen et al. (33) showed that C. jejuni isolates were highly diverse by PFGE 
analysis. A recent study characterizing Australian isolates by MLST and PFGE (34) reported that 
PFGE profiles are not good predictors of CC. Overall, C. jejuni genotypes found in GBS patients 
partially overlap with those found in enteritis patients. There seems to be a similar partial overlap 
between genotypes isolated from chicken and enteritis patients. Interestingly, no overlap was 
documented between C. jejuni genotypes encountered in GBS patients and in poultry. However, the 
number of GBS-related C. jejuni is notably too small to allow for definite conclusion in this respect. 
In the present study, we identified five distinct clonal complexes with 16 STs in C. jejuni 
isolated from poultry. Consistent with our results, Dingle et al. 16 identified six clonal complexes in 34 
isolates obtained from poultry. Kinana et al. (35) found seven clonal complexes in 46 isolates from 
poultry in Senegal. In contrast to previous studies in which the ST-21 complex was the largest 
complex (16, 17, 36), this complex appears to be uncommon among Camylobacter poultry isolates 
from Bangladesh. However, the ST-21 complex is widespread in multiple hosts and has previously 
been described to be associated with infections in humans, and with livestock and environmental 
sources (poultry, cattle, contaminated milk, and water) (16, 37). The ST-353 complex, the most  
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Figure 5. UPGMA dendrogram of AFLP fingerprints from 66 C. jejuni isolates related with chicken. 
The percentage of genetic homology between banding patterns is indicated. AFLP types and PFGE 
clonal groups plotted next to dendrogram.  
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 common complex in this present study, and the ST-574 and ST-354 complexes have all been found 
previously in poultry (38). A study carried out in Senegal by Kinana et al. (35) found that the ST-353 
complex is the most common complex among Senegalese poultry in accordance with our findings.  
We recently reported that ST-403 is prevalent among GBS and enteritis-related C. jejuni from 
Bangladesh (26, 27). Our comparative genotyping analysis suggests that these ST-403 isolates are 
uncommon or absent in poultry in Bangladeshi chicken. Larger studies and nationwide studies will be 
necessary to confirm this preliminary observation. Recently, ST-403 has been demonstrated in C. 
jejuni isolated from dogs in England (39); this clonal complex has also been found in porcine isolates 
and also occasionally in cattle (40, 41,10, 42). This ST complex has also been observed in humans 
previously, and was reported to be the dominating genotype in a study in Curacao (16, 17, 43).  In a 
large study carried out in New Zealand, McTavish SM et al. concluded that ST-403 strains were 
predominantly linked to cattle but not to poultry (44). A number of new STs from chicken isolates were 
identified in this study (ST-3740, ST-3741, ST-3744, ST-3745, ST-3746, and ST-3747), but were not 
assigned to any known complex.  
Cluster analysis of AFLP data in this study supports previous reports that no distinct 
subpopulation of C. jejuni is associated with poultry, enteritis, or GBS (43). The AFLP fingerprints of all 
C. jejuni appeared to be highly heterogeneous, and no characteristic pattern of isolates infecting either 
chickens or humans was identified. Also, no separate grouping of GBS related isolates was obtained. 
The high diversity of AFLP fingerprints may be a reflection of the normal genetic diversity among C. 
jejuni as several other studies also have identified significant diversity among both human and chicken 
isolates (43).  
A leading risk factor for human Campylobacteriosis is thought to be the consumption of 
contaminated poultry meat or cross-contaminated food (6). Only 11 (22%) out of 50 C. jejuni isolated 
from humans shared genotypes with poultry isolates. This suggests that sources other than poultry are 
likely to exist.  A study carried out in Denmark by Siemer et al. (45) also recommend that poultry might 
not be the sole source of Campylobacter infection in human, and other sources should be considered 
as sources of human infection. Additional AFLP analysis of C. jejuni from other sources, including 
domestic pets, other animals and environmental samples, is needed.  
This study has several limitations: first, the number of isolates from chicken was relatively 
small and the resuting loss of power may leave true associations undetected; second, although we 
sampled poultry from different geographical area, the precise origin was unknown. Larger, follow-up 
studies should include GPS mapping of all poultry and sample locations; third, as we identified only 
one bacterial colony per chicken sample, we cannot exclude the presence of more than one 
Campylobacter genotype/phenotype in poultry.  
In conclusion, there appears to be considerable genetic diversity between C. jejuni obtained 
from poultry and humans in Bangladesh. Our data provide an insight into the complex population 
structure of C. jejuni in chickens. The dissimilarity of the sequence types/or genotypes of C. jejuni from 
human and poultry origin suggests the presence of sources other than poultry in Bangladesh.  
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 common complex in this present study, and the ST-574 and ST-354 complexes have all been found 
previously in poultry (38). A study carried out in Senegal by Kinana et al. (35) found that the ST-353 
complex is the most common complex among Senegalese poultry in accordance with our findings.  
We recently reported that ST-403 is prevalent among GBS and enteritis-related C. jejuni from 
Bangladesh (26, 27). Our comparative genotyping analysis suggests that these ST-403 isolates are 
uncommon or absent in poultry in Bangladeshi chicken. Larger studies and nationwide studies will be 
necessary to confirm this preliminary observation. Recently, ST-403 has been demonstrated in C. 
jejuni isolated from dogs in England (39); this clonal complex has also been found in porcine isolates 
and also occasionally in cattle (40, 41,10, 42). This ST complex has also been observed in humans 
previously, and was reported to be the dominating genotype in a study in Curacao (16, 17, 43).  In a 
large study carried out in New Zealand, McTavish SM et al. concluded that ST-403 strains were 
predominantly linked to cattle but not to poultry (44). A number of new STs from chicken isolates were 
identified in this study (ST-3740, ST-3741, ST-3744, ST-3745, ST-3746, and ST-3747), but were not 
assigned to any known complex.  
Cluster analysis of AFLP data in this study supports previous reports that no distinct 
subpopulation of C. jejuni is associated with poultry, enteritis, or GBS (43). The AFLP fingerprints of all 
C. jejuni appeared to be highly heterogeneous, and no characteristic pattern of isolates infecting either 
chickens or humans was identified. Also, no separate grouping of GBS related isolates was obtained. 
The high diversity of AFLP fingerprints may be a reflection of the normal genetic diversity among C. 
jejuni as several other studies also have identified significant diversity among both human and chicken 
isolates (43).  
A leading risk factor for human Campylobacteriosis is thought to be the consumption of 
contaminated poultry meat or cross-contaminated food (6). Only 11 (22%) out of 50 C. jejuni isolated 
from humans shared genotypes with poultry isolates. This suggests that sources other than poultry are 
likely to exist.  A study carried out in Denmark by Siemer et al. (45) also recommend that poultry might 
not be the sole source of Campylobacter infection in human, and other sources should be considered 
as sources of human infection. Additional AFLP analysis of C. jejuni from other sources, including 
domestic pets, other animals and environmental samples, is needed.  
This study has several limitations: first, the number of isolates from chicken was relatively 
small and the resuting loss of power may leave true associations undetected; second, although we 
sampled poultry from different geographical area, the precise origin was unknown. Larger, follow-up 
studies should include GPS mapping of all poultry and sample locations; third, as we identified only 
one bacterial colony per chicken sample, we cannot exclude the presence of more than one 
Campylobacter genotype/phenotype in poultry.  
In conclusion, there appears to be considerable genetic diversity between C. jejuni obtained 
from poultry and humans in Bangladesh. Our data provide an insight into the complex population 
structure of C. jejuni in chickens. The dissimilarity of the sequence types/or genotypes of C. jejuni from 
human and poultry origin suggests the presence of sources other than poultry in Bangladesh.  
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Guillain-Barré syndrome (GBS) is an acute post-infectious immune-mediated peripheral 
neuropathy with a marked patient-to-patient variation in pathology, clinical presentation and prognosis, 
and worldwide the most frequent cause of acute flaccid paralysis (AFP) with an incidence of 1.2 to 2.3 
per 100,000 persons per year (1). Bangladesh has achieved a remarkable success in its drive to 
eradicate poliomyelitis, however, non-polio AFP still exist. Campylobacter jejuni has been identified as 
the predominant cause of antecedent infection in GBS and its rare variant called Miller Fisher 
syndrome (MFS). Considering the crucial role of C. jejuni infections in triggering GBS, we 
hypothesized that this disease may be more frequent in countries with a high incidence of diarrhea 
and a poor hygienic infrastructure. To test this hypothesis, we determined the crude incidence of GBS 
in Bangladesh among children <15 years of age (Chapter 2.1); and we investigated the frequency of 
C. jejuni infection and anti-gangliosides antibodies in GBS patients, family controls and age- and sex-
matched controls with other neurological diseases (Chapter 2.2). Molecular mimicry between 
Campylobacter LOS and gangliosides in human nerves is thought to be the underlying 
pathophysiological mechanism. We investigated the cross-reactivity of anti-ganglioside antibodies with 
C. jejuni strains from patients with GBS. We also determined the LOS outer core structures of C. jejuni 
strains associated with GBS/MFS (Chapter 4). In addition, to investigate whether specific bacterial 
determinants are related to GBS, we analysed the genetic heterogeneity among C. jejuni strains 
isolated from GBS, enteritis patients and poultry using various comparative microbial genotyping 
methods (Chapter 5.1, 5.2 and 5.3).   
In this Chapter, the results of previous Chapters will be outlined and discussed, followed by 
concluding remarks and suggestions for further research.  
 
 
Guillain–Barré syndrome in Bangladesh 
Bangladesh has made an impressive progress towards the eradication of poliomyelitis, and no 
new cases have been reported since 2000. However, non-polio AFP cases are frequently diagnosed, 
and the incidence rate is currently 3.25 per 100,000 children less than 15 year of age. In Chapter 2.1, 
we aimed to determine the crude incidence rate of GBS in Bangladesh among children <15 years of 
age. As a part of South East Asia Region’s polio eradication strategies, the Government of 
Bangladesh, in collaboration with World Health Organization, is conducting an active surveillance 
program for AFP. We obtained clinical and demographic data on the reported AFP cases in 
Bangladesh, and defined a case definition of GBS based on clinical data that is routinely collected as 
part of the AFP surveillance. The analysis indicates that poliomyelitis is absent, but that a great 
proportion of the AFP cases in Bangladesh are diagnosed as GBS. In this study, we calculated the  
 
General Introduction
Figure 1. Guillain-Barré syndrome incidence among children (<15 years) in the world. 
crude incidence of GBS for per division and per district in Bangladesh. In general, the crude incidence 
rates of GBS in children varied from 1.5 to 2.5 per 100,000 per year in Bangladesh. The incidence rate 
in the northern part of Bangladesh varied from 1.5 to 1.7 per 100,000 per year, whereas the rate in the 
southern part varied from 2.1 to 2.5 per 100,000 per year. A remarkable high incidence rate of more 
than 5.0 per 100,000 was observed in the Meherpur and Barisal district, in the southern part of 
Bangladesh. Thus, there appears to be a clear distinction between the three northern divisions and the 
three coastal divisions for which we currently have no explanation. A recent review reports that the 
overall incidence of GBS varies between 1.1/100,000/year and 1.8/100,000/year. The incidence of 
GBS increased with age after 50 years from 1.7/100,000/year to 3.3/100,000/year with lower rates 
reported in children (<15 years) of around 0.6/100,000/year (2). This review predominantly reports 
studies from Europe and North America. A limited number of rates was presented from other parts of 
the world, e.g. Asia and Africa. Thus, it is difficult to comment on possible geographical variation. A 
recent study carried out in Latin America and the Caribbean countries in children <15 years reports a 
GBS incidence of 0.82 cases per 100,000 children per year using the ongoing AFP surveillance 
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Guillain-Barré syndrome (GBS) is an acute post-infectious immune-mediated peripheral 
neuropathy with a marked patient-to-patient variation in pathology, clinical presentation and prognosis, 
and worldwide the most frequent cause of acute flaccid paralysis (AFP) with an incidence of 1.2 to 2.3 
per 100,000 persons per year (1). Bangladesh has achieved a remarkable success in its drive to 
eradicate poliomyelitis, however, non-polio AFP still exist. Campylobacter jejuni has been identified as 
the predominant cause of antecedent infection in GBS and its rare variant called Miller Fisher 
syndrome (MFS). Considering the crucial role of C. jejuni infections in triggering GBS, we 
hypothesized that this disease may be more frequent in countries with a high incidence of diarrhea 
and a poor hygienic infrastructure. To test this hypothesis, we determined the crude incidence of GBS 
in Bangladesh among children <15 years of age (Chapter 2.1); and we investigated the frequency of 
C. jejuni infection and anti-gangliosides antibodies in GBS patients, family controls and age- and sex-
matched controls with other neurological diseases (Chapter 2.2). Molecular mimicry between 
Campylobacter LOS and gangliosides in human nerves is thought to be the underlying 
pathophysiological mechanism. We investigated the cross-reactivity of anti-ganglioside antibodies with 
C. jejuni strains from patients with GBS. We also determined the LOS outer core structures of C. jejuni 
strains associated with GBS/MFS (Chapter 4). In addition, to investigate whether specific bacterial 
determinants are related to GBS, we analysed the genetic heterogeneity among C. jejuni strains 
isolated from GBS, enteritis patients and poultry using various comparative microbial genotyping 
methods (Chapter 5.1, 5.2 and 5.3).   
In this Chapter, the results of previous Chapters will be outlined and discussed, followed by 
concluding remarks and suggestions for further research.  
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we aimed to determine the crude incidence rate of GBS in Bangladesh among children <15 years of 
age. As a part of South East Asia Region’s polio eradication strategies, the Government of 
Bangladesh, in collaboration with World Health Organization, is conducting an active surveillance 
program for AFP. We obtained clinical and demographic data on the reported AFP cases in 
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proportion of the AFP cases in Bangladesh are diagnosed as GBS. In this study, we calculated the  
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Figure 1. Guillain-Barré syndrome incidence among children (<15 years) in the world. 
crude incidence of GBS for per division and per district in Bangladesh. In general, the crude incidence 
rates of GBS in children varied from 1.5 to 2.5 per 100,000 per year in Bangladesh. The incidence rate 
in the northern part of Bangladesh varied from 1.5 to 1.7 per 100,000 per year, whereas the rate in the 
southern part varied from 2.1 to 2.5 per 100,000 per year. A remarkable high incidence rate of more 
than 5.0 per 100,000 was observed in the Meherpur and Barisal district, in the southern part of 
Bangladesh. Thus, there appears to be a clear distinction between the three northern divisions and the 
three coastal divisions for which we currently have no explanation. A recent review reports that the 
overall incidence of GBS varies between 1.1/100,000/year and 1.8/100,000/year. The incidence of 
GBS increased with age after 50 years from 1.7/100,000/year to 3.3/100,000/year with lower rates 
reported in children (<15 years) of around 0.6/100,000/year (2). This review predominantly reports 
studies from Europe and North America. A limited number of rates was presented from other parts of 
the world, e.g. Asia and Africa. Thus, it is difficult to comment on possible geographical variation. A 
recent study carried out in Latin America and the Caribbean countries in children <15 years reports a 
GBS incidence of 0.82 cases per 100,000 children per year using the ongoing AFP surveillance 
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system (3). Therefore, the incidence rates in Bangladesh reported in this thesis appear to be at least 
2-3 times higher compared to the incidence in the Americas and in Europe. 
The use of the well-recognized National Institute of Neurological and Communicative 
Disorders and Stroke (NINCDS) criteria or a comparable set of diagnostic criteria is critical as this 
allows comparisons to be made between studies. Therefore, our population-based study has some 
limitations. As our study was designed as a retrospective analysis of already collected clinical and 
demographic data focused on poliomyelitis, we cannot confirm if all cases fulfill the diagnostic criteria 
of the NINCDS. Further prospective surveillance studies are clearly indicated. Recently, a debate has 
been reopened on the association of H1N1 influenza virus infections and vaccination with the 
development of GBS. An assessment of the current or a modified AFP surveillance system for the 
purpose of GBS surveillance is, therefore, both timely and relevant.  
Chapter 2.2 describes the clinical phenotype, course and outcome of GBS in Bangladesh. We 
conducted a prospective matched case-control study with a follow-up of six months including hospital-
admitted patients in the Dhaka area of Bangladesh fulfilling the NINDS diagnostic criteria of GBS. 
Data were collected regarding age, sex, antecedent events, detailed neurological signs and 
symptoms, treatment, days to nadir, complications, duration of admission, GBS disability score and 
Medical Research Council (MRC) sum score at standard points (entry, and 2 weeks, 4 weeks, and 6 
months after entry). Our study indicates that GBS in Bangladesh may predominantly affect young 
adult males, living in rural areas, and suffering from a severe, pure motor and axonal variant of GBS. 
The majority of patients (77%) did not receive specific treatment with IV immunoglobulin (IVIg). A poor 
outcome, defined as the inability to walk unaided at 6 months after disease onset, was found in 34 
(43%) GBS patients. The demography and phenotype of GBS fluctuates significantly between different 
geographical areas. In Australia, Western Europe and North America, a preponderance of men is 
observed. The mean age of the patients in those areas is approximately 50 years. No seasonal 
variation has been reported for GBS incidence from developed countries (4-6). The most frequent 
subtype of GBS in those countries is AIDP, which accounts for at least 90% of GBS cases (7). 
However, in Asia, South and Central America, the axonal form of GBS constitutes 30% to 47% of 
cases (7) (Table 1). We reported that the majority (92%) of the GBS cases in Bangladesh have a pure 
motor variant with a predominantly axonal degeneration (67%). Also, the incidence of GBS, and of the 
AMAN subgroup in particular, appears to peak between January and March. Substantial variation in 
outcome exists and the prognosis of GBS is difficult to determine for individual GBS patients (1).  A 
relatively large proportion of the patients in our cohort either died (14%) or remained severely disabled 
(29%) after a follow of 6 months. 
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system (3). Therefore, the incidence rates in Bangladesh reported in this thesis appear to be at least 
2-3 times higher compared to the incidence in the Americas and in Europe. 
The use of the well-recognized National Institute of Neurological and Communicative 
Disorders and Stroke (NINCDS) criteria or a comparable set of diagnostic criteria is critical as this 
allows comparisons to be made between studies. Therefore, our population-based study has some 
limitations. As our study was designed as a retrospective analysis of already collected clinical and 
demographic data focused on poliomyelitis, we cannot confirm if all cases fulfill the diagnostic criteria 
of the NINCDS. Further prospective surveillance studies are clearly indicated. Recently, a debate has 
been reopened on the association of H1N1 influenza virus infections and vaccination with the 
development of GBS. An assessment of the current or a modified AFP surveillance system for the 
purpose of GBS surveillance is, therefore, both timely and relevant.  
Chapter 2.2 describes the clinical phenotype, course and outcome of GBS in Bangladesh. We 
conducted a prospective matched case-control study with a follow-up of six months including hospital-
admitted patients in the Dhaka area of Bangladesh fulfilling the NINDS diagnostic criteria of GBS. 
Data were collected regarding age, sex, antecedent events, detailed neurological signs and 
symptoms, treatment, days to nadir, complications, duration of admission, GBS disability score and 
Medical Research Council (MRC) sum score at standard points (entry, and 2 weeks, 4 weeks, and 6 
months after entry). Our study indicates that GBS in Bangladesh may predominantly affect young 
adult males, living in rural areas, and suffering from a severe, pure motor and axonal variant of GBS. 
The majority of patients (77%) did not receive specific treatment with IV immunoglobulin (IVIg). A poor 
outcome, defined as the inability to walk unaided at 6 months after disease onset, was found in 34 
(43%) GBS patients. The demography and phenotype of GBS fluctuates significantly between different 
geographical areas. In Australia, Western Europe and North America, a preponderance of men is 
observed. The mean age of the patients in those areas is approximately 50 years. No seasonal 
variation has been reported for GBS incidence from developed countries (4-6). The most frequent 
subtype of GBS in those countries is AIDP, which accounts for at least 90% of GBS cases (7). 
However, in Asia, South and Central America, the axonal form of GBS constitutes 30% to 47% of 
cases (7) (Table 1). We reported that the majority (92%) of the GBS cases in Bangladesh have a pure 
motor variant with a predominantly axonal degeneration (67%). Also, the incidence of GBS, and of the 
AMAN subgroup in particular, appears to peak between January and March. Substantial variation in 
outcome exists and the prognosis of GBS is difficult to determine for individual GBS patients (1).  A 
relatively large proportion of the patients in our cohort either died (14%) or remained severely disabled 
(29%) after a follow of 6 months. 
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We conclude that GBS patients in Bangladesh have a much poorer prognosis as compared to 
patients in developed countries (8). The poor outcome can be explained in part by the high frequency 
of preceding Campylobacter diarrhea and the severity of the disease in the acute phase, which are to 
defined poor prognostic factors (8, 9). Only 23% of GBS patients from our cohort received a specific 
treatment with IVIg. There was no appear to be the most frequently observed GBS variants in 
Bangladesh. A great majority of patients are children and young adults who do not receive any specific 
treatment. Our study has limitation; first, all patients in our cohort enrolled from three largest tertiary 
hospital in Dhaka area of Bangladesh which may admit more severe patients. Second, selection bias 
could possibly have been introduced as preferential selection of males in hospitalization is not an 
unknown phenomenon in developing countries.  
 
C. jejuni and other antecedent infections  
GBS is a typical post-infectious disease with a wide spectrum of clinical phenotypes, and 
differences in immunologic, electrophysiological and pathologic findings (10, 11). At present, infections 
that trigger the disease are identified in about two-third of all GBS patients. The most common triggers 
reported in case-control studies are preceding infections caused by C. jejuni, Cytomegalovirus (CMV), 
Mycoplasma pneumoniae and Epstein-Barr virus (EBV) (12). The etiology and diagnosis of preceding 
infections is complicated by the fact that in many GBS patients the antecedent infection is subclinical 
and may therefore not be noticed. C. jejuni has been identified as the most frequently diagnosed 
infection, preceding GBS in 14-66% of all cases (Chapter 1). However, there is still a paucity of 
information from the developing parts of the world. Prior to the study reported in this thesis, no 
systematic etiological study was ever done in Bangladesh.  
In Chapter 2.2, we described the frequency of preceding C. jejuni infections in GBS patients 
and controls. Pretreatment serum samples, obtained within 2 weeks of neurological onset, were 
available in 97 (97%) of these patients for ELISA. Positive C. jejuni serology was found in 57% of the 
patients as compared to very low frequencies in the control group (8% of FC and 3 % of OND, 
P<0.001). Diarrhea in the four weeks preceding GBS was reported in 28 (51%) of the 55 C. jejuni-
positive patients, as compared to 8 out of 42 (19%) C. jejuni-negative patients (P<0.01). The 
association between GBS in Bangladesh and recent C. jejuni infections is further supported by the 
culture of C. jejuni in 10 GBS patients. C. jejuni frequently induces a severe form of axonal GBS in 
young adults in Bangladesh. The geographical differences in demography and phenotype may relate 
to differences in exposure to specific infectious agents and/or to host-related or environmental factors. 
Studies from The Netherlands, UK, Mexico and Japan report that C. jejuni infections are the 
predominant cause of antecedent infections in GBS (9-14). Infections with C. jejuni are common in 
Chinese GBS patients. However, if stringent criteria for seropositivity are used, only 24% of these 
Chinese GBS cases were associated with Campylobacter (15). The frequency of C. jejuni-related 
GBS in many counties is not comparable due to the differences in diagnostic assays used. However, 
the diagnostic assay used in our study has been reported to be very sensitive and specific with GBS 
sera (16).  
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In addition, recent infections with CMV, EBV, and M. pneumoniae, were also demonstrated in 
GBS patients, but comparison with controls did not revealed statistical significance (Chapter 3). The 
seroprevalence of coxsackieviruses (36%) is significantly associated with GBS (p<0.01). In this study, 
64% of coxsackieviruse-associated GBS patients have a positive serology for C. jejuni infection, as 
was found in other serological studies as well (12). A recent prospective multicentre study in children 
with GBS demonstrated that coxsackie viruses are associated as antecedent infection (17). Our 
findings on coxsackievirus-associated GBS must be confirmed in prospective large case-control 
studies using sensitive and specific serological assays and new molecular detection tools. Based on 
our prospective case control study, we conclude that antecedent Campylobacter infections play a 
prominent role in GBS in Bangladesh, but that in addition, several other agents may be involved may 
play an important role as well. Our data strongly indicate that infections with C. jejuni are the most 
important trigger for axonal variants of GBS in Bangladesh and are associated with significant 
morbidity and mortality. C. jejuni related GBS appears to be a dominant cause of AFP after the 
eradication of poliomyelitis in Bangladesh. This study generates some interesting questions 
concerning the high frequency of occurrence of the axonal variant of GBS in Bangladesh, associated 
with preceding C. jejuni infection: 1) Which anti-ganglioside antibodies are present in sera from GBS 
patients? 2) Which is the disease mechanism and are the C. jejuni lipooligosaccharides that cross-
react with anti-ganglioside antibodies the only inducing neural damage as in other geographical 
locales?; 3) Are there genetic characteristics that distinguish GBS and MFS-associated C. jejuni 
strains from other C. jejuni strains? These issues are discussed in the following sections. 
 
Anti-ganglioside antibodies in GBS 
Previous studies showed that high titers of serum antibodies to gangliosides are associated 
with immune-mediated neuropathies, in particular with GBS. Antibodies to GM1, GD1a and GQ1b are 
associated with specific immunopathological subgroup in GBS. Interestingly, GM1 and GD1a are 
predominantly expressed in motor nerves and axons, and GQ1b has found to be enriched in cranial 
nerves (18). The study in Chapter (2.2 & 4) describes the presence of anti-gangliosides antibodies (to 
GM1, GD1a and GQ1b) which were more frequent as compared with controls (P<0.001). In GBS 
patients, antibodies to GM1 were more frequent (50%) than antibodies to GD1a (14%). C. jejuni 
infection was more often found in GBS patients with anti-ganglioside antibodies (78%) as compared to 
patients without anti-gangliosides antibodies (26%) (P<0.001). Anti-ganglioside antibodies of the IgG 
class are almost exclusively (49%) produced in patients with GBS. Our results are consistent with 
earlier findings that the presence of anti-GM1 antibodies is significantly associated with C. jejuni 
infection (18-20). Diarrhea in the four weeks preceding GBS was significantly associated with 
ganglioside-positive patients compared with ganglioside-negative patients (P<0.01). We did not find an 
association between anti-GM1/GD1a antibodies and overall disability at the peak of the illness. 
However, recent C. jejuni infection and anti-ganglioside antibodies are significantly associated with 
poor outcome of GBS patients after 6 months follow up. 
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and controls. Pretreatment serum samples, obtained within 2 weeks of neurological onset, were 
available in 97 (97%) of these patients for ELISA. Positive C. jejuni serology was found in 57% of the 
patients as compared to very low frequencies in the control group (8% of FC and 3 % of OND, 
P<0.001). Diarrhea in the four weeks preceding GBS was reported in 28 (51%) of the 55 C. jejuni-
positive patients, as compared to 8 out of 42 (19%) C. jejuni-negative patients (P<0.01). The 
association between GBS in Bangladesh and recent C. jejuni infections is further supported by the 
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predominant cause of antecedent infections in GBS (9-14). Infections with C. jejuni are common in 
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associated with specific immunopathological subgroup in GBS. Interestingly, GM1 and GD1a are 
predominantly expressed in motor nerves and axons, and GQ1b has found to be enriched in cranial 
nerves (18). The study in Chapter (2.2 & 4) describes the presence of anti-gangliosides antibodies (to 
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infection was more often found in GBS patients with anti-ganglioside antibodies (78%) as compared to 
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Molecular mimicry and cross-reactive antibodies against C. jejuni LOS  
Molecular mimicry is the mechanism by which infections trigger cross-reactive antibodies or T- 
cells that cause the symptoms of autoimmune disease (21). Many studies on the pathogenesis of GBS 
report findings that are consistent with the mimicry hypothesis, but none of these studies originate 
from a developing country such as Bangladesh. Several examples of molecular mimicry between 
microbial and “self” components are known, but in most cases no epidemiological relationship 
between autoimmune disease and microbial infection has been established. In 2004, Ang et al. 
proposed four criteria for auto immune-mediated disease and molecular mimicry: (1) The 
establishment of an epidemiological association between the infectious agent and the immune-
mediated disease; (2) The identification of T-cells or antibodies directed against the patient’s target 
antigens; (3) The identification of microbial mimics of the target antigen; and (4) Reproduction of the 
disease in an animal model. Many have concluded that GBS subsequent to C. jejuni enteritis fulfills all 
4 criteria, although a reliable, reproducible animal model has not been described yet. Molecular 
mimicry may be responsible for the initiation of human autoimmune diseases (22). In general, 
autoimmune diseases occur in adults >50 years of age and the reported mean age of GBS patients in 
developed countries is in line with this observation. However, as the mean age in our prospective 
cohort was 21 years (Chapter 2.2), we wondered whether molecular mimicry was likely to be involved 
in this young age group.    
The studies described in Chapter 4 provide serological evidence for the involvement of 
molecular mimicry in the pathogenesis of C. jejuni-related GBS in Bangladesh. In this regard, we 
aimed to determine the frequency of anti-LOS antibodies in GBS patients. In addition, we studied the 
cross-reactive activity of serum ganglioside antibodies with autologous C. jeuni LOS. Anti-LOS IgG 
antibody was significantly associated with GBS as compared with data from two control groups 
(p<0.001). Anti-LOS antibody presence is strongly associated with recent C. jejuni infection and anti-
ganglioside antibodies from our cohort of GBS patients. In an earlier section, we described that C. 
jejuni is the causative agent of the predominant antecedent infection in GBS (Chapter 2.2). Some GBS 
patients in our study did not develop anti-ganglioside antibodies although anti-LOS antibodies were 
detected. This result is not new as others have reported on the absence of binding of anti-ganglioside 
antibodies to LOS of C. jejuni from MFS and GBS patients (23). These patients may have antibodies 
against ganglioside complexes (24). Preliminary data from our cohort suggests that patients with anti-
LOS reactivity but without reactivity against single gangliosides have antibodies against complexes of 
different gangliosides (Islam et al., unpublished data, 25). This is in agreement with earlier studies 
reporting that ganglioside complexes are important target antigens in GBS as well as in MFS (26, 27). 
The current study supports the hypothesis that cross-reactive antibodies to single gangliosides or 
ganglioside complexes in these patients contribute to the development of GBS in Bangladesh. Our 
study results are in accordance with earlier studies that report that antecedent C. jejuni infections in 
GBS trigger the production of antibodies that cross-react with gangliosides (22, 23).  
The role of molecular mimicry between LOS and gangliosides is further strengthened by the 
binding of mouse monoclonal anti-ganglioside antibodies with LOS of C. jejuni isolates from GBS and 
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enteritis controls (Chapter 4). Biochemical analysis of the LOS core structures identified the presence 
of sialic acid containing ganglioside-like moieties that show a large variation among different C. jejuni 
strains (Chapter 1). The GBS-associated C. jejuni strains express core oligosaccharides with a 
tetrasaccharide identical to GM1 (28), but also oligosaccharides similar to GD1a, GD3 and GT1a were 
identified (29). Our studies have clearly shown that LOS from GBS associated C. jejuni is recognized 
by anti-ganglioside antibodies from GBS patients. Serum from patients with GBS showed a dramatic 
reduction in anti-ganglioside reactivity after incubation with LOS from the autologous C. jejuni strains. 
Incubation with LOS that lacked ganglioside-mimics did not inhibit ganglioside-reactivity. In conclusion, 
these binding studies indicate that carbohydrate molecular mimicry exists between gangliosides and 
LOS from C. jejuni isolated from Bangladeshi GBS patients can result in the production of cross-
reactive antibodies in GBS patients following C. jejuni infection. 
The variety of ganglioside-like structures among C. jejuni strains may contribute to the 
heterogeneity of the anti-ganglioside antibody specificities in GBS. Our observations also indicate that 
a one-dimensional approach is inadequate in describing the relationship between antibody specificity 
and LOS carbohydrate composition. Several host but also pathogen-related factors may be involved in 
a continuing process of changing forms and shapes of molecules that potentially play a role as 
receptor or immune-modulating factor interacting between cells and pathogens.  
 
Ganglioside mimics in GBS-associated C. jejuni strains 
In the previous section, we described serological methods to identify ganglioside-like 
structures in the C. jejuni LOS. The set of C. jejuni isolates from Bangladeshi GBS patients available 
for the studies described in this thesis provided a unique opportunity to study both pathogen and host-
related factors in GBS pathogenesis. Further molecular characterization of epitopes present in the 
carbohydrate part of C. jejuni LOS by mass spectrometry is described in Chapter 4. A structural 
analysis demonstrates that various ganglioside mimics are found in the LOS of neuropathy-associated 
strains in Bangladesh (Table 2). Interestingly, 57% of GBS-associated strains express a mixture of 
GM1a- and GD1a-like LOS. This finding suggests that a cluster or complex of the GM1a/GD1a 
ganglioside mimics, which is only expressed by strains with a class LOS A locus, may be the primary 
target antigens in a subgroup of GBS, rather than single ganglioside mimics. Our finding is consistent 
with the results described earlier (30, 31). However, it does not support the outcome of another study 
that reports that the expression of GD1a and not GM1 was associated with GBS (32). In Chapter 4, 
we described that C. jejuni strains isolated from GBS/MFS with ophthalmoplegia have a novel 
structure with two extension sites from the inner core and two branches mimicking gangliosides GA2 
and GD3. The Cst-II variant in these strains is bi-functional (Asn51) which further supports the 
presence of di-NeuAc. The absence of a terminal Galβ-1,3-linked residue is consistent with a cgtB 
gene that has a frame-shift mutation. Others also report that the LOS core oligosaccharide from MFS-
associated C. jejuni bears a GD3-like terminal trisaccharide rather than a GQ1b moiety (33). Our data 
strongly support the previous observation that the ganglioside–like structures in LOS may not always 
correspond exactly with the specificity of the serum anti-ganglioside antibodies (30).    
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enteritis controls (Chapter 4). Biochemical analysis of the LOS core structures identified the presence 
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presence of di-NeuAc. The absence of a terminal Galβ-1,3-linked residue is consistent with a cgtB 
gene that has a frame-shift mutation. Others also report that the LOS core oligosaccharide from MFS-
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Table 2: True molecular mimicry of C. jejuni LOS confirmed by mass spectrometry analysis 
 
Strains  C. jejuni LOS class LOS structure Anti-ganglioside 
antibodies 
BD-07 A GM1a, GD1a GD1a 
BD-10 B GA2/GD3 GD1a/GQ1b 
BD-22 B GA2/GD3 GM1 
BD-27 A GM1a, GD1a GM1 
BD-34 B GA2/GD3 GM1 
BD-39 A GM1a, GD1a GM1 
BD-67 B GA2/GD3 GM1/GD1a/GQ1b 
BD-74 B GA2/GD2 GD1a/GQ1b 
BD-75 A GM1a, GD1a GM1/GD1a 
BD-94 E No ganglioside mimic - 
 
In conclusion, these antibody binding studies and biochemical studies give strong support for the 
hypothesis that carbohydrate molecular mimicry exists between gangliosides and LOS from C. jejuni 
isolated from Bangladeshi GBS patients which can be recognized by cross-reactive mouse 
monoclonal and patients serum antibodies. The cross-reactive antibody response associated with C. 
jejuni infections is probably the predominant cause of GBS in Bangladesh.       
However, mass spectrometry showed that only 1 of 10 GBS-associated strain did not express 
ganglioside mimics. Absence of ganglioside mimics in a strain isolated from a GBS patient does not 
necessarily imply that ganglioside mimicry was not the causative mechanism for GBS in that patient. 
Co-infection with different C. jejuni strains may occur in GBS patients (30). It is possible that a 
ganglioside-mimicking C. jejuni strain induces GBS, but that a co-infecting strain without ganglioside 
mimics is isolated from the stool sample and wrongfully regarded as the strain that caused GBS. In 
addition, it is possible that the expression of ganglioside mimics down regulated in the course of 
infection or during subculture after isolation of the C. jejuni strain from the feces. This form of phase 
variability has been convincingly demonstrated for C. jejuni as a species.  
   
 
General Introduction
Comparative genomic analysis of C. jejuni strains isolated from humans and poultry 
Campylobacter strains with certain Penner heat-stable (HS) serotypes, including HS:19 and 
HS:41, are overrepresented among isolates from GBS cases as compared with enteritis cases in 
Japan, South Africa, China, and Mexico (34, 35). Several studies indicate that C. jejuni HS:19 and 
HS:41 have a clonal population structure and suggest that these serotypes might have unique 
virulence properties that are intricately linked to the development of GBS (31). However, data from the 
United Kingdom and The Netherlands suggest that such virulence properties may not be restricted to 
specific HS serotypes since various other serotypes are also associated with GBS in other parts of the 
world (36). In other studies, no clustering of the GBS or MFS-associated strains was found using 
several genotyping methods. To understand the molecular epidemiology of C. jejuni-related GBS in 
Bangladesh we analyzed C. jejuni strains isolated from GBS and relevant control strains. In addition, 
we describe the population structure analysis of C. jejuni strains isolated from GBS patients and 
enteritis patients, and poultry by various comparative genotyping methods.  
In Chapter 5.1 we described that C. jejuni HS:23 serotype was highly prevalent (50%)  among 
GBS-related C. jejuni strains from Bangladesh. C. jejuni HS:23 serotype was also common (28%) in 
uncomplicated enteritis patients in Bangladesh. In other reports, serotypes HS:19 or HS:41 are linked 
to the development of GBS (31, 37). Our serotyping results indicate that in addition to HS:19 and 
HS:41 strains, other serotypes also have the potential to induce anti-ganglioside antibodies and GBS. 
We found that C. jejuni HS:23 serotype and the  new ST-3219  is highly prevalent among GBS-related 
C. jejuni strains from Bangladesh. This observation is consistent with previous reports that specific 
serotypes are overrepresented among GBS-related C. jejuni strains. These observations support the 
hypothesis that, although a great variety of C. jejuni serotypes can be isolated from GBS patients in 
some geographical areas (36), specific clonal serotypes and multi-locus types are prevalent in GBS 
patients in other places (37).  
  Chapter 5.2 describes the comparative genotyping analysis of C. jejuni strains isolated from 
GBS and enteritis patients in Bangladesh by MLST, AFLP, PFGE fingerprinting, and LOS typing. C. 
jejuni strains isolated from GBS patients in the developed world have been extensively characterized. 
We for the first time report the molecular characterization of GBS and enteritis related C. jejuni strains 
from Bangladesh. At present, many molecular typing methods are available to study the population 
structure of Campylobacter (34). PFGE detects genetic variation between strains using rare-cutting 
restriction endonuclease, followed by separation of the resulting large genomic fragments on an 
agarose gel. PFGE is known to be highly discriminatory and it is a frequently used technique for 
outbreak investigations. However, the stability of PFGE may be insufficient for reliable application in 
long-term epidemiological studies (38). Despite the efforts to standardize protocols and interpretation 
criteria of PFGE data, comparison of inter-laboratory results usually remains difficult. Multilocus 
sequence typing (MLST) has been considered the state-of-the-art technique for bacterial population 
genetics (39) and is now recognized as the gold standard typing method for the phylogenetic study of 
the Campylobacter genus (40). AFLP is an alternative whole genome typing method, which has a high 
potential for strain identification (41-45).    
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We found 7 distinct clonal complexes with 22 different STs by MLST (Chapter 5.2). The 
predominant Bangladeshi lineage was the ST-403 complex. This ST-403 complex contained 50% of 
the GBS-related strains studied and 26% of the enteritis strains. Our result is consistent with earlier 
studies that the ST-403 complex has also been observed in humans, and has been reported to be the 
dominating genotype in a study in Curacao (46).  According to the pubMLST database, ST-21 is the 
prevalent complex in the general population structure of C. jejuni (39), it is common in multiple hosts 
and has previously been described to be associated with infections in humans, and with livestock and 
environmental sources; as in chicken, cattle, contaminated milk and water (39, 47, 48). No 
representatives of ST-21 were present among GBS and enteritis related strains from Bangladesh. A 
recent study from Belgium demonstrates that strains from the ST-21 complex also shared a class C 
LOS locus (49). Both ST-21 and LOS C appear to be rare in Bangladesh. Our GBS-associated strains 
are assigned to different clonal complexes, which correlated with earlier data describing heterogeneity 
among neuropathogenic C. jejuni strains (36, 39). In our study, the ST-22 complex coincided with the 
HS:19 serotype. These types were only found among GBS-related C. jejuni ; ST-362 complex was the 
second most prevalent complex found in both GBS and enteritis strains. A significant number of new 
STs were identified in this study (ST-3442, ST-3741, ST-3743, ST-3748, ST-3968, ST-3969 and ST-
3970), but these have not yet been assigned to any known complex. AFLP analysis demonstrated that 
not a single distinct subpopulation of C. jejuni strains was associated with GBS or enteritis. However, 
AFLP analysis revealed that HS:23 strains are clonal but substantial heterogeneity is found among 
non-HS:23 strains. Our population structure analyses demonstrate that a significant overlap of C. 
jejuni genotypes can be demonstrated by AFLP, PFGE and MLST. As in previous studies we could 
not identify GBS-specific genetic markers by comparing the genomes of C. jejuni strains from GBS vs 
non-GBS patients. (36, 39, 50, 51). A very recent study from Godschalk et al., did not report molecular 
markers specific to GBS on the basis of high-throughput AFLP (30). Based on our study, it can be 
concluded that C. jejuni serotype HS:23 strains are over represented among GBS related strains in 
Bangladesh and appear to be clonally related.  
Biochemical analysis demonstrates that the lipooligosaccharides (LOS) of C. jejuni exhibit 
molecular mimicry with gangliosides in peripheral nerves (52). The LOS biosynthesis genes are 
clustered in the LOS locus. Variation in gene content is clearly reflected by the different classes of the 
LOS locus (53). In Chapter (5.1, 5.2), we determined the presence of five specific classes (A-E) of 
LOS. Interestingly, the class A locus was significantly associated with GBS without oculomotor 
symptoms whereas the class B locus associated with GBS with oculomotor symptoms. We showed 
that the class A and B LOS loci are associated with the expression of ganglioside mimics and with 
neuropathy. Others have reported a strong association between GBS-associated C. jejuni isolates and 
simultaneous presence of three LOS biosynthesis genes, cst-II, cgtA and cgtB (32). This observation 
is consistent with our findings, as these three genes are present in class A and B LOS loci, only. 
Comparison of the LOS loci of various C. jejuni strains has demonstrated that only the class A, B and 
C loci contain the genes that are necessary for the biosynthesis of ganglioside mimics (53, 54). Our 
observation that only C. jejuni with a class A and B LOS locus are associated with neuropathy is, 
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therefore, consistent with the ganglioside mimicry hypothesis. In our study 46% of the control C. jejuni 
isolated from enteritis patients also contained a class A or B LOS locus. This finding is in accordance 
with Dutch study as more than half of the enteritis-related C. jejuni strains contained a neuropathy-
related LOS locus (55). Indeed, all GBS-related strains and 64% of the other clinical and 
environmental strains belonged to an LOS class (LOS class A, B, or C) that allowed the synthesis of a 
sialylated LOS (53). The LOS class may, therefore, be a necessary but not a sufficient determinant 
involved in the pathogenesis of GBS. Other, yet undetected host-related or pathogen-related factors 
may therefore interact in addition and drive the development of post-infection neuropathy (31).  
In Chapter 4, we described that C. jejuni with the class A LOS locus are associated with GBS 
and GM1-like mimicry and that those strains with a class B locus are associated with MFS and GQ1b-
like mimicry. There is only one difference in LOS cluster content between the class A and B. Class B 
contains a duplication of cgtA, encoding a β-1,4-GalNAc transferase. Because cgtA is not directly 
involved in the sialylation of the LOS outer core, it is less likely to be a determinant involved in the 
synthesis of cross-reactive structures and probably other factors are more likely to be involved. In our 
study, we did not find any class C LOS containing strain among the GBS-related C. jejuni strains 
(Chapter 5.1). Studies described in this thesis and by others show that most class A strains express a 
mixture of GM1a and GD1a mimics (31). Further research is needed to determine whether the 
GM1a/GD1a mixture is more effective than single ganglioside mimics in order to assist in the  
development of a crossreactive immune response that leads to GBS.  
Chapter 5.3 describes the diversity and clonal relationships among C. jejuni from humans and 
poultry origin with three well-known typing methods, PFGE, MLST, and AFLP. We determined the 
population structure of 66 C. jejuni isolated from poultry, and also determined the similarities with C. 
jejuni isolated from enteritis patients by a comparative genotyping approach. MLST defined 16 
sequence types (STs) and 5 clonal complexes (CCs) among poultry isolates, including 6 STs not 
previously documented in the PubMed database. We investigated the distribution of the C. jejuni 
isolated from humans and poultry origin by MLST clonal frame tree analysis to demonstrate the 
genetic relationship of certain sequence types. GBS isolates were found in ST-22, 403, and 362 
complexes. The isolates from enteritis were most frequently represented with the ST-403 (28%), and 
ST-362 complexes (13%) (Chapter 5.2). The most frequent poultry ST-353 clonal complex was 
infrequently found among human isolates (4%). The ST-403 complex, the predominant ST in humans 
(GBS and enteritis) was not found among the isolates from poultry. However, ST-22, which was only 
found among the isolates from GBS patients. We also compared 5 predominant STs from human and 
poultry; among them 22% of all isolates overlapped genetically. In contrast to earlier studies, the ST-
21 complex was the largest complex among poultry isolates of C. jejuni (39, 40, 56); however, this 
complex appears to be uncommon among Camylobacter poultry isolates from Bangladesh. The ST-
353 complex, the most common complex in this present study, and the ST-574 and ST-354 
complexes have all been found previously in poultry (57). The ST-353 complex is the most common 
complex among Senegalese poultry in accordance with our findings (58). Our comparative genotyping 
analysis suggests that the ST-403 isolates are uncommon or absent in poultry in Bangladeshi chicken. 
Our study and those of others suggest that the main source of ST-403 may be of non-poultry nature. A 
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Our study and those of others suggest that the main source of ST-403 may be of non-poultry nature. A 
Chapter 6 
156
  
 
 
recent study from England demonstrated that ST-403 has been found among C. jejuni isolated from 
dogs (59); this clonal complex has also been detected among porcine isolates and also occasionally in 
cattle (48, 60- 62). A large study carried out in New Zealand concluded that ST-403 strains were 
predominantly linked to cattle and not to poultry (63). A nationwide larger study will be necessary to 
confirm our preliminary observation and determine the source of the predominant STs in 
Campylobacter-related GBS in Bangladesh. 
Highly heterogeneous fingerprints among C. jejuni strains in Bangladesh have been 
demonstrated by AFLP, and no typical pattern of isolates infecting either poultry or humans was 
identified. Others before us also reported on the high diversity of AFLP fingerprints among both human 
and chicken isolates (51). In this study, only 22% of human-related strains shared AFLP genotypes 
with poultry isolates. This finding is in accordance with our MLST data; and the most commonly 
identified AFLP type coincided with the ST-353 complex. Considering the AFLP and MLST data it 
could be concluded that other sources than poultry are accountable for human Campylobacteriosis in 
Bangladesh. Poultry might not be the sole source of Campylobacter infection in humans, and other 
sources might be considered as sources of human infection (64). However, our studies have some 
limitations: first, the number of isolates from poultry was too small to draw any straight forward 
conclusion for human Campylobacteriosis in Bangladesh; second, the precise origin of several strains 
was not known; third, as we considered only one bacterial colony per chicken sample, we cannot 
exclude the presence of more than one Campylobacter genotype/phenotype in poultry. Others also 
reported that it would be extremely difficult to disclose the sources of infection in humans as mixed 
infections have been demonstrated by analysis of fecal samples from flocks (65). A Dutch study 
reports that a single chicken may harbor a multiplicity of at least four different strains (45). Finally, 
substantial genetic diversity was found among C. jejuni strains isolated from poultry and humans in 
Bangladesh. Further studies with a larger numbers of isolates, including isolates from humans, poultry, 
other animals and environmental sources will provide more insight on the epidemiology of 
Campylobacter in Bangladesh. 
 
Conclusions 
The studies described in this thesis lead to the following conclusions:  
• Despite the fact that polio has been eradicated in Bangladesh non-polio AFP is still 
prevalent in children <15 year of age. A significant proportion of these cases of non-
polio AFP is caused by GBS. The AFP surveillance program can be used to obtain 
crude incidence data of GBS. We recommend a proper validation and further 
expansion of the surveillance system for this purpose (Chapter 2.1).   
• Pure motor and axonal variants are the predominant forms of GBS in Bangladesh. 
Cranial nerve involvement is infrequent. C. jejuni is the locally predominant 
antecedent infectious agent in GBS. Anti-ganglioside antibodies are significantly 
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associated with C. jejuni infection. The axonal variant of GBS associated with C. jejuni 
infection, severe residual disability, and high mortality (Chapter 2.2).  
• There is no significant association between cytomegalovirus, Epstein-Barr virus, and 
Mycoplasma pneumoniae and GBS in Bangladesh (Chapter 3). 
• Our results strongly support the hypothesis that anti-GM1 antibodies in GBS patients 
are induced by antecedent infections with GM1-mimicking C. jejuni strains. Molecular 
mimicry between gangliosides and C. jejuni LOS appears to be causally involved in 
the pathogenesis of C. jejuni-related GBS in Bangladesh. Antibodies against 
gangliosides cross-reacted with corresponding C. jejuni LOS. The LOS structures of 
the Campylobacter strains isolated from GBS patients are similar to those in the 
corresponding ganglioside, suggesting that conformational epitopes may trigger the 
antibody response in these cases (Chapter 4).  
• A new C. jejuni HS:23 serotype and a new sequence type (ST-3219) is highly 
prevalent among GBS-related C. jejuni strains from Bangladesh. LOS class A is 
associated with GBS and monosialylated ganglioside (GM1-like) mimics. LOS class B 
is associated with GBS/MFS and disialyated ganglioisde (GD3-like) mimics (Chapter 
4, 5.1). 
• Comparative genotyping analysis by MLST, AFLP and PFGE demonstrate that HS:23 
strains from GBS or enteritis patients are clonal. We did not identify specific genetic 
determinants that differentiate GBS-associated C. jejuni strains from enteritis strains 
(Chapter 5.2).    
• The population structure of C. jejuni isolated from poultry, and humans are highly 
heterogeneous. The most common ST-353 clonal complex in poultry is infrequent 
among human isolates. The predominant ST-403 complex in humans (GBS and 
enteritis) is not found among poultry.  
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Future perspective 
 
GBS epidemiology: situation of Bangladesh in a global perspective  
In order to acquire a global perspective, we compared our findings of the incidence of GBS in 
Bangladesh with similar data available in published reports from other countries both from developed 
and developing parts of the world (Fig.1). We compared the GBS incidence data <15 years of children. 
In order to make a fair comparison, we included only those data from published reports, which are 
comparable with our data. Our case definition therefore does not meet the strict NINDS criteria. 
Therefore, future studies should include a validation of the case definition used here. Minor 
modifications and additions in the AFP surveillance record form may increase the performance of the 
system to adequately detect GBS cases. Insight into the incidence of GBS in Bangladesh is important 
to a worldwide audience and to better document the geographical differences in incidence and clinical 
phenotype. In addition, changing patterns of antecedent infections triggering GBS may lead to local or 
global changes in the incidence of the disease. The emergence of e.g. H1N1 flu and H1N1 vaccination 
has been followed by increasing demands for a post-marketing surveillance of GBS, and to determine 
any changes in incidence following exposure to new environmental factors. 
 
Extensive neurophysiological investigation in GBS patients in Bangladesh 
In this study, we were able to perform EMG and nerve conduction study on 64 out of 100 
patients. Electrophysiological studies showed that 67% of patients had an axonal variant of GBS, 
whereas 22% had AIDP. Eleven patients (14%) died and 23 (29%) remained severely disabled during 
6 months follow up after disease onset. Despite its importance in GBS, the pathophysiology of 
weakness is only partly understood. At present, more advanced electrophysiological techniques are 
available (muscle scan, excitability testing, multichannel recordings) to improve insight in the 
pathophysiology of weakness in GBS, and to further classify GBS patients in electrodiagnostic and 
prognostic subgroups (66). New, non invasive electrophysiological tests performed at the onset of the 
disease may detect subgroups of patients with a bad prognosis who will likely benefit from more 
aggressive therapeutic interventions.   
 
Antecedent infections and ganglioside antibodies 
We identified the predominant cause of the antecedent infection in GBS patients and detected 
anti-ganglioside antibodies (GM1, GD1a and GQ1b) in more than half of the patients. Although 
Campylobacter infections in Bangladesh appear to play a prominent role in the pathogenesis GBS in 
Bangladesh, other agents may be involved as well. Cutting-edge microbial discovery laboratory 
platforms and modern and powerful high-throughput sequencing tools may detect other, yet unknown, 
pathogens that intervene in the pathogenesis of GBS. Antibodies against other glycoconjugates may 
be present in the Campylobacter negative GBS patients. Our preliminary data suggest that complex 
ganglioside antibodies are present in the serum samples from in our cohort of GBS patients. These 
antibodies seem to be even more prevalent than those against single gangliosde. The presence of 
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neuronal glycolipid targets in antigens of C. jejuni and GBS-related pathogens should be studied 
further.  
  
Host-pathogen interaction  
Although certain types of Campylobacter are implicated in GBS, it is host factors that drive the 
immune respons that will lead to GBS. Some C. jejuni strains isolated from diarrhea patients contain 
similar GM1 ganglioside-like epitopes (67), and yet these patients do not develop an anti-ganglioside 
immune respons nor GBS. We also described two clonally related Campylobacter strains isolated from 
two different GBS patients, expressing identical ganglioside-mimicking structures (GM1 and GD1a); 
however, one patient developed an anti-GD1a immune response while other patient developed an 
anti-GM1 response. The specific neuropathogenic Campylobacter types are therefore not sufficient to 
trigger GBS and other, yet unknown host factors are involved. Further research is necessary to 
elucidate the mechanism by which C. jejuni determine the fine-specificity of the anti-ganglioside 
antibodies.  
 
Other Campylobacter factors 
In this thesis, we did not detect any molecular markers specific for GBS-associated strains by 
our comparative genomic analysis; however, LOS class typing significantly differentiated GBS-related 
strains from enteritis-associated ones in Bangladesh. Many studies tried to identify Campylobacter-
related GBS factors beside the LOS, but did not succeed (50). The availability of new molecular 
techniques may warrant some additional studies. Micro-arrays can be used to detect differences in 
mRNA expression levels. GBS factors that result in differential expression of mRNA may be detected 
with this approach. Comparison of the proteomes (protein expression) or glycomes (polysaccharide 
expression) may also be used to search for additional GBS factors including large number of C. jejuni 
strains. In our study, we found that one GBS patient did not have an anti-ganglioside antibody 
response and was infected with a C. jejuni strain without ganglioside mimic (Chapter 4). Therefore, 
mechanisms other than ganglioside mimicry may be involved in the development and progression of 
GBS.   
 
Occurrence of C. jejuni in environment, and other sources in Bangladesh 
We did a comparative genotyping analysis using humans and poultry isolates of C. jejuni in 
Bangladesh. The dissimilarity of the sequence types and genotypes of C. jejuni from humans and 
poultry suggests the presence of additional sources other than poultry in Bangladesh. Though poultry 
is considered to be the main vector of C. jejuni, other domestic farm animals such as cattle, sheep, 
and pigs, and pet animals such as cats and dogs, may act as a vector for human Campylobacterosis. 
Contaminated surface water may also be involved (68). Therefore, future studies should focus not only 
on poultry, but also on other animals and environmental sources including water. This will undoubtedly 
provide more insight on the epidemiology of Campylobacter in Bangladesh.  
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Summary 
 
Guillain-Barré syndrome (GBS) is probably the most frequent cause of acute flaccid paralysis 
(AFP) in Bangladesh. GBS is characterized by demyelination and axonal degeneration of peripheral 
nerves, leading to a typical acute, progressive, symmetric paralysis with areflexia of arms and legs. 
Some patients show involvement of cranial nerves or paresis of respiratory muscles for which they 
require ventilation. Other patients have the Miller Fisher syndrome (MFS), a variant of GBS is which 
the paresis is most evident in the muscles involved in eye movements. GBS and MFS are post-
infectious immune mediated diseases and Campylobacter jejuni is considered to be the predominant 
cause of these antecedent infections. Molecular mimicry between Campylobacter lipooligosaccharides 
(LOS) and gangliosides in nervous tissue most likely induces a cross-reactive antibody response 
leading to nerve damage and the clinical symptoms of GBS or MFS. 
 The aim of the research described in this thesis was to define the clinical 
epidemiology, preceding infections and antibody response in GBS in Bangladesh. Most current 
knowledge of GBS is based on studies in patients from developed countries and very little is known 
about patients from developing countries. Considering the important role of preceding infections in the 
pathogenesis of GBS and the high exposure to infections in people from developing countries, we 
hypothesized that the disease frequency and characteristics of GBS in Bangladesh may differ from 
those in developed countries. In these studies we especially focused on C. jejuni since the high 
incidence of diarrhea in Bangladesh. Campylobacter strains from Bangladesh may also differ 
genetically or structurally from isolates from other geographical areas, influencing the pathogenesis 
and neurological manifestations. More specifically, in the studies described in this thesis was 
investigated in Bangladesh (i) the epidemiology of GBS in children, and the clinical presentation, 
course and outcome of GBS, (ii) the spectrum of antecedent infections and anti-ganglioside 
antibodies, (iii) the molecular mimicry of C. jejuni and gangliosides, and (iv) a comparative genomics 
of C. jejuni strains isolated from poultry and from patients with GBS and control enteritis.       
First, the crude incidence rate of GBS in children (<15 years) was determined using the data 
from a WHO surveillance on AFP (Chapter 2.1). This surveillance is conducted to define the 
frequency of poliomyelitits, but can also be used to study the epidemiology of GBS which usually 
meets the clinical criteria for AFP. The incidence rate in the northern part of Bangladesh varied from 
1.5 to 1.7 per 100,000 per year, whereas the rate in the southern part varied from 2.1 to 2.5 per 
100,000 per year. A remarkable high incidence rate of more than 5.0 per 100,000 per year was found 
in the districts of Meherpur and Barisal, in the southern part of Bangladesh. In general, the crude 
incidence rates of GBS in children from Bangladesh varied from 1.5 to 2.5 per 100,000 per year. 
In Chapter 2.2 the clinical phenotype, course and outcome of GBS was described. We 
conducted a prospective matched case-control study in the Dhaka area of Bangladesh with a follow-
up of six months including 100 hospital-admitted patients fulfilling the NINDS diagnostic criteria of 
GBS. In this cohort a relatively large proportion of patients were young males from rural areas in 
Bangladesh. The majority of patients suffered from a severe form of GBS  
 
 
 
(92%), further characterized as a pure motor and axonal variant (67%). Most patients (77%) did not 
receive specific treatment with IV immunoglobulin (IVIg). Poor outcome, defined as the inability to walk 
unaided at 6 months after disease onset, was found in 34 (43%) patients with GBS. 
In a case-control study with these GBS patients and 194 controls (patients with other 
neurological diseases and healthy family controls), we determined the types of preceding infections 
associated with GBS (Chapter 2.2 and 3). The predominant cause of the antecedent infection in GBS 
patients was C. jejuni (57%). Much lower frequencies of recent infections with C. jejuni were observed 
in the in the control groups (3% of patients with other neurological diseases and 8% of family controls, 
P<0.001). Diarrhea in the four weeks preceding GBS was reported in 28 (51%) of the 55 C. jejuni-
positive patients, as compared to 8 (19%) of 42 C. jejuni-negative patients (P<0.01). In addition, recent 
infections with cytomegalovirus, Epstein-Barr virus and Mycoplasma pneumoniae, were also 
demonstrated in GBS patients, but in comparison with controls did not revealed statistical significance 
(Chapter 3). The seroprevalence of coxsackieviruses (36%) is significantly associated with GBS 
(P<0.01).  In this study, 64% of coxsackievirus-associated GBS patients have a positive serology for 
C. jejuni infection. This putative association needs further confirmation.  
In Chapter 3.2 the research was described on the association between recent infection with 
C. jejuni and the presence of anti-ganglioside antibodies in patients with GBS. The presence of 
antibodies to the gangliosides GM1, GD1a and GQ1b in GBS patients was more frequent compared to 
the control groups (P<0.001). In GBS patients, antibodies to GM1 were predominant (50%), followed 
by antibodies to GD1a (14%). Preceding infections with C. jejuni were more often found in GBS 
patients with anti-ganglioside antibodies (78%) compared to patients without anti-gangliosides 
antibodies (26%) (P<0.001). Both the presence of recent C. jejuni infection and anti-ganglioside 
antibodies were significantly associated with poor outcome after 6 months of follow up. 
Chapter 4 reports the serum antibody specificity to C. jejuni LOS in patients with GBS and the 
cross-reactivity of these antibodies to gangliosides. These studies were important to determine the 
involvement of molecular mimicry in the pathogenesis of C. jejuni-related GBS.  
 Serum antibodies to C. jejuni LOS were significantly more frequently found in patients with GBS than 
in the two control groups (56% vs 3%, P<0.001). The presence of these anti-LOS antibodies in GBS 
patients was strongly associated with a positive serology for a recent C. jejuni infection and with the 
presence of anti-ganglioside antibodies. In addition, our studies showed that antibodies to 
gangliosides in serum from these patients cross-reacted with LOS from C. jejuni isolated from GBS 
patients. Moreover, mass spectrometry of the LOS from a selection of C. jejuni isolates from 
Bangladeshi GBS patients showed a similar carbohydrate structure as gangliosides. In conclusion, 
there is epidemiological, serological and structural evidence to support the hypothesis that  
infections with C. jejuni strains expressing ganglioside-mimicking LOS induce cross-reactive 
antibodies to gangliosides in patients with GBS. This molecular mimicry and cross-reactivity may play 
a role in the pathogenesis of half of the GBS patients. 
Interestingly, these mass spectrometry studies identified a variety of ganglioside mimics in 
LOS from C. jejuni isolates (Chapter 4). In 57% of these isolates the LOS was heterogeneous and 
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Guillain-Barré syndrome (GBS) is probably the most frequent cause of acute flaccid paralysis 
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investigated in Bangladesh (i) the epidemiology of GBS in children, and the clinical presentation, 
course and outcome of GBS, (ii) the spectrum of antecedent infections and anti-ganglioside 
antibodies, (iii) the molecular mimicry of C. jejuni and gangliosides, and (iv) a comparative genomics 
of C. jejuni strains isolated from poultry and from patients with GBS and control enteritis.       
First, the crude incidence rate of GBS in children (<15 years) was determined using the data 
from a WHO surveillance on AFP (Chapter 2.1). This surveillance is conducted to define the 
frequency of poliomyelitits, but can also be used to study the epidemiology of GBS which usually 
meets the clinical criteria for AFP. The incidence rate in the northern part of Bangladesh varied from 
1.5 to 1.7 per 100,000 per year, whereas the rate in the southern part varied from 2.1 to 2.5 per 
100,000 per year. A remarkable high incidence rate of more than 5.0 per 100,000 per year was found 
in the districts of Meherpur and Barisal, in the southern part of Bangladesh. In general, the crude 
incidence rates of GBS in children from Bangladesh varied from 1.5 to 2.5 per 100,000 per year. 
In Chapter 2.2 the clinical phenotype, course and outcome of GBS was described. We 
conducted a prospective matched case-control study in the Dhaka area of Bangladesh with a follow-
up of six months including 100 hospital-admitted patients fulfilling the NINDS diagnostic criteria of 
GBS. In this cohort a relatively large proportion of patients were young males from rural areas in 
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associated with GBS (Chapter 2.2 and 3). The predominant cause of the antecedent infection in GBS 
patients was C. jejuni (57%). Much lower frequencies of recent infections with C. jejuni were observed 
in the in the control groups (3% of patients with other neurological diseases and 8% of family controls, 
P<0.001). Diarrhea in the four weeks preceding GBS was reported in 28 (51%) of the 55 C. jejuni-
positive patients, as compared to 8 (19%) of 42 C. jejuni-negative patients (P<0.01). In addition, recent 
infections with cytomegalovirus, Epstein-Barr virus and Mycoplasma pneumoniae, were also 
demonstrated in GBS patients, but in comparison with controls did not revealed statistical significance 
(Chapter 3). The seroprevalence of coxsackieviruses (36%) is significantly associated with GBS 
(P<0.01).  In this study, 64% of coxsackievirus-associated GBS patients have a positive serology for 
C. jejuni infection. This putative association needs further confirmation.  
In Chapter 3.2 the research was described on the association between recent infection with 
C. jejuni and the presence of anti-ganglioside antibodies in patients with GBS. The presence of 
antibodies to the gangliosides GM1, GD1a and GQ1b in GBS patients was more frequent compared to 
the control groups (P<0.001). In GBS patients, antibodies to GM1 were predominant (50%), followed 
by antibodies to GD1a (14%). Preceding infections with C. jejuni were more often found in GBS 
patients with anti-ganglioside antibodies (78%) compared to patients without anti-gangliosides 
antibodies (26%) (P<0.001). Both the presence of recent C. jejuni infection and anti-ganglioside 
antibodies were significantly associated with poor outcome after 6 months of follow up. 
Chapter 4 reports the serum antibody specificity to C. jejuni LOS in patients with GBS and the 
cross-reactivity of these antibodies to gangliosides. These studies were important to determine the 
involvement of molecular mimicry in the pathogenesis of C. jejuni-related GBS.  
 Serum antibodies to C. jejuni LOS were significantly more frequently found in patients with GBS than 
in the two control groups (56% vs 3%, P<0.001). The presence of these anti-LOS antibodies in GBS 
patients was strongly associated with a positive serology for a recent C. jejuni infection and with the 
presence of anti-ganglioside antibodies. In addition, our studies showed that antibodies to 
gangliosides in serum from these patients cross-reacted with LOS from C. jejuni isolated from GBS 
patients. Moreover, mass spectrometry of the LOS from a selection of C. jejuni isolates from 
Bangladeshi GBS patients showed a similar carbohydrate structure as gangliosides. In conclusion, 
there is epidemiological, serological and structural evidence to support the hypothesis that  
infections with C. jejuni strains expressing ganglioside-mimicking LOS induce cross-reactive 
antibodies to gangliosides in patients with GBS. This molecular mimicry and cross-reactivity may play 
a role in the pathogenesis of half of the GBS patients. 
Interestingly, these mass spectrometry studies identified a variety of ganglioside mimics in 
LOS from C. jejuni isolates (Chapter 4). In 57% of these isolates the LOS was heterogeneous and 
Summary 
168 
mimicked not one but several different gangliosides, such as the combination of GM1 and GD1a. 
Some patients also produced antibodies to combinations or complexes of GM1 and GD1a instead of 
antibodies to single gangliosides. Whether C. jejuni strains express mono- or disialylated LOS is 
determined by the polymorphism of the cst-II gene. This relation between polymorphisms in the 
bacterial cst-II gene and the expression of ganglioside-like LOS was confirmed in the Bangladeshi 
collection of C. jejuni isolates. We identified in C. jejuni strains isolated from GBS/MFS patients with 
ophthalmoplegia a novel LOS structure with two extension sites from the inner core and two branches 
mimicking GA2 and the ganglioside GD3. Our data also suggest that there is no absolute association 
between the presence of ganglioside mimics in C. jejuni LOS and cross-reactive serum antibodies to 
gangliosides, suggesting that other mechanisms than molecular mimicry may play a role in inducing 
GBS.  
In Chapter 5.1 we described that the HS:23 serotype is highly prevalent (50%) among GBS-
related C. jejuni strains from Bangladesh. The comparative genotyping analysis of C. jejuni strains 
isolated from GBS and enteritis patients by MLST, AFLP, PFGE fingerprinting, and LOS typing is 
described in Chapter 5.2. Overlapping clonal groups were defined by MLST, AFLP and PFGE for 
strains from patients with GBS and gastroenteritis. C. jejuni HS:23 isolates from patients with GBS or 
enteritis were clonal and all strains belonged to ST-403 complex. We did not identify specific genetic 
determinants that differentiate C. jejuni strains associated with GBS versus strains from enteritis 
controls. In Chapter 5.1 and 5.2, we determined the presence of five specific genetic classes of LOS 
(A-E). The class A locus was significantly associated with GBS without oculomotor symptoms whereas 
the class B locus associated with GBS with oculomotor symptoms. We showed that the class A and B 
LOS loci are associated with the expression of ganglioside mimics and with neuropathy. We also 
described that C. jejuni with the class A LOS locus are associated with GBS and GM1-like mimicry 
and that those strains with a class B locus are associated with MFS and GQ1b-like mimicry. In 
Chapter 5.3 we determined the genotypes of the C. jejuni isolated from poultry, and compared these 
with the genotypes of the C. jejuni isolated from patients. Comparative genomic studies showed that 
the population structure of C. jejuni isolated from poultry and humans are different and highly diverse. 
The most common ST-353 clonal complex in poultry was infrequent among human isolates. The 
predominant ST-403 complex in humans (GBS and enteritis) was not found among poultry.  
Chapter 6 includes an extensive discussion of the results described in Chapters 2 to 5 and 
suggestions for future research. The most important conclusions are that in Bangladesh a significant 
proportion of non-polio AFP in children is caused by GBS. Pure motor and axonal variants of GBS are 
also predominant in Bangladesh. C. jejuni is the most frequent antecedent infection in GBS and 
related with the induction of cross-reactive anti-ganglioside antibodies. Our data confirm that 
molecular mimicry between gangliosides and C. jejuni LOS appears to be causally involved in the 
pathogenesis of C. jejuni-related GBS in Bangladesh. 
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Het Guillain-Barré syndrome (GBS) is waarschijnlijk de meest voorkomende oorzaak van 
acute hypotone verlamming (of ‘acute flaccid paralyisis’, AFP) in Bangladesh. GBS wordt gekenmerkt 
door demyelinisatie en axonale degeneratie van perifere zenuwen welke leidt tot een progressieve, 
symmetrische verlamming en areflexie van armen en benen. Bij een deel van de patiënten ontstaat 
tevens uitval van hersenzenuwen of verlamming van de ademhalingsspieren waarvoor de patiënten 
moeten worden beademend. Andere patiënten krijgen een Miller Fisher syndroom (MFS), een variant 
van GBS waarbij er vooral sprake is van een verlamming van de spieren die betrokken zijn bij 
oogbewegingen. GBS en MFS zijn post-infectieuze immuun-gemedieerde ziekten en Campylobacter 
jejuni wordt beschouwd als de meest voorkomende oorzaak van deze vooafgaande infecties. 
Moleculaire mimicry tussen C. jejuni lipo-oligosacchariden (LOS) en gangliosiden in zenuwweefsel 
veroorzaakt mogelijk een kruis-reactieve antistofrespons welke resulteert in zenuwbeschadiging en de 
klinische symptomen van GBS en MFS. 
 Het doel van het onderzoek beschreven in dit proefschrift was om de klinische epidemiologie, 
voorafgaande infecties en antistofrespons van GBS in Bangladesh te bepalen. De meeste huidige 
kennis over GBS is gebaseerd op studies bij patiënten uit ontwikkelde landen en heel weinig is 
bekend over patiënten van ontwikkelingslanden. Gegeven de belangrijke rol van voorafgaande 
infecties in de pathogenese van GBS en de hoge mate van bloodstelling van mensen in 
ontwikkelingslanden aan infecties, hebben wij gehypothetiseerd dat de frequentie en kenmerken van 
GBS in Bangladesh mogelijk verschilden van die in ontwikkelde landen. In deze studies hebben we 
ons vooral gericht op C. jejuni vanwege de hoge incidentie van diarree in Bangladesh. C. jejuni 
stammen in Bangladesh verschillen mogelijk genetisch of biochemisch van isolaten uit andere 
geografische gebieden en zij beinvloeden daardoor mogelijk de pathogenese en neurologische 
manifestaties. Meer specifiek, in de studies beschreven in dit proefschrift werd onderzocht in 
Bangladesh: (i) de epidemiologie van GBS bij kinderen en de klinische presentatie, het ziektebeloop 
en de prognose van GBS, (ii) het spectrum van voorafgaande infecties en anti-ganglioside antistoffen, 
(iii) de moleculaire mimicry van C. jejuni en gangliosiden, en (iv) vergelijkende genetische analyse van 
C. jejuni stammen geisoleerd van gevogelte en van patiënten met GBS en controle entritis. 
Eerst werd de incidentie van GBS bepaald in kinderen (<15 jaar) waarbij gebruik werd 
gemaakt van data van een WHO surveillence studie gericht op AFP (Hoofdstuk 2.1). Deze 
surveillence studie wordt uitgevoerd om de incidentie van poliomyelitis te bepalen, maar kon ook 
gebruikt worden om de epidemiologie van GBS te onderzoeken aangezien GBS meestal ook voldoet 
aan de klinische kriteria voor AFP. The incidentie in het noordelijk deel van Bangladesh varieerde van 
1,5 tot 1,7 per 100.000 pe jaar, terwijl de incidentie in het zuidelijk deel van Bangladesh varieerde van 
2.1 tot 2.5 per 100.000 per jaar. Een opmerkelijk hoge incidentie van meer dan 5,0 per 100.000 per 
jaar werd gevonden voor de districten Meherpur en Barisal in het zuiden van Bangladesh. In het 
algemeen varieerde de incidentie van GBS bij kinderen in Bangladesh tussen 1.5. en 2.5 per 100.000 
per jaar.           
 
 
 
In Hoofdstuk 2.2 werd het klinische fenotype, het ziekte beloop en de prognose van GBS  
beschreven. Wij hebben een prospectieve gematchte case-controlstudie uitgevoerd in het gebied rond 
Dhaka in Bangladesh met een follow-up van 6 maanden bij 100 in het zieknhuis opgenomen patiënten 
die volden aan de diagnostische kriteria van de NINDS voor GBS. In dit cohort kwamen jonge mannen 
afkomstig van de niet-verstedelijkte gebieden van Bangladesh relatef vaak voor. De meerderheid van 
de patiënten in Bangladesh leden aan een ernstige vorm van GBS (92%), nader gekarakteriseerd als 
een puur motore en axonale variant (67%). De meeste patiënten kregen geen specifieke behandeling 
met IV immunoglobulinen (IVIg). Een slecht herstel, gedefinieerd als onvermogen om zonder hulp te 
kunnen lopen na 6 maanden na het begin van de ziekte, werd gevonden in 34 (43%) van de patiënten 
met GBS. 
In een case-control studie met deze GBS patiënten en 194 controle personen (patiënten met 
andere neurologische ziekten en gezonde familiecontroles), werden door ons bepaald welke type 
voorafgaande infecties ware geassocieerd met GBS (Hoofdstuk 2.2 en 3). De meestvoorkomende 
oorzaak van de voorafgeaande infecties bij patiënten met GBS was C. jejuni (57%). Veel lagere 
frequenties van een recente infectie met C. jejuni werden gevonden bij de controlegroepen (3% van 
de patiënten met andere neurologische ziekten en 8% van de gezonde familiecontroles, P<0.001). 
Diarree in de 4 weken voorafgaand aan GBS werden gemeld door 28 (51%) van de 55 C. jejuni-
positieve patiënten, vergeleken met  8 (19%) van de 42 C. jejuni-neagatieve patiënten (P<0.01). 
Daarnaast werden ook recente infecties cytomegalovirus, Epstein-Barr virus en Mycoplasma 
pneumoniae aangetoond in patiënten met GBS, maar vergeleken met de controles bleken deze niet 
significant vaker voor te komen (Hoofdstuk 3). De seroprevalentie van coxsackievirus (36%) bleek 
significant geassocieerd te zijn met GBS  (P<0.01). In deze studie had 64% van de GBS patiënten met 
een positieve coxsackie-serologie tevens een positieve serologie voor C. jejuni. Deze mogelijke 
associatie moet  worden bevestigd.         
In hoofdstuk 3.2 werd het onderzoek beschreven naar de associatie tussen recente infecties 
met C. jejuni en de aanwezigheid van anti-ganglioside antistoffen bij patiënten met GBS. De 
aanwezigheid van antistoffen tegen de ganglisodien GM1, GD1a en GQ1b bij patiënten met GBS 
bleek meer frequent dan in de controlegroepen (P<0.001). In GBS patiënten bleken antistoffen tegen 
GM1 (50%) het vaakste voor te komen, gevolgd door antistoffen tegen GD1a (14%). Voorafgaande 
infecties met C. jejuni warden vaker gevonden bij GBS patiënten met anti-ganglioside antistoffen 
(78%) dan bij patiënten zonder anti-gangliside antistoffen (26%) (P<0.001). Zowel de aanwezigheid 
van recente C. jejuni infecties als anti-ganglisoide antistoffen bleken significant geassocieerd te zijn 
met een slecht klinisch herstel na 6 maanden van follow-up.    
Hoofdstuk 4 beschrijft de specificiteit van antistoffen in het serum van patiënten met GBS 
voor C. jejuni LOS en de kruisreactiviteit van deze antistoffen met gangliosiden. Deze studies waren 
belangrijk om te bepalen of moleculaire mimicry een rol speelt in de pathogenese van C. jejuni-
gerelateerde GBS. Serum antistoffen tegen C. jejuni LOS werden significant vaker gevonden bij 
patiënten met GBS dan bij de twee controlegroepen (56% vs 3%, P<0.001). De aanwezigheid van 
deze anti-LOS antistoffen bij de GBS patiënten bleek sterk geassocieerd te zijn met een positieve 
serologie voor een recente C. jejuni infectie en met de aanwezigheid van anti-ganglioside antistoffen. 
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Daarnaast.werd in onze studies aangetoond dat antistoffen tegen gangliosiden in het serum van 
patiënten kruisreageerden met het LOS van C. jejuni isolaten van patiënten met GBS. Verder werd 
met behulp van massa spectrometrie aangetoond dat het LOS van een selectie van C. jejuni isolaten 
van Bangladese GBS patiënten een vergelijkbare suikerstructuur heeft als gangliosiden. Er zijn 
derhalve epidemiologische, serologische en structurele aanwijzingen ter ondersteunig van van de 
hypothese dat in Bangladesh infecties met C. jejuni stammen die op ganglioside gelijkend LOS tot 
expressie brengen bij GBS patiënten kruisreactieve antistoffen tegen gangliosiden kunnen 
veroorzaken. Deze moleculaire mimicry en kruisreactiviteit speelt mogelijk een rol in de pathogenese 
bij ongeveer de helft van de patiënten met GBS in Bangladesh.         
Interessant genoeg bleek uit deze massa spectometrie-studies dat de C. jejuni isolaten uit 
Bangladesh een varieteit aan verschillende ganglioside mimics tot expressie kunnen brengen 
(Hoofdstuk 4). Bij 57% van deze isolaten was het LOS heterogeen en vertoonde deze gelijkenis met 
niet één maar met meerdere verschillende gangliosiden, zoals de combinatie van GM1 en GD1a. 
Sommige patiënten produceerden antistoffen tegen combinaties of complexen van GM1 en GD1a in 
plaats van antistoffen tegen enkelvoudige gangliosiden. Of een C. jejuni mono- of disialyl-gangliosiden 
tot expressie brengt wordt bepaald door het polymorfisme van het cst-II gen. Deze relatie tussen de 
polymorfismen van het bacteriële cst-II gene en de expressie van op ganglioside-gelijkend LOS werd 
bevestigd in de Bangladese collectie van C. jejuni-isolaten. Wij identificeerden in C. jejuni isolaten van 
patiënten met GBS/MFS en ophthalmoplegia een nieuwe LOS-structuur met in de ‘inner core’ van het 
LOS twee plaatsten voor extensies en met twee mimics voor GA2 en het ganglioside GD3. Onze 
resultaten suggereren verder dat er geen absolute associatie bestaat tussen de aanwezigheid van 
ganglioside mimics in C. jejuni LOS en kruis-reactive antistoffen tegen gangliosiden in het serum. 
Deze bevindingen suggereren mogelijk dat er ook andere mechanismen dan moleculaire mimicry een 
rol spelen bij het ontstaan van GBS.     
In Hoofdstuk 5.1 beschreven we dat het HS:23 serotype vaak voorkomt (50%) bij C. jejuni-
isolaten van patiënten met GBS uit Bangladesh. De vergelijkende genotype analyse van C.jejuni-
isolaten van GBS patiënten en eneteritis patiënten met behulp van MLST, AFLP en PFGE en met 
LOS biosynthese klassetypering werden beschreven in Hoofdstuk 5.2. Overlappende klonale 
groepen werden bepaald met behulp van MLST, AFLP en PFGE van patiënten met GBS en 
gastroenteritis. C. jejuni HS:23 isolaten van GBS patiënten en enteritis patiënten bleken klonaal te zijn 
en alle stammen bleken te behoorden tot het ST-403-complex. We vonden geen specifieke 
genetische determinanten die differentieerden tussen C. jejuni van GBS patiënten en 
controlepersonen met enteritis. In Hoofdstuk 5.1 en 5.2 bepaalden we de aanwezigheid van vijf 
specifieke genetische klassen van LOS (A-E). Het klasse A locus was significant geassocieerd met 
GBS met oculomotore symptomen. We toonden aan dat klasse A en B van LOS loci waren 
geassocieerd met de expressie van ganglioside mimics en met het voorkomen van neuropathie. We 
beschreven verder dat C. jejuni met het klasse A LoS locus waren geassocieerd met GBS en met op 
GM1-gelijkend LOS en dat isolaten met het klasse B locus waren geassocieerd met het MFS en op 
GQ1b-gelijkend LOS. In Hoofdstuk 5.1 bepaalden we het genotype van C. jejuni bij de isolaten uit 
gevogelte en vergeleken deze met het genotype van C. jejuni bij de isolaten van patiënten. In een 
 
 
 
vergelijkend genomische analyse bleek de populatiestructuur van de C. jejuni geisoleerd uit gevogelte 
en mensen verschillend en bovendien heel divers. Het bij isolaten van gevogelte meest voorkomend 
clonale complex ST-353 bleek zeldzaam te zijn bij isolaten van mensen. Het meest voorkomende ST-
403 complex bij isolaten van mensen (GBS en controle enteritis) werd niet gevonden bij isolaten van 
gevogelte.             
Hoofdstuk 6 bevat een uitgebreide discussie over de resultaten beschreven in de 
hoofdstukken 2 tot en met 5. De meest belangrijke conclusies zijn dat in Bangladesh een groot deel 
van de non-polio AFP bij kinderen wordt veroorzaakt door GBS. Puur motore en axonal vormen van 
GBS zijn in Bangladesh het meest voorkomend. C. jejuni is de meest frequente voorafgaande infectie 
bij GBS en gerelateerd met de vorming van kruis-reactieve anti-ganglioside antistoffen. Onze 
resulaten bevestigen dat moleculaire mimicry tussen C. jejuni LOS en gangiosiden een belangrijke 
oorzaak lijkt te zijn in de pathogenese van C. jejuni-gerelateerde GBS in Bangladesh.  
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